{
  "filename": "ehab484.pdf",
  "title": "ehab484.pdf",
  "type": "heart_failure",
  "year": null,
  "total_pages": 111,
  "extracted_at": "2026-01-15T16:08:28.190600",
  "chapters": [
    {
      "number": "1",
      "title": "1. Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3233 2. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .",
      "start_page": 1,
      "end_page": 6,
      "content": "2.1. Definition and rationale . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3235 2.2. Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236 2.3. Cost-effectiveness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236 2.4. What is new? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236 3. Risk factors and clinical conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236\n3.1. Target population for assessing cardiovascular disease risk . . 3236 3.2. Risk factors and risk classification . . . . . . . . . . . . . . . . . . . . . . . . . . 3236\n3.2.1. Risk factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3236 3.2.1.1 Cholesterol  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3242 3.2.1.2 Blood pressure  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3242\n3.2.1.3 Cigarette smoking  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3242 3.2.1.4 Diabetes mellitus  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3243 3.2.1.5 Adiposity  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3243 3.2.2. Sex and gender and their impact on health . . . . . . . . . . . . . 3243 3.2.3. Atherosclerotic cardiovascular disease risk classification . 3243 3.2.3.1 A stepwise approach to risk factor treatment and treatment intensification  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3243 3.2.3.2 Risk estimation in apparently healthy people  . . . . . . . . . . . 3245 3.2.3.3 Translating cardiovascular disease risk to treatment thresholds  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3250 3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 50 \u0002 69 years of age  . . . . . . . . . . . . . . . 3253 3.2.3.5 Risk estimation and risk factor treatment estimation in apparently healthy people  \u0003 70 years of age  . . . . . 3253\n3228 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people  < 50 years of age  . . . . . . . . . . . . . . . . . 3254 3.2.3.7 Risk estimation and risk factor treatment in patients with established atherosclerotic cardiovascular disease  . . . . . . . . . 3254 3.2.3.8 Risk estimation and risk factor treatment in persons with type 2 diabetes mellitus  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3256 3.2.3.9 Risk estimation and risk factor treatment in persons with type 1 diabetes mellitus  . . . . . . . . . . . . . . . . . . . . . . . . 3257 3.2.4. Communication of cardiovascular disease risk . . . . . . . . . . 3257 3.3. Potential risk modifiers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258\n3.3.1. Psychosocial factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258 3.3.2. Ethnicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3258 3.3.3. Imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 3.3.3.1 Coronary artery calcium  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.3.2 Contrast computed tomography coronary angiography  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.3.3 Carotid ultrasound  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.3.4 Arterial stiffness  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.3.5 Ankle brachial index  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.3.6 Echocardiography  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.4. Frailty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.5. Family history . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3259 3.3.6. Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260 3.3.7. Socioeconomic determinants . . . . . . . . . . . . . . . . . . . . . . . . . 3260 3.3.8. Environmental exposure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260 3.3.9. Biomarkers in blood or urine . . . . . . . . . . . . . . . . . . . . . . . . . . 3260 3.3.10. Body composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260 3.3.10.1 Which index of obesity is the best predictor of cardiovascular risk?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3261 3.3.10.2 Risk reclassification  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3261 3.3.10.3 Assess risk factors and cardiovascular disease risk in persons with obesity  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262 3.4. Clinical conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262\n3.4.1. Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262 3.4.2. Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262 3.4.3. Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3262 3.4.4. Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3263 3.4.4.1 Diagnosis and screening  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3264 3.4.4.2 Prevention of cardiotoxicity and cardiovascular risk factors  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3264 3.4.5. Chronic obstructive pulmonary disease . . . . . . . . . . . . . . . . 3264 3.4.6. Inflammatory conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265 3.4.7. Infections (human immunodeficiency virus, influenza, periodontitis) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265 3.4.8. Migraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265 3.4.9. Sleep disorders and obstructive sleep apnoea . . . . . . . . . . 3265 3.4.10. Mental disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3265 3.4.11. Non-alcoholic fatty liver disease . . . . . . . . . . . . . . . . . . . . . . 3266 3.4.12. Sex-specific conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266 3.4.12.1 Obstetric conditions  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266 3.4.12.2 Non-obstetric conditions  . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266 3.4.12.3 Erectile dysfunction  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266 4. Risk factors and interventions at the individual level . . . . . . . . . . . . . 3266\n4.1. Treatment recommendations: classes, grades, and freedom of choice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3266 4.2. Optimizing cardiovascular risk management . . . . . . . . . . . . . . . . 3268\n4.2.1. Goals of clinician-patient communication . . . . . . . . . . . . . . 3268\n4.2.2. How to improve motivation? . . . . . . . . . . . . . . . . . . . . . . . . . . 3268 4.2.3. Optimizing drug adherence . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268 4.2.4. Treatment goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268 4.3. Optimizing lifestyle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268\n4.3.1. Physical activity and exercise . . . . . . . . . . . . . . . . . . . . . . . . . . 3268 4.3.1.1 Physical activity prescription  . . . . . . . . . . . . . . . . . . . . . . . . . . 3269 4.3.1.2 Aerobic physical activity  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269 4.3.1.3 Resistance exercise  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269 4.3.1.4 Sedentary behaviour  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269 4.3.2. Nutrition and alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4269 4.3.2.1 Fatty acids  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270 4.3.2.2 Minerals and vitamins  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270 4.3.2.3 Fibre  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270 4.3.2.4 Specific foods and food groups  . . . . . . . . . . . . . . . . . . . . . . . 3270 4.3.2.4.1. Fruits, vegetables, and pulses . . . . . . . . . . . . . . . . . . 3270 4.3.2.4.2. Nuts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271 4.3.2.4.3. Meat . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271 4.3.2.4.4. Fish and fish oil supplements . . . . . . . . . . . . . . . . . . 3271 4.3.2.4.5. Alcoholic beverages . . . . . . . . . . . . . . . . . . . . . . . . . . 3271 4.3.2.4.6. Soft drinks and sugar . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 4.3.2.4.7. Coffee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 4.3.2.4.8. Functional foods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 4.3.2.4.9. Dietary patterns . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 4.3.3. Bodyweight and composition . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 4.3.3.1 Treatment goals and modalities  . . . . . . . . . . . . . . . . . . . . . . 3272 4.3.3.2 Diets for weight loss  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 4.4. Mental healthcare and psychosocial interventions . . . . . . . . . . 3273 4.5. Smoking intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273\n4.5.1. Smoking cessation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273 4.5.2. Evidence-based drug interventions . . . . . . . . . . . . . . . . . . . . 3275 4.5.2.1 Electronic cigarettes  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275 4.6. Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275\n4.6.1. Measurement of lipids and lipoproteins . . . . . . . . . . . . . . . . 3275 4.6.1.1 Fasting vs. non-fasting measurements  . . . . . . . . . . . . . . . . . 3275 4.6.1.2 Low-density lipoprotein cholesterol measurement  . . . . . . . . 50 4.6.1.3 Non-high-density lipoprotein cholesterol  . . . . . . . . . . . . . . . 3276 4.6.1.4 Apolipoprotein B  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3276 4.6.2. Defining lipid goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3276 4.6.2.1 Low-density lipoprotein cholesterol goals  . . . . . . . . . . . . . . 3276 4.6.2.2 Triglyceride-rich lipoproteins and their remnants  . . . . . . . . 3276 4.6.2.3 High-density lipoprotein cholesterol  . . . . . . . . . . . . . . . . . . . 3276 4.6.3. Strategies to control dyslipidaemias . . . . . . . . . . . . . . . . . . . . 3278 4.6.3.1 Strategies to control low-density lipoprotein cholesterol  . . 3278 4.6.3.1.1. Diet and lifestyle modifications . . . . . . . . . . . . . . . . 3278 4.6.3.1.2. Drugs for treatment of dyslipidaemias . . . . . . . . . 3278 4.6.3.1.3. Statins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3279 4.6.3.1.3.1. Adverse effects, interactions, and adherence to statin therapy . . . . . . . . . . . . . . . . . . . . . . . . . 3279 4.6.3.1.4. Cholesterol absorption inhibitors (ezetimibe) . 3279 4.6.3.1.5. Proprotein convertase subtilisin/kexin type 9 inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3279 4.6.3.2 Strategies to control plasma triglycerides  . . . . . . . . . . . . . . 3279 4.6.3.2.1. Fibrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3279 4.6.4. Important groups . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3280 4.6.4.1 Women  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3280 4.6.4.2 Older patients ( \u0003 70 years)  . . . . . . . . . . . . . . . . . . . . . . . . . . 3280 4.6.4.3 Diabetes mellitus  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3280\nESC Guidelines 3229\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.6.4.4 Chronic kidney disease  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281 4.6.4.5 Familial hypercholesterolaemia  . . . . . . . . . . . . . . . . . . . . . . 3281 4.7. Blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281\n4.7.1. Definition and classification of hypertension . . . . . . . . . . . . 3283 4.7.2. Blood pressure measurement . . . . . . . . . . . . . . . . . . . . . . . . . 3283 4.7.2.1 Office blood pressure measurement  . . . . . . . . . . . . . . . . . . 3283 4.7.2.2 Unattended automated office blood pressure measurement  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3283 4.7.2.3 Ambulatory blood pressure monitoring  . . . . . . . . . . . . . . . . 3283 4.7.2.4 Home blood pressure monitoring  . . . . . . . . . . . . . . . . . . . . . 3283 4.7.3. Screening and diagnosis of hypertension . . . . . . . . . . . . . . . 3283 4.7.3.1 White-coat and masked hypertension  . . . . . . . . . . . . . . . . . 3284 4.7.4. Clinical evaluation and risk stratification in hypertensive patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284 4.7.5. Treatment of hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3285 4.7.5.1 Lifestyle interventions to lower blood pressure and/or reduce cardiovascular risk  . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3285 4.7.5.2 Initiation of drug treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . 3285 4.7.5.3 Blood pressure treatment targets  . . . . . . . . . . . . . . . . . . . . . 3285 4.7.5.3.1. Blood pressure targets according to ambulatory and home blood pressure monitoring . . . . . . . . . . . . . . . . . . 3287 4.7.5.4 Drug treatment of hypertension  . . . . . . . . . . . . . . . . . . . . . . 3288 4.7.6. Resistant hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3288 4.7.7. Management of hypertension in women . . . . . . . . . . . . . . . 3288 4.7.8. Duration of treatment and follow-up . . . . . . . . . . . . . . . . . . 3288 4.8. Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3288\n4.8.1. Key risk factor concepts and newer paradigms . . . . . . . . . 3289 4.8.1.1 Lifestyle intervention  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3289 4.8.1.2 Glycaemic control  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3289 4.8.1.3 Newer diabetes mellitus drug classes: cardiovascular disease benefits  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3290 4.8.2. Type 1 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3290 4.9. Antithrombotic therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3290\n4.9.1. Antithrombotic therapy in individuals without atherosclerotic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291 4.9.2. Antithrombotic therapy in individuals with established atherosclerotic disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291 4.9.3. Proton pump inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291 4.10. Anti-inflammatory therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3291 4.11. Cardiac rehabilitation and prevention programmes . . . . . . . . 3292 5. Policy interventions at the population level . . . . . . . . . . . . . . . . . . . . . 3292\n5.1. Population-level approaches to the prevention of cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293 5.2. Specific risk factor interventions at the population level . . . . . 3293\n5.2.1. Physical activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293 5.2.2. Diet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293 5.2.3. Smoking and tobacco use . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293 5.2.4. Alcohol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3293 5.3. Environment, air pollution, and climate change . . . . . . . . . . . . . 3293\n5.3.1. Climate change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3294 5.4. Implications for public health policy and advocacy at the governmental and non-governmental level . . . . . . . . . . . . . . . . . . . . . 3294 6. Risk management of disease-specific cardiovascular disease . . . . . 3294\n6.1. Coronary artery disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3294 6.2. Heart failure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3295 6.3. Cerebrovascular diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3296 6.4. Lower extremity artery disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3297\n6.5. Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3298 6.6. Atrial fibrillation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3298 6.7. Multimorbidity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3299 7. Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3299 8. Gaps in evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3302 9. ‘What to do’ and ‘what not to do’ messages from the guidelines . 3205 10. Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310 11. Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310 12. Author information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310 13. Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3311 14. References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3312\nRecommendations\nRecommendations for CVD risk assessment . . . . . . . . . . . . . . . . . . . . . . 3242 Recommendations for CVD risk estimation . . . . . . . . . . . . . . . . . . . . . . 3256 Recommendation for CVD risk communication . . . . . . . . . . . . . . . . . . 3257 Recommendations for CVD risk modifiers . . . . . . . . . . . . . . . . . . . . . . . . 3257 Recommendations for cardiovascular disease risk related to air pollution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3260 Recommendations for cardiovascular disease assessment in specific clinical conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3261 Recommendations for physical activity . . . . . . . . . . . . . . . . . . . . . . . . . . . 3268 Recommendations for nutrition and alcohol . . . . . . . . . . . . . . . . . . . . . . 3269 Recommendations for body weight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3272 Recommendations for mental healthcare and psychosocial interventions at the individual level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3273 Recommendations for smoking intervention strategies . . . . . . . . . . . . 3273 Recommendation on low-density lipoprotein cholesterol goals . . . . 3276 Recommendations for pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age (for recommendations for persons aged >_70 years, see respective recommendations tables) . . . . . . . . . . . . 3278 Recommendations for drug treatments of patients with hypertriglyceridaemia.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284 Recommendations for the treatment of dyslipidaemias in older people (>_70 years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284 Recommendations for the treatment of dyslipidaemias in diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284 Recommendations for lipid management in patients with moderate- tosevere chronic kidney disease (Kidney Disease Outcomes Quality Initiative stages 3 \u0002 5) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281 Summary of recommendations for the clinical management of hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3282 Recommendations for the treatment of patients with diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3288 Recommendations for antithrombotic therapy . . . . . . . . . . . . . . . . . . . . 3290 Recommendation for anti-inflammatory therapy . . . . . . . . . . . . . . . . . . 3291 Recommendations for cardiac rehabilitation . . . . . . . . . . . . . . . . . . . . . . 3292 Recommendations for policy interventions at the population level . . 3292 Recommendations for patients with coronary artery disease . . . . . . 3294 Recommendations regarding pharmacological and non- pharmacological interventions for patients with symptomatic (New York Heart Association class II-IV) heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) with proven benefits on clinical outcomes, including cardiovascular morbidity and mortality . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3295 Recommendations for patients with cerebrovascular disease . . . . . . 3297\n3230 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Recommendations for patients with lower extremity artery disease: best medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3297 Recommendations in patients with chronic kidney disease: best medical therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3310 Recommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial fibrillation . . 3310\nTables\nTable 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3234 Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3234 Table 3 New recommendations and new and revised concepts . . . . 3237 Table 4 Patient categories and associated cardiovascular disease risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3244 Table 5 Cardiovascular disease risk categories based on Systemic Coronary Risk Estimation 2 and Systemic Coronary Risk Estimation 2-Older Persons in apparently healthy people according to age . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3251 Table 6 Treatment goals for different patient categories . . . . . . . . . . . 3267 Table 7 Classification of physical activity intensity and examples of absolute and relative intensity levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3269 Table 8 Healthy diet characteristics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3270 Table 9 ‘Very brief advice’ for smoking cessation . . . . . . . . . . . . . . . . . . 3275 Table 10 Corresponding non-high-density lipoprotein cholesterol and apolipoprotein B levels for commonly used low-density lipoprotein cholesterol goals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3275 Table 11 Dutch Lipid ClinicNetwork diagnostic criteria for familial hypercholesterolaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3281 Table 12 Categories for conventionally measured seated office blood pressurea . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3283 Table 13 Definitions of hypertension according to office, ambulatory, and home blood pressure . . . . . . . . . . . . . . . . . . . . . . . . . . . 3283 Table 14 Considerations in blood pressure measurement . . . . . . . . . 3283 Table 15 Indications for home blood pressure monitoring or ambulatory blood pressuremonitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . 3284 Table 16 Routine tests for patients with hypertension . . . . . . . . . . . . . 3285 Table 17 Patient characteristics that should raise the suspicion of secondary hypertension . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3285 Table 18 Recommended office blood pressure target ranges. The first step in all groups is a reduction to systolic blood pressure <140 mmHg . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3287\nFigures\nFigure 1 Central Illustration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3235 Figure 2 Examples of a stepwise approach to risk stratification and treatment options . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3245 Figure 3 Systematic Coronary Risk Estimation 2 and Systematic Coronary Risk Estimation 2-Older Persons risk charts for fatal and non-fatal (myocardial infarction, stroke) cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3246 Figure 4 Risk regions based on World Health Organization cardiovascular mortality rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3250 Figure 5 Schematic representation of increasing 10-year cardiovascular disease risk thresholds across age groups . . . . . . . . . . 3251 Figure 6 Flow chart of cardiovascular disease risk and risk factor treatment in apparently healthy persons . . . . . . . . . . . . . . . . . . . . . . . . . . 3252\nFigure 7 Flow chart of cardiovascular risk and risk factor treatment in patients with established atherosclerotic cardiovascular disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3253 Figure 8 Flow chart of cardiovascular risk and risk factor treatment in patients with type 2 diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . 3255 Figure 9 The role of risk factors and comorbidities in atrial fibrillation 3263 Figure 10 Estimated percentage change in risk of coronary heart disease associated with isocaloric substitutions of saturated fat for other types of fat or carbohydrates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3271 Figure 11 Lifetime atherosclerotic cardiovascular disease benefit from smoking cessation for apparently healthy persons, based on the following risk factors: age, sex, systolic blood pressure, and non-high-density lipoprotein-cholesterol . . . . . . . . . . . . . . . . . . . . . . . . . 3274 Figure 12 Average years-free-of-cardiovascular disease gained per 1 mmol/L (40 mg/dL) low-density lipoprotein cholesterol reduction in apparently healthy persons . . . . . . . . . . . . . . . . . . . . . . . . . . 3277 Figure 13 Expected low-density lipoprotein cholesterol reductions for combination therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3278 Figure 14 Screening and diagnosis of hypertension . . . . . . . . . . . . . . . . 3284 Figure 15 Lifetime benefit from lowering systolic blood pressure by 10 mmHg for apparently healthy persons, based on the following risk factors: age, sex, current smoking, systolic blood pressure, non-highdensity lipoprotein cholesterol . . . . . . . . . . . . . . . . . 3286 Figure 16 Core drug treatment strategy for hypertension . . . . . . . . . . 3287\nAbbreviations and acronyms\n% HR max Percentage of maximum heart rate ABC Atrial ﬁbrillation Better Care ABI Ankle brachial index ABPM Ambulatory blood pressure monitoring ACCORD Action to Control Cardiovascular Risk in Diabetes ACE Angiotensin-converting enzyme ACR Albumin-to-creatinine ratio ACS Acute coronary syndromes ADA American Diabetes Association ADVANCE Action in Diabetes and Vascular Disease: preterAx and diamicroN-MR Controlled Evaluation AF Atrial ﬁbrillation AMI Acute myocardial infarction ARB Angiotensin receptor blocker ARNI Angiotensin receptor neprilysin inhibitor ASCEND A Study of Cardiovascular Events in Diabetes ASCVD Atherosclerotic cardiovascular disease b.i.d. Bis in die (twice a day) BMI Body mass index BP Blood pressure b.p.m. Beats per minute CAC Coronary artery calcium CAD Coronary artery disease CANTOS Canakinumab Antiinﬂammatory Thrombosis Outcome Study CCB Calcium channel blocker CCS Chronic coronary syndromes\nESC Guidelines 3231\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ........................................................................................................................................................................... CCTA Contrast computed tomography angiography CHD Coronary heart disease CI Conﬁdence interval CKD Chronic kidney disease CKD-EPI Chronic Kidney Disease Epidemiology COLCOT Colchicine Cardiovascular Outcomes Trial COMPASS Cardiovascular Outcomes for People Using Anticoagulation Strategies COPD Chronic obstructive pulmonary disease CR Cardiac rehabilitation CTA Computed tomography angiography CV Cardiovascular CVD Cardiovascular disease DAPA-CKD Dapagliﬂozin and Prevention of Adverse Outcomes in Chronic Kidney Disease DAPT Dual antiplatelet therapy DASH Dietary Approaches to Stop Hypertension DBP Diastolic blood pressure DCCT Diabetes Control and Complications Trial DIAL Diabetes lifetime-perspective prediction DM Diabetes mellitus e-cigarettes Electronic cigarettes EAPC European Association of Preventive Cardiology EAS European Atherosclerosis Society EASD European Association for the Study of Diabetes EBCR Exercise-based cardiac rehabilitation ECG Electrocardiographic/electrocardiogram ED Erectile dysfunction eGFR Estimated glomerular ﬁltration rate EORP EURObservational Research Programme EPIC European Prospective Investigation into Cancer and Nutrition ESC European Society of Cardiology ESH European Society of Hypertension ESVS European Society for Vascular Surgery EU European Union EUROASPIRE European Action on Secondary and Primary Prevention by Intervention to Reduce Events EuroHeart European Uniﬁed Registries On Heart Care Evaluation and Randomized Trials EXPERT EXercise Prescription in Everyday practice & Rehabilitation Training FEV1 Forced expiratory volume in 1 second FH Familial hypercholesterolaemia FITT Frequency, intensity, time duration, and type of exercise GFR Glomerular ﬁltration rate GLP-1RA Glucagon-like peptide-1 receptor agonist HbA1c Glycated haemoglobin HBPM Home blood pressure monitoring HDL-C High-density lipoprotein cholesterol HF Heart failure HFpEF Heart failure with preserved ejection fraction HFrEF Heart failure with reduced ejection fraction HIV Human immunodeﬁciency virus HMOD Hypertension-mediated organ damage\nHR Hazard ratio IL Interleukin IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efﬁcacy International Trial IMT Intima-media thickness INVEST INternational VErapamil-SR/Trandolapril STudy LDL Low-density lipoprotein LDL-C Low-density lipoprotein cholesterol LDLR Low-density lipoprotein receptor LEAD Lower extremity artery disease LIFE-CVD LIFEtime-perspective CardioVascular Disease LoDoCo Low-dose colchicine LV Left ventricular/ventricle LVEF Left ventricular ejection fraction MACE Major adverse cardiovascular events MET Metabolic equivalent of task mHealth Mobile device-based healthcare MRA Mineralocorticoid receptor antagonist MUFA Monounsaturated fatty acid N/A Not applicable NAFLD Non-alcoholic fatty liver disease NRT Nicotine-replacement therapy NYHA New York Heart Association o.d. Omni die  (once a day) OARS Open-ended questions, Afﬁrmation, Reﬂecting listening, and Summarizing OR Odds ratio OSA Obstructive sleep apnoea PA Physical activity PAD Peripheral artery disease PAP Positive airway pressure PCI Percutaneous coronary intervention PCSK9 Proprotein convertase subtilisin/kexin type 9 PM Particulate matter PM 2.5 Particulate matter <2.5  m m PUFA Polyunsaturated fatty acid QI Quality indicator RAAS Renin-angiotensin-aldosterone system RAS Renin-angiotensin system RCT Randomized controlled trial REDUCE-IT Reduction of Cardiovascular Events with Icosapent Ethyl \u0002 Intervention Trial REWIND Researching Cardiovascular Events With a Weekly Incretin in Diabetes RPE Rating of perceived exertion RR Relative risk SAVOR-TIMI 53 Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction SBP Systolic blood pressure SCORE Systemic Coronary Risk Estimation SCORE2 Systemic Coronary Risk Estimation 2 SCORE2-OP Systematic Coronary Risk Estimation 2-Older Persons SCOT-HEART Scottish Computed Tomography of the Heart SGLT2 Sodium-glucose cotransporter 2\n3232 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...................................................................................................................................................................... SHARP Study of Heart and Renal Protection SMART Secondary Manifestations of Arterial Disease SMART Speciﬁc, Measurable, Achievable, Realistic, Timely SMART-REACH Secondary Manifestations of Arterial Disease-Reduction of Atherothrombosis for Continued Health SNRI Serotonin-noradrenaline reuptake inhibitor SPRINT Systolic Blood Pressure Intervention Trial SSRI Selective serotonin reuptake inhibitor STAREE STAtin Therapy for Reducing Events in the Elderly STRENGTH Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia SUPRIM Secondary Prevention in Uppsala Primary Health Care project SWITCHD Stockholm Women’s Intervention Trial for Coronary Heart Disease TIA Transient ischaemic attack TNF Tumour necrosis factor TOD Target organ damage UK United Kingdom UKPDS UK Prospective Diabetes Study VADT Veterans Affairs Diabetes Trial VITAL Vitamin D and Omega-3 Trial VO 2 Oxygen consumption WHO World Health Organization\n",
      "keywords": [
        "obesity",
        "alcohol",
        "peripheral artery",
        "cvd risk",
        "lipid",
        "hypertension",
        "introduction",
        "atherosclerosis",
        "intima-media",
        "sedentary",
        "risk stratification",
        "diabetes",
        "hfpef",
        "coronary artery",
        "electrocardiogram",
        "arb",
        "score2-op",
        "sex",
        "triglyceride",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "nyha",
        "atrial fibrillation",
        "risk factor",
        "smoking",
        "echocardiography",
        "angiography",
        "ejection fraction"
      ],
      "tables": []
    },
    {
      "number": "2",
      "title": "1. Preamble",
      "start_page": 6,
      "end_page": 7,
      "content": "Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final deci- sions concerning an individual patient must be made by the responsi- ble health professional(s) in consultation with the patient and caregiver as appropriate. A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other soci- eties and organizations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been estab- lished in order to make all decisions transparent to the user. The rec- ommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated. In addition to the publication of Clinical Practice Guidelines, the ESC carries out the EURObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to guidelines. These registries aim at\nproviding a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice. Furthermore, the ESC has developed and embedded in this docu- ment a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the guidelines and may be used by the ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes. The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a comprehensive review of the published evi- dence for management of a given condition according to ESC Clinical Practice Guidelines Committee (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was per- formed, including assessment of the risk \u0002 benefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to pre- defined scales, as outlined below. The experts of the writing and reviewing panels provided decla- ration of interest forms for all relationships that might be per- ceived as real or potential sources of conflicts of interest. Their declarations of interest were reviewed according to the ESC dec- laration of interest rules and can be found on the ESC website (http://www.escardio.org/guidelines )and have been compiled in a report and published in a supplementary document simultane- ously to the guidelines.\nThis process ensures transparency and prevents potential biases in the development and review processes. Any changes in declarations of interest that arise during the writing period were notified to the ESC and updated. The Task Force received its entire financial support from the ESC without any involvement from the healthcare industry. The ESC CPG supervises and coordinates the preparation of new guidelines. The Committee is also responsible for the endorsement process of these guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the guidelines are signed-off by all the experts involved in the Task Force. The finalized document is signed-off by the CPG for publica- tion in the European Heart Journal. The guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The task of developing ESC Guidelines also includes the creation of educational tools and implementation programmes for the recom- mendations including condensed pocket guideline versions, summary slides, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access to the full text version of the guidelines, which is freely available via the ESC website and hosted on the EHJ website. The National Cardiac Societies of the ESC are encouraged to endorse, adopt, translate and implement all ESC Guidelines. Implementation\nESC Guidelines 3233\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................ programmes are needed because it has been shown that the out- come of disease may be favourably influenced by the thorough appli- cation of clinical recommendations. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient or the patient’s caregiver where appropriate and/or\nnecessary. It is also the health professional’s responsibility to verify the rules and regulations applicable in each country to drugs and devi- ces at the time of prescription.\n",
      "keywords": [
        "guideline",
        "preamble"
      ],
      "tables": [
        {
          "title": "3234 ESC Guidelines",
          "page_number": 7,
          "content": "Class I | Evidence and/or general agreement\nthat a given treatment or procedure is | Is recommended or is indicated",
          "bbox": [
            120.30909729003906,
            104.78900146484375,
            490.67011108398435,
            158.260986328125
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3234 ESC Guidelines",
          "page_number": 7,
          "content": "Class II |  |  | \n |  |  | \nClass IIa | Weight o | f evidence/opinion is in | Should be considered\n |  |  | \nClass IIb | establish | ed by evidence/opinion. | May be considered",
          "bbox": [
            120.30909729003906,
            164.42095947265625,
            490.67011108398435,
            266.38572692871094
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3234 ESC Guidelines",
          "page_number": 7,
          "content": "Class III | Evidence or general agreement that the\ngiven treatment or procedure is not\nuseful/effective, and in some cases\nmay be harmful. | Is not recommended",
          "bbox": [
            120.30909729003906,
            272.1669921875,
            490.67011108398435,
            325.2679748535156
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "3",
      "title": "2. Introduction",
      "start_page": 7,
      "end_page": 9,
      "content": "Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are declining in many countries in Europe, but it is still a major cause of morbidity and mortality. Over the past few deca- des, major ASCVD risk factors have been identified. The most\nTable 2 Levels of evidence\nLevel of  evidence A Data derived from multiple randomized clinical trials  or meta-analyses.\nLevel of  evidence B Data derived from a single randomized clinical trial or large non-randomized studies.\nLevel of  evidence C Consensus of opinion of the experts and/or small studies,  retrospective studies, registries.\n©ESC 2021\nTable 1 Classes of recommendations\n©ESC 2021\nClasses of recommendations\nClass I  Evidence and/or general agreement  that a given treatment or procedure is\nIs recommended or is indicated\nWording to use\nClass III  Evidence or general agreement that the  given treatment or procedure is not  useful/effective, and in some cases  may be harmful .\nIs not recommended\nClass IIb\nestablished by evidence/opinion. May be considered\nClass IIa Weight of evidence/opinion is in  Should be considered\nClass II\n3234 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................ important way to prevent ASCVD is to promote a healthy lifestyle throughout life, especially not smoking. Effective and safe risk factor treatments have been developed, and most drugs are now generic and available at low costs. Nevertheless, the prevalence of unhealthy lifestyle is still high, and ASCVD risk factors are often poorly treated, even in patients considered to be at high (residual) CVD risk. 1\nPrevention of CV events by reducing CVD risk is the topic of these guidelines.\n2.1. Definition and rationale The present guidelines have been developed to support healthcare professionals in their efforts to reduce the burden of ASCVD in both individual patients, as well as at a population level. The previous European Guidelines on CVD prevention in clinical practice were published in 2016. 2 Recent developments in prediction of\ncardiovascular disease ( CVD) risk and treatment benefit, as well as novel treatments and treatment goals, necessitated new, up-to-date guidelines. The current guidelines on CVD prevention in clinical prac- tice concentrate principally but not exclusively on the risk factors, risk classification, and prevention of ASCVD. The current guidelines provide recommendations on ASCVD pre- vention to support shared decision-making by the patient and their healthcare professional based on individual patient characteristics. Special considerations have been given to differences in age, sex and gender, life expectancy, risk factor profiles, ethnic, and geographic dif- ferences. Estimating CVD risk not only in apparently healthy subjects, but also in older persons and in patients with established ASCVD or diabetes mellitus (DM), provides information for tailored interven- tion on an individual level. Treatment goals can be individualized in a stepwise approach. ‘Residual’ CVD risk is defined as the risk\nPrevention goals for all\nReduction of CVD burden\nAbout CVD (lifetime) risk and treatment benefits tailored to individual needs and preferences considering age, comorbidities, frailty, polypharmacy\nInformed discussion\nDiabetes mellitus, CKD, Familial Hypercholesterolaemia\nSpecific risk conditions\nResidual CVD risk\nPatients with established ASCVD\n10-year CVD risk\nApparently healthy people\nCVD risk estimation\nIndividual-level interventions and treatment goals\nLifestyle (physical activity, body weight, nutrition) Psychosocial factors Risk factor treatment (smoking, lipids, blood pressure, diabetes) Anti-thrombotic therapy Disease-specific interventions\nCost-effectiveness considerations\nRisk modifiers\nComorbidity e.g. cancer, COPD, inflammatory disease, mental disorders, sex-specific conditions\nPsychosocial stress Ethnicity Imaging (e.g. coronary calcium scoring)\nPopulation-level interventions\nPublic health policy and advocacy Specific risk factor interventions at the population level (physical activity, diet, alcohol, smoking) Environment, air pollution, climate change\nPersonalized treatment decisions\nFigure 1  Central Illustration. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular disease\nESC Guidelines 3235\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ estimated after initial lifestyle changes and risk factor treatment, and is mostly used in patients with established ASCVD. For younger apparently healthy subjects, lifetime CVD risk estimates are available to support treatment decisions, replacing 10-year risk algorithms that consistently estimate low 10-year risk even in the presence of high risk factor levels. In an ageing population, treatment decisions require a specific CVD risk score that takes competing non-CVD risk into account, as well as specific low-density lipoprotein cholesterol (LDL- C) and blood pressure (BP) treatment considerations. Estimating lifetime benefit in individual patients of smoking cessation, LDL-C lowering, and BP lowering provides opportunities to communicate benefit of treatment in an easy-to-understand way. Personalized treatment decisions using CVD risk estimations and a stepwise approach to treatment is more complex than a more general one- size-fits-all prevention strategy, but reflects the diversity in patients and patient characteristics in clinical practice. Regarding LDL-C, BP, and glycaemic control in patients with DM, goals and targets remain as recommended in recent European Society of Cardiology (ESC) Guidelines. 3 \u0002 5   These prevention g uidelines propose a new, stepwise approach to treatment intensifi- cation as a tool to help physicians and patients pursue these targets in a way that fits patient profile and preferences. Of note, however, new evidence and/or new consensus may have resulted in some differen- ces with these recent domain-specific ESC Guidelines. New evidence on antithrombotic treatment regimens for ASCVD prevention is also presented. Sex-specific aspects are included. ASCVD prevention needs an integrated, interdisciplinary approach including input from several disciplines and areas of expertise. We must work together in a patient- and family-centred way to address each of the core components of prevention and rehabilitation, includ- ing lifestyle modification, psychosocial factors, risk factor treatment, and social determinants ( Central Illustration ).\n2.2. Development The Task Force chairs and members were appointed by the ESC Clinical Practice Guidelines Committee (CPG). Each member of the Task Force was assigned specific writing tasks, which were reviewed by other (sub)section writers, the section coordinators, and the chairs. The text was developed over 11 months, during which the Task Force members met collectively on three occa- sions and corresponded intensively between meetings. The review panel consisted of experts selected by all the scientific societies that were involved in the development of these guide- lines, not only the ESC.\n2.3. Cost-effectiveness The Task Force acknowledge the fact that healthcare budgets are, in many circumstances, limited and thus that certain recommendations and goals may not always be attainable. However, the current guide- lines do not provide cost-effectiveness analyses. Large national and regional differences in budgets and costs associated with both inter- ventions and diseases/events preclude valid universal cost- effectiveness analyses. However, some recommendations clearly have financial implications, either in terms of costs for individual patients and/or in terms of budget impact. Some of these recommen- dations pertain to diagnosis (e.g. large-scale use of expensive imaging tests such as computed tomography), others to interventions (e.g.\nexpensive drugs, such as novel lipid-lowering or anti-diabetic drugs). For such recommendations, it is inappropriate to ‘unconditionally’ implement them without first considering cost-effectiveness in a national or regional context or, ideally, to perform formal cost- effectiveness analyses with country-specific input parameters and cost-effectiveness thresholds.\n2.4. What is new? New recommendations, and new and revised concepts, are pre- sented in  Table  3 .\n",
      "keywords": [
        "alcohol",
        "cvd risk",
        "10-year risk",
        "lipid",
        "introduction",
        "class i",
        "diabetes",
        "sex",
        "ascvd",
        "smoking",
        "recommended",
        "risk factor",
        "may be considered",
        "diet",
        "diabetic",
        "physical activity",
        "risk estimation",
        "ethnicity",
        "gender",
        "cholesterol",
        "class ii",
        "ldl-c",
        "older",
        "blood pressure",
        "lipoprotein",
        "class iii",
        "should be considered",
        "ethnic",
        "weight",
        "age"
      ],
      "tables": []
    },
    {
      "number": "4",
      "title": "3. Risk factors and clinical conditions",
      "start_page": 9,
      "end_page": 14,
      "content": "3.1. Target population for assessing cardiovascular disease risk CVD risk assessment or screening can be done opportunistically or systematically. Opportunistic screening, which means screening with- out a predefined strategy, is done when a person presents for some other reason. Systematic screening can be done in the general popu- lation as part of a formal screening programme, with call and recall of patients, or in targeted subpopulations such as subjects with type 2 DM, or family history of premature CVD. Systematic screening results in improvements in risk factors, but has no effect on CVD out- comes. 6 \u0002 9   Opportunistic screening for ASCVD risk factors, such as BP or lipids, is effective at increasing detection rates and is recom- mended, although a beneficial effect on clinical outcome is uncertain. 10\nStructured national programmes aiming to identify undocumented ASCVD risk factors in adults over 40 years of age without DM or ASCVD and treat them have shown better risk factor control, but there are conflicting results as to clinical outcomes. 11 , 12   A high-risk strategy of inviting the population predicted to be at the highest risk according to an integrated risk score would be equally effective at preventing new cases of CVD and have potential cost savings. 13   One large trial of mobile ultrasound screening for aortic aneurysm, periph- eral artery disease (PAD), and hypertension in males aged 65 \u0002 74 years showed a 7% mortality reduction at 5 years. 14\nA common criticism of screening in general is the potential that false positive and false negative results may cause harm. However, evidence on CVD screening shows that those who participate do not report mental distress. 15 \u0002 18\nSystematic CVD risk assessment assessment in the general popula- tion (adult men >40 and women >50 years of age) with no known CV risk factors appears not cost-effective in reducing subsequent vas- cular events and premature death, at least in short-term follow-up, but does increase detection of CV risk factors. Risk assessment is not a one-time event; it should be repeated, for example, every 5 years, although there are no empirical data to guide intervals.\n3.2. Risk factors and risk classification 3.2.1. Risk factors The main causal and modifiable ASCVD risk factors are blood apolipoprotein-B-containing lipoproteins [of which low-density lipo- protein (LDL) is most abundant], high BP, cigarette smoking, and DM.\n3236 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nTable 3 What is new\nNew or revised Recommendations in 2013 version Class Recommendations in 2021 version Class\nRisk factors and clinical conditions  \u0002  section 3\nNew In apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation\nof 10-year fatal and nonfatal CVD risk with SCORE2 is\nrecommended.\nI\nNew In apparently healthy people >_70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estimation\nof 10-year fatal and nonfatal CVD risk with SCORE2-OP is\nrecommended.\nI\nNew Patients with established ASCVD and/or DM and/or moderate-\nto-severe renal disease and/or genetic/rarer lipid or BP disorders\nare to be considered at high or very high CVD risk.\nI\nNew A stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is recommended for apparently healthy peo-\nple at high or very high ASCVD risk, as well as patients with estab-\nlished ASCVD and/or DM, with consideration of CVD risk, treatment beneﬁt of risk factors, risk modiﬁers, comorbidities,\nand patient preferences.\nI\nNew Treatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid or BP disor-\nders who are at very high CVD risk (SCORE2 >_7.5% for age\nunder 50; SCORE2 >_10% for age 50 \u0002 69; SCORE2-OP >_15% for age >_70).\nI\nNew An informed discussion about CVD risk and treatment beneﬁts\ntailored to the needs of a patient is recommended. I\nNew It is recommended that mental disorders with either signiﬁcant functional impairment or decreased use of healthcare systems be\nconsidered as inﬂuencing\nI\nNew Treatment of ASCVD risk factors should be considered in appa-\nrently healthy people without DM, CKD, genetic/rarer lipid, or BP disorders who are at high CVD risk (SCORE2 2.5 to <7.5% for\nage under 50; SCORE2 5 to <10% for age 50 \u0002 69; SCORE2-OP\n7.5 to <15% for age >_70 years), taking ASCVD risk modiﬁers, life- time risk and treatment beneﬁt, and patient preferences into\naccount.\nIIa\nNew In apparently healthy people, after estimation of 10-year fatal and non-fatal CVD risk, lifetime risk and treatment beneﬁt, risk modi-\nﬁers, frailty, polypharmacy, and patient preferences should be\nconsidered.\nIIa\nNew Presence of migraine with aura should be considered in CVD risk assessment. IIa\nNew Assessment of CVD risk should be considered in men with ED. IIa\nNew In women with a history of premature or stillbirth, periodic\nscreening for hypertension and DM may be considered. IIb\nNew Assessment of total CVD risk may be considered in adults with\nchronic inﬂammatory conditions. IIb\nNew Avoidance of combined hormonal contraceptives may be consid-\nered in women with migraine with aura. IIb\nRisk factors and interventions at the individual level  \u0002  section 4\nNew It is recommended to reduce sedentary time to engage in at least\nlight activity throughout the day to reduce all-cause and CV mor-\ntality and morbidity.\nI\nContinued\nESC Guidelines 3237\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nTable 3 Continued\nNew or revised Recommendations in 2013 version Class Recommendations in 2021 version Class\nNew It is recommended to adopt a Mediterranean or similar diet to\nlower risk of CVD. I\nNew It is recommended to restrict alcohol consumption to a maximum\nof 100 g per week. I\nNew It is recommended to eat ﬁsh, preferably fatty, at least once a\nweek and restrict (processed) meat. I\nNew Patients with mental disorders need intensiﬁed attention and sup-\nport to improve adherence to lifestyle changes and drug treatment.\nI\nNew Smoking cessation is recommended regardless of weight gain, as\nweight gain does not lessen the ASCVD beneﬁts of cessation. I\nNew In patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50%\nreduction of LDL-C vs. baseline is recommended.\nI\nNew For secondary prevention patients not achieving their goals on a maximum tolerated dose of a statin and ezetimibe, combination\ntherapy including a PCSK9 inhibitor is recommended.\nI\nNew In patients with type 2 DM at very high risk (e.g. with established\nASCVD and/or severe TOD), intensive lipid-lowering therapy, ultimately aiming at >_50% LDL-C reduction and an LDL-C of <1.4\nmmol/L (<55 mg/dL) is recommended.\nI\nNew In patients with type 2 DM >40 years of age at high risk, lipid-low- ering treatment with an ultimate LDL-C goal of >_50% LDL-C\nreduction and an LDL-C of <1.8 mmol/L (70 mg/dL) is\nrecommended.\nI\nNew It is recommended that the ﬁrst objective of treatment is to lower BP to <140/90 mmHg in all patients, and that subsequent BP tar-\ngets are tailored to age and speciﬁc comorbidities.\nI\nNew In treated patients aged 18 \u0002 69 years, it is recommended that SBP should ultimately be lowered to a target range of 120 \u0002 130\nmmHg in most patients.\nI\nNew In treated patients aged >_70 years, it is recommended that SBP\nshould generally be targeted to <140 and down to 130 mmHg if tolerated.\nI\nNew In all treated patients, DBP is recommended to be lowered to\n<80 mmHg. I\nNew In persons with type 2 DM and ASCVD, the use of a GLP-1RA or SGLT2 inhibitor with proven outcome beneﬁts is recommended\nto reduce CV and/or cardiorenal outcomes.\nI\nNew In patients with type 2 DM and CKD, the use of an SGLT2 inhibi- tor is recommended to improve CVD and/or cardiorenal\noutcomes.\nI\nNew In patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor\nwith proven outcome beneﬁts is recommended to lessen HF hos- pitalizations and CV death.\nI\nNew Participation in a medically supervised, structured, comprehen-\nsive, multidisciplinary EBCR and prevention programme for patients after ASCVD events and/or revascularization, and for\npatients with HF (mainly HFrEF), is recommended to improve\npatient outcomes.\nI\nContinued\n3238 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nTable 3 Continued\nNew or revised Recommendations in 2013 version Class Recommendations in 2021 version Class\nNew Lifestyle interventions, such as group or individual education,\nbehaviour-change techniques, telephone counselling, and use of\nconsumer-based wearable activity trackers, should be considered to increase PA participation.\nIIa\nNew Bariatric surgery for obese high-risk individuals should be consid-\nered when lifestyle change does not result in maintained weight\nloss.\nIIa\nNew ASCVD patients with stress should be considered for referral to\npsychotherapeutic stress management to improve CVD out-\ncomes and reduce stress symptoms.\nIIa\nNew Patients with CHD and moderate-to-severe major depression should be considered for antidepressive treatment with an SSRI. IIa\nNew An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and LDL-C\nreduction of >_50% from baseline should be considered in appa- rently healthy persons <70 years at very high risk.\nIIa\nNew An ultimate LDL-C goal of <1.8 mmol/L (70 mg/dL) and LDL-C\nreduction of >_50% from baseline should be considered in appa-\nrently healthy persons <70 years at high risk.\nIIa\nNew For those motivated to try, considerable weight loss with use of\nlow-calorie diets followed by food reintroduction and weight-\nmaintenance phases early after diagnosis can lead to DM remis- sion and should be considered.\nIIa\nNew In patients with type 2 DM and TOD, the use of an SGLT2 inhibi-\ntor or GLP-1RA with proven outcome beneﬁts may be consid-\nered to reduce future CVD and total mortality.\nIIb\nNew For primary prevention patients at very high risk, but without FH,\nif the LDL-C goal is not achieved on a maximum tolerated dose of\na statin and ezetimibe, combination therapy including a PCSK9 inhibitor may be considered.\nIIb\nNew In high-risk (or above) patients with triglycerides >1.5 mmol/L\n(135 mg/dL) despite statin treatment and lifestyle measures, n-3\nPUFAs (icosapent ethyl 2 X 2 g/day) may be considered in combi- nation with a statin.\nIIb\nNew Initiation of statin treatment for primary prevention in older peo-\nple aged >_70 may be considered, if at high risk or above. IIb\nNew Statin therapy may be considered in persons aged <_40 years with type 1 or type 2 DM with evidence of TOD and/or an LDL-C\nlevel >2.6 mmol/L (100 mg/dL), as long as pregnancy is not being planned.\nIIb\nNew In patients with DM at high or very high CVD risk, low-dose\naspirin may be considered for primary prevention in the absence\nof clear contraindications.\nIIb\nNew Home-based CR, telehealth, and mHealth interventions may be\nconsidered to increase patient participation and long-term adher-\nence to healthy behaviours.\nIIb\nNew In patients with HF and major depression, SSRIs, SNRIs, and tricy- clic antidepressants are not recommended. III\nNew In patients with dialysis-dependent CKD who are free of ASCVD,\ncommencing statin therapy is not recommended. III\nContinued\nESC Guidelines 3239\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nTable 3 Continued\nNew or revised Recommendations in 2013 version Class Recommendations in 2021 version Class\nPolicy interventions at the population level  \u0002  section 5\nNew Putting in place measures to reduce air pollution, including reduc-\ning PM emission and gaseous pollutants, reducing the use of fossil\nfuels, and limiting carbon dioxide emissions, are recommended to reduce CVD mortality and morbidity.\nI\nRisk management of disease-speciﬁc cardiovascular disease  \u0002  section 6\nNew It is recommended that patients with HF are enrolled in a com-\nprehensive CR programme to reduce the risk of HF hospitaliza- tion and death.\nI\nNew It is recommended to screen patients with HF for both CV and\nnon-CV comorbidities which, if present, should be treated, pro- vided safe and effective interventions exist, not only to alleviate\nsymptoms but also to improve prognosis.\nI\nNew In patients with a cerebrovascular event, improvement of lifestyle\nfactors in addition to appropriate pharmacological management is recommended.\nI\nNew Identiﬁcation and management of risk factors and concomitant\ndiseases are recommended to be an integral part of treatment in patients with AF.\nI\nNew Adding a second antithrombotic drug (a P2Y 12  inhibitor or low-\ndose rivaroxaban) to aspirin for long-term secondary prevention\nshould be considered in patients with a high risk of ischaemic events and without high bleeding risk.\nIIa\nNew In patients with DM and chronic symptomatic LEAD without high\nbleeding risk, a combination of low-dose rivaroxaban (2.5 mg b.i.d.) and aspirin (100 mg o.d.) may be considered.\nIIb\nAdding a second antithrombotic drug to aspirin for long-term sec-\nondary prevention may be considered in patients with a moderate\nrisk of ischaemic events and without a high bleeding risk.\nIIb\nRisk factors and clinical conditions  \u0002  section 3\nRevised ABI may be considered as a risk modiﬁer in\nCVD risk assessment. IIb\nThe routine collection of other potential modiﬁers, such as\ngenetic risk scores, circulating or urinary biomarkers, or vascular\ntests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended.\nIII\nRisk factors and interventions at the individual level  \u0002  section 4\nRevised Drug treatment should be considered in\npatients with grade 1 or 2 hypertension who are at high CVD risk.\nIIa For grade 1 hypertension, treatment initiation based on absolute\nCVD risk, estimated lifetime beneﬁt, and the presence of HMOD is recommended.\nI\nRevised In patients with type 2 DM and CVD, use\nof an SGLT2 inhibitor should be consid- ered early in the course of the disease to\nreduce CVD and total mortality.\nIIa\nIn persons with type 2 DM and ASCVD, the use of a GLP-1RA or\nSGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce CV and/or cardiorenal outcomes. I\nABI = ankle brachial index; AF = atrial ﬁbrillation; ASCVD = atherosclerotic cardiovascular disease;  b.i.d . =  bis in die  (twice a day); BP = blood pressure; CAC = coronary artery calcium; CHD = coronary heart disease; CKD = chronic kidney disease; CR = cardiac rehabilitation; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes melli- tus; EBCR = exercise-based cardiac rehabilitation; ED = erectile dysfunction; FH = familial hypercholesterolaemia; GLP-1RA = glucagon-like peptide-1 receptor agonist; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HMOD = hypertension-mediated organ damage; LDL-C = low-density lipoprotein cholesterol; LEAD = lower extremity artery disease; mHealth = mobile device-based healthcare;  o.d . =  omni die  (once a day); PA = physical activity; PCSK9 = proprotein convertase subtilisin/kexin type 9; PM = particulate matter; PUFA = polyunsaturated fatty acid; SBP = systolic blood pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons; SGLT2 = sodium-glucose cotransporter 2; SNRI = serotonin-noradrenaline reuptake inhibitor; SSRI = selective seroto- nin reuptake inhibitor; TOD = target organ damage.\nESC 2021\n3240 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nNew sections\nSection 3 3.2.2 Sex and gender and their impact on health\n3.2.3 Atherosclerotic cardiovascular disease risk classiﬁcation\n3.2.3.1 A stepwise approach to risk factor treatment and treatment intensiﬁcation 3.2.3.2 Risk estimation in apparently healthy people\n3.2.3.3 Translating atherosclerotic cardiovascular disease risk to treatment thresholds\n3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 50 \u0002 69 years of age 3.2.3.5 Risk estimation and risk factor treatment estimation in apparently healthy people >_70 years of age\n3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people <50 years of age\n3.2.3.7 Risk estimation and risk factor treatment in patients with established atherosclerotic cardiovascular disease 3.2.4 Communication of cardiovascular disease risk\n3.3.1 Psychosocial factors\n3.3.4 Frailty 3.3.8 Environmental exposure\n",
      "keywords": [
        "alcohol",
        "clinical",
        "cvd risk",
        "lipid",
        "hypertension",
        "aneurysm",
        "genetic",
        "sedentary",
        "diabetes",
        "coronary artery",
        "sex",
        "score2-op",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "ejection fraction",
        "may be considered",
        "diet",
        "pcsk9",
        "heart failure",
        "conditions",
        "physical activity",
        "risk estimation",
        "gender",
        "score2",
        "sglt2"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3237",
          "page_number": 10,
          "content": "New or\nrevised |  | Recommendations in 2013 version |  | Class | Recommendations in 2021 version |  | Class\nRisk factors and clinical conditions \u0002 section 3 |  |  |  |  |  |  | \nNew |  |  |  |  | In apparently healthy people <70 years of age without established\nASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation\nof 10-year fatal and nonfatal CVD risk with SCORE2 is\nrecommended. |  | I\nNew |  |  |  |  | In apparently healthy people >70 years of age without established\n_\nASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estimation\nof 10-year fatal and nonfatal CVD risk with SCORE2-OP is\nrecommended. |  | I\nNew |  |  |  |  | Patients with established ASCVD and/or DM and/or moderate-\nto-severe renal disease and/or genetic/rarer lipid or BP disorders\nare to be considered at high or very high CVD risk. |  | I\nNew |  |  |  |  | A stepwise treatment-intensification approach aiming at intensive\nrisk factor treatment is recommended for apparently healthy peo-\nple at high or very high ASCVD risk, as well as patients with estab-\nlished ASCVD and/or DM, with consideration of CVD risk,\ntreatment benefit of risk factors, risk modifiers, comorbidities,\nand patient preferences. |  | I\nNew |  |  |  |  | Treatment of ASCVD risk factors is recommended in apparently\nhealthy people without DM, CKD, genetic/rarer lipid or BP disor-\nders who are at very high CVD risk (SCORE2 >7.5% for age\n_\nunder 50; SCORE2 >10% for age 50\u000269; SCORE2-OP >15% for\n_ _\nage >70).\n_ |  | I\nNew |  |  |  |  | An informed discussion about CVD risk and treatment benefits\ntailored to the needs of a patient is recommended. |  | I\nNew |  |  |  |  | It is recommended that mental disorders with either significant\nfunctional impairment or decreased use of healthcare systems be\nconsidered as influencing |  | I\nNew |  |  |  |  | Treatment of ASCVD risk factors should be considered in appa-\nrently healthy people without DM, CKD, genetic/rarer lipid, or BP\ndisorders who are at high CVD risk (SCORE2 2.5 to <7.5% for\nage under 50; SCORE2 5 to <10% for age 50\u000269; SCORE2-OP\n7.5 to <15% for age >70 years), taking ASCVD risk modifiers, life-\n_\ntime risk and treatment benefit, and patient preferences into\naccount. |  | IIa\nNew |  |  |  |  | In apparently healthy people, after estimation of 10-year fatal and\nnon-fatal CVD risk, lifetime risk and treatment benefit, risk modi-\nfiers, frailty, polypharmacy, and patient preferences should be\nconsidered. |  | IIa\nNew |  |  |  |  | Presence of migraine with aura should be considered in CVD risk\nassessment. |  | IIa\nNew |  |  |  |  | Assessment of CVD risk should be considered in men with ED. |  | IIa\nNew |  |  |  |  | In women with a history of premature or stillbirth, periodic\nscreening for hypertension and DM may be considered. |  | IIb\nNew |  |  |  |  | Assessment of total CVD risk may be considered in adults with\nchronic inflammatory conditions. |  | IIb\nNew |  |  |  |  | Avoidance of combined hormonal contraceptives may be consid-\nered in women with migraine with aura. |  | IIb\nRisk factors and interventions at the individual level \u0002 section 4 |  |  |  |  |  |  | \nNew |  |  |  |  | It is recommended to reduce sedentary time to engage in at least\nlight activity throughout the day to reduce all-cause and CV mor-\ntality and morbidity. |  | I",
          "bbox": [
            49.904033367450424,
            81.77099609375,
            554.2628735351562,
            746.692372639974
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3238 ESC Guidelines",
          "page_number": 11,
          "content": "New or\nrevised |  | Recommendations in 2013 version |  | Class | Recommendations in 2021 version |  | Class\nNew |  |  |  |  | It is recommended to adopt a Mediterranean or similar diet to\nlower risk of CVD. |  | I\nNew |  |  |  |  | It is recommended to restrict alcohol consumption to a maximum\nof 100 g per week. |  | I\nNew |  |  |  |  | It is recommended to eat fish, preferably fatty, at least once a\nweek and restrict (processed) meat. |  | I\nNew |  |  |  |  | Patients with mental disorders need intensified attention and sup-\nport to improve adherence to lifestyle changes and drug\ntreatment. |  | I\nNew |  |  |  |  | Smoking cessation is recommended regardless of weight gain, as\nweight gain does not lessen the ASCVD benefits of cessation. |  | I\nNew |  |  |  |  | In patients with established ASCVD, lipid-lowering treatment with\nan ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >50%\n_\nreduction of LDL-C vs. baseline is recommended. |  | I\nNew |  |  |  |  | For secondary prevention patients not achieving their goals on a\nmaximum tolerated dose of a statin and ezetimibe, combination\ntherapy including a PCSK9 inhibitor is recommended. |  | I\nNew |  |  |  |  | In patients with type 2 DM at very high risk (e.g. with established\nASCVD and/or severe TOD), intensive lipid-lowering therapy,\nultimately aiming at >50% LDL-C reduction and an LDL-C of <1.4\n_\nmmol/L (<55 mg/dL) is recommended. |  | I\nNew |  |  |  |  | In patients with type 2 DM >40 years of age at high risk, lipid-low-\nering treatment with an ultimate LDL-C goal of >50% LDL-C\n_\nreduction and an LDL-C of <1.8 mmol/L (70 mg/dL) is\nrecommended. |  | I\nNew |  |  |  |  | It is recommended that the first objective of treatment is to lower\nBP to <140/90 mmHg in all patients, and that subsequent BP tar-\ngets are tailored to age and specific comorbidities. |  | I\nNew |  |  |  |  | In treated patients aged 18\u000269 years, it is recommended that SBP\nshould ultimately be lowered to a target range of 120\u0002130\nmmHg in most patients. |  | I\nNew |  |  |  |  | In treated patients aged >70 years, it is recommended that SBP\n_\nshould generally be targeted to <140 and down to 130 mmHg if\ntolerated. |  | I\nNew |  |  |  |  | In all treated patients, DBP is recommended to be lowered to\n<80 mmHg. |  | I\nNew |  |  |  |  | In persons with type 2 DM and ASCVD, the use of a GLP-1RA or\nSGLT2 inhibitor with proven outcome benefits is recommended\nto reduce CV and/or cardiorenal outcomes. |  | I\nNew |  |  |  |  | In patients with type 2 DM and CKD, the use of an SGLT2 inhibi-\ntor is recommended to improve CVD and/or cardiorenal\noutcomes. |  | I\nNew |  |  |  |  | In patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor\nwith proven outcome benefits is recommended to lessen HF hos-\npitalizations and CV death. |  | I\nNew |  |  |  |  | Participation in a medically supervised, structured, comprehen-\nsive, multidisciplinary EBCR and prevention programme for\npatients after ASCVD events and/or revascularization, and for\npatients with HF (mainly HFrEF), is recommended to improve\npatient outcomes. |  | I",
          "bbox": [
            45.36403783162435,
            81.77099609375,
            549.7233694571036,
            722.0962439643013
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3239",
          "page_number": 12,
          "content": "New or\nrevised |  | Recommendations in 2013 version |  | Class | Recommendations in 2021 version |  | Class\nNew |  |  |  |  | Lifestyle interventions, such as group or individual education,\nbehaviour-change techniques, telephone counselling, and use of\nconsumer-based wearable activity trackers, should be considered\nto increase PA participation. |  | IIa\nNew |  |  |  |  | Bariatric surgery for obese high-risk individuals should be consid-\nered when lifestyle change does not result in maintained weight\nloss. |  | IIa\nNew |  |  |  |  | ASCVD patients with stress should be considered for referral to\npsychotherapeutic stress management to improve CVD out-\ncomes and reduce stress symptoms. |  | IIa\nNew |  |  |  |  | Patients with CHD and moderate-to-severe major depression\nshould be considered for antidepressive treatment with an SSRI. |  | IIa\nNew |  |  |  |  | An ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and LDL-C\nreduction of >50% from baseline should be considered in appa-\n_\nrently healthy persons <70 years at very high risk. |  | IIa\nNew |  |  |  |  | An ultimate LDL-C goal of <1.8 mmol/L (70 mg/dL) and LDL-C\nreduction of >50% from baseline should be considered in appa-\n_\nrently healthy persons <70 years at high risk. |  | IIa\nNew |  |  |  |  | For those motivated to try, considerable weight loss with use of\nlow-calorie diets followed by food reintroduction and weight-\nmaintenance phases early after diagnosis can lead to DM remis-\nsion and should be considered. |  | IIa\nNew |  |  |  |  | In patients with type 2 DM and TOD, the use of an SGLT2 inhibi-\ntor or GLP-1RA with proven outcome benefits may be consid-\nered to reduce future CVD and total mortality. |  | IIb\nNew |  |  |  |  | For primary prevention patients at very high risk, but without FH,\nif the LDL-C goal is not achieved on a maximum tolerated dose of\na statin and ezetimibe, combination therapy including a PCSK9\ninhibitor may be considered. |  | IIb\nNew |  |  |  |  | In high-risk (or above) patients with triglycerides >1.5 mmol/L\n(135 mg/dL) despite statin treatment and lifestyle measures, n-3\nPUFAs (icosapent ethyl 2 X 2 g/day) may be considered in combi-\nnation with a statin. |  | IIb\nNew |  |  |  |  | Initiation of statin treatment for primary prevention in older peo-\nple aged >70 may be considered, if at high risk or above.\n_ |  | IIb\nNew |  |  |  |  | Statin therapy may be considered in persons aged <40 years with\n_\ntype 1 or type 2 DM with evidence of TOD and/or an LDL-C\nlevel >2.6 mmol/L (100 mg/dL), as long as pregnancy is not being\nplanned. |  | IIb\nNew |  |  |  |  | In patients with DM at high or very high CVD risk, low-dose\naspirin may be considered for primary prevention in the absence\nof clear contraindications. |  | IIb\nNew |  |  |  |  | Home-based CR, telehealth, and mHealth interventions may be\nconsidered to increase patient participation and long-term adher-\nence to healthy behaviours. |  | IIb\nNew |  |  |  |  | In patients with HF and major depression, SSRIs, SNRIs, and tricy-\nclic antidepressants are not recommended. |  | III\nNew |  |  |  |  | In patients with dialysis-dependent CKD who are free of ASCVD,\ncommencing statin therapy is not recommended. |  | III",
          "bbox": [
            49.9000358581543,
            81.77099609375,
            554.2586963129978,
            708.886221991645
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3240 ESC Guidelines",
          "page_number": 13,
          "content": "New or\nrevised |  | Recommendations in 2013 version |  | Class | Recommendations in 2021 version |  | Class | ESC 2021\nPolicy interventions at the population level \u0002 section 5 |  |  |  |  |  |  |  | \nNew |  |  |  |  | Putting in place measures to reduce air pollution, including reduc-\ning PM emission and gaseous pollutants, reducing the use of fossil\nfuels, and limiting carbon dioxide emissions, are recommended to\nreduce CVD mortality and morbidity. |  | I | \nRisk management of disease-specific cardiovascular disease \u0002 section 6 |  |  |  |  |  |  |  | \nNew |  |  |  |  | It is recommended that patients with HF are enrolled in a com-\nprehensive CR programme to reduce the risk of HF hospitaliza-\ntion and death. |  | I | \nNew |  |  |  |  | It is recommended to screen patients with HF for both CV and\nnon-CV comorbidities which, if present, should be treated, pro-\nvided safe and effective interventions exist, not only to alleviate\nsymptoms but also to improve prognosis. |  | I | \nNew |  |  |  |  | In patients with a cerebrovascular event, improvement of lifestyle\nfactors in addition to appropriate pharmacological management is\nrecommended. |  | I | \nNew |  |  |  |  | Identification and management of risk factors and concomitant\ndiseases are recommended to be an integral part of treatment in\npatients with AF. |  | I | \nNew |  |  |  |  | Adding a second antithrombotic drug (a P2Y inhibitor or low-\n12\ndose rivaroxaban) to aspirin for long-term secondary prevention\nshould be considered in patients with a high risk of ischaemic\nevents and without high bleeding risk. |  | IIa | \nNew |  |  |  |  | In patients with DM and chronic symptomatic LEAD without high\nbleeding risk, a combination of low-dose rivaroxaban (2.5 mg\nb.i.d.) and aspirin (100 mg o.d.) may be considered. |  | IIb | \n |  |  |  |  | Adding a second antithrombotic drug to aspirin for long-term sec-\nondary prevention may be considered in patients with a moderate\nrisk of ischaemic events and without a high bleeding risk. |  | IIb | \nRisk factors and clinical conditions \u0002 section 3 |  |  |  |  |  |  |  | \nRevised |  | ABI may be considered as a risk modifier in\nCVD risk assessment. |  | IIb | The routine collection of other potential modifiers, such as\ngenetic risk scores, circulating or urinary biomarkers, or vascular\ntests or imaging methods (other than CAC scoring or carotid\nultrasound for plaque determination), is not recommended. |  | III | \nRisk factors and interventions at the individual level \u0002 section 4 |  |  |  |  |  |  |  | \nRevised |  | Drug treatment should be considered in\npatients with grade 1 or 2 hypertension\nwho are at high CVD risk. |  | IIa | For grade 1 hypertension, treatment initiation based on absolute\nCVD risk, estimated lifetime benefit, and the presence of HMOD\nis recommended. |  | I | \nRevised |  | In patients with type 2 DM and CVD, use\nof an SGLT2 inhibitor should be consid-\nered early in the course of the disease to\nreduce CVD and total mortality. |  | IIa | In persons with type 2 DM and ASCVD, the use of a GLP-1RA or\nSGLT2 inhibitor with proven outcome benefits is recommended\nto reduce CV and/or cardiorenal outcomes. |  | I | ",
          "bbox": [
            45.37348695234819,
            81.77099609375,
            554.9690551757812,
            623.7350387573242
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3241",
          "page_number": 14,
          "content": "New sections | ESC 2021\nSection 3\n3.2.2 Sex and gender and their impact on health\n3.2.3 Atherosclerotic cardiovascular disease risk classification\n3.2.3.1 A stepwise approach to risk factor treatment and treatment intensification\n3.2.3.2 Risk estimation in apparently healthy people\n3.2.3.3 Translating atherosclerotic cardiovascular disease risk to treatment thresholds\n3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 50\u000269 years of age\n3.2.3.5 Risk estimation and risk factor treatment estimation in apparently healthy people >70 years of age\n_\n3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people <50 years of age\n3.2.3.7 Risk estimation and risk factor treatment in patients with established atherosclerotic cardiovascular disease\n3.2.4 Communication of cardiovascular disease risk\n3.3.1 Psychosocial factors\n3.3.4 Frailty\n3.3.8 Environmental exposure\n3.4 Clinical conditions\n3.4.2 Atrial fibrillation\n3.4.3 Heart failure\n3.4.5 Chronic obstructive pulmonary disease\n3.4.6 Inflammatory conditions\n3.4.7 Infections (human immunodeficiency virus, influenza, periodontitis)\n3.4.8 Migraine\n3.4.9 Sleep disorders and obstructive sleep apnoea\n3.4.10 Mental disorders\n3.4.11 Non-alcoholic fatty liver disease\n3.4.12 Sex-specific conditions | \nSection 4\n• 4.10 Anti-inflammatory treatment | \nNew /revised concepts | \nSection 3\n• SCORE2 and SCORE2-OP risk charts for fatal and non-fatal (myocardial infarction, stroke) ASCVD\n• Estimating 10-year total CVD risk in apparently healthy people 50\u000269 years of age\n• Estimating lifetime risk in apparently healthy people <50 years of age\n• Estimating 10-year total CVD risk in apparently healthy people >70 years of age\n_\n• Cut-offs of 10-year CVD risk, based on SCORE2/SCORE2-OP, to define low\u0002moderate risk, high risk, and very high risk for\napparently healthy people in different age groups (<50, 50\u000269,\nand >70 years)\n_\n• Estimating 10-year CVD risk in patients with established CVD and/or DM\n• Lifetime benefit of stopping smoking, reducing LDL-C, or lowering SBP (sections 3 and 4)\n• A stepwise approach to attaining ultimate treatment goals (sections 3 and 4)\n• Communication of CVD risk and benefit of treatment to patients in an understandable way\n• Stepwise approach to risk factor treatment and treatment intensification | \nSection 4\n• Explicitly addressing cost-effectiveness (on a loco-regional or national level) before implementing some recommendations\n• Non-fasting lipid measurement (section 4.6.1.1)\n• A stepwise approach to attaining treatment goals (sections 3 and 4)\n• Anti-inflammatory treatment for very-high-risk patients | \nSection 5\n• Taking into consideration population level interventions to mitigate the effects of pollution on CVD health | \nSection 6\n• Risk management of disease-specific CVD. This section addresses CVD prevention when certain underlying diseases are present and aims to provide\nguidance on how to prevent the worsening of existing, or the development of further, comorbidities that could increase the overall risk of CVD\n• Subsections include: 6.1 Coronary artery disease; 6.2 Heart failure; 6.3 Cerebrovascular disease; 6.4 Lower extremity artery disease; 6.5 Chronic kidney\ndisease; 6.6 Atrial fibrillation; 6.7 Multimorbidity | ",
          "bbox": [
            49.91488374982561,
            60.696268717447914,
            559.5040283203125,
            718.4276184082031
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "5",
      "title": "3.4 Clinical conditions",
      "start_page": 14,
      "end_page": 18,
      "content": "3.4.2 Atrial ﬁbrillation 3.4.3 Heart failure\n3.4.5 Chronic obstructive pulmonary disease\n3.4.6 Inﬂammatory conditions 3.4.7 Infections (human immunodeﬁciency virus, inﬂuenza, periodontitis)\n3.4.8 Migraine\n3.4.9 Sleep disorders and obstructive sleep apnoea 3.4.10 Mental disorders\n3.4.11 Non-alcoholic fatty liver disease\n3.4.12 Sex-speciﬁc conditions\nSection 4 •   4.10 Anti-inﬂammatory treatment\nNew /revised concepts\nSection 3 •   SCORE2 and SCORE2-OP risk charts for fatal and non-fatal (myocardial infarction, stroke) ASCVD •   Estimating 10-year total CVD risk in apparently healthy people 50 \u0002 69 years of age •   Estimating lifetime risk in apparently healthy people <50 years of age •   Estimating 10-year total CVD risk in apparently healthy people >_70 years of age •   Cut-offs of 10-year CVD risk, based on SCORE2/SCORE2-OP, to deﬁne low \u0002 moderate risk, high risk, and very high risk for\napparently healthy people in different age groups (<50, 50 \u0002 69,\nand >_70 years) •   Estimating 10-year CVD risk in patients with established CVD and/or DM •   Lifetime beneﬁt of stopping smoking, reducing LDL-C, or lowering SBP ( sections 3  and  4 ) •   A stepwise approach to attaining ultimate treatment goals ( sections 3  and  4 ) •   Communication of CVD risk and beneﬁt of treatment to patients in an understandable way •   Stepwise approach to risk factor treatment and treatment intensiﬁcation\nSection 4 •   Explicitly addressing cost-effectiveness (on a loco-regional or national level) before implementing some recommendations •   Non-fasting lipid measurement ( section 4.6.1.1 ) •   A stepwise approach to attaining treatment goals ( sections 3  and  4 ) •   Anti-inﬂammatory treatment for very-high-risk patients\nSection 5 •   Taking into consideration population level interventions to mitigate the effects of pollution on CVD health\nSection 6 •   Risk management of disease-speciﬁc CVD. This section addresses CVD prevention when certain underlying diseases are present and aims to provide\nguidance on how to prevent the worsening of existing, or the development of further, comorbidities that could increase the overall risk of CVD •   Subsections include: 6.1 Coronary artery disease; 6.2 Heart failure; 6.3 Cerebrovascular disease; 6.4 Lower extremity artery disease; 6.5 Chronic kidney disease; 6.6 Atrial ﬁbrillation; 6.7 Multimorbidity\nASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; DM =diabetes mellitus; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood- pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons.\nESC 2021\nESC Guidelines 3241\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ........................................................................................................................................................................\nAnother important risk factor is adiposity, which increases CVD risk via both major conventional risk factors and other mechanisms. In addition to these, there are many other relevant risk factors, modi- fiers, and clinical conditions, which are addressed under risk modifiers and clinical conditions ( sections 3.3  and  3.4 ).\n3.2.1.1 Cholesterol The causal role of LDL-C, and other apo-B-containing lipoproteins, in the development of ASCVD is demonstrated beyond any doubt by genetic, observational, and interventional studies. 20   The key attrib- utes of LDL-C as a risk factor for ASCVD are:\n•   Prolonged lower LDL-C is associated with lower risk of ASCVD throughout the range studied, and the results of randomized controlled trials (RCTs) indicate that lowering LDL-C safely reduces CVD risk even at low LDL-C levels [e.g. LDL-C <1.4 mmol/L (55 mg/dL)]. 20\n•   The relative reduction in CVD risk is proportional to the abso- lute size of the change in LDL-C, irrespective of the drug(s) used to achieve such change. 21\n•   The absolute benefit of lowering LDL-C depends on the abso- lute risk of ASCVD and the absolute reduction in LDL-C, so\neven a small absolute reduction in LDL-C may be beneficial in a high- or very-high-risk patient. 22\n•   Non-high-density lipoprotein cholesterol (HDL-C) encom- passes all atherogenic (apo-B-containing) lipoproteins, and is cal- culated as: total cholesterol  \u0002  HDL-C = non-HDL-C. The relationship between non-HDL-C and CV risk is at least as strong as the relationship with LDL-C. Non-HDL-C levels con- tain, in essence, the same information as a measurement of apo- B plasma concentration. 23 , 24   Non-HDL-C is used as an input in the Systemic Coronary Risk Estimation 2 (SCORE2) and SCORE2-Older Persons (SCORE2-OP) risk algorithms.\nHDL-C is inversely associated with CVD risk. Very high HDL-C levels may signal an increased CVD risk. There is, however, no evidence from Mendelian randomization studies, or randomized trials of cho- lesteryl ester transfer protein inhibitors, that raising plasma HDL-C reduces CVD risk. 25 \u0002 28   HDL-C is nonetheless a useful biomarker to refine risk estimation using the SCORE2 algorithms. The SCORE2 algorithm cannot be used for patients with a genetic lipid disorder, such as familial hypercholesterolaemia (FH). Specific LDL-C thresh- olds and targets are recommended irrespective of estimated CV risk for patients with FH or other rare/genetic lipid disorders.\n3.2.1.2 Blood pressure Longitudinal studies, genetic epidemiological studies, and RCTs have shown that raised BP is a major cause of both ASCVD and non- atherosclerotic CVD [particularly heart failure (HF)], accounting for 9.4 million deaths and 7% of global disability adjusted life-years. 29\nElevated BP is a risk factor for the development of coronary artery disease (CAD), HF, cerebrovascular disease, lower extremity arterial disease (LEAD), chronic kidney disease (CKD), and atrial fibrillation (AF). The risk of death from either CAD or stroke increases linearly from BP levels as low as 90 mmHg systolic and 75 mmHg diastolic upwards. 30 , 31   The absolute benefit of reducing systolic BP (SBP) depends on absolute risk and the absolute reduction in SBP, except that lower limits of SBP are imposed by tolerability and safety consid- erations. Management is determined by the category of hypertension (optimal, normal, high-normal, stages 1 to 3, and isolated systolic hypertension), defined according to seated office BP, ambulatory BP monitoring (ABPM), or home BP average values (see  section 4.7 ). Evidence suggests that lifetime BP evolution differs in women compared to men, potentially resulting in an increased CVD risk at lower BP thresholds. 32 \u0002 34   The SCORE2 algorithm cannot be used for patients with secondary causes and rarer forms of hypertension, such as primary hyperaldosteronism.\n3.2.1.3 Cigarette smoking Cigarette smoking is responsible for 50% of all avoidable deaths in smokers, with half of these due to ASCVD. A lifetime smoker has a 50% probability of dying due to smoking, and on average will lose 10 years of life. 35   The CVD risk in smokers <50 years of age is five-fold higher than in non-smokers. 36   Prolonged smoking is more hazardous for women than for men. 37   Worldwide, after high SBP, smoking is the leading risk factor for disability adjusted life-years. 38   Second-hand smoke is associated with an increase in CVD risk. 39   Some smokeless tobacco is also associated with increased risk of CVD. 40\nRecommendations for CVD risk assessment\nRecommendations Class a Level b\nSystematic global CVD risk assessment is recom- mended in individuals with any major vascular\nrisk factor (i.e. family history of premature CVD,\nFH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or\ncomorbidities increasing CVD risk).\nI C\nSystematic or opportunistic CV risk assessment in the general population in men >40 years of\nage and in women >50 years of age or postme-\nnopausal with no known ASCVD risk factors may be considered. 9\nIIb C\nIn those individuals who have undergone CVD\nrisk assessment in the context of opportunistic\nscreening, a repetition of screening after 5 years (or sooner if risk was close to treatment thresh-\nolds) may be considered.\nIIb C\nOpportunistic screening of BP in adults at risk for the development of hypertension, such as\nthose who are overweight or with a known fam-\nily history of hypertension, should be considered. 19\nIIa B\nSystematic CVD risk assessment in men <40\nyears of age and women <50 years of age with\nno known CV risk factors is not recommended. 9\nIII C\nASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CV = car- diovascular; CVD = cardiovascular disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia. a Class of recommendation. b Level of evidence.\nESC 2021\n3242 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 3.2.1.4 Diabetes mellitus Type 1 DM, type 2 DM, and prediabetes are independent risk factors for ASCVD, increasing risk of ASCVD by about two-fold, depending on the population and therapeutic control. 41   Women with type 2 DM appear to have a particularly higher risk for stroke. 42   Patients with type 2 DM are likely to have multiple ASCVD risk factors (including dyslipidaemia and hypertension), each of which mediates an increase in risk of both ASCVD and non-ASCVD.\n3.2.1.5 Adiposity Over recent decades, body mass index (BMI)—measured as weight (in kg) divided by squared height (in m 2 )—has increased substantially worldwide in children, adolescents, and adults. 43   Mendelian random- ization analyses suggest a linear relation between BMI and mortality in non-smokers and a J-shaped relation in ever-smokers. 44   All-cause mortality is lowest at a BMI of 20 \u0002 25 kg/m 2   in apparently healthy people, with a J-shaped or U-shaped relation. 45 , 46   In HF patients, there is evidence for an obesity paradox, with lower mortality risk in patients with higher BMI. A meta-analysis concluded that both BMI and waist circumference are similarly, strongly, and continuously associated with ASCVD and type 2 DM. 47\n3.2.2. Sex and gender and their impact on health The current prevention guidelines recognize the importance of inte- grating sex, gender, and gender identity considerations into the risk assessment and clinical management of individuals and populations. These guidelines also acknowledge the complexity of the inter- relationship between these concepts and CV, as well as psychologi- cal, health. There is, at present, no official ESC position on the specific terminology to be used. According to the World Health Organization (WHO), sex ‘refers to the different biological and phys- iological characteristics of females, males, and intersex persons, such as chromosomes, hormones and reproductive organs’. 48\nThis is to be distinguished from gender, which ‘refers to the char- acteristics of women, men, girls and boys that are socially con- structed. This includes norms, behaviours and roles associated with being a woman, man, girl or boy, as well as relationships with each other. As a social construct, gender varies from society to society and can change over time’. 48   The Global Health 50/50 definition fur- ther states that gender refers ‘to the socially constructed norms that impose and determine roles, relationships, and positional power for all people across their lifetime’. 49\nWhere evidence exists on the risk modifying effect of sex or where sex-specific clinical conditions and clinical management strat- egies exist, this has been included in these guidelines. 50   The influence of gender on an individual’s experience and access to healthcare is paramount. 50   The specific health concerns related to gender are thus also acknowledged in these prevention Guidelines.\nEpigenetic effects of social constructs appear to condition the translation of biological sex into disease pathophysiology. Furthermore, social constructs can also be determinants of health access, healthcare utilization, disease perception, decision-making, and perhaps therapeutic response, 50   including in the field of CVD and ASCVD prevention. Research is ongoing, but gaps in evidence remain and this has also been recognized in the guidelines.\nExamples of specific topics regarding physiological, pathological, and clinical differences related to sex and gender that have been\nstudied include left ventricular (LV) ejection fraction (LVEF), adverse drug reactions, trends in ASCVD risk factors and awareness, sex dis- parities in the management of and outcomes after acute coronary syndromes (ACS). 51 \u0002 58   Furthermore, CVD health after menopause transition, pregnancy disorders, and gynaecologic conditions have recently been reviewed. 59\n3.2.3. Cardiovascular disease risk classification The current guidelines on CVD prevention in clinical practice con- centrate principally, but not exclusively, on risk and prevention of ASCVD. This includes risk factors, risk prediction, risk modifiers, as well as clinical conditions that often increase the likelihood of ASCVD. Identifying patients who will benefit most from ASCVD risk factor treatment is central to ASCVD prevention efforts. In general, the higher the absolute CVD risk, the higher the absolute benefit of risk factor treatment, and thus the lower the  number needed to treat  to prevent one CVD event during a period of time. 60 , 61   With this in mind, the estimation of CVD risk remains the cornerstone of these guidelines and thus appears at the forefront of the proposed manage- ment schemes, which are summarized in flowcharts.\nAge is the major driver of CVD risk. Women below 50 years and men below 40 years of age are almost invariably at low 10-year CVD risk, but may have unfavourable modifiable risk factors that sharply increase their longer-term CVD risk. Conversely, men over 65 years and women over 75 years of age are almost always at high 10-year CVD risk. Only between the ages of 55 and 75 years in women and 40 and 65 years in men does the 10-year CVD risk vary around com- monly used thresholds for intervention. The age categories <50, 50 \u0002 69, and >_70 years should be used with common sense and flexi- bility. Different age ranges may be considered for men and women and may differ according to geographic region. Uncertainty around risk estimations should also be considered. CVD risk can also be assessed in patients with type 2 DM and in patients with established ASCVD. The populations or patient groups in whom CVD risk needs to be considered are summarized and pre- sented in  Table  4 . Lifetime CVD risk estimation is available for various groups of patients, and enables estimation of lifetime benefit from preventive interventions such as smoking cessation (see  section 4.5.1 ), lipid-lowering (see  section 4.6.2.1 ), and BP treatment (see  section 4.7.5.2 ). Lifetime risk and benefit estimation may be used for commu- nication in the shared decision-making process, together with consid- eration of comorbidities, frailty, patient preferences for initiating (STEP 1) and intensifying (STEP 2) risk factor treatment ( Figure  2 ).\n3.2.3.1 A stepwise approach to risk factor treatment and treatment intensification As explained before, targets and goals for LDL-C, BP, and glycaemic control in DM remain as recommended in recent ESC Guidelines. 3 \u0002 5\nThese guidelines propose a stepwise approach to treatment intensifi- cation as a tool to help physicians and patients pursue these targets in a way that fits patient profiles and preferences. This principle (out- lined in  Figure  2 , using the example of a stepwise approach) is not conceptually novel, but rather reflects routine clinical practice, in which treatment strategies are initiated and then intensified, both as part of a shared decision-making process involving healthcare profes- sionals and patients.\nESC Guidelines 3243\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nTable 4 Patient categories and associated cardiovascular disease risk.\nPatient category Subgroups Risk  categories\nApparently healthy persons\nPersons without established  ASCVD, diabetes mellitus, CKD,  Familial Hypercholesterolemia <50 years Low- to high-risk\n10-year CVD risk estimation (SCORE2). Lifetime risk\n(e.g. with the LIFE-CVD lifetime model) to facilitate the\n50-69 years Low- to very high-risk\n10-year CVD risk estimation (SCORE2). Lifetime\n(e.g. with the LIFE-CVD lifetime model) to facilitate the\n≥70 years Low- to very high-risk\n10-year CVD risk estimation (SCORE2-OP). Lifetime\n(e.g. with the LIFE-CVD lifetime model) to facilitate the\nPatients with CKD\nCKD without diabetes or ASCVD Moderate CKD (eGFR 30−44 mL/min/1.73 m 2   and ACR <30  or   eGFR 45−59 mL/min/1.73 m 2  and   ACR 30−300  or    eGFR ≥60 mL/min/1.73 m 2  and ACR >300)\nHigh-risk N/A\nSevere CKD (eGFR<30 mL/min/1.73 m 2   or eGFR 30−44 mL/min/1.73 m 2  and ACR >30)\nVery  high-risk N/A\nFamilial Hypercholesterolemia\nAssociated with markedly elevated  cholesterol levels N/A High-risk N/A\nPatients with type 2 diabetes mellitus\nPatients with type 1 DM above\naccording to these criteria\nPatients with well controlled short-standing  DM (e.g. <10 years), no evidence of TOD  and no additional ASCVD risk factors\nModerate- risk N/A\nPatients with DM without ASCVD and/or\nrisk criteria.  High-risk\nResidual 10-year CVD risk estimation after general  prevention goals (e.g. with the ADVANCE risk score or\nestimation of risk factor treatment (e.g. DIAL model).\nPatients with DM with established ASCVD  and/or severe TOD: 87, 93-95\n• eGFR <45 mL/min/1.73 m 2  irrespective     of albuminuria  • eGFR 45-59 mL/min/1.73 m 2  and     microalbuminuria (ACR 30 -300 mg/g)  • Proteinuria (ACR >300 mg/g)  • Presence of microvascular disease          microalbuminuria plus retinopathy     plus neuropathy)\nVery high-risk\nResidual 10-year CVD risk estimation after general  prevention goals (e.g. with the SMART risk score for  established CVD or with the ADVANCE risk score or  with the DIAL model). Consider lifetime CVD risk and\nmodel).\nPatients with established ASCVD\nDocumented ASCVD, clinical or  unequivocal on imaging. Documented  clinical ASCVD includes previous  AMI, ACS, coronary revascularization  and other arterial revascularization  procedures, stroke and TIA, aortic  aneurysm and PAD. Unequivocally  documented ASCVD on imaging  includes plaque on coronary  angiography or carotid ultrasound  or on CTA. It does NOT include  some increase in continuous imaging  parameters such as intima–media  thickness of the carotid artery.\nN/A Very high-risk\nResidual CVD risk estimation after general prevention  goals (e.g. 10-year risk with the SMART risk score for  patients with established CVD or 1- or 2-year risk  with EUROASPIRE risk score for patients with CHD).\nrisk factor treatment (e.g. SMART-REACH model; or  DIAL model if diabetes).\nACR = albumin-to-creatinine ratio: (to convert mg/g to mg/mmol: divide by 10); ACS = acute coronary syndromes; ADVANCE = Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; AMI = acute myocardial infarction; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CTA = computed tomography angiography; CV = cardiovascular; CVD = cardiovascular disease; DIAL = Diabetes lifetime-perspective prediction; DM = diabetes mellitus; FH = familial hypercholesterolaemia; eGFR = estimated glomerular ﬁltration rate; IMT = intima-media thickness; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; N/A = not applicable; PAD = peripheral artery disease; REACH = Reduction of Atherothrombosis for Continued Health; SBP = systolic blood pressure; SCORE = Systematic Coronary Risk Estimation; SMART = Secondary Manifestations of Arterial Disease; TIA = transient ischaemic attack.\nESC 2021\n3244 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...................................................... A stepwise approach starts with prevention goals for all, regardless of CVD risk. This is followed by CVD risk stratification and discussion of potential benefits of treatment with the patient. If treatment is initi- ated, its effect must be evaluated, and subsequent treatment intensifi- cation to reach ultimate risk factor goals must be considered in all patients, taking into account additional benefit, comorbidities, and frailty, all of which converge with patient preferences in a shared decision-making process. In the field of DM, studies have shown benefit of a stepwise approach to treatment intensification and do not support the conten- tion of ‘therapeutic nihilism’ occurring in either physicians or patients. In fact, it appears that attainment of treatment goals is similar, side- effects are fewer, and patient satisfaction is significantly higher with such an approach. 66 , 67   We do, however, emphasize that stopping assessment of treatment goals and/or treatment routinely after the first step is inappropriate. The evidence-based ultimate targets of treatment intensification are optimal from the perspective of CVD risk reduction and are to be considered in all patients.\n3.2.3.2 Risk estimation in apparently healthy people Apparently healthy people are those without established ASCVD, type 2 DM, or severe comorbidities. In the 2016 ESC prevention guidelines, 2   the Systemic Coronary Risk Estimation (SCORE) algo- rithm was used to estimate 10-year risk of CVD death. However, CVD morbidity (non-fatal myocardial infarction, non-fatal stroke) combined with CVD mortality better reflects the total burden of ASCVD. The updated SCORE algorithm— SCORE2—used in these guidelines (see  Figure  3 ), estimates an individual’s 10-year risk of  fatal and non-fatal  CVD events (myocardial infarction, stroke) in appa- rently healthy people aged 40 \u0002 69 years with risk factors that are untreated or have been stable for several years. 68\nSeveral specific considerations apply to CVD risk estimation in older people. First, the gradient of the relationship between classical risk factors, such as lipids and BP, with CVD risk attenuates with age. 69   Second, CVD-free survival dissociates from overall survival progressively with increasing age, because risk for non-CVD mortal- ity increases (‘competing risk’). 70   For these reasons, traditional risk\nCategories of individuals considered for prevention\nSTEP 1\n10-year CVD risk Lifetime CVD risk and treatment benefit Comorbidities Patient preferences\n",
      "keywords": [
        "obesity",
        "clinical",
        "peripheral artery",
        "cvd risk",
        "10-year risk",
        "lipid",
        "hypertension",
        "aneurysm",
        "genetic",
        "intima-media",
        "biomarker",
        "risk stratification",
        "diabetes",
        "coronary artery",
        "sex",
        "score2-op",
        "familial hypercholesterolemia",
        "atrial fibrillation",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "angiography",
        "ejection fraction",
        "may be considered",
        "heart failure",
        "conditions",
        "level b",
        "risk estimation"
      ],
      "tables": [
        {
          "title": "3242 ESC Guidelines",
          "page_number": 15,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nSystematic global CVD risk assessment is recom-\nmended in individuals with any major vascular\nrisk factor (i.e. family history of premature CVD,\nFH, CVD risk factors such as smoking, arterial\nhypertension, DM, raised lipid level, obesity, or\ncomorbidities increasing CVD risk). | I | C | \nSystematic or opportunistic CV risk assessment\nin the general population in men >40 years of\nage and in women >50 years of age or postme-\nnopausal with no known ASCVD risk factors\nmay be considered.9 | IIb | C | \nIn those individuals who have undergone CVD\nrisk assessment in the context of opportunistic\nscreening, a repetition of screening after 5 years\n(or sooner if risk was close to treatment thresh-\nolds) may be considered. | IIb | C | \nOpportunistic screening of BP in adults at risk\nfor the development of hypertension, such as\nthose who are overweight or with a known fam-\nily history of hypertension, should be\nconsidered.19 | IIa | B | \nSystematic CVD risk assessment in men <40\nyears of age and women <50 years of age with\nno known CV risk factors is not recommended.9 | III | C | ESC 2021",
          "bbox": [
            44.45519117875533,
            76.96976928710937,
            289.5812096228966,
            393.9131633213588
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3244 ESC Guidelines",
          "page_number": 17,
          "content": "Patient category | Subgroups | Risk\ncategories | \nApparently healthy persons |  |  | \nPersons without established\nASCVD, diabetes mellitus, CKD,\nFamilial Hypercholesterolemia | <50 years | 10-year CVD risk estim\nLow- to\nhigh-risk (e.g. with the LIFE-CVD | ation (SCORE2). Lifetime risk\nlifetime model) to facilitate the\n | 50-69 years | 10-year CVD risk estim\nLow- to\nvery high-risk (e.g. with the LIFE-CVD | ation (SCORE2). Lifetime\nlifetime model) to facilitate the\n | ≥70 years | 10-year CVD risk estim\nLow- to\nvery high-risk (e.g. with the LIFE-CVD | ation (SCORE2-OP). Lifetime\nlifetime model) to facilitate the\nPatients with CKD |  |  | \nCKD without diabetes or ASCVD | Moderate CKD (eGFR 30−44 mL/min/1.73 m2\nand ACR <30 or\neGFR 45−59 mL/min/1.73 m2 and\nACR 30−300 or\neGFR ≥60 mL/min/1.73 m2 and ACR >300) | High-risk N/A | \n | Severe CKD (eGFR<30 mL/min/1.73 m2 or\neGFR 30−44 mL/min/1.73 m2 and ACR >30) | Very\nN/A\nhigh-risk | \nFamilial Hypercholesterolemia |  |  | \nAssociated with markedly elevated\ncholesterol levels | N/A | High-risk N/A | \nPatients with type 2 diabetes mellitus |  |  | \nPatients with type 1 DM above\naccording to these criteria | Patients with well controlled short-standing\nDM (e.g. <10 years), no evidence of TOD\nand no additional ASCVD risk factors | Moderate-\nN/A\nrisk | \n | Patients with DM without ASCVD and/or\nrisk criteria. | Residual 10-year CVD\nprevention goals (e.g. w\nHigh-risk\nestimation of risk facto | risk estimation after general\nith the ADVANCE risk score or\nr treatment (e.g. DIAL model).\n | Patients with DM with established ASCVD\nand/or severe TOD:87, 93-95\n• eGFR <45 mL/min/1.73 m2 irrespective\nof albuminuria\n• eGFR 45-59 mL/min/1.73 m2 and\nmicroalbuminuria (ACR 30 -300 mg/g)\n• Proteinuria (ACR >300 mg/g)\n• Presence of microvascular disease\nmicroalbuminuria plus retinopathy\nplus neuropathy) | Residual 10-year CVD\nprevention goals (e.g. w\nVery established CVD or wit\nhigh-risk with the DIAL model).\nmodel). | risk estimation after general\nith the SMART risk score for\nh the ADVANCE risk score or\nConsider lifetime CVD risk and\nPatients with established ASCVD |  |  | \nDocumented ASCVD, clinical or\nunequivocal on imaging. Documented\nclinical ASCVD includes previous\nAMI, ACS, coronary revascularization\nand other arterial revascularization\nprocedures, stroke and TIA, aortic\naneurysm and PAD. Unequivocally\ndocumented ASCVD on imaging\nincludes plaque on coronary\nangiography or carotid ultrasound\nor on CTA. It does NOT include\nsome increase in continuous imaging\nparameters such as intima–media\nthickness of the carotid artery. | N/A | Residual CVD risk esti\ngoals (e.g. 10-year risk\npatients with establishe\nVery\nwith EUROASPIRE risk\nhigh-risk\nrisk factor treatment (e\nDIAL model if diabetes | mation after general prevention\nwith the SMART risk score for\nd CVD or 1- or 2-year risk\nscore for patients with CHD).\n.g. SMART-REACH model; or\n).",
          "bbox": [
            93.37707242098722,
            92.85595703125,
            502.4571075439453,
            674.8616104125977
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "6",
      "title": "Intensified prevention and treatment goals based on:",
      "start_page": 18,
      "end_page": 18,
      "content": "Apparently healthy persons (See Figure 6)\nSTEP 2\nPatients with established ASCVD (See Figure 7)\nPatients with type 2 diabetes mellitus (See Figure 8)\nPatients with specific risk factors such as CKD and FH (See Table 4)\nPrevention goals for all Prevention goals for all Prevention goals for all\nSpecific risk factor prevention and treatment goals based on risk categories\nEstimate 10-year CVD risk\nConsider risk modifiers, lifetime CVD risk, treatment benefit and patient preferences\nPrevention goals\nUltimate prevention goals\nPrevention goals based on whether patients are without or with established ASCVD and/or severe TOD\n10-year CVD risk Lifetime CVD risk and treatment benefit Comorbidities Patient preferences\n",
      "keywords": [
        "ascvd",
        "cvd risk",
        "risk factor",
        "treatment",
        "goals",
        "based",
        "diabetes",
        "prevention",
        "intensified"
      ],
      "tables": []
    },
    {
      "number": "7",
      "title": "Intensified prevention and treatment goals based on:",
      "start_page": 18,
      "end_page": 18,
      "content": "Ultimate prevention goals\n10-year CVD risk Lifetime CVD risk and treatment benefit Comorbidities Patient preferences\n",
      "keywords": [
        "cvd risk",
        "treatment",
        "goals",
        "based",
        "prevention",
        "intensified"
      ],
      "tables": []
    },
    {
      "number": "8",
      "title": "Intensified prevention and treatment goals based on:",
      "start_page": 18,
      "end_page": 25,
      "content": "Ultimate prevention goals\nFigure 2  Examples of a stepwise approach to risk stratification and treatment options. ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia; TOD = target organ damage.\nESC Guidelines 3245\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n1 1 1 1\n1 1 1 1\n8 8 9 9\n7\n5 5 5 5\n5 6 6 6\n7 7 7 7\n3 3 4 4\n4 4 4 5\n5 5 5 6\n6 6 7\n3 4 4 4\n2 2 3 3\n3 3 3 3\n3 4 4 4\n4 5 5 5\n2 2 2 2\n2 2 2 3\n2 3 3 3\n2 2 2 3\n3 3 3 3\n1 1 1 1\n1 2 2 2\n2 2 2 3\n1 2 2 2\n2 2 2 2\n2 2 3 3\n12 12 13 13\n11\n7 7 7 8\n8 9 9 9\n10 10 11 11\n5 6 6 6\n6 7 7 8\n8 8 9 9\n10 10 11\n6 7 7 8\n4 4 5 5\n5 6 6 6\n6 7 7 8\n8 8 9 10\n3 3 4 4\n4 4 5 5\n5 5 6 7\n4 4 5 5\n5 5 6 6\n2 3 3 3\n3 3 4 4\n4 4 5 6\n3 3 4 4\n1 2 2 2\n2 2 3 3\n11 12 12 13\n10\n6 7 7 8\n8 8 9 10\n9 10 11 11\n5 5 6 6\n6 6 7 8\n7 8 8 9\n8 9 11\n5 6 7 8\n4 4 4 5\n4 5 5 6\n5 6 7 8\n7 7 8 9\n3 3 3 4\n3 4 4 5\n4 5 6 6\n3 4 4 5\n4 5 5 6\n2 2 3 3\n2 3 3 4\n3 4 5 5\n2 3 3 4\n3 3 4 5\n3 4 5 5\n15 16 17 19\n15\n9 10 11 11\n11 12 13 13\n13 14 15 16\n7 8 9 10\n9 10 10 11\n10 11 13 14\n13 14 17\n9 10 11 13\n6 6 7 8\n7 8 9 10\n9 10 11 12\n10 12 13 15\n4 5 6 7\n6 7 8 9\n7 8 10 11\n6 6 7 8\n7 8 9 10\n3 4 5 6\n5 5 6 8\n6 7 8 10\n4 5 6 7\n28 29 30 31\n20 21 22 23\n23 24 25 26\n24 25 26 27\n26 27 28 29\n15 15 16 17\n16 17 18 19\n18 19 20 21\n11 11 12 13\n13 13 14 15\n15 15 16 17\n10\n10 11 12\n9 10 10 11\n6 6 6 7\n7 7 8 8\n9 9 10\n12\n31 32 33 34\n25 26 28 29\n25 26 27 28\n27 28 29 30\n29 30 31 32\n18 19 20 21\n20 21 22 23\n23 24 25 26\n15 16 17 18\n18 19 20 21\n21 22 23 24\n16\n17 18 20\n13 14 15 15\n9 10 10 11\n11 12 13 14\n14 15 16\n19\n29 35 42 49\n23 27 32 37\n25 30 36 43\n26 32 38 45\n28 33 40 47\n17 20 24 28\n19 22 26 31\n21 25 29 34\n14 15 18 20\n16 18 21 23\n19 21 24 27\n16\n15 16 19\n12 13 15 17\n8 8 9 10\n10 11 12 13\n12 13 14\n18\n29 35 42 49\n26 31 36 41\n25 30 36 43\n26 32 38 45\n27 33 40 47\n19 23 27 31\n22 25 30 34\n24 28 33 38\n18 20 23 26\n21 23 26 30\n24 27 31 34\n23\n22 24 28\n15 17 19 22\n12 13 14 15\n14 16 17 19\n18 19 21\n26\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n85-89\n80-84\n75-79\n70-74\n65-69\n60-64\n55-59\n50-54\n45-49\n40-44\nSystolic blood pressure (mmHg)\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\nNon-smoking\nSmoking\nAge (y)\n< 50 years <2.5% 2.5 to <7.5% ≥ 7.5%\n50-69 years <5% 5 to <10% ≥ 10%\n≥ 70 years <7.5% 7.5 to <15% ≥ 15%\nSCORE2 & SCORE2-OP 10-year risk of (fatal and non-fatal) CV events in populations at low CVD risk\nNon-smoking\nSmoking\nNon-HDL cholesterol\nWomen Men\nSCORE2-OP\nSCORE2\nmmol/L\n150 200 250 150 200 250 150 200 250 150 200 250 mg/dL\nFigure 3  Systematic Coronary Risk Estimation 2 and Systematic Coronary Risk Estimation 2-Older Persons risk charts for fatal and non-fatal (myocardial infarction, stroke) cardiovascular disease. 68 , 72   ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; CVD = cardiovascular disease; SBP = systolic blood pressure; HDL-C = high-density lipoprotein cholesterol; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons; TFYR = The Former Yugoslav Republic; UK = United Kingdom. For apparently healthy people aged 40 \u0002 69 years, the SCORE2 algorithm 68   is used to estimate 10-year risk of fatal and non-fatal (myocardial infarction, stroke) CVD. For apparently healthy people >_70 years of age, the SCORE2-OP is used. 72 .  Low-risk countries : Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, the Netherlands, and the UK.  Moderate-risk countries : Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia, and Sweden.  High-risk countries : Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan, Poland, Slovakia, and Turkey.  Very-high-risk countries : Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Republic of Moldova, Romania, Russian Federation, Serbia, Syria, TFYR (Macedonia), Tunisia, Ukraine, and Uzbekistan.\n3246 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n1 1 1 1\n1 1 1 2\n10 10 11 12\n8\n5 6 6 6\n7 7 7 8\n8 9 9 9\n4 4 4 5\n5 5 5 6\n6 6 7 7\n7 8 9\n4 4 5 5\n3 3 3 3\n3 3 4 4\n4 4 5 5\n5 6 6 7\n2 2 2 2\n2 2 3 3\n3 3 3 4\n2 2 3 3\n3 3 4 4\n1 1 1 2\n1 2 2 2\n2 2 3 3\n2 2 2 2\n2 2 2 3\n3 3 3 4\n15 16 17 18\n14\n9 9 9 10\n10 11 12 12\n13 13 14 15\n6 7 7 8\n8 9 9 10\n10 11 11 12\n12 13 15\n8 8 9 10\n5 5 6 6\n6 7 7 8\n8 8 9 10\n10 11 11 12\n3 4 4 5\n5 5 6 6\n6 7 8 9\n5 5 6 6\n6 6 7 8\n3 3 3 4\n3 4 5 5\n5 5 6 7\n3 4 4 5\n2 2 2 3\n2 3 3 4\n14 15 17 18\n13\n8 9 10 10\n10 11 12 13\n12 13 14 15\n6 7 7 8\n7 8 9 10\n9 10 11 12\n11 12 15\n7 8 9 10\n4 5 6 6\n5 6 7 8\n7 8 9 10\n9 10 11 12\n3 4 4 5\n4 5 5 6\n5 6 7 8\n4 5 5 6\n5 6 7 8\n2 3 3 4\n3 4 4 5\n4 5 6 7\n3 4 4 5\n3 4 5 6\n4 5 6 7\n20 22 23 25\n20\n12 13 14 15\n14 15 17 18\n17 18 20 21\n9 10 11 12\n11 13 14 15\n14 15 17 18\n17 18 22\n11 13 15 17\n7 8 9 10\n9 10 11 13\n11 13 14 16\n14 16 17 20\n5 6 7 8\n7 8 10 12\n9 11 13 15\n7 8 9 11\n9 10 12 14\n4 5 6 8\n6 7 8 10\n8 9 11 13\n5 7 8 9\n37 39 40 42\n27 28 30 31\n30 32 33 34\n32 34 35 37\n35 36 38 39\n19 20 21 22\n21 22 24 25\n24 25 27 28\n14 15 15 16\n16 17 18 19\n19 20 21 23\n13\n13 14 16\n12 12 13 14\n7 7 8 8\n9 9 10 11\n11 11 12\n15\n41 43 44 46\n34 35 37 39\n34 35 37 38\n36 38 39 41\n39 40 42 43\n24 25 27 28\n27 28 30 31\n30 32 33 35\n20 21 22 24\n24 25 26 28\n27 29 30 32\n22\n22 23 26\n17 18 19 20\n12 13 13 14\n15 16 17 18\n18 19 20\n25\n37 45 53 62\n30 35 41 47\n32 39 47 55\n34 41 49 57\n36 43 51 59\n22 26 31 36\n25 29 34 40\n27 32 37 43\n17 20 23 26\n21 23 27 30\n24 27 31 35\n20\n19 21 25\n15 17 19 22\n10 11 12 13\n12 13 15 16\n15 17 18\n23\n37 45 53 61\n34 40 46 53\n32 39 46 55\n34 41 48 57\n35 43 51 59\n25 30 35 40\n28 33 38 44\n31 36 42 48\n23 26 29 33\n27 30 34 38\n31 35 39 44\n30\n28 31 36\n19 22 25 29\n15 16 18 20\n19 20 22 24\n23 25 28\n34\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n85-89\n80-84\n75-79\n70-74\n65-69\n60-64\n55-59\n50-54\n45-49\n40-44\nSystolic blood pressure (mmHg)\nNon-smoking\nSmoking\nAge (y)\n< 50 years <2.5% 2.5 to <7.5% ≥ 7.5%\n50-69 years <5% 5 to <10% ≥ 10%\n≥ 70 years <7.5% 7.5 to <15% ≥ 15%\nSCORE2 & SCORE2-OP 10-year risk of (fatal and non-fatal) CV events in populations at moderate CVD risk\nNon-smoking\nSmoking\nNon-HDL cholesterol\nWomen Men\nSCORE2-OP\nSCORE2\nmmol/L\n150 200 250 150 200 250 150 200 250 150 200 250 mg/dL\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\nFigure 3  Continued.\nESC Guidelines 3247\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n1 1 1 1\n1 1 2 2\n15 16 17 18\n12\n8 8 8 9\n10 10 11 11\n12 13 14 14\n5 5 6 6\n6 7 7 8\n8 9 9 10\n11 11 13\n5 5 6 7\n3 3 4 4\n4 4 5 5\n5 6 7 7\n7 8 9 10\n2 2 2 3\n2 3 3 4\n3 4 4 5\n3 3 3 4\n3 4 4 5\n1 1 1 2\n1 2 2 2\n2 2 3 4\n2 2 2 2\n2 2 3 3\n3 3 4 5\n26 27 29 30\n23\n13 14 14 15\n16 17 18 19\n21 22 23 24\n9 10 11 11\n12 13 14 15\n15 16 18 19\n20 21 25\n11 13 14 16\n6 7 8 8\n8 9 10 11\n11 12 14 15\n15 16 18 20\n4 5 6 6\n6 7 8 9\n8 10 11 13\n6 7 8 9\n8 9 10 12\n3 4 4 5\n4 5 6 7\n6 7 9 10\n4 5 6 6\n1 2 2 3\n2 2 3 4\n17 18 20 22\n16\n9 10 11 12\n11 12 13 15\n14 15 16 18\n6 7 8 9\n8 9 10 11\n10 11 13 14\n13 13 18\n7 8 10 11\n4 5 6 7\n6 6 7 9\n7 8 10 11\n9 11 12 14\n3 3 4 5\n4 5 6 7\n5 6 8 9\n4 5 5 6\n5 6 7 9\n2 2 3 4\n3 3 4 5\n4 5 6 7\n3 3 4 5\n3 4 5 6\n4 5 6 7\n25 28 30 32\n25\n14 15 17 18\n17 19 20 22\n21 23 25 27\n10 12 13 15\n13 15 16 18\n16 18 20 23\n20 23 28\n13 15 18 21\n8 9 10 12\n10 11 13 15\n13 15 17 19\n16 19 21 24\n6 7 8 9\n8 9 11 14\n10 13 15 18\n7 9 10 12\n10 12 14 16\n4 5 7 8\n6 7 9 11\n8 10 13 16\n6 7 8 10\n53 55 57 58\n40 42 44 45\n44 46 48 50\n47 49 51 52\n50 52 54 55\n29 31 32 34\n32 34 36 37\n36 38 39 41\n22 23 24 25\n25 27 28 29\n29 31 32 34\n20\n21 22 25\n18 19 20 22\n11 12 13 14\n14 15 16 17\n17 18 19\n24\n58 59 61 63\n49 51 53 55\n49 51 52 54\n52 53 55 57\n55 56 58 60\n36 38 40 41\n40 42 44 46\n44 46 48 50\n31 32 34 36\n35 37 39 41\n41 43 45 47\n33\n33 35 39\n26 28 29 31\n19 20 21 22\n23 24 26 27\n28 29 31\n37\n42 49 57 65\n34 40 45 51\n36 43 51 58\n38 45 53 61\n40 47 55 63\n26 30 35 40\n29 33 38 44\n31 36 42 47\n21 24 27 30\n24 27 31 34\n28 32 35 39\n24\n23 25 29\n18 20 23 26\n12 14 15 16\n15 17 18 20\n19 20 22\n27\n41 49 56 65\n38 44 50 56\n36 43 50 58\n38 45 52 60\n40 47 54 62\n29 34 39 44\n32 37 42 48\n35 40 46 52\n27 30 34 37\n31 34 38 43\n35 39 44 48\n34\n33 35 41\n23 26 29 33\n18 20 22 23\n22 24 26 28\n27 29 32\n38\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n85-89\n80-84\n75-79\n70-74\n65-69\n60-64\n55-59\n50-54\n45-49\n40-44\nSystolic blood pressure (mmHg)\nNon-smoking\nSmoking\nAge (y)\n< 50 years <2.5% 2.5 to <7.5% ≥ 7.5%\n50-69 years <5% 5 to <10% ≥ 10%\n≥ 70 years <7.5% 7.5 to <15% ≥ 15%\nSCORE2 & SCORE2-OP 10-year risk of (fatal and non-fatal) CV events in populations at high CVD risk\nNon-smoking\nSmoking\nNon-HDL cholesterol\nWomen Men\nSCORE2-OP\nSCORE2\nmmol/L\n150 200 250 150 200 250 150 200 250 150 200 250 mg/dL\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\nFigure 3  Continued.\n3248 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n2 2 2 3\n3 3 4 4\n27 28 30 31\n22\n15 16 16 17\n18 19 20 21\n22 23 24 26\n10 11 11 12\n12 13 14 15\n16 17 18 19\n20 21 24\n10 11 12 14\n7 7 8 9\n8 9 10 11\n11 12 13 14\n14 15 17 18\n4 5 5 6\n5 6 7 8\n7 8 9 10\n6 6 7 8\n8 9 9 11\n3 3 3 4\n4 4 5 6\n5 6 7 8\n4 4 5 6\n5 6 6 7\n7 8 9 10\n41 42 44 46\n37\n23 24 26 27\n28 30 31 33\n34 36 37 39\n17 18 20 21\n22 23 25 26\n27 29 30 32\n33 35 39\n21 23 25 28\n13 14 15 16\n16 18 19 21\n21 23 24 26\n26 28 31 33\n9 10 11 13\n12 14 15 17\n16 18 21 23\n12 13 15 17\n16 18 19 22\n7 8 9 10\n9 11 12 14\n13 15 17 19\n9 10 12 13\n3 4 4 5\n4 5 6 7\n26 28 30 32\n25\n15 17 18 19\n18 20 21 23\n22 24 26 27\n11 12 14 15\n14 15 17 18\n17 19 20 22\n20 23 27\n12 14 16 19\n8 9 10 12\n10 11 13 15\n13 14 16 18\n16 18 20 23\n6 7 8 9\n7 8 10 12\n9 11 13 16\n7 9 10 12\n10 11 13 15\n4 5 6 7\n5 6 8 10\n7 9 11 13\n5 6 8 9\n6 7 9 11\n8 9 11 13\n36 39 42 44\n36\n22 24 26 28\n26 28 30 33\n31 33 36 38\n17 19 21 23\n21 23 25 28\n25 28 31 33\n31 33 40\n21 24 28 31\n13 15 17 19\n17 19 21 24\n21 23 26 29\n25 28 32 35\n10 12 14 16\n13 16 18 22\n17 20 24 28\n13 15 17 20\n17 19 22 25\n8 10 12 14\n11 13 16 19\n14 17 20 24\n10 12 14 17\n62 63 64 65\n53 54 55 57\n56 57 58 60\n58 59 60 61\n60 61 62 63\n44 45 47 48\n47 48 49 51\n50 51 52 54\n37 39 40 41\n41 42 43 45\n44 46 47 48\n36\n37 38 41\n34 35 36 37\n26 27 28 29\n29 30 31 32\n33 34 35\n39\n65 66 67 68\n59 60 62 63\n59 60 61 63\n61 62 63 65\n63 64 65 66\n50 51 53 54\n53 54 56 57\n56 57 59 60\n46 47 48 49\n49 51 52 53\n53 55 56 58\n47\n48 49 52\n42 43 44 46\n34 36 37 38\n39 40 41 43\n43 44 46\n51\n49 54 59 64\n44 48 52 56\n46 50 55 60\n47 52 56 61\n48 53 58 63\n38 41 45 48\n40 43 47 51\n42 46 49 53\n34 36 39 41\n37 39 42 44\n40 42 45 48\n36\n35 37 40\n31 33 36 38\n25 26 28 29\n28 30 31 33\n32 33 35\n39\n49 54 59 64\n47 51 55 59\n46 50 55 60\n47 52 56 61\n48 53 58 63\n40 44 48 51\n43 46 50 54\n45 49 52 56\n39 41 44 47\n42 44 47 50\n45 48 51 54\n44\n43 45 49\n36 38 41 43\n31 33 34 36\n35 36 38 40\n39 41 42\n47\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n85-89\n80-84\n75-79\n70-74\n65-69\n60-64\n55-59\n50-54\n45-49\n40-44\nSystolic blood pressure (mmHg)\nNon-smoking\nSmoking\nAge (y)\n< 50 years <2.5% 2.5 to <7.5% ≥ 7.5%\n50-69 years <5% 5 to <10% ≥ 10%\n≥ 70 years <7.5% 7.5 to <15% ≥ 15%\nSCORE2 & SCORE2-OP 10-year risk of (fatal and non-fatal) CV events in populations at very high CVD risk\nNon-smoking\nSmoking\nNon-HDL cholesterol\nWomen Men\nSCORE2-OP\nSCORE2\nmmol/L\n150 200 250 150 200 250 150 200 250 150 200 250 mg/dL\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\nFigure 3  Continued.\nESC Guidelines 3249\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................................................. models that do not take into account the competing risk of non- CVD mortality, tend to overestimate the actual 10-year risk of CVD, and hence overestimate the potential benefit of treatment. 71   The SCORE2-OP algorithm estimates 5-year and 10-year fatal and non- fatal CVD events (myocardial infarction, stroke) adjusted for compet- ing risks in apparently healthy people aged >_70 years. 72\nSCORE2 and SCORE2-OP are calibrated to four clusters of coun- tries (low, moderate, high, and very high CVD risk) that are grouped based on national CVD mortality rates published by the WHO ( Supplementary Table 3  and  Figure  4 ). 73   Low-risk countries: Belgium, Denmark, France, Israel, Luxembourg, Norway, Spain, Switzerland, the Netherlands, and the United Kingdom (UK). Moderate-risk countries:  Austria, Cyprus, Finland, Germany, Greece, Iceland, Ireland, Italy, Malta, Portugal, San Marino, Slovenia, and Sweden. High-risk countries: Albania, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Kazakhstan, Poland, Slovakia, and Turkey.  Very high-risk countries:  Algeria, Armenia, Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kyrgyzstan, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Republic of Moldova, Romania, Russian Federation, Serbia, Syria, The Former Yugoslav Republic (Macedonia), Tunisia, Ukraine, and Uzbekistan. A multiplier approach has been used for converting CVD mortality\nrates to fatal and non-fatal CVD events. 74   The SCORE2 algorithm can be accessed in the ESC CVD Risk app (freely available from app stores) and in risk charts for the four clusters of countries ( Figure  4 ). The SCORE2 charts do not apply to persons with documented CVD or other high-risk conditions such as DM, FH, or other genetic or rare lipid or BP disorders, CKD, and in pregnant women.\nTo estimate a person’s 10-year risk of total CVD events, one must first identify the correct cluster of countries and the accompanying risk table for their sex, smoking status, and (nearest) age. Within that table, one then finds the cell nearest to the person’s BP and non- HDL-C. Risk estimates then need to be adjusted upwards as the per- son approaches the next age category.\n3.2.3.3 Translating cardiovascular disease risk to treatment thresholds While no risk threshold is universally applicable, the intensity of treat- ment should increase with increasing CVD risk. In individual cases, however, no lower threshold of total CVD risk precludes treatment of risk factors. Conversely, no high threshold for total CVD risk implies ‘mandatory’ treatment. Across the entire range of CVD risk, the decision to initiate interventions remains a matter of individual consideration and shared decision-making (see also  section 4.1 ). In general, risk factor treatment recommendations are based on\nHigh risk Moderate risk\nVery high risk Low risk\nFigure 4  Risk regions based on World Health Organization cardiovascular mortality rates. 68 , 72 , 73\n3250 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ......................................................................... categories of CVD risk (‘low-to-moderate’, ‘high’, and ‘very high’). The cut-off risk levels for these categories are numerically different for various age groups to avoid undertreatment in the young and to avoid overtreatment in older persons. As age is a major driver of CVD risk, but lifelong risk factor treatment benefit is higher in younger people, the risk thresholds for considering treatment are lower for younger people ( Table  5 ). Risk categories do not ‘automatically’ translate into recommenda- tions for starting drug treatment. In all age groups, consideration of risk modifiers, lifetime CVD risk, treatment benefit, comorbidities, frailty, and patient preferences may further guide treatment decisions. Also, note that many patients can move themselves towards a lower risk category without taking drugs just by stopping smoking. Finally, note that persons >_70 years old may be at very high risk whilst being at target SBP, and primary prevention with lipid-lowering drugs in older persons is a Class IIb (‘may consider’) recommendation; see section 4.6 . In the 50 \u0002 69-year age range, a 10-year CVD mortality risk thresh- old of 5% estimated with the previously used SCORE algorithm cor- responds, on average, to a 10-year fatal and non-fatal CVD risk threshold of 10% estimated with SCORE2, as approximately the same number of people are above the risk threshold and would qual- ify for treatment. 68\nTable 5 Cardiovascular disease risk categories based on SCORE2 and SCORE2-OP in apparently healthy people according to age\n< 50 years 50 \u0002 69\nyears\n\u0003 70 years a\nLow-to-moderate CVD\nrisk:  risk factor treatment gen-\nerally not recommended\n<2.5% <5% <7.5%\nHigh CVD risk:  risk factor treatment should be\nconsidered\n2.5 to <7.5% 5 to <10% 7.5 to <15%\nVery high CVD risk:  risk fac- tor treatment generally\nrecommended a\n>_7.5% >_10% >_15%\nCVD = cardiovascular disease. a In apparently healthy people >_70 years old, the treatment recommendation for lipid-lowering drugs is Class IIb (‘may be considered’). The division of the population into three distinct age groups (<50, 50 \u0002 69, and >_70 years) results in a discontinuous increase in risk thresholds for low-to-mod- erate, high, and very high risk. In reality, age is obviously continuous, and a sensi- ble application of the thresholds in clinical practice would require some ﬂexibility in handling these risk thresholds as patients move towards the next age group, or recently passed the age cut-off.  Figure  5  illustrates how a continuous increase in age relates to increasing risk thresholds, and may be used as a guide for daily practice.\nESC 2021\n30\n25\n22.5\n20\n17.5\n15\n12.5\n10\n7.5\n5\n2.5\n40 50 60 70 80 90\nAge groups (years)\n50-69 <50 ≥ 70\n10-year CVD risk (%)\nCVD risk thresholds (%)\nVery high CVD risk\nHigh CVD risk\nLow-to-moderate CVD risk\nFigure 5  Schematic representation of increasing 10-year cardiovascular disease risk thresholds across age groups. CVD = atherosclerotic cardiovascular disease.\nESC Guidelines 3251\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nEstimate 10-year CVD risk (SCORE2)\nApparently healthy persons a\nAND\nStop smoking, lifestyle recommendations and SBP <160 mmHg (Class I) STEP 1\nConsider risk modiﬁers, lifetime CVD risk and treatment beneﬁt b , patient preferences\nEstimate 10-year CVD risk (SCORE2) Estimate 10-year CVD risk (SCORE2-OP)\nAge 50 – 69 years sr a e y 0 7  ≥  e g A sr a e y 0 5  <  e g A b\nNo additional prevention goals\nSBP <140 to 130 mmHg if tolerated (Class I)\nSBP <140 to 130 mmHg if tolerated (Class I)\nLDL-C <2.6 mmol/L (<100 mg/dL) (Class IIb)\n<2.5% ≥ 7.5% % 5 1 ≥ % 5.7 < % 5.7 <  o t 5.2 7.5 to <15%\nConsider risk modiﬁers, lifetime treatment beneﬁt b , comorbidities, frailty, polypharmacy, patient preferences\nNo additional prevention goals\nAND\nNo additional prevention goals\nLDL-C <2.6 mmol/L (<100 mg/dL) (Class IIa)\nFor speciﬁc risk factor management in patients  ≥ 70 years, please see Section 4\nSTEP 2\n10-year CVD risk (SCORE2) Lifetime CVD risk and treatment beneﬁt b\nComorbidities, frailty Patient preferences\n",
      "keywords": [
        "cvd risk",
        "10-year risk",
        "lipid",
        "genetic",
        "treatment",
        "goals",
        "class i",
        "based",
        "risk stratification",
        "diabetes",
        "sex",
        "score2-op",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "may be considered",
        "risk estimation",
        "score2",
        "cholesterol",
        "hdl-c",
        "ldl-c",
        "older",
        "systolic",
        "primary prevention",
        "blood pressure",
        "lipoprotein",
        "intensified",
        "hdl cholesterol"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3251",
          "page_number": 24,
          "content": " | <50 years | 50\u000269\nyears | \u000370 yearsa | ESC 2021\nLow-to-moderate CVD\nrisk: risk factor treatment gen-\nerally not recommended | <2.5% | <5% | <7.5% | \nHigh CVD risk: risk factor\ntreatment should be\nconsidered | 2.5 to <7.5% | 5 to <10% | 7.5 to <15% | \nVery high CVD risk: risk fac-\ntor treatment generally\nrecommendeda | >7.5%\n_ | >10%\n_ | >15%\n_ | ",
          "bbox": [
            49.87405204772949,
            95.81245252821181,
            295.1741027832031,
            232.60484212239584
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "9",
      "title": "Intensiﬁed treatment based on:",
      "start_page": 25,
      "end_page": 26,
      "content": "SBP <130 mmHg if tolerated (Class I)\nLDL-C (Class IIa)\nHigh risk <1.8 mmol/L (<70 mg/dL)\nVery high risk <1.4 mmol/L (<55 mg/dL)\nAND\nSTEP 2\nConsider risk modiﬁers, lifetime CVD risk\npatient preferences\nNo additional prevention goals\n<5% ≥ 10% 5 to <10%\nand treatment beneﬁt b ,\nFigure 6  Flow chart of cardiovascular disease risk and risk factor treatment in apparently healthy persons. ASCVD = atherosclerotic cardiovascular dis- ease; CKD = chronic kidney disease; CVD = cardiovascular disease; DM = diabetes mellitus; ESC = European Society of Cardiology; FH = familial hyper- cholesterolaemia; LDL-C = low-density lipoprotein cholesterol; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; SBP = systolic blood pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons. Solid lines represent default options for the majority of people. Dotted lines represent alternative choices for some, depending on the patient-specific characteristics and condi- tions indicated in the boxes. Ultimate treatment goals for SBP (<130 mmHg) and LDL-C (according to level of risk) according to the respective ESC Guidelines are to be pursued as indicated. The stepwise approach has to be applied as a whole: after STEP 1, considering proceeding to the intensified goals of STEP 2 is mandatory. Risk scores are available in the ESC CVD Risk Calculator app for mobile devices (https://www.escardio.org/Education/ESC- Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app) and at websites such as https://www.u-prevent.com.   a Does not include patients with CVD, DM, CKD, or FH.   b The LIFE-CVD model for estimating lifetime CVD risk and treatment benefit is calibrated for low- and moderate- risk regions (see  Box  1 ).\n3252 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................ As the 10-year CVD risk thresholds guide treatment decisions and have an impact on healthcare costs and resources, countries or regions may decide on using higher or lower treatment thresholds.\n3.2.3.4 Risk estimation and risk factor treatment in apparently healthy people 50 \u0002 69 years of age Stopping smoking, lifestyle recommendations, and SBP <160 mmHg are recommended for all ( Figure  6 ). A 10-year CVD risk (fatal and non- fatal ASCVD events) >_10% is generally considered ‘very high risk’, and treatment of CVD risk factors is recommended. A 10-year CVD risk of 5 to <10% is considered ‘high risk’, and treatment of risk factors should\nbe considered, taking CVD risk modifiers, lifetime risk and treatment benefit (in low- and moderate-risk regions,  Box  1 ), and patient preferen- ces into account. A 10-year CVD risk <5% is considered ‘low-to-mod- erate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers (see  section 3.3 ) increase risk, or the estimated lifetime risk and treatment benefit is considered substantial.\n3.2.3.5 Risk estimation and risk factor treatment estimation in appa- rently healthy people  \u0003 70 years of age Stop smoking, lifestyle recommendations and a SBP <160 mmHg are recommended for all ( Figure  6 ). Age is the dominant driver of CVD\nSTEP 2\nPatients with established ASCVD a\nStop smoking and lifestyle recommendations (Class I)\nLDL-C ≥ 50% reduction and <1.8 mmol/L (<70 mg/dL) (Class I)\nSBP <140  to 130 mmHg if tolerated (Class I)\nAntithrombotic Therapy (Class I)\nAND\nResidual 10-year CVD risk c\nLifetime CVD risk and treatment benefit d\nComorbidities, frailty Patient preferences\n",
      "keywords": [
        "cvd risk",
        "risk calculator",
        "treatment",
        "class i",
        "based",
        "diabetes",
        "score2-op",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "risk estimation",
        "score2",
        "cholesterol",
        "ldl-c",
        "older",
        "systolic",
        "blood pressure",
        "lipoprotein",
        "age",
        "lifetime risk"
      ],
      "tables": []
    },
    {
      "number": "10",
      "title": "Intensified treatment based on:",
      "start_page": 26,
      "end_page": 28,
      "content": "STEP 1 b\nSBP <130 mmHg if tolerated (Class I)\nLDL-C <1.4 mmol/L (<55 mg/dL) (Class I)\nDAPT, DPI, novel upcoming interventions (e.g. colchicine, EPA) (Class IIb)\nAND AND\nFigure 7  Flow chart of cardiovascular risk and risk factor treatment in patients with established atherosclerotic cardiovascular disease. Ultimate treat- ment goals for SBP (<130 mmHg) and LDL-C (according to level of risk) according to the respective ESC Guidelines 3 , 4   are to be pursued as indicated. The stepwise approach has to be applied as a whole: after STEP 1, considering proceeding to the intensified goals of STEP 2 is mandatory. ACS = acute coro- nary syndromes; ASCVD = atherosclerotic cardiovascular disease; CR = cardiac rehabilitation; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; ESC = European Society of Cardiology; EUROASPIRE = European Action on Secondary and Primary Prevention by Intervention to Reduce Events; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure; SMART = Secondary Manifestations of Arterial Disease. Risk scores are available in the ESC CVD Risk Calculator app for mobile devices (https://www.escardio.org/Education/ESC-Prevention- of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation-app) and at websites such as https://www.u-prevent.com.   a For patients with DM see DM flow chart ( Figure  8 ).   b For patients with recent ACS, these prevention goals are part of participation in CR (Class I/A).   c For patients aged >_70 years, a high 10-year risk may be associated with a lower absolute lifetime benefit from treatment due to limited life expectancy.   d Lifetime treatment benefit is expressed as extra CVD-free life gained from a certain intervention or treatment intensification.\nESC Guidelines 3253\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................................................................................. risk, and estimated 10-year CVD risk of almost all individuals >_70 years exceeds conventional risk thresholds. Also, lifetime benefit of treatment in terms of time gained free of CVD is lower in older peo- ple. Therefore, the CVD risk thresholds for risk factor treatment are higher in apparently healthy people >_70 years. A 10-year CVD risk >15% is generally considered ‘very high risk’, and treatment of ASCVD risk factors is recommended (note: the recommendation for lipid-lowering treatment in apparently healthy people >_70 years is class IIb; ‘may be considered’; see  section 4.6 ). A 10-year CVD risk of 7.5 to <15% is considered ‘high risk’, and treatment of risk factors should be considered taking CVD risk modifiers, frailty, lifetime treat- ment benefit (in low and moderate risk regions,  Box  1 ), comorbid- ities, polypharmacy, and patient preferences into account. Given the subjective nature of many of these factors, it is not possible to define strict criteria for these considerations. A 10-year CVD risk <7.5% is considered ‘low-to-moderate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers ( section 3.3 ) increase risk or the estimated lifetime risk and treatment benefit is considered substantial. 75 \u0002 79\n3.2.3.6 Risk estimation and risk factor treatment in apparently healthy people  < 50 years of age Stopping smoking, lifestyle recommendations, and SBP <160 mmHg are recommended for all ( Figure  6 ). The 10-year CVD risk in relatively young, apparently healthy people is on average low, even in the pres- ence of high risk factor levels, but the lifetime CVD risk is in these cir- cumstances very high. In apparently healthy people <50 years of age, a 10-year CVD risk >_7.5% is generally considered ‘very high risk’ as this risk relates to a high lifetime risk, and treatment of ASCVD risk factors is recommended. A 10-year CVD risk of 2.5 to <7.5% is considered ‘high risk’, and treatment of risk factors should be considered, taking CVD risk modifiers, lifetime risk and treatment benefit (in low- and\nmoderate-risk regions), and patient preferences into account. A 10- year CVD risk <2.5% is considered ‘low-to-moderate risk’, and would generally not qualify for risk factor treatment unless one or several risk modifiers (see  section 3.3 ) increase risk or the estimated lifetime risk and treatment benefit is considered substantial (see  Box  1 ) ( Figure  6 ). 75 \u0002 78\nIn risk communication with younger people, the lifetime benefit perspective may be useful, as well as discussing the potential of avoid- ing a devastating CVD event in the short-to-intermediate term, despite the fact that 10-year CVD risk may be very low. CVD risk predictions, as well as predictions of lifetime benefit of risk factor treatment, are likely to be imprecise at very young age (<40 years). At that age, lipid-lowering and BP-lowering drug treat- ment are not usually considered, except for patients with FH or spe- cific BP disorders. A healthy lifestyle that is maintained throughout life is more relevant for the very young. Mendelian randomization studies illustrate very nicely that relatively small differences in LDL-C or SBP maintained throughout life have large implications on CVD risk over a lifespan. 80\n3.2.3.7 Risk estimation and risk factor treatment in patients with estab- lished atherosclerotic cardiovascular disease Patients with clinically established ASCVD are, on average, at very high risk of recurrent CVD events if risk factors are not treated. Therefore, smoking cessation, adoption of a healthy lifestyle, and risk factor treatment is recommended in all patients (STEP 1). Further intensification of risk factor treatment by aiming at lower treatment goals (STEP 2) is beneficial in most patients and must be considered, taking 10-year CVD risk, comorbidities, lifetime risk and treatment benefit ( Box  1 ), frailty, and patient preferences into account in a shared decision-making process ( Figure  7 ). After initial risk factor treatment and the achievement of risk factor treatment goals, the individual  residual  risk for recurrent\nBox 1. Lifetime CVD risk and treatment benefit estimation\nPrevention of CVD by treating risk factors is usually done with a lifetime perspective. Lifetime CVD risk can be approximated by clinical expe- rience with clinical criteria such as age, (change in) risk factor levels, risk modifiers, etc. or estimated in apparently healthy people, patients with established ASCVD, and persons with type 2 DM with specific lifetime CVD risk scores. 75 \u0002 77   Lifetime benefit from risk factor manage- ment can be estimated by combining lifetime risk models with HRs derived from RCTs, meta-analyses of RCTs, or Mendelian randomization studies, which may provide estimates of the effects of longer-term treatment of risk factors. Online calculators (such as the ESC CVD Risk app) can be used to estimate the average lifetime benefit of smoking cessation (see also  Figure  11 ), lipid lowering (see also  Figure  12 ), and BP lowering (see also  Figure  15 ) on an individual patient level expressed as extra CVD-free life-years. 78   Average lifetime benefit is easy to interpret and may improve the communication of potential therapy benefits to patients in a shared decision-making process. This may in turn increase patient engagement, self-efficacy, and motivation to adhere to lifestyle changes and drug treatment.\nThe lifetime risk is an estimate of the age at which there is a 50 %  probability that a person will either have experienced a CVD event or have died. Lifetime benefit is the numerical difference between the predicted age at which there is a 50 %  probability that a person will either have experienced a CVD event or have died with and without a proposed treatment. Currently there are no formal treatment thresholds for aver- age lifetime benefit. In addition, the estimated individual lifetime benefit should be viewed in the light of the estimated duration of treatment. Duration of lifelong treatment will generally be longer in young persons compared to older people. Both treatment effect and treatment dura- tion determine the individual ‘return on investment’ of risk factor treatment. In a shared decision-making process between healthcare provider and patient, the minimum desired benefit of a certain treatment needs to be established, a process in which patient preference, expected treatment harms, and costs can be taken into account.\nBP = blood pressure; CVD = cardiovascular disease; DM = diabetes mellitus; ESC = European Society of Cardiology; HR = hazard ratio; RCT = randomized controlled trial.\n3254 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nHigh b Moderate b\nEstablished ASCVD or severe TOD a\nPatients with type 2 diabetes mellitus\nAND Stop smoking and lifestyle recommendations (Class I) HbA1c: <53 mmol/mol (<7.0%) (Class I)\nSTEP 1\nRisk\nResidual 10-year CVD risk\nLifetime CVD risk and treatment benefit d\nComorbidities, frailty\nPatient preferences\n",
      "keywords": [
        "cvd risk",
        "10-year risk",
        "lipid",
        "risk calculator",
        "treatment",
        "class i",
        "based",
        "diabetes",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "may be considered",
        "risk estimation",
        "cardiovascular risk",
        "cholesterol",
        "ldl-c",
        "older",
        "systolic",
        "primary prevention",
        "hba1c",
        "blood pressure",
        "lipoprotein",
        "intensified",
        "should be considered",
        "age",
        "lifetime risk"
      ],
      "tables": []
    },
    {
      "number": "11",
      "title": "Intensified treatment based on:",
      "start_page": 28,
      "end_page": 28,
      "content": "SBP <130 mmHg if tolerated (Class I)\nSGLT2-i or GLP-1RA if not already on it c\n(Class I)\nLDL-C <1.4 mmol/L (<55 mg/dL) (Class I)\nDAPT, DPI, novel upcoming interventions (e.g. colchicine, EPA) (Class IIb)\n10-year CVD risk\nLifetime CVD risk and treatment benefit d\nComorbidities, frailty\nPatient preferences\n",
      "keywords": [
        "sglt2",
        "sbp",
        "cvd risk",
        "ldl-c",
        "treatment",
        "class i",
        "based",
        "intensified"
      ],
      "tables": []
    },
    {
      "number": "12",
      "title": "Intensified treatment based on:",
      "start_page": 28,
      "end_page": 30,
      "content": "SBP <130 mmHg if tolerated (Class I)\nSGLT2-i or GLP-1RA if not already on it (Class IIb)\nLDL-C <1.8 mmol/L (<70 mg/dL) (Class I)\nSBP <140 to 130 mmHg if tolerated (Class I)\nLDL-C  ≥ 50% reduction and <1.8 mmol/L  (<70 mg/dL) (Class I)\nAntithrombotic therapy (Class I)\nSGLT2-i or GLP-1RA... c\n… for TOD: Class IIb\n… for CVD: Class I\nSBP <140 to 130 mmHg if tolerated (Class I)\nLDL-C  <2.6 mmol/ (<100 mg/dL) (Class I)\nAdditional prevention goals generally not recommended (Class III)\nSTEP 2\nWithout\nWith\nFigure 8  Flow chart of cardiovascular risk and risk factor treatment in patients with type 2 diabetes mellitus. Ultimate treatment goals for SBP (<130 mmHg) and LDL-C (according to level of risk) according to the respective ESC Guidelines 3 , 4   are to be pursued as indicated. The stepwise approach has to be applied as a whole: after STEP 1, considering proceeding to the intensified goals of STEP 2 is mandatory. Risk scores are available in the ESC CVD Risk Calculator app for mobile devices (https://www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/Risk-assessment/esc-cvd-risk-calculation- app) and at websites such as https://www.u-prevent.com. ACR = albumin-to-creatinine ratio; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; ESC = European Society of Cardiology; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; HF = heart failure; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure; SGLT2 = sodium-glucose cotransporter 2; TOD = target organ damage (retin- opathy, nephropathy, neuropathy).   a Severe TOD is defined as at least one of: eGFR <45 mL/min/1.73 m 2   irrespective of the presence or absence of albumi- nuria; eGFR 46 \u0002 59 mL/min/1.73 m 2   and microalbuminuria (ACR 30 \u0002 300 mg/g or 3 \u0002 30 mg/mmol); proteinuria (ACR >300 mg/g or >30 mg/mmol); presence of microvascular disease in at least three different sites (e.g. microalbuminuria plus retinopathy plus neuropathy).   b See  Table  4  for CVD risk groups. c Patients with prevalent HF or CKD are recommended for SGLT2 inhibitor, and patients post stroke are recommended for GLP-1RA treatment.  d Lifetime treatment benefit is expressed as extra CVD-free life gained from a certain intervention or treatment intensification. See  Box  1 .\nESC Guidelines 3255\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nCVD varies widely and should be considered. 81   It is evident that patients with a recent ACS or progressive vascular disease, and patients with DM and vascular disease, are all at exceptionally high risk for recurrent CVD events. For other patients with established ASCVD, the residual risk may be less evident and could be esti- mated based on clinical criteria such as age, (change in) risk factor levels, and risk modifiers, or by calculation of residual CVD risk with a calculator.\nThe risk of recurrent CVD is influenced mainly by classical risk fac- tors, vascular disease site, and kidney function. Risk stratification tools for secondary prevention include the SMART (Secondary Manifestations of Arterial Disease) risk score (available in the ESC CVD Risk app) for estimating 10-year residual CVD risk in patients with stable ASCVD, defined as CAD, PAD, or cerebrovascular dis- ease, 81   and the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) risk model, which estimates 2-year risk of recurrent CVD in patients with stable CAD. 82\nOccasionally, recurrent CVD risk is very high despite maximum (tolerated) conventional treatments. In such cases, novel but less well-established preventive treatments such as dual antithrombotic pathway inhibition, 83   icosapent ethyl, 84   or anti-inflammatory therapy with colchicine (see  section 4.10 ) 85 , 86   may be considered.\n3.2.3.8 Risk estimation and risk factor treatment in persons with type 2 diabetes mellitus Most adults with type 2 DM are at high or very high risk for future CVD, particularly from middle age onwards. On average, type 2 DM doubles CVD risk and reduces life expectancy by 4 - 6 years, with absolute risks highest in those with any target organ damage (TOD). Type 2 DM also increases the risk for cardiorenal outcomes, in par- ticular HF and CKD. Relative risks (RRs) for CVD in type 2 DM are higher at younger ages of onset and are modestly higher in women compared with men. 87   Smoking cessation and adoption of a healthy lifestyle are recommended for all people with type 2 DM, and risk fac- tor treatment should be considered in all people with DM, at least those above the age of 40 years (see  sections 4.6  and  4.7 ). Still, there is a wide range in individual risk for CVD events, especially after initial risk factor management. 88\nPersons with DM with severe TOD (for definition: see  Table  4 ) can be considered to be at very high CVD risk, similar to people with established CVD (see  Table  4 ). Most others with DM are considered to be at high ASCVD risk. 64   However, an exception can be made for patients with well-controlled short-standing DM (e.g. <10 years), no evidence of TOD, and no additional ASCVD risk factors, who may be considered as being at moderate CVD risk.\nIn addition to the semi-quantitative division into three risk catego- ries described above, DM-specific risk models may refine risk esti- mates and illustrate the impact of treatments. These models generally include duration of DM, glycated haemoglobin (HbA1c) level, and presence of TOD. Examples are the ADVANCE (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation) risk score, which predicts 10-year CVD risk, and the UKPDS (UK Prospective Diabetes Study) risk engine, which predicts fatal and non-fatal CVD risk and is available for use in the UK. However, we recommend cautious use of these calculators, since both are based on older cohort data 89 , 90   ( Figure  8 ).\nRecommendations for CVD risk estimation\nRecommendations Class a Level b\nIn apparently healthy people <70 years without established ASCVD, DM, CKD, genetic/rarer\nlipid or BP disorders, estimation of 10-year fatal\nand non-fatal CVD risk with SCORE2 is recommended. 68\nI B\nIn apparently healthy people >_70 years without\nestablished ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estimation of 10-year fatal\nand non-fatal CVD risk with SCORE2-OP is\nrecommended. 72\nI B\nIn apparently healthy people, after estimation of 10-year fatal and non-fatal CVD risk, lifetime\nrisk and treatment beneﬁt, risk modiﬁers, frailty,\npolypharmacy, and patient preferences should be considered.\nIIa C\nPatients with established ASCVD and/or DM\nand/or moderate-to-severe renal disease and/or genetic/rarer lipid or BP disorders are to be\nconsidered at high or very high CVD\nrisk. 75 , 77 , 81 , 88 \u0002 90\nI A\nA stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is rec-\nommended for apparently healthy people at\nhigh or very high CVD risk, as well as patients with established ASCVD and/or DM, with con-\nsideration of CVD risk, treatment beneﬁt of risk\nfactors, risk modiﬁers, comorbidities, and patient preferences. 66 , 67\nI B\nTreatment of ASCVD risk factors is recom-\nmended in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP\ndisorders who are at very high CVD risk\n(SCORE2 >_7.5% for age under 50; SCORE2 >_10% for age 50 \u0002 69; SCORE2-OP >_15% for\nage >_70 years). 68 , 72\nI C\nTreatment of ASCVD risk factors should\nbe considered in apparently healthy people without DM, CKD, genetic/rarer lipid, or BP\ndisorders who are at high CVD risk (SCORE2\n2.5 to <7.5% for age under 50; SCORE2 5 to <10% for age 50 \u0002 69; SCORE2-OP 7.5 to\n<15% for age >_70 years), taking CVD risk\nmodiﬁers, lifetime risk and treatment beneﬁt, and patient preferences into\naccount.\nIIa C\nASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CKD = chronic kidney disease (see deﬁnition in  Table  4 ); DM = diabetes mellitus; SCORE2 = Systemic Coronary Risk Estimation 2; SCORE2-OP = Systemic Coronary Risk Estimation 2-Older Persons. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................................................................................\n3256 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...........................................................\nIntensification of risk factor treatment in STEP 2 must be consid- ered in all patients, taking into account 10-year CVD risk, comorbid- ities, lifetime risk and treatment benefit ( Box  1 ), frailty, and patient preferences in a shared decision-making process. 75\n3.2.3.9 Risk estimation and risk factor treatment in persons with type 1 diabetes mellitus People with type 1 DM are at increased CVD risk, and earlier manifes- tation of type 1 DM relates to more life-years lost in women than men, mostly due to CVD. 91   RRs of CVD are, on average, higher in type 1 vs. type 2 DM, due to an average of three to four extra decades of hyper- glycaemia, and usual risk factors contribute strongly to CVD outcomes in type 1 DM. 92   CVD risks have declined over time, commensurate with improvements in life expectancy. 93   Lifetime CVD risks in type 1 DM are higher with poorer glycaemic control, lower social class, and younger age of onset. The absolute risk of CVD events or CVD mor- tality is highest among those with any evidence of microvascular dis- ease, particularly renal complications, and is strongly influenced by age. CVD risk stratification in persons with type 1 DM may be based on the same risk classification as for type 2 DM, summarized in  Table  4 , although the level of evidence for type 1 DM is weaker.\n3.2.4. Communication of cardiovascular disease risk Reducing CVD risk at the individual level begins with appropriate assessment of individual risk and effective communication of risk and anticipated risk reduction by risk factor treatment. Patient-doctor interactions are complex and communicating risk is challenging. 94 , 95\nThere is no single ‘correct’ approach; rather, it will depend on the individual’s preferences and understanding, which may differ with education status and numeracy. Risk perception is also strongly affected by emotional factors such as fear, optimism, etc. (‘patients don’t think risk, they feel risk’). 96\nIt is important to explore whether patients understand their risk, the anticipated risk reduction, and the pros and cons of intervention, and to identify what is important to them. For example, one patient may focus on living free of medications, whereas another may be less able to change their lifestyle. In terms of outcomes, reducing mortal- ity risk is crucial to some, whereas disease risk is more important to others. Short-term risk may motivate some patients, whereas lifetime benefit (see  Box  1 ) will have more impact in others. In general, visual aids (graphs etc.) improve risk understanding, absolute risk (reduc- tion) is better understood than RR (reduction), and the use of ‘num- bers needed to treat’ is less well understood. In apparently healthy people, the standard approach is to report absolute 10-year risk of a CVD event with SCORE2 or SCORE2-OP, which can be found at the ESC CVD Risk Calculator app (https:// www.escardio.org/Education/ESC-Prevention-of-CVD-Programme/ Risk-assessment/esc-cvd-risk-calculation-app) or at http:// www.heartscore.org or https://www.u-prevent.com. In specific situa- tions, one may opt for expressing risk in terms other than absolute 10-year risk. Examples of such situations include risks in young or very old people. In young people, lifetime risk might be more infor- mative, as 10-year CVD risk is usually low even in the presence of risk factors. In older persons, specific risk estimation is required, tak- ing competing non-CVD mortality into account. 78   Direct translation\nof RRs to treatment decisions is not recommended, as absolute risk remains the key criterion for starting treatment.\nAn alternative way of expressing individual risk is to calculate a per- son’s ‘risk age’. 96   The risk age of a person with several ASCVD risk factors is the age of a person of the same sex with the same level of risk but with low levels of risk factors. Risk age is an intuitive and easily understood way of illustrating the likely reduction in life expectancy that a young person with a low absolute but high RR of CVD will be exposed to if preventive measures are not adopted. Risk age is also automatically calculated as part of HeartScore (http://www.hearts- core.org/). 97 \u0002 99\nCVD risk may also be expressed with a lifetime rather than a 10- year horizon, for example, the LIFE-CVD (LIFEtime-perspective CardioVascular Disease) calculator (ESC CVD Risk Calculation app or https://www.u-prevent.com) (also see  Box  1 ). 78   Lifetime CVD risk-prediction models identify high-risk individuals both in the short and long term. Such models account for predicted risk in the context of competing risks from other diseases over the remaining expected lifespan of an individual. A similar approach also employing lifetime perspective is to calculate lifetime benefit of preventive\nRecommendation for CVD risk communication\nRecommendation Class a Level b\nAn informed discussion about CVD risk and treatment beneﬁts tailored to the needs of a\npatient is recommended. 96\nI C\nCVD = cardiovascular disease. a Class of recommendation. b Level of evidence.\nRecommendations for CVD risk modiﬁers\nRecommendations Class a Level b\nStress symptoms and psychosocial stressors modify CVD risk. Assessment of these stressors\nshould be considered. 100 \u0002 102\nIIa B\nCAC scoring may be considered to improve risk classiﬁcation around treatment decision thresh-\nolds. Plaque detection by carotid ultrasound is\nan alternative when CAC scoring is unavailable or not feasible. 103 , 104\nIIb B\nMultiplication of calculated risk by RR for speciﬁc\nethnic subgroups should be considered. 105 IIa B\nThe routine collection of other potential modi- ﬁers, such as genetic risk scores, circulating or\nurinary biomarkers, or vascular tests or imaging\nmethods (other than CAC scoring or carotid ultrasound for plaque determination), is not\nrecommended.\nIII B\nCVD = cardiovascular disease; CAC = coronary artery calcium; RR = relative risk. a Class of recommendation. b Level of evidence.\n",
      "keywords": [
        "cvd risk",
        "10-year risk",
        "lipid",
        "risk calculator",
        "genetic",
        "treatment",
        "class i",
        "based",
        "risk stratification",
        "diabetes",
        "coronary artery",
        "sex",
        "score2-op",
        "secondary prevention",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "may be considered",
        "heart failure",
        "level b",
        "risk estimation",
        "score2",
        "cardiovascular risk",
        "cholesterol",
        "sglt2",
        "ldl-c",
        "older",
        "systolic"
      ],
      "tables": [
        {
          "title": "3256 ESC Guidelines",
          "page_number": 29,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn apparently healthy people <70 years without\nestablished ASCVD, DM, CKD, genetic/rarer\nlipid or BP disorders, estimation of 10-year fatal\nand non-fatal CVD risk with SCORE2 is\nrecommended.68 | I | B | \nIn apparently healthy people >70 years without\n_\nestablished ASCVD, DM, CKD, genetic/rarer\nlipid or BP disorders, estimation of 10-year fatal\nand non-fatal CVD risk with SCORE2-OP is\nrecommended.72 | I | B | \nIn apparently healthy people, after estimation of\n10-year fatal and non-fatal CVD risk, lifetime\nrisk and treatment benefit, risk modifiers, frailty,\npolypharmacy, and patient preferences should\nbe considered. | IIa | C | \nPatients with established ASCVD and/or DM\nand/or moderate-to-severe renal disease and/or\ngenetic/rarer lipid or BP disorders are to be\nconsidered at high or very high CVD\nrisk.75,77,81,88\u000290 | I | A | \nA stepwise treatment-intensification approach\naiming at intensive risk factor treatment is rec-\nommended for apparently healthy people at\nhigh or very high CVD risk, as well as patients\nwith established ASCVD and/or DM, with con-\nsideration of CVD risk, treatment benefit of risk\nfactors, risk modifiers, comorbidities, and\npatient preferences.66,67 | I | B | \nTreatment of ASCVD risk factors is recom-\nmended in apparently healthy people\nwithout DM, CKD, genetic/rarer lipid, or BP\ndisorders who are at very high CVD risk\n(SCORE2 >7.5% for age under 50; SCORE2\n_\n>10% for age 50\u000269; SCORE2-OP >15% for\n_ _\nage >70 years).68,72\n_ | I | C | \nTreatment of ASCVD risk factors should\nbe considered in apparently healthy people\nwithout DM, CKD, genetic/rarer lipid, or BP\ndisorders who are at high CVD risk (SCORE2\n2.5 to <7.5% for age under 50; SCORE2 5 to\n<10% for age 50\u000269; SCORE2-OP 7.5 to\n<15% for age >70 years), taking CVD risk\n_\nmodifiers, lifetime risk and treatment\nbenefit, and patient preferences into\naccount. | IIa | C | ESC 2021",
          "bbox": [
            308.77730778285434,
            76.96976928710937,
            553.9181303136489,
            648.3002232142857
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3257",
          "page_number": 30,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nAn informed discussion about CVD risk and\ntreatment benefits tailored to the needs of a\npatient is recommended.96 | I | C | ESC 2021",
          "bbox": [
            313.3902330069706,
            71.86734212239584,
            558.5274772644043,
            131.9972381591797
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3257",
          "page_number": 30,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nStress symptoms and psychosocial stressors\nmodify CVD risk. Assessment of these stressors\nshould be considered.100\u0002102 | IIa | B | \nCAC scoring may be considered to improve risk\nclassification around treatment decision thresh-\nolds. Plaque detection by carotid ultrasound is\nan alternative when CAC scoring is unavailable\nor not feasible.103,104 | IIb | B | \nMultiplication of calculated risk by RR for specific\nethnic subgroups should be considered.105 | IIa | B | \nThe routine collection of other potential modi-\nfiers, such as genetic risk scores, circulating or\nurinary biomarkers, or vascular tests or imaging\nmethods (other than CAC scoring or carotid\nultrasound for plaque determination), is not\nrecommended. | III | B | ESC 2021",
          "bbox": [
            313.3902330069706,
            220.11935628255208,
            558.5274772644043,
            439.9264439174107
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "13",
      "title": "ESC 2021 ESC 2021",
      "start_page": 30,
      "end_page": 39,
      "content": ". ...........................................................................................................................................................................\nESC Guidelines 3257\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ........................................................................................................................................ interventions. 78   Lifetime benefit of preventive interventions can be expressed as gain in CVD-free life (years), which is easier to commu- nicate to  a patient and may support the shared decision-making process.\n3.3. Potential risk modifiers Apart from the conventional CVD risk factors included in the risk charts, additional risk factors or types of individual information can also modify calculated risk. Assessment of a potential modifier may be considered if:\n•   It improves measures of risk prediction, such as discrimination or reclassification (e.g. by calculation of net reclassification index) •   Public health impact is clear (e.g. number needed to screen or net benefit) •   It is feasible in daily practice •   Information is not just available on how risk increases with an unfavourable result, but also on how risk decreases if the modi- fier shows a favourable result •   The literature on this potential modifier is not distorted by publi- cation bias.\nVery few potential modifiers meet all of these criteria. Meta- analyses in this field are, for example, susceptible to substantial publi- cation bias. 106   Also, the exact way of integrating additional informa- tion on top of regular risk calculator input parameters is mostly unknown. Finally, RCTs to determine whether the added risk infor- mation eventually leads to improved health outcomes are generally lacking.\nAssessment of potential risk modifiers seems particularly relevant if the individual’s risk is close to a decision threshold. In low-risk or very-high-risk situations, additional information is less likely to alter management decisions. The number of individuals in this ‘grey zone’ is large. Therefore, feasibility becomes a limitation as modifiers become more complex or expensive, such as some imaging techniques. Care should be taken not to use risk modifiers solely to increase risk estimates when the modifier profile is unfavourable, but also vice versa. Although an unfavourable risk modifier may increase an indi- vidual’s estimated risk, a more favourable profile than would be expected based on other patient characteristics must have the oppo- site effect. Finally, it is important to acknowledge that the degree to which calculated absolute risk is affected by modifiers is generally much smaller than the (independent) RRs reported for these modi- fiers in the literature. 107\nTaking the above into account, we summarize the literature on several popular risk modifiers in this section.\n3.3.1. Psychosocial factors Psychosocial stress is associated, in a dose-response pattern, with the development and progression of ASCVD, independently of conven- tional risk factors and sex. Psychosocial stress includes stress symptoms (i.e. symptoms of mental disorders), as well as stressors such as loneli- ness and critical life events. The RRs of psychosocial stress are com- monly between 1.2 and 2.0 108 , 109   ( Supplementary Table 4 ). Conversely, indicators of mental health, such as optimism and a strong sense of pur- pose, are associated with lower risk. 109   Psychosocial stress has direct biological effects, but is also highly correlated with socioeconomic and behavioural risk factors (e.g. smoking, poor adherence). 100 , 109 \u0002 113\nAlthough the associations of psychosocial stress with CV health are robust, only ‘vital exhaustion’ has been proven to improve risk reclassi- fication. 101   Owing to the importance of stress symptoms among ASCVD patients, several guidelines and scientific statements recom- mend screening of ASCVD patients for psychological stress 113 \u0002 115\n( Box  2  and  Supplementary Table 5 ). A recent prospective cohort study with a median follow-up of 8.4 years reported favourable effects of screening for depression on major ASCVD events. 102\n3.3.2. Ethnicity Europe includes many citizens whose ethnic background originates in countries such as India, China, North Africa, and Pakistan. Given the considerable variability in ASCVD risk factors between immigrant groups, no single CVD risk score performs adequately in all groups. Rather, the use of a multiplying factor would be helpful to take account of CVD risk imposed by ethnicity independent of other risk factors in the risk score. The most contemporary relevant data come from the QRISK3 findings in the UK, 105   although this focuses on a wider range of CVD outcomes and not simply on  CVD mortality. Immigrants from South Asia (notably India and Pakistan) present higher CVD rates independent of other risk factors, whereas adjusted CVD risks appear lower in most other ethnic groups. The reasons for such differences remain inadequately studied, as do the risks associated with other ethnic backgrounds. Based on such data, the following correction factors, based on data from the UK, could be applied when assessing CVD risk using risk calculators. 105   Ideally, country and risk-calculator-specific RRs should be used, as the impact of ethnicity may vary between regions and risk  calculators.\n•   Southern Asian: multiply the risk by 1.3 for Indians and Bangladeshis, and 1.7 for Pakistanis. •   Other Asian: multiply the risk by 1.1. •   Black Caribbean: multiply the risk by 0.85. •   Black African and Chinese: multiply the risk by 0.7.\nBox 2. Core topics for psychosocial assessment\nSimultaneous diagnostic assessment At least one in five patients carries a diagnosis of a mental disorder, usually presenting with bodily symptoms (e.g. chest tightness, shortness of breath). Therefore, physicians should be equally atten- tive to somatic as to emotional causes of symptoms. Screening Screening instruments assessing depression, anxiety, and insomnia are recommended (e.g. Patient Health Questionnaire, 116   see  Supplementary Table 5 ). 117 , 118\nStressors There are simple questions to get into a conversation about significant stressors 112 : Are you both- ered by stress at work, financial problems, difficulties in the family, loneliness, or any stressful events? Need for mental health support Are you interested in a referral to a psychotherapist or mental health service?\n3258 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 3.3.3. Imaging 3.3.3.1 Coronary artery calcium Coronary artery calcium (CAC) scoring can reclassify CVD risk upwards and downwards in addition to conventional risk factors, and may thus be considered in men and women with calculated risks around decision thresholds. 103 , 104   Availability and cost- effectiveness of large-scale CAC scanning must, however, be con- sidered in a locoregional context (see  section 2.3  on cost- effectiveness). If CAC is detected, its extent should be compared with what would be expected for a patient of the same sex and age. Higher-than-expected CAC increases the person’s calculated risk, whereas absent or lower-than-expected CAC is associated with lower than calculated risk. CAC scoring does not provide direct information on total plaque burden or stenosis severity, and can be low or even zero in middle-aged patients with soft non-calcified plaque. Clinicians are advised to consult existing pro- tocols for details of how to assess and interpret CAC scores.\n3.3.3.2 Contrast computed tomography coronary angiography Contrast computed tomography angiography (CCTA) allows identification of coronary stenoses and predicts cardiac events. 119 In the SCOT-HEART (Scottish Computed Tomography of the Heart) study, 5-year rates of coronary death or myocardial infarction were reduced when CCTA was used in patients with stable chest pain. 120   The relative reduction in myo- cardial infarction was similar in patients with non-cardiac chest pain. Whether CCTA improves risk classification or adds prog- nostic value over CAC scoring is unknown.\n3.3.3.3 Carotid ultrasound Systematic use of intima-media thickness (IMT) to improve risk assessment is not recommended due to the lack of methodological standardization, and the absence of added value of IMT in predicting future CVD events, even in the intermediate-risk group. 121\nPlaque is defined as the presence of a focal wall thickening that is >_50% greater than the surrounding vessel wall, or as a focal region with an IMT measurement >_1.5 mm that protrudes into the lumen. 122   Although the evidence is less extensive than it is for CAC, carotid artery plaque assessment using ultrasonography probably also reclassifies CVD risk, 104 , 122   and may be considered as a risk modifier in patients at intermediate risk when a CAC score is not feasible.\n3.3.3.4 Arterial stiffness Arterial stiffness is commonly measured using either aortic pulse wave velocity or arterial augmentation index. Studies suggest that arterial stiffness predicts future CVD risk and improves risk classifica- tion. 123   However, measurement difficulties and substantial publica- tion bias 106   argue against widespread use.\n3.3.3.5 Ankle brachial index Estimates are that 12 \u0002 27% of middle-aged individuals have an ankle brachial index (ABI) <0.9, around 50 \u0002 89% of whom do not have typical claudication. 124   An individual patient data meta- analysis concluded that the reclassification potential of ABI was limited, perhaps with the exception of women at intermediate risk. 125\n3.3.3.6 Echocardiography In view of the lack of convincing evidence that it improves CVD risk reclassification, echocardiography is not recommended to improve CV risk prediction.\n3.3.4.Frailty Frailty is a multidimensional state, independent of age and multimor- bidity, that makes the individual more vulnerable to the effect of stressors. It constitutes a functional risk factor for unfavourable out- comes, including both high CV and non-CV morbidity and mortality. 126 , 127\nFrailty is not the same as ageing and the two should not be con- fused. The incidence of frailty increases with age, but people of the same chronological age can differ significantly in terms of health status and vitality. ‘Biological age’ is much more important in the context of clinical status (including frailty features) and hard clinical outcomes (including CVD events). 126 , 127   Similarly, although the presence of comorbidities can exacerbate frailty within an individual, frailty is not the same as multimorbidity (see  section 6.7 ).\nFrailty screening is indicated in every elderly patient, but should also be performed in every individual regardless of his/her age, when being at risk of accelerated ageing. 126 , 127   Most of the tools relate to frail fea- tures, including slowness, weakness, low physical activity (PA), exhaus- tion, and shrinking (e.g. Fried scale, Short Physical Performance Battery, Rockwood Clinical Frailty Scale, handgrip strength, gait speed). 126 \u0002 129   Frailty assessment is important at each stage of an ASCVD trajectory. During an acute CVD event, however, frailty assessment is more difficult, and either relies on history taking or should be postponed to when patients return to a stable condition.\nFrailty is a potential modifier of global CVD risk. The impact of frailty on CVD risk has been demonstrated across the spectrum of ASCVD, including people with ASCVD risk factors, patients with subclinical ASCVD, stable ASCVD, acute cerebral and coronary syndromes, and HF, 126 \u0002 130   with frailty itself rather than classical CVD risk factors pre- dicting both all-cause and CVD mortality in the very old. 130 , 131\nImportantly, the ability of frailty measures to improve CVD risk predic- tion has not been formally assessed. Hence, we do not recommend that frailty measures are integrated into formal CVD risk assessment.\nImportantly, frailty may influence treatment. Non-pharmacological interventions (e.g. balanced nutrition, micronutrient supplementa- tion, exercise training, social activation) aiming to prevent, attenuate, or reverse frailty are of utmost importance. 126 , 127 , 132   In terms of pharmacotherapy and device implantations, frailty assessment is not a method to determine the eligibility for any particular treatment, but rather serves to build an individualized care plan with predefined pri- orities. Frail individuals often have comorbidities, polypharmacy, and may be more susceptible to drug side-effects and serious complica- tions during invasive and surgical procedures. 126 , 127\n3.3.5. Family history Family history of premature CVD is a simple indicator of CVD risk, reflecting the genetic and environment interplay. 133   In the few studies that simultaneously assessed the effects of family history and genetics, family history remained significantly associated with CVD after adjust- ing for genetic scores. 134 , 135   However, family history only marginally improves the prediction of CVD risk beyond conventional ASCVD risk factors. 136 \u0002 141   Possible explanations are the varying definitions\nESC Guidelines 3259\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .................................... of family history applied and that conventional ASCVD risk factors largely explain the impact of family history.\nA family history of premature CVD is simple, inexpensive informa- tion that can trigger comprehensive risk assessment in individuals with a family history of premature CVD. 136\n3.3.6. Genetics The aetiology of ASCVD has a genetic component, but this informa- tion is not currently used in preventive approaches. 142   Advances on polygenic risk scores for risk stratification could increase the use of genetics in prevention. 143 \u0002 145   For ASCVD, there is, however, a lack of consensus regarding which genes and corresponding single nucleo- tide polymorphisms should be included, and whether to use risk factor-specific or outcome-specific polygenic risk scores. 146\nPolygenic risk scoring has shown some potential to improve ASCVD risk prediction for primary prevention, 147 \u0002 149   but the incremental prediction accuracy is relatively modest and needs further evaluation in both men and women. 150 , 151   Additional evidence is also needed to evaluate the clinical utility of polygenic risk scores in other clinical set- tings, such as in patients with pre-existing ASCVD. 152\n3.3.7. Socioeconomic determinants Low socioeconomic status and work stress are independently associ- ated with ASCVD development and prognosis in both sexes. 153 , 154\nThe strongest association has been found between low income and CVD mortality, with a RR of 1.76 [95% confidence interval (CI) 1.45 \u0002 2.14]. 155   Work stress is determined by job strain (i.e. the com- bination of high demands and low control at work) and effort-reward imbalance. There is preliminary evidence that the detrimental impact of work stress on ASCVD health is independent of conventional risk factors and their treatment. 156\n3.3.8. Environmental exposure Environmental exposures with CVD risk modifying potential include air and soil pollution as well as above-threshold noise levels. Evaluating individual cumulative exposure to pollutants and noise remains challenging, but when available, might impact on individual risk assessment. Components of outdoor air pollution include airborne particulate matter [PM; ranging in size from coarse particles 2.5 \u0002 10  m m in diam- eter, to fine (<2.5  m m; PM 2.5 ), and ultrafine (<0.1  m m)] and gaseous pollutants (e.g. ozone, nitrogen dioxide, volatile organic compounds, carbon monoxide, sulphur dioxide), produced primarily by combus- tion of fossil fuels. Soil and water pollutions are also CVD risk modi- fiers; increased exposure to lead, arsenic, and cadmium is associated with multiple CVD outcomes including hypertension, coronary heart disease (CHD), stroke, and CVD mortality. 157   Ambient PM pollution recently ranked as a leading modifiable mortality risk factor and also responsible for attributable disability adjusted life-years at the global level. 158   A recent model estimated that loss of life expectancy due to ambient air pollution is similar to, if not exceeding , that due to tobacco smoking, and accounts for a global excess mortality esti- mated at 8.8 million/year. 159\nThe short-term attributable effects on mortality are linked primar- ily to exposure to PM, nitrogen dioxide, and ozone, with an average 1.0% increase of all-cause mortality for an increment of 10  l g/m 3   in\nexposure to PM 2.5 ; the long-term effects are associated mainly with PM 2.5 . The evidence linking exposure to PM and CVD events is based on large-scale epidemiological studies and experimental studies. Associations with ASCVD mortality vary, but the majority of cohort studies link long-term air pollution with an increased risk of fatal or non-fatal CAD, and with subclinical atherosclerosis. Evidence sug- gests that reduction of PM 2.5  is associated with improvements in inflammation, thrombosis, and oxidative stress, and a decrease in death from ischaemic heart disease. 38 , 160 , 161   As sufficiently precise individual exposure estimates are hard to obtain, formal risk reclassi- fication is difficult to quantify at present.\n3.3.9. Biomarkers in blood or urine Many biomarkers have been suggested to improve risk stratification. Some may be causal [e.g. lipoprotein(a), reflecting a pathogenic lipid fraction], whereas others may reflect underlying mechanisms (e.g. C- reactive protein reflecting inflammation) or indicate early cardiac damage (e.g. natriuretic peptides or high-sensitivity cardiac troponin). In the 2016 Guidelines, 2   we recommended against the routine use of biomarkers because most do not improve risk prediction, and pub- lication bias seriously distorts the evidence. 106 , 162   New studies con- firm that C-reactive protein has limited additional value. 103   There is renewed interest in lipoprotein(a), but it too provides limited addi- tional value in terms of reclassification potential. 163 , 164   Cardiac bio- markers are promising, 165 , 166   but further work is needed.\n3.3.10. Body composition Worldwide, BMI has increased substantially in recent decades, in chil- dren, adolescents, and adults. 43   In observational studies, all-cause mortality is minimal at a BMI of 20 - 25 kg/m 2 , with a J- or U-shaped relation in current smokers. 45 , 46   Mendelian randomization analyses suggest a linear relation between BMI and mortality in never-smokers and a J-shaped relation in ever-smokers. 44   A meta-analysis concluded that both BMI and waist circumference are similarly strongly and con- tinuously associated with ASCVD in the elderly and the young and in men and women. 47\nAmong those with established ASCVD, the evidence is contradic- tory. Systematic reviews of patients with ACS or HF have suggested an ‘obesity paradox’ whereby obesity appears protective. 167 , 168 169\nHowever, this evidence should be interpreted with caution as reverse causality and other biases may be operating. 45\nRecommendations for cardiovascular disease risk related to air pollution\nRecommendations Class a Level b\nPatients at (very) high risk for CVD may be\nencouraged to try to avoid long-term exposure to regions with high air pollution.\nIIb C\nIn regions where people have long-term exposure\nto high levels of air pollution, (opportunistic) CVD risk screening programmes may be considered.\nIIb C\nCVD = cardiovascular disease. a Class of recommendation. b Level of evidence.\n. .......................................................................................................................................\nESC 2021\n3260 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n3.3.10.1 Which index of obesity is the best predictor of cardiovascular risk? BMI can be measured easily and is used extensively to define catego- ries of body weight (see  Supplementary Table 6 ). Body fat stored in visceral and other ectopic depots carries a higher risk than subcuta- neous fat. Several measures of global and abdominal fat are available, of which waist circumference is the simplest to measure. The WHO thresholds for waist circumference are widely accepted in Europe. Two action levels are recommended:\n•   Waist circumference >_94 cm in men and >_80 cm in women: no further weight gain •   Waist circumference >_102 cm in men and >_88 cm in women: weight reduction advised.\nDifferent cut-offs for anthropometric measurements may be required in different ethnicities. The phenotype of ‘metabolically healthy obesity’, defined by the presence of obesity in the absence of metabolic risk factors, has gained interest. Long-term results support the notion that metabol- ically healthy obesity is a transient phase moving towards glucometa- bolic abnormalities rather than a specific ‘state’. 170\n3.3.10.2 Risk reclassification The associations between BMI, waist circumference, and waist-to-hip ratio and CVD are maintained after adjustment for conventional risk factors. However, these measures did not improve CVD risk predic- tion as assessed by reclassification. 47\nRecommendations for cardiovascular disease assess- ment in speciﬁc clinical conditions\nClinical\ncondition\nRecommendations Class a Level b\nCKD In all CKD patients, with or with- out DM, appropriate screening for\nASCVD and kidney disease pro-\ngression, including monitoring changes in albuminuria is\nrecommended. 172\nI C\nCancer It is recommended to monitor cardiac dysfunction using imaging\ntechniques and circulating bio-\nmarkers before, periodically dur- ing, and after cancer treatment. 173\nI B\nCardioprotection in high-risk\npatients (those receiving high\ncumulative doses or combined radiotherapy) receiving anthracy-\ncline chemotherapy may be con-\nsidered for prevention of LV dysfunction. 174 , 175\nIIb B\nScreening for ASCVD risk factors\nand optimization of the CVD risk proﬁle is recommended in\npatients on treatment for cancer.\nI C\nContinued\nCOPD It is recommended that all COPD\npatients be investigated for\nASCVD and ASCVD risk factors.\nI C\nInﬂammatory conditions Assessment of total CVD risk may be considered in adults with chronic\ninﬂammatory conditions. 176\nIIb B\nMultiplication of calculated total CVD risk by a factor of 1.5 should\nbe considered in adults with rheu-\nmatoid arthritis. 177 , 178\nIIa B\nMigraine Presence of migraine with aura\nshould be considered in CVD risk\nassessment. 179 \u0002 181\nIIa B\nAvoidance of combined hormonal contraceptives may be considered\nin women with migraine with\naura. 182 , 183\nIIb B\nSleep\ndisorders\nand OSA\nIn patients with ASCVD, obesity,\nand hypertension, regular screen-\ning for non-restorative sleep is indicated (e.g. by the question:\n‘how often have you been both-\nered by trouble falling or staying asleep, or sleeping too much?’).\nI C\nIf there are signiﬁcant sleep prob-\nlems, which are not responding\nwithin 4 weeks to sleep hygiene, referral to a specialist is\nrecommended.\nI C\nMental disorders It is recommended that mental dis- orders with either signiﬁcant func-\ntional impairment or decreased use\nof healthcare systems be considered as inﬂuencing total CVD risk.\nI C\nSex-speciﬁc\nconditions\nIn women with a history of pree-\nclampsia and/or pregnancy-\ninduced hypertension, periodic screening for hypertension and\nDM should be considered. 184 \u0002 187\nIIa B\nIn women with a history of poly- cystic ovary syndrome or gesta-\ntional DM, periodic screening for\nDM should be considered. 188 \u0002 191\nIIa B\nIn women with a history of pre- mature or stillbirth, periodic\nscreening for hypertension and\nDM may be considered. 192 , 193\nIIb B\nAssessment of CVD risk should\nbe considered in men with ED. IIa C\nASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; ED = erectile dysfunction; LV = left ventricular; OSA = obstructive sleep apnoea. a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................................................................................\nESC Guidelines 3261\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 3.3.10.3 Assess risk factors and cardiovascular disease risk in persons with obesity Comprehensive CVD risk assessment should be considered in individ- uals with unfavourable body composition. The main risk-related sequa- lae of adiposity include hypertension, dyslipidaemia, insulin resistance, systemic inflammation, a prothrombotic state, albuminuria, as well as a decline in estimated glomerular filtration rate (eGFR) 171   and the devel- opment of type 2 DM, CVD events, as well as HF and AF.\n3.4. Clinical conditions Individual calculated risks of CVD, as evaluated by conventional risk factors in risk scores, are subject to refinement by potential risk modifiers as highlighted in  section 3.3 . Beyond these potential modi- fiers, specific clinical conditions can influence CVD risk. These clinical conditions often increase the likelihood of CVD, or are associated with poorer clinical prognosis. The current section reviews some of these conditions, which are not often included in traditional risk scores but may be integrated in some national risk scores. Here we discuss how these conditions increase this risk. Many clinical conditions share common CVD and ASCVD risk fac- tors and therefore treating these allows a synergistic reduction in the overall burden of disease.\n3.4.1. Chronic kidney disease Worldwide, the total number of individuals with chronic kidney dis- ease (CKD) who are not treated with kidney replacement therapy was approximately 850 million in 2017. 194   This number accounts to a prevalence of 10 - 12% among men and women. CKD is the third fastest growing cause of death globally. 195\nCKD is defined as abnormalities of kidney structure or function, present for >3 months, with health implications. Criteria and markers of kidney damage, especially kidney disease due to DM, are albuminu- ria [albumin-to-creatinine ratio (ACR) >30 mg/g in spot urine speci- mens] and glomerular filtration rate (GFR) <60 mL/min/1.73 m 2 . GFR can be estimated (eGFR) from calibrated serum creatinine and estimating equations using the CKD-EPI (Chronic Kidney Disease Epidemiology) Collaboration formula. Kidney disease severity is dif- ferentiated into stages (categories) according to the level of GFR and albuminuria; a patient with an eGFR <60 mL/min/1.73 m 2   is classified as having CKD stage 3a, which represents an advanced kidney func- tion impairment. 172\nAmong persons with CKD, CVD is the leading cause of morbidity and death. 196   Even after adjustment for known CAD risk factors, includ- ing DM and hypertension, mortality risk progressively increases with worsening CKD. 197   As GFR declines below approximately 60- 75 mL/ min/1.73 m 2 , the probability of developing CAD increases linearly, 198\nwith up to triple the CVD mortality risk when reaching an eGFR of 15 mL/min/1.73 m 2 . Kidney disease is associated with a very high CVD risk. Among persons with CKD, there is a high prevalence of traditional CAD risk factors, such as DM and hypertension. The use of CAC score to risk stratify patients with CKD might be a promising tool. 199 \u0002 203\nFurthermore, persons with CKD are also exposed to other non- traditional ASCVD risk factors such as uraemia-related ones, including inflammation, oxidative stress, and promotors of vascular calcification. CKD and kidney failure not only increase the risk of CAD, they also modify its clinical presentation and cardinal symptoms. 204\n3.4.2. Atrial fibrillation Atrial fibrillation (AF) appears to be associated with an increased risk of death and of CVD and kidney disease. 205   Furthermore, AF appears to be a stronger risk factor for CVD in women than in men. 206\nThe prevalence of AF ranges between 2% and 4%, and a 2.3-fold rise is expected, owing in part to ageing of the population and intensi- fied searching for undiagnosed AF, as well as lower CV death. 207   The age-adjusted incidence, prevalence, and lifetime risk of AF are lower in women vs. men and in non-white vs. white cohorts. 208 , 209   The life- time AF risk estimate is now 1 in 3 individuals of European ancestry at an index age of 55 years. 210   ASCVD risk factor burden and comor- bidities, including lifestyle factors, and age significantly affect the life- time risk for AF development. 211 \u0002 213   The observed effect of clinical ASCVD risk factor burden and multiple comorbidities on the lifetime risk of AF (significantly increasing from 23.4% among individuals with an optimal clinical risk factor profile to 33.4% and 38.4% in those with borderline and elevated clinical risk factors, respectively 214 ) suggests that early intervention and control of modifiable ASCVD risk factors could reduce incident AF. The continuum of unhealthy lifestyle, risk factor(s), and CVDs can contribute to atrial remodelling/cardiomy- opathy and development of AF that commonly results from a com- bined effect of multiple interacting factors ( Figure  9 ). 215   Risk factor and CVD management reduces AF burden. Targeted therapy of underlying conditions may significantly improve maintenance of sinus rhythm in patients with persistent AF and HF. 216   However, studies addressing isolated management of specific conditions alone (e.g. hypertension) yielded inconsistent findings. 217\nThe overall annual risk of ischaemic stroke in patients with AF is 5%, but varies considerably according to comorbidities. 215\nCardioembolic strokes associated with AF are usually more severe, and often recurrent. 218   Furthermore, AF appears to be a stronger predictor of stroke in women than in men. 215   AF is also associated with impaired cognitive function, ranging from mild cognitive impair- ment to dementia. 219   AF is independently associated with a two-fold increased risk of all-cause mortality in women and a 1.5-fold increased risk in men. 220   In one population, the most common causes of death were HF (14.5%), malignancy (23.1%), and infection/sepsis (17.3%), while stroke-related mortality was only 6.5%. 221   These data indicate that, in addition to anticoagulation and HF treatment, comor- bid conditions need to be actively treated to reduce AF-related mor- tality and morbidity.\nRegarding PA, both sedentary lifestyles and very high levels of PA are associated with development of AF (U-shaped association), through different mechanisms. Furthermore, when AF develops in athletes it is not associated with the same increased risk of stroke.\n3.4.3. Heart failure Heart failure (HF) of ischaemic origin constitutes a severe clinical manifestation of ASCVD. Conversely, HF itself (predominantly of ischaemic aetiology) increases the risk of CVD events (myocardial infarction, arrhythmias, ischaemic stroke, CV death). Asymptomatic LV dysfunction (systolic or/and diastolic dysfunc- tion) as well as overt symptomatic HF [across the spectrum of LVEF, i.e. HF with reduced ejection fraction (HFrEF), HF with mid-range ejection fraction, 222   and HF with preserved ejection fraction (HFpEF)] increases the risk of urgent CV hospitalizations (including hospitalizations due to HF worsening) and CV and all-cause deaths.\n3262 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................ These unfavourable effects on clinical outcomes have been demon- strated in asymptomatic subjects without overt CVD, in patients with acute and previous myocardial infarction, in patients with acute and previous stroke, and in patients with other clinical manifestations of CVD. 223\nThe diagnosis of ischaemic HF positions individuals at very high CV risk, and justifies recommendations as for secondary prevention ther- apeutic strategies. Additionally, for patients with symptomatic HFrEF, several drugs are recommended to reduce the risk of CV morbidity and mortality (see  section 6.2 ).\n3.4.4. Cancer In patients with cancer, there is an overlap between cancer and ASCVD risk factors, with shared biological mechanisms and genetic predispositions. Prevention and treatment of these is therefore\nbeneficial in reducing both CVD as well as cancer risk. Moreover, the rates of the extent of CVD risk depend on both the CVD toxicity of treatments and patient-related factors. Owing to recent improve- ments in clinical outcomes for many patients with cancer, CVD mor- tality may ultimately exceed those from most forms of cancer recurrence. 224 , 225\nThe rapidly expanding variety of novel anticancer drugs/adjuvant therapies has demonstrated a wide range of both early and late CVD side-effects, including cardiomyopathy, LV dysfunction, HF, hyperten- sion, CAD, arrhythmias, and other injuries. Therefore, effective strat- egies for the prediction and prevention of CVD toxicities are critically important. The latency and severity of radiotherapy cardio- toxicity, as well as accelerated atherosclerosis and cerebral vascular disease, is related to multiple factors, including the dose (total per fraction), the volume of the heart irradiated, concomitant\nRisk factors for AF\nHypertension Obesity Diabetes mellitus Physical activity OSA Alcohol Dyslipidemia Smoking\nLifestyle modification AF risk factors modification Treatment of underlying CV conditions\nReduction of mortality and morbidity Primary prevention of AF\nReduction of mortality and morbidity Symptomatic improvement Secondary prevention of AF\nModifiable\nAgeing Genetics Heart failure CAD Valvular heart disease COPD\nLifestyle modification AF risk factors modification Treatment of underlying CV conditions\nStroke prevention Rate control AAD therapy\nCardioversion Catheter ablation Surgery\nNon- or partly modifiable\nLA remodeling\nElectrical Biochemical Inflammation\nReversible\nFibrosis Scarring Dilatation\nNon-reversible\nAF outcomes\nMortality Stroke/systemic thromboembolism Symptoms and quality of life Heart failure Dementia Myocardial infarction Hospitalizations and healthcare costs\nAF development and progression\nParoxysmal Persistent Permanent\nFigure 9  The role of risk factors and comorbidities in atrial fibrillation. 215   AF = atrial fibrillation; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; CV = cardiovascular; DM = diabetes mellitus; HF = heart failure; OSA = obstructive sleep apnoea.\nESC Guidelines 3263\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ administration of other cardiotoxic drugs, and patient factors (which include, amongst other factors, younger age, traditional risk factors, and history of heart disease). 226 , 227   Furthermore, radio- and chemo- therapy may exert direct vascular effects and increase atherosclerosis-related CVD outcomes. 227 , 228\n3.4.4.1 Diagnosis and screening Signs or symptoms of cardiac dysfunction should be monitored before and periodically during and after cancer treatment for early detection of abnormalities in patients receiving potentially cardio- toxic chemotherapy. Detection of subclinical abnormalities using imaging and measurement of circulating biomarkers (such as cardiac troponins and natriuretic peptides) is currently recommended. 173 , 229\nMeasures of myocardial strain, particularly systolic global longitudinal strain, may precede a significant decline in LVEF. 230 \u0002 233\n3.4.4.2 Prevention of cardiotoxicity and cardiovascular risk factors RCTs of preventive therapy with renin-angiotensin-aldosterone sys- tem (RAAS) inhibitors and/or beta-blockers after trastuzumab or anthracyclines have reported contradictory results. 230 , 234 , 235   The main benefits are less marked LV remodelling or a reduced decline in LVEF observed with cardiac magnetic resonance, but translation into better outcomes remains speculative.\nExercise should be strongly advised. In particular, aerobic exercise is considered a promising non-pharmacological strategy to prevent and/ or treat chemotherapy toxicity. 236   A study showed a significantly higher risk of CVD in survivors of childhood cancer than in non-cancer adult controls, and particularly in survivors of adult-onset cancer with underlying ASCVD risk factors. 237   Therefore, aggressive management of ASCVD risk factors in this population is recommended.\n3.4.5. Chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is a complex, pro- gressive respiratory disorder and currently the fourth leading cause of death worldwide. It is characterized by chronic airflow limitation with respiratory symptoms and is associated with an increased inflammatory response and abnormalities of the airways caused by significant exposure to noxious particles or gases (mainly smoking). Although COPD is recognized and thoroughly investigated as a CVD comorbidity, its role as an ASCVD risk factor is not well established. Nevertheless, COPD patients have a two- to three- fold increased risk of CVD compared with age-matched controls when adjusted for tobacco smoking. Patients with mild-to-moderate COPD are 8 \u0002 10 times more likely to die from ASCVD than respiratory failure, having higher rates of hospitalization and death due to CVD, stroke, and HF. 238 , 239   CVD also runs undiagnosed; less than one-third of COPD patients with electrocardiographic (ECG) evidence of myocardial infarction are diagnosed with CVD. 240   CVD mortality increases by 28%, and the frequency of non-fatal coronary events by 20%, for every 10% decrease in the forced expiratory volume in 1 second (FEV1). 241   Acute COPD exacerbations, mainly due to infections, are frequent and are responsible for a four-fold increase of CVD events. 242   The risk of both myocardial infarction and ischaemic stroke is increased during the 3 months after an acute exacerbation. 243\nThe high prevalence of CVD in COPD patients may be explained by the fact that both diseases share common risk factors, such as smoking, ageing, hypertension, and dyslipidaemia. 244   Metabolic\nsyndrome and reduced PA is present in 34% of COPD patients, with its most prevalent components being hypertension (56%), abdominal obesity (39%), and hyperglycaemia (44%). 245   CVD may be caused by hypoxia during exercise due to lung hyperinflation, high resting heart rates, impaired vasodilatory capacity, and peripheral, cardiac, and neurohumoral sympathetic stress. Atherosclerosis and coronary artery calcification may be the result of oxidative stress, and reduc- tions in antiaging molecules causing both lung and vascular ageing. 246\nSystemic inflammation is prominent in COPD, with circulating bio- markers in high concentrations and associated with increased mortal- ity. 247   Troponin is elevated during an acute exacerbation of COPD, and 10% of hospitalized patients meet the definition of acute myocar- dial infarction (AMI). 248   B-natriuretic peptide level, if elevated, increases the mortality risk. 249\nSystemic inflammation and oxidative stress caused by COPD pro- mote vascular remodelling, stiffness, and atherosclerosis, and induce a ‘procoagulant’ state that affects all vasculature types. 250   Cognitive impairment and dementia due to cerebral microvascular damage is correlated with COPD severity; patients have a 20% increased risk for both ischaemic and haemorrhagic stroke, which may be up to seven-fold higher following an acute exacerbation. 251   PAD is present in about 9% of COPD patients, 252   who have an almost doubled risk of developing PAD, 253   as well as an increased prevalence of carotid plaques related to the disease severity. 254   Finally, COPD is positively associated with abdominal aortic aneurysm, regardless of smoking status. 255\nCardiac arrhythmias are common and may be due to the haemo- dynamic effects (pulmonary hypertension, diastolic dysfunction, atrial structural, and electrical remodelling) caused by the disease in combi- nation with autonomic imbalance and abnormal ventricular repolari- zation. 256   AF is frequent, directly associated with FEV1, usually triggered by acute exacerbations of COPD, and an independent pre- dictor of in-hospital COPD mortality. 257 , 258   COPD is also a risk fac- tor for ventricular tachycardia independent of LVEF, 259   and for sudden cardiac death independent of CVD risk profile. 260\nUnrecognized ventricular dysfunction is common in COPD, 261\nalthough HF is 3.8 times more common in COPD patients than in controls. 262   Patients with frequent acute exacerbations have a high frequency of diastolic dysfunction; HFpEF risk is higher because of a high prevalence of hypertension and DM. 263\nConsidering these facts, it seems of upmost importance to screen COPD patients for ASCVD and ASCVD risk factors, bearing in mind that COPD affects the accuracy of CVD diagnostic tests. Achieving adequate exercise is difficult, vasodilators for myocardial perfusion scanning may be contraindicated because of the risk of broncho- spasm, and stress or transthoracic echocardiography is often dis- turbed by poor ultrasound windows. Computed tomography coronary angiography or magnetic resonance imaging may be alterna- tives, but remain expensive, time consuming, and not always available. The use of COPD medications (i.e. long-acting muscarinic antago- nists and long-acting beta agonists) is not associated with overall CV adverse events in patients with stable COPD. Olodaterol may reduce the risk of overall CV adverse events and formoterol may decrease the risk of cardiac ischaemia. Long-acting beta agonists may reduce the incidence of hypertension, but may also increase the risk of HF, so should be used with caution in HF patients. 264\n3264 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 3.4.6. Inflammatory conditions Inflammatory conditions increase CVD risk both acutely and over time. The best evidence for chronic inflammation increasing CVD risk is available for rheumatoid arthritis, which increases CVD risk by approximately 50% beyond established risk factors. 176   Hence, a low threshold for assessment of total CVD risk is appropriate in adults with rheumatoid arthritis, and one should consider increasing the risk estimate based on the level of disease activity. 176   There is also evi- dence for an approximately 20% increased CVD risk in patients with active inflammatory bowel disease. 265\nIn other chronic inflammatory conditions, such as psoriasis 177   and ankylosing spondylitis, 178   CVD risk may also be increased. However, the strength of the evidence is less strong, as is the independence of such increased risks from the classical ASCVD risk factors. Nonetheless, it seems prudent to at least consider CVD risk assess- ment in patients with any chronic inflammatory condition, and to take into account the presence of such conditions when there is doubt regarding initiation of preventive interventions. The cumulative disease burden and recent degree of inflammation are important determinants of the risk-enhancing effect.\nApart from optimal anti-inflammatory treatment, CVD risk in inflammatory conditions should be treated with similar interventions as in the general high-risk population, as there is evidence that tradi- tional methods to lessen risk (e.g. lipid-lowering treatment) are just as beneficial in preventing ASCVD.\n3.4.7. Infections (human immunodeficiency virus, influenza, periodontitis) Infection with human immunodeficiency virus (HIV) is associated with a 19% increased risk of LEAD and CAD beyond that explained by traditional atherosclerotic risk factors. 266 , 267   However, for those with sustained CD4 cell counts <200 cells/mm 3 , the risk of incident LEAD events is nearly two-fold higher, whereas for those with sus- tained CD4 cell counts >_500 cells/mm 3 , there is no excess risk of incident LEAD events compared with uninfected people. 268\nCVD and influenza have long been associated, due to an overlap in the peak incidence of each disease during winter months. Epidemiological studies have noted an increase in CV deaths during influenza epidemics, indicating that CV complications of influenza infection, including acute ischaemic heart disease and, less often, stroke, are important contributors to morbidity and mortality during influenza infection. The risk of AMI or stroke is more than four times higher after a respiratory tract infection, with the highest risk in the first 3 days after diagnosis. 269   Preventing influenza, particularly by means of vaccina- tion, could prevent influenza-triggered AMI. 270\nStudies have linked periodontal disease to both atherosclerosis and CVD, 271 \u0002 273   and serological studies have linked elevated antibody titres of periodontal bacteria to atherosclerotic disease. 274   Nevertheless, if active treatment or prevention of periodontitis improves, clinical prog- nosis requires further studies despite preliminary evidence. 275 \u0002 277\n3.4.8. Migraine Migraine is a highly prevalent condition affecting around 15% of the general population. 278   There are two main types of migraine— migraine without aura, which is the most common subtype, and\nmigraine with aura, which accounts for about one-third of all migraines; in many patients the two forms coexist. Available data indicate that migraine overall is associated with a two-fold increased risk of ischaemic stroke and a 1.5-fold increase in the risk of cardiac ischaemic disease. 179 \u0002 181 , 279 , 280   The associations are more evident for migraine with aura. 179 , 180 , 280   Given the young mean age of the population affected by migraine, the absolute increase in risk is small at the individual level, but high at the popula- tion level because of the high migraine prevalence. 281\nSeveral lines of evidence also indicate that the vascular risk of sub- jects with migraine may be magnified by cigarette smoking 182   and by the use of combined hormonal contraceptives. 183 , 281 \u0002 283   Contraception using combined hormonal contraceptives should therefore be avoided in women with migraine. 282 , 283   However, further information is needed as good-quality studies assessing risk of stroke associated with low- dose oestrogen use in women with migraine are lacking.\n3.4.9.Sleep disorders and obstructive sleep apnoea Sleep disturbances or abnormal sleep durations are associated with increased CVD risk. 284 \u0002 286   Regarding sleep duration, 7 h seems to be optimal for CV health. 287\nIn the general population, the prevalence of general sleep distur- bances is around 32.1%: 8.2% for insomnia, 6.1% for parasomnia, 5.9% for hypersomnolence, 12.5% for restless legs disorder and limb movements during sleep, and 7.1% for sleep-related breathing disor- der [e.g. obstructive sleep apnoea (OSA)]. 288   All sleep disturbances are strongly associated with mental disorders and share hyperarousal as an underlying mechanism. 289 , 290\nThe most important sleep-related breathing disorder is OSA, which is characterized by repetitive episodes of apnoea, each exceed- ing 10 seconds. Despite the strong associations of OSA with CVD, including hypertension, stroke, HF, CAD, and AF, treatment of OSA by positive airway pressure (PAP) has failed to improve hard CV out- comes in patients with established CVD. 291 \u0002 293   Therefore, interven- tions that include behaviour change (reduction of obesity, alcohol abstinence), sleep hygiene, and stress reduction in addition to PAP are needed. 290 , 294   Regarding hypertension and OSA, there are modest effects of PAP on BP levels, but only in patients with ABPM-confirmed resistant hypertension who use PAP for more than 5.8 h/night. 295\n3.4.10. Mental disorders The 12-month prevalence of mental disorders or mental health dis- orders in the general European population is between 27% and 38% depending on sources and definitions. 296   All mental disorders (e.g. anxiety disorders, somatoform disorders, substance disorders, per- sonality disorders, mood disorders, and psychotic disorders) are associated with the development of CVD and reduced life expect- ancy in both sexes. 297 \u0002 300   The risk increases with the severity of the mental disturbance and vigilance for (often non-specific) symptoms is crucial. 301   The onset of CVD is associated with an approximately 2 \u0002 3-fold increased risk of mental disorders compared to a healthy population. 115 , 302   In this context, screening should be performed at every consultation (or 2 \u0002 4 times/year). The 12-month prevalence of mental disorders in CVD patients is around 40%, leading to signifi- cantly worse prognosis. 100 , 108 , 303 , 304   The onset of CVD increases the risk of committing suicide. 305   In this context, awareness of anxiety and depression symptoms should be increased.\nESC Guidelines 3265\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ The precise mechanism by which mental disorders increase CVD remains uncertain. The detrimental effects are potentially caused by unhealthy lifestyle, increased exposure to socioeconomic stressors, and cardiometabolic side-effects of some medications, 113   but also by direct effects of the amygdala-based fear-defence system and other direct pathophysiological pathways. 303   Abuse of psychostimulants (e.g. cocaine) is a powerful trigger of myocardial ischaemia. 306\nFurther, the capacity of these patients to adaptively use the health- care systems is impaired due to their mental condition (e.g. not being able to trust other people and seek help, impaired capacity to be adherent). 100   Barriers on the part of healthcare providers are stigma- tizing attitudes, insufficient mental health literacy, and lack of confi- dence in mental healthcare. 307 \u0002 309   Although patients with mental disorders have an increased CVD risk, they receive a lower rate of recognition and treatment of traditional ASCVD risk factors. 310\nPreliminary evidence suggests that taking mental disorders into account improves classical CVD risk models. 311 , 312\nCertain categories of patients with learning difficulties and associ- ated disorders (such as Down’s syndrome) are at increased risk of CVD disease, but perhaps not specifically ASCVD. However, health inequalities and the prevalence of CV risk factors may be greater in these populations, although epidemiology research is scarce.\n3.4.11. Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease (NAFLD) has been associated with an increased risk of myocardial infarction and stroke. NAFLD repre- sents accumulation of ectopic fat; persons with NAFLD are often overweight or obese, and not uncommonly have abnormal BP, glu- cose, and lipid levels. A recent study investigating whether NAFLD increases CV risk beyond traditional risk factors 313   shows that after adjusting for established risk factors, the associations did not persist. Nevertheless, patients with NAFLD should have their CVD risk cal- culated, be screened for DM, and be recommended a healthy lifestyle with a reduction of alcohol intake.\n3.4.12. Sex-specific conditions 3.4.12.1 Obstetric conditions Pre-eclampsia (defined as pregnancy-related hypertension accompa- nied by proteinuria) occurs in 1 \u0002 2% of all pregnancies and is associated with an increase in CVD risk by a factor of 1.5 \u0002 2.7 compared with all women, 185 , 186 , 314   while the RR of developing hypertension is 3 187   and DM is 2. 184 , 185   It has not been established whether the increased CVD risk after preeclampsia occurs independently  of CV risk factors. The rationale for screening these women for the occurrence of hyperten- sion and DM is, however, quite strong. At present, no separate risk model for women with a history of hypertensive disorders of preg- nancy seems necessary, despite their higher baseline risk. 315\nPregnancy-related hypertension affects 10 \u0002 15% of all pregnancies. The associated risk of later CVD is lower than for preeclampsia but is still elevated (RR 1.7 \u0002 2.5). 193 , 314 , 316 , 317   Also, the risk for sustained or future hypertension is elevated (RRs vary, from 2.0 to 7.2 or even higher). 187 , 318   Again, however, there was incomplete adjustment for conventional risk factors. The risk of developing DM is also elevated in these women (RR 1.6 \u0002 2.0). 314 , 319   Both preterm (RR 1.6) and still- birth (RR 1.5) have been associated with a moderate increase in risk of CVD. 316\nFinally, gestational DM confers a sharply elevated risk of future DM, with up to 50% of affected women developing DM within 5 years after pregnancy, and an up to two-fold increased risk of CVD in the future. 188 , 320   Screening by fasting glucose or HbA1c may be pref- erable to oral glucose tolerance testing. 191 , 321\n3.4.12.2 Non-obstetric conditions Polycystic ovary syndrome affects 5% of all women in their fertile years. 322 , 323   It has been associated with an increased risk of CVD. 314\nThe risk of developing hypertension is probably increased, but data are conflicting. 324   Polycystic ovary syndrome is associated with a higher risk of developing DM (RR 2 \u0002 4), 189 , 190   suggesting that peri- odic screening for DM is appropriate.\nPremature menopause occurs in roughly 1% of women <_40 years of age. Up to 10% of women experience an early menopause, defined as that occurring by 45 years of age. 314 , 325   Early menopause is associ- ated with an increased risk of CVD (RR 1.5). 326 \u0002 328   A linear inverse relationship between earlier menopause and CHD risk has been found, whereby each 1-year decrease in age at menopause por- tended a 2% increased risk of CHD. 329\n3.4.12.3 Erectile dysfunction Erectile dysfunction (ED), defined as the consistent inability to reach and maintain an erection satisfactory for sexual activity, has a multi- factorial cause. It affects almost 40% and more than 50% of men over 40 years and 60 years of age, respectively. 330 , 331   Men with ED have an increased risk of all-cause mortality [odds ratio (OR) 1.26, 95% CI 1.01 \u0002 1.57] and CVD mortality (OR 1.43, 95% CI 1.00 \u0002 2.05). ED and CVD share common risk factors (hypercholesterolaemia, hyper- tension, insulin resistance and DM, smoking, obesity, metabolic syn- drome, sedentary lifestyle, and depression) and a common pathophysiological basis of aetiology and progression. 332 , 333\nMedication used to prevent CVD, such as aldosterone receptor antagonists, some beta-blockers, and thiazide diuretics, can cause ED. 330 , 332 \u0002 335   ED is associated with subclinical vascular disease, 336   and precedes CAD, stroke, and PAD by a period that usually ranges from 2 to 5 years (average 3 years). Men with ED have a 44 \u0002 59% higher risk for total CV events, 62% for AMI, 39% for stroke, and 24 \u0002 33% for all- cause mortality, with a higher risk in those with severe ED. 337 \u0002 341\nThere is strong evidence that CVD risk assessment is needed in men presenting with ED. 336 , 342   In men with ED and low-to-intermediate CVD risk, detailed risk profiling by, for example, CAC score is sug- gested, but so far not supported by evidence. 338 , 341   Assessment of ED severity and physical examination should be part of the first-line CVD risk assessment in men. 333 , 341   Lifestyle changes are effective in improving sexual function in men: these include vigorous physical exercise, 334 , 343\nimproved nutrition, weight control, and smoking cessation. 343 \u0002 345\n",
      "keywords": [
        "obesity",
        "alcohol",
        "cvd risk",
        "risk modifier",
        "lipid",
        "risk calculator",
        "hypertension",
        "aneurysm",
        "atherosclerosis",
        "pulmonary hypertension",
        "intima-media",
        "genetic",
        "risk stratification",
        "diabetes",
        "hfpef",
        "coronary artery",
        "sedentary",
        "sex",
        "secondary prevention",
        "atrial fibrillation",
        "ascvd",
        "smoking",
        "recommended",
        "risk factor",
        "angiography",
        "echocardiography",
        "ejection fraction",
        "may be considered",
        "heart failure",
        "sudden cardiac death"
      ],
      "tables": [
        {
          "title": "3260 ESC Guidelines",
          "page_number": 33,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nPatients at (very) high risk for CVD may be\nencouraged to try to avoid long-term exposure\nto regions with high air pollution. | IIb | C | \nIn regions where people have long-term exposure\nto high levels of air pollution, (opportunistic) CVD\nrisk screening programmes may be considered. | IIb | C | ESC 2021",
          "bbox": [
            308.8738778921274,
            229.8137634277344,
            554.011962890625,
            327.1851697649275
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3261",
          "page_number": 34,
          "content": "COPD | It is recommended that all COPD\npatients be investigated for\nASCVD and ASCVD risk factors. | I | C | \nInflammatory\nconditions | Assessment of total CVD risk may\nbe considered in adults with chronic\ninflammatory conditions.176 | IIb | B | \n | Multiplication of calculated total\nCVD risk by a factor of 1.5 should\nbe considered in adults with rheu-\nmatoid arthritis.177,178 | IIa | B | \nMigraine | Presence of migraine with aura\nshould be considered in CVD risk\nassessment.179\u0002181 | IIa | B | \n | Avoidance of combined hormonal\ncontraceptives may be considered\nin women with migraine with\naura.182,183 | IIb | B | \nSleep\ndisorders\nand OSA | In patients with ASCVD, obesity,\nand hypertension, regular screen-\ning for non-restorative sleep is\nindicated (e.g. by the question:\n‘how often have you been both-\nered by trouble falling or staying\nasleep, or sleeping too much?’). | I | C | \n | If there are significant sleep prob-\nlems, which are not responding\nwithin 4 weeks to sleep hygiene,\nreferral to a specialist is\nrecommended. | I | C | \nMental\ndisorders | It is recommended that mental dis-\norders with either significant func-\ntional impairment or decreased use\nof healthcare systems be considered\nas influencing total CVD risk. | I | C | \nSex-specific\nconditions | In women with a history of pree-\nclampsia and/or pregnancy-\ninduced hypertension, periodic\nscreening for hypertension and\nDM should be considered.184\u0002187 | IIa | B | \n | In women with a history of poly-\ncystic ovary syndrome or gesta-\ntional DM, periodic screening for\nDM should be considered.188\u0002191 | IIa | B | \n | In women with a history of pre-\nmature or stillbirth, periodic\nscreening for hypertension and\nDM may be considered.192,193 | IIb | B | 21\n | Assessment of CVD risk should\nbe considered in men with ED. | IIa | C | ESC 20",
          "bbox": [
            313.2236392372533,
            60.35842940386604,
            558.4326123046875,
            662.6346910264757
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3261",
          "page_number": 34,
          "content": " |  |  |  | \nClinical\ncondition | Recommendations | Classa | Levelb | \n |  |  |  | \nCKD | In all CKD patients, with or with-\nout DM, appropriate screening for\nASCVD and kidney disease pro-\ngression, including monitoring\nchanges in albuminuria is\nrecommended.172 | I | C | \nCancer | It is recommended to monitor\ncardiac dysfunction using imaging\ntechniques and circulating bio-\nmarkers before, periodically dur-\ning, and after cancer treatment.173 | I | B | \n | Cardioprotection in high-risk\npatients (those receiving high\ncumulative doses or combined\nradiotherapy) receiving anthracy-\ncline chemotherapy may be con-\nsidered for prevention of LV\ndysfunction.174,175 | IIb | B | \n | Screening for ASCVD risk factors\nand optimization of the CVD risk\nprofile is recommended in\npatients on treatment for cancer. | I | C | ",
          "bbox": [
            49.0673713684082,
            426.8316232781661,
            294.0290222167969,
            730.6096666124132
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "14",
      "title": "4. Risk factors and interventions at the individual level",
      "start_page": 39,
      "end_page": 45,
      "content": "4.1. Treatment recommendations: classes, grades, and freedom of choice Clear communication about risks and benefits is crucial before any treatment is initiated. Risk communication is discussed in  section 3.2.4 ,\n3266 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nTable 6 Treatment goals for different patient categories\nPatient category Prevention goals (STEP 1) Intensified/additional prevention goals a   (STEP 2)\nApparently healthy persons For BP and lipids: initiation of drug treatment based on CVD risk assessment ( Table  5 ) or SBP >160 mmHg\n<50 years Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if tolerated b\nLDL-C <2.6 mmol/L (100 mg/dL)\nSBP <130 mmHg if tolerated b\nLDL-C <1.8 mmol/L (70 mg/dL) and >_50% reduction in high-risk patients\nLDL-C <1.4 mmol/L (55 mg/dL) and >_50% reduction\nin very-high-risk patients\n50 - 69 years Stop smoking and lifestyle optimization SBP <140 down to 130 mmHg if tolerated b\nLDL-C <2.6 mmol/L (100 mg/dL)\nSBP <130 mmHg if tolerated b\nLDL-C <1.8 mmol/L (70 mg/dL) and >_50% reduction\nin high-risk patients\nLDL-C <1.4 mmol/L (55 mg/dL) and >_50% reduction in very-high-risk patients\n>_70 years Stop smoking and lifestyle optimization\nSBP <140 mmHg if tolerated b\nLDL-C <2.6 mmol/L (100 mg/dL)\nFor speciﬁc risk factor management in patients >_70\nyears old, please see relevant sections in  section 4 .\nPatients with CKD Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if tolerated b\nLDL-C <2.6 mmol/L (100 mg/dL) and >_50% LDL-C reduction\nOtherwise according to ASCVD and DM history\nLDL-C <1.8 mmol/L (70 mg/dL) in high-risk patients\nand <1.4 mmol/L (55 mg/dL) in very-high risk patients\n(see  Table  4 )\nPatients with FH Stop smoking and lifestyle optimization SBP <140 down to 130 mmHg if tolerated b\nLDL-C <2.6 mmol/L (100 mg/dL) and >_50% LDL-C\nreduction Otherwise according to ASCVD and DM history\nLDL-C <1.8 mmol/L (70 mg/dL) in high-risk patients and <1.4 mmol/L (55 mg/dL) in very-high risk patients\n(see  Table  4 )\nPeople with type 2 DM\nWell-controlled short-standing\nDM (e.g. <10 years), no evidence of TOD and no additional ASCVD\nrisk factors\nStop smoking and lifestyle optimization\nWithout  established ASCVD or\nsevere TOD (see  Table  4  for deﬁnitions)\nStop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if tolerated b\nLDL-C <2.6 mmol/L (100 mg/dL)\nHbA1c <53 mmol/mol (7.0%)\nSBP <130 mmHg if tolerated b\nLDL-C <1.8 mmol/L (70 mg/dL) and >_50% reduction SGLT2 inhibitor or GLP-1RA\nWith  established ASCVD and/or severe TOD (see  Table  4  for\ndeﬁnitions)\nStop smoking and lifestyle optimisation SBP <140 down to 130 mmHg if tolerated b\nLDL-C <1.8 mmol/L (70 mg/dL)\nHbA1c <64 mmol/mol (8.0%) SGLT2 inhibitor or GLP1-RA\nCVD: antiplatelet therapy\nSBP <130 mmHg if tolerated b\nLDL-C <1.4 mmol/L (55 mg/dL) and >_50% reduction\nSGLT2 inhibitor or GLP-1RA if not already on\nMay additionally consider novel upcoming treatments: DAPT, dual pathway inhibition,a colchicine, icosapent ethyl\nPatients with established\nASCVD\nStop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if tolerated b\nIntensive oral lipid-lowering therapy aiming at >_50%\nLDL-C reduction and LDL-C <1.8 mmol/L (70 mg/dL)\nAntiplatelet therapy\nSBP <130 mmHg if tolerated b\nLDL-C <1.4 mmol/L (55 mg/dL) May additionally consider novel upcoming treatments:\nDAPT, dual pathway inhibition, colchicine, icosapent ethyl,\netc.\nASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CKD = chronic kidney disease; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DBP = diastolic blood pressure; DM = diabetes mellitus; EAS = European Atherosclerosis Society; ESC = European Society of Cardiology; FH = familial hypercholesterolaemia; GLP- 1RA = glucagon-like peptide-1receptor agonist; HbA1c = glycated haemoglobin; LDL-C = low-density lipoprotein cholesterol; SBP = systolic blood pressure (ofﬁce); SGLT2 = sodium-glucose cotransporter 2; TOD = target organ damage. a Depending on 10-year (residual) risk and/or estimated lifetime beneﬁt (see  Table  4  for details), comorbidities, and patient preference. Levels of evidence of intensiﬁed goals vary, see recommendation tables in  sections 4.6  and  4.7 . For CKD and FH, LDL-C targets are taken form the 2019 ESC/EAS Guidelines for the treatment of dyslipidaemias. 3\nb Ofﬁce DBP treatment target range <80 mmHg.\nESC 2021\nESC Guidelines 3267\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .................................................................. and benefits of individual treatment are the topic of this section. In all scenarios where recommendations for individual interventions to reduce risk are ‘strong’ (class I or IIa), it is important to realize that many patients who have received appropriate risk information often (in up to 50% of cases, some studies suggest) consciously opt to forego the proposed intervention. This applies not only to lifestyle measures, but also to drug interventions. Apparently, what professio- nals feel is sufficient risk reduction for a reasonable effort or initiation of a drug with few side-effects does not always correspond to patients’ views. The reverse is also true: not only may some patients at (very) high risk forego interventions, some patients with low-to- moderate risk may be highly motivated to decrease their risk even further. Hence, treatment recommendations are never ‘imperative’ for (very) high risk patients, nor are interventions ever ‘prohibited’ for patients at low-to-moderate risk. There is evidence that a higher proportion of women, compared to men, have a low awareness of their CVD risk and the need for therapeutic interventions. This war- rants efforts to improve awareness, risk assessment, and treatment in women. 52 , 346 \u0002 351\n4.2. Optimizing cardiovascular risk management 4.2.1. Goals of clinicianpatient communication Clinicians should provide a personalized presentation of guidelines to improve understanding, encourage lifestyle changes, and support adherence to drug therapy. Applying this in daily practice faces differ- ent barriers. 352   Patients’ ability to adopt a healthy lifestyle depends on cognitive and emotional factors, the impact of a diagnosis or symp- toms, socioeconomic factors, educational level, and mental health. Perceived susceptibility to illness and the anticipated severity of the consequences are also prominent components of patients’ motivation. 353\n4.2.2. How to improve motivation? Communication strategies such as motivational interviewing are use- ful. 354   Consultation sessions may include a family member or friend, especially for elderly patients. Connection is paramount: focus before greeting; listen intently; agree on what matters most; connect with the person’s story; and explore emotions. 355   The OARS (Open-ended questions, Affirmation, Reflective listening, and Summarizing) principle helps patients to present their perceptions, and clinicians to summa- rize. The SMART (Specific, Measurable, Achievable, Realistic, Timely) principle may help with setting goals for behavioural change. 353 , 356\nHealthcare professionals must consider capability, opportunity (physi- cal, social, or environmental) and motivation for behavioural change. 357   Multidisciplinary behavioural approaches that combine the knowledge and skills of different caregivers are recommended. 358\n4.2.3. Optimizing drug adherence Medication adherence ranges from 50% for primary ASCVD preven- tion to 66% for secondary prevention. 359   Physicians should consider non-adherence in every patient and inquire non-judgmentally about it. 360   Approximately 9% of cases of ASCVD in Europe can be attrib- uted to poor medication adherence. 361   Contributors to non- adherence include polypharmacy, complexity of drug/dose regimes, poor doctor-patient relationship, lack of disease acceptance, beliefs\nabout consequences and side-effects, intellectual/cognitive abilities, mental disorders, physical limitations, financial aspects, and living alone. 360 , 362 \u0002 364   Importantly, only substantial risk reduction moti- vates patients for preventive drug treatment, which obviates the need for appropriate risk communication. 365 , 366   Depression is another important factor, and adequate treatment thereof improves adherence. 367 , 368\nMobile phone applications may improve adherence to both medi- cation and behavioural changes. 369   Their use is easy and probably cost-effective. 370\n4.2.4. Treatment goals In the subsequent sections, different domains of individual treatment are discussed.  Table  6  summarizes the treatment goals and some key interventions for different categories of patients. For additional infor- mation on risk categories and the principle of a stepwise approach to treatment targets, please refer to  section 3.2.3.1 . For details on treat- ment goals, how to achieve them, strengths of recommendations and levels of supporting evidence, please go to the relevant subsections.\n4.3.Optimizing lifestyle 4.3.1. Physical activity and exercise\nPA reduces the risk of many adverse health outcomes and risk factors in all ages and both sexes. There is an inverse relationship between moderate-to-vigorous PA and all-cause mortality, CV morbidity and\nRecommendations for physical activity\nRecommendations Class a Level b\nIt is recommended for adults of all ages to strive for at least 150 - 300 min a week of moderate-\nintensity or 75 - 150 min a week of vigorous-\nintensity aerobic PA, or an equivalent combina- tion thereof, to reduce all-cause mortality, CV\nmortality, and morbidity. 371 , 372\nI A\nIt is recommended that adults who cannot per- form 150 min of moderate-intensity PA a week\nshould stay as active as their abilities and health\ncondition allow. 373 , 374\nI B\nIt is recommended to reduce sedentary time to engage in at least light activity throughout the\nday to reduce all-cause and CV mortality and\nmorbidity. 375 \u0002 377\nI B\nPerforming resistance exercise, in addition to\naerobic activity, is recommended on 2 or more\ndays per week to reduce all-cause mortality. 378 , 379\nI B\nLifestyle interventions, such as group or individ-\nual education, behaviour-change techniques, tel-\nephone counselling, and use of consumer-based wearable activity trackers, should be considered\nto increase PA participation. 380 \u0002 382\nIIa B\nCV = cardiovascular; PA = physical activity. a Class of recommendation. b Level of evidence.\nESC 2021\n. .........................................................................................................\n3268 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .............................................................................................. mortality, as well as incidence of type 2 DM. 371 \u0002 373 , 383 \u0002 387   The reduction in risk continues across the full range of PA volumes, and the slope of risk decline is steepest for the least active individu- als. 371 \u0002 374 , 386 , 387   More information on PA prescription can be found in a recent ESC Guideline. 388\n4.3.1.1 Physical activity prescription PA should be individually assessed and prescribed in terms of fre- quency, intensity, time (duration), type, and progression. 389\nRecommendations regarding pre-participation screening can be found in previous ESC Guidelines. 388   Interventions shown to increase PA level or reduce sedentary behaviour include behaviour theory- based interventions, such as goal-setting, re-evaluation of goals, self- monitoring, and feedback. 372 , 380 , 381   Using a wearable activity tracker may help increase PA. 382   Most important is to encourage activity that people enjoy and/or can include in their daily routines, as such activ- ities are more likely to be sustainable.\n4.3.1.2 Aerobic physical activity Examples of aerobic PA include walking, jogging, cycling, etc. 389\nAdults are recommended to perform at least 150 \u0002 300 min a week of moderate-intensity PA, or 75 \u0002 150 min of vigorous-intensity PA, or an equivalent combination of both, spread throughout the week. 371 , 372   Additional benefits are gained with even more PA. Practising PA should still be encouraged in individuals unable to meet the minimum. In sedentary individuals, a gradual increase in activity level is recommended. When older adults or individuals with chronic conditions cannot achieve 150 min of moderate-intensity PA a week, they should be as active as their abilities and conditions allow. 371 \u0002 375 , 384 , 385   PA accumulated in bouts of even <10 min is associated with favourable outcomes, including mortality. 371 , 390\nPA can be expressed in absolute or relative terms. 389   Absolute intensity is the amount of energy expended per minute of activity, assessed by oxygen uptake per unit of time (mL/min or L/min) or by metabolic equivalent of task (MET). A compendium of the energy cost in MET values for various activities is available. 391   An absolute measure does not consider individual factors such as body weight, sex, and fitness level. 389\nRelative intensity is determined based on an individual’s maximum (peak) effort, e.g. percentage of cardiorespiratory fitness (%VO 2 max), percentage of maximum (peak) heart rate (%HR max ) or using rating of perceived exertion according to the Borg scale. Less fit indi- viduals generally require a higher level of effort than fitter people to perform the same activity. A relative intensity measure is necessary to provide an individualized PA prescription. 389\nClassification for both absolute and relative intensity and examples are presented in  Table  7 .\n4.3.1.3 Resistance exercise Resistance exercise in addition to aerobic PA is associated with lower risks of total CV events and all-cause mortality. 378 , 379 , 393 \u0002 395   The sug- gested prescription is one to three sets of 8 \u0002 12 repetitions at the intensity of 60 \u0002 80% of the individual’s 1 repetition maximum at a fre- quency of at least 2 days a week in a variety of 8 \u0002 10 different exercises involving each major muscle group. For older adults or deconditioned individuals, it is suggested to start with one set of 10 \u0002 15 repetitions at 40 \u0002 50% of 1 repetition maximum. 389   In addition, older adults are rec- ommended to perform multicomponent PA that combines aerobic, muscle-strengthening, and balance exercises to prevent falls. 372\n4.3.1.4 Sedentary behaviour Sedentary time is associated with greater risk for several major chronic diseases and mortality. 371 , 372 , 375 \u0002 377 , 396 \u0002 399   For physically inactive adults, light-intensity PA, even as little as 15 minutes a day, is likely to produce benefits. There is mixed evidence to suggest how activity bouts that interrupt sedentary behaviour are associated with health outcomes. 375 , 398 , 400\n4.3.2. Nutrition and alcohol\n................................................................................................................ ................................................................................................\nTable 7 Classiﬁcation of physical activity intensity and examples of absolute and relative intensity levels.\nAbsolute intensity Relative intensity\nIntensity MET a Examples % HR max RPE (Borg scale score) Talk test\nLight 1.1 \u0002 2.9 Walking <4.7 km/h, light household work 57 \u0002 63 10 \u0002 11\nModerate 3 \u0002 5.9 Walking at moderate or brisk pace (4.1 \u0002 6.5 km/h),\nslow cycling (15 km/h), painting/decorating, vacuuming, gardening (mowing lawn), golf (pulling clubs in trolley),\ntennis (doubles), ballroom dancing, water aerobics\n64 \u0002 76 12 \u0002 13 Breathing is faster but compatible with\nspeaking full sentences\nVigorous >_6 Race-walking, jogging, or running, cycling >15 km/h, heavy gardening (continuous digging or hoeing), swim-\nming laps, tennis (singles)\n77 \u0002 95 14 \u0002 17 Breathing very hard, incompatible with carrying on a conversation\ncomfortably\n%HR max  = percentage of measured or estimated maximum heart rate (220 \u0002 age); MET = metabolic equivalent of task; RPE = rating of perceived exertion (Borg-scale 6 \u0002 20); VO 2  = oxygen consumption. a MET is estimated as the energy cost of a given activity divided by resting energy expenditure: 1 MET = 3.5 mL oxygen kg \u0002 1  min \u0002 1  VO 2 . Modiﬁed from   392\nESC 2021\nRecommendations for nutrition and alcohol\nRecommendations Class a Level b\nA healthy diet is recommended as a cornerstone of CVD prevention in all individuals. 401 , 402 I A\nContinued . ...................\nESC Guidelines 3269\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...................................................................................................\nDietary habits influence CV risk, mainly through risk factors such as lipids, BP, body weight, and DM. 401 , 402   Table 8  summarizes the char- acteristics of a healthy diet. Although recommendations about nutrients and foods remain important for CV health, there is a grow- ing concern about environmental sustainability, supporting a shift from an animal- to a more plant-based food pattern. 411 , 412\n4.3.2.1 Fatty acids Risk of CHD is reduced when dietary saturated fats are replaced appropriately ( Figure  10 ). This is also the case when replacing meat and dairy foods. 406 , 407   Polyunsaturated fats (-25%), monounsaturated fats (-15%), and to a lesser extent carbohydrates from whole grains (-9%), were all associated with reduced CHD risk when isocalorically substituted for dietary saturated fat. 408 , 409\nReducing saturated fatty acid intake to less than 10% of energy may have additional benefits. 405   However, the LDL-C-lowering effect of substituting polyunsaturated fatty acids (PUFAs) for saturated fatty acids may be less in obese (5.3%) than in normal-weight persons (9.7%). 421\nTrans fatty acids, formed during industrial processing of fats, have unfavourable effects on total cholesterol (increase) and HDL-C (decrease). On average, a 2% increase in energy intake from trans fatty acids is associated with a 23% higher CHD risk. 422   A regulation of the European Union (EU) Commission has set the upper limit to 2 g per 100 g of fat (April 2019) (https://ec.europa.eu/food/safety/label- ling_nutrition/trans-fat-food_en).\nWhen guidelines to lower saturated fat intake are followed, reduc- tions in dietary cholesterol intake follow.\n4.3.2.2 Minerals and vitamins A reduction in sodium intake may reduce SBP by, on average, 5.8 mmHg in hypertensive, and 1.9 mmHg in normotensive patients. 410\nThe DASH (Dietary Approaches to Stop Hypertension) trial showed a dose \u0002 response relation between sodium reduction and BP reduction. 423   In a meta-analysis, salt reduction of 2.5 g/day resulted in a 20% reduction of ASCVD events (RR 0.80). 410   A U- or J-shaped relation between a low salt intake and ASCVD is debated. 424\nUnderlying illness and malnutrition may explain both low food and salt intakes as well as increased ASCVD. 410 , 425 , 426   The totality of evi- dence warrants salt reduction to prevent CHD and stroke.\nIn most Western countries, salt intake is high ( \u0004 9 \u0002 10 g/day), whereas the recommended maximum intake is 5 g/day. Optimal intake might be as low as  \u0004 3 g/day. Salt reduction can be achieved by dietary choices (fewer processed foods) and the reformulation of foods by lowering their salt content (see  section 5.2.2 ). Potassium (e.g. in fruits and vegetables) has favourable effects on BP and risk of stroke (RR 0.76). 427\nAs for vitamins, observational studies have found inverse associa- tions between vitamins A and E and risk of ASCVD. However, inter- vention trials have failed to confirm these findings. Also, trials of supplementation with B vitamins (B6, folic acid, and B12), and vita- mins C and D have not shown beneficial effects. 428 , 429\n4.3.2.3 Fibre Each 7 g/day higher intake of total fibre is associated with a 9% lower risk of CAD (RR 0.91). 430   A 10 g/day higher fibre intake was associ- ated with a 16% lower risk of stroke (RR 0.84) and a 6% lower risk of type 2 DM (RR 0.94). 431 , 432   A high fibre intake may reduce postpran- dial glucose responses after carbohydrate-rich meals and also lower triglyceride levels. 433\n4.3.2.4 Specific foods and food groups\n4.3.2.4.1. Fruits, vegetables, and pulses. A meta-analysis reported a 4% lower risk in CV mortality for each additional serving of fruits\nIt is recommended to adopt a Mediterranean or\nsimilar diet to lower risk of CVD. 403 , 404 I A\nIt is recommended to replace saturated with\nunsaturated fats to lower the risk of CVD. 405 \u0002 409\nI A\nIt is recommended to reduce salt intake to lower\nBP and risk of CVD. 410 I A\nIt is recommended to choose a more plant- based food pattern, rich in ﬁbre, that includes\nwhole grains, fruits, vegetables, pulses, and nuts. 411 , 412\nI B\nIt is recommended to restrict alcohol consump-\ntion to a maximum of 100 g per week. 413 \u0002 415 I B\nIt is recommended to eat ﬁsh, preferably fatty, at least once a week and restrict (processed)\nmeat. 406 , 416 \u0002 418\nI B\nIt is recommended to restrict free sugar con-\nsumption, in particular sugar-sweetened bever- ages, to a maximum of 10% of energy\nintake. 419 , 420\nI B\nCVD = cardiovascular disease; BP = blood pressure. a Class of recommendation. b Level of evidence.\nTable 8 Healthy diet characteristics\nAdopt a more plant- and less animal-based food pattern\nSaturated fatty acids should account for <10% of total energy\nintake, through replacement by PUFAs, MUFAs, and carbohydrates from whole grains\nTrans unsaturated fatty acids should be minimized as far as possible, with\nnone from processed foods\n<5 g total salt intake per day\n30 \u0002 45 g of ﬁbre of per day, preferably from wholegrains\n>_200 g of fruit per day (>_2 \u0002 3 servings)\n>_200 g of vegetables per day (>_2 \u0002 3 servings)\nRed meat should be reduced to a maximum of 350 - 500 g a week, in par-\nticular processed meat should be minimized\nFish is recommended 1 \u0002 2 times per week, in particular fatty ﬁsh\n30 g unsalted nuts per day\nConsumption of alcohol should be limited to a maximum of 100 g per\nweek\nSugar-sweetened beverages, such as soft drinks and fruit juices, must be discouraged\nMUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid.\nESC 2021\nESC 2021\n. .......................................................................\n3270 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ..................................................................................................... (equivalent to 77 g) and vegetables (equivalent to 80 g) per day, while all-cause mortality was not reduced further with intakes of more than five servings. 434   A meta-analysis reported an 11% lower risk for stroke associated with three to five daily servings of fruits and vegeta- bles and of 26% with five servings a day compared with fewer than three servings. 435 , 436   A single portion of pulses (legumes) a day low- ers LDL-C by 0.2 mmol/L and is associated with a lower risk of CHD. 437 , 438\n4.3.2.4.2. Nuts. A meta-analysis of prospective cohort studies sug- gested that daily consumption of 30 g of (mixed) nuts was associated with a  \u0004 30% lower risk of ASCVD. 437   Both pulses and nuts contain fibre and other bioactive components. 438\n4.3.2.4.3. Meat. From both a health and an environmental point of view, a lower consumption of meat, especially processed meat, is rec- ommended. 411   A restriction of red meat may have little or no effect on major cardiometabolic outcomes. 416   However, substituting red meat with high-quality plant foods (i.e. nuts, soy, and legumes) does improve LDL-C concentrations. 406   A recent analysis showed that higher intake of processed meat and unprocessed red meat is associ- ated with a 7% and 3%, respectively, increased risk of ASCVD. 417\nBy reducing processed meats, salt intake will also be reduced. The World Cancer Research Fund recommends limiting red meat con- sumption to 350 \u0002 500 g per week. 439\n4.3.2.4.4. Fish and fish oil supplements. Studies indicate that eating fish, particularly fish rich in n-3 PUFA, at least once a week, is associ- ated with a 16% lower risk of CAD, 418   and eating fish two to four times a week is associated with a 6% lower risk of stroke. 440   The highest risk was observed in the range of no or very low intakes.\nSeveral meta-analyses and a recent Cochrane review showed no benefits of fish oils on CV outcomes and/or mortality, 441 \u0002 443\nalthough a 7% lower risk of CHD events was observed. A meta-anal- ysis of 13 RCTs included the results of VITAL (Vitamin D and Omega-3 Trial), ASCEND (A Study of Cardiovascular Events in Diabetes), and REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl \u0002 Intervention Trial). 444   In the analysis excluding REDUCE-IT, fish oil reduced total ASCVD (RR 0.97) and CHD death (RR 0.92). 444   Including REDUCE-IT (a study done in participants with high triglycerides, comparing very high icosapent ethyl doses vs. min- eral oil placebo) strengthened the results. 444   However, this is the only study that tested a high icosapent ethyl dose and questions have been raised regarding the choice of placebo. Very recently, STRENGTH (Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia) failed to demonstrate benefit of a combined eicosapentaenoic acid and docosahexaenoic acid preparation. 445\n4.3.2.4.5. Alcoholic beverages. The upper safe limit of drinking alco- holic beverages is about 100 g of pure alcohol per week. How this translates into number of drinks depends on portion size, the stand- ards of which differ per country, mostly between 8 and 14 g per drink. This limit is similar for men and women. 413   Drinking above this limit lowers life expectancy.\nResults from epidemiological studies have suggested that, whereas higher alcohol consumption is roughly linearly associated with a higher risk of all stroke subtypes, coronary disease, HF, and several less common CVD subtypes, it appeared approximately log-linearly associated with a lower risk of myocardial infarction. 413   Moreover, Mendelian randomization studies do not support the apparently pro- tective effects of moderate amounts vs. no alcohol against ASCVD, suggesting that the lowest risks for CVD outcomes are in abstainers and that any amount of alcohol uniformly increases BP and BMI. 414 , 415   These data challenge the concept that moderate alcohol consumption is universally associated with lower CVD risk.\nTrans fat (2%)\nMUFA (5%)\nPUFA (5%)\nCarbohydrates from refined starches/sugars (5%)\nCarbohydrates from whole grains (5%)\nChanges in risk (%)\n-35 -30 -25 -20 -15 -10 -5 0 5 10 15 20\nFigure 10  Estimated percentage change in risk of coronary heart disease associated with isocaloric substitutions of saturated fat for other types of fat or carbohydrates. Reproduced from Sacks  et al . 409   MUFA = monounsaturated fatty acid; PUFA = polyunsaturated fatty acid.\nESC Guidelines 3271\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ......................................................................................................................................................\n4.3.2.4.6. Soft drinks and sugar. Regular consumption of sugar- sweetened beverages (i.e. two servings per day compared with one serving per month) was associated with a 35% higher risk of CAD in women in the Nurses’ Health Study, whereas artificially sweetened beverages were not associated with CAD. In the EPIC (European Prospective Investigation into Cancer and Nutrition) cohort, both arti- ficially and sugar-sweetened soft drinks were associated with all-cause mortality, while only the former was associated with circulatory dis- eases. 419   The WHO guideline recommends a maximum intake of 10% of energy from free sugars (mono- and disaccharides), which includes added sugars as well as sugars present in fruit juices. 420\n4.3.2.4.7. Coffee. Non-filtered coffee contains LDL-C-raising cafestol and kahweol, and may be associated with an up to 25% increased risk of ASCVD mortality by consumption of nine or more drinks a day. 446\nNon-filtered coffee includes boiled, Greek, and Turkish coffee and some espresso coffees. Moderate coffee consumption (3 \u0002 4 cups per day) is probably not harmful, perhaps even moderately beneficial. 447\n4.3.2.4.8. Functional foods. Functional foods containing phytosterols (plant sterols and stanols) are effective in lowering LDL-C levels by an average of 10% when consumed in amounts of 2 g/day. 448   The effect is in addition to that obtained with a low-fat diet or use of sta- tins. No studies with clinical endpoints have been performed yet.\nRed yeast rice supplements are not recommended and may even cause side-effects. 449\n4.3.2.4.9. Dietary patterns. Studying the impact of a total dietary pat- tern shows the full preventive potential of diet. The Mediterranean diet includes high intakes of fruits, vegetables, pulses, wholegrain products, fish, and olive oil, moderate consumption of alcohol, and low consumption of (red) meat, dairy products, and saturated fatty acids. Greater adherence to a Mediterranean diet is associated with a 10% reduction in CV incidence or mortality and an 8% reduction in all-cause mortality. 403   Following a Mediterranean diet enriched with nuts over a 5-year period, compared with a control diet, lowered the risk of ASCVD by 28% and by 31% with a diet enriched with extra- virgin olive oil. 404\nAlso, a shift from a more animal-based to a plant-based food pat- tern may reduce ASCVD. 411\n4.3.3. Body weight and composition\n4.3.3.1 Treatment goals and modalities Although diet, exercise, and behaviour modification are the main therapies for overweight and obesity, they are often unsuccessful in the long term. Yet, maintaining even a moderate weight loss of 5- 10% from baseline has salutary effects on risk factors including BP, lipids, and glycaemic control, 450 , 451   as well as on premature all-cause mortality. 456   Weight loss is associated with lower morbidity but higher mortality in (biologically) older adults (the ‘obesity paradox’). In this group, emphasis should be less on weight loss and more on maintaining muscle mass and good nutrition.\n4.3.3.2 Diets for weight loss Energy restriction is the cornerstone of management. PA is essential to maintain weight loss and prevent rebound weight gain, but is not reviewed here. Hypocaloric diets may be categorized as:\n",
      "keywords": [
        "obesity",
        "alcohol",
        "cvd risk",
        "lipid",
        "hypertension",
        "atherosclerosis",
        "class i",
        "sedentary",
        "diabetes",
        "sex",
        "triglyceride",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "diet",
        "level b",
        "physical activity",
        "individual",
        "diastolic",
        "cardiovascular risk",
        "cholesterol",
        "sglt2",
        "hdl-c",
        "ldl-c",
        "older",
        "dbp"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3267",
          "page_number": 40,
          "content": "Patient category |  | Prevention goals (STEP 1) |  | Intensified/additional prevention goalsa (STEP 2) | ESC 2021\nApparently healthy persons |  | For BP and lipids: initiation of drug treatment based on\nCVD risk assessment (Table 5) or SBP >160 mmHg |  |  | \n<50 years |  | Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if toleratedb\nLDL-C <2.6 mmol/L (100 mg/dL) |  | SBP <130 mmHg if toleratedb\nLDL-C <1.8 mmol/L (70 mg/dL) and >50% reduction\n_\nin high-risk patients\nLDL-C <1.4 mmol/L (55 mg/dL) and >50% reduction\n_\nin very-high-risk patients | \n50 - 69 years |  | Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if toleratedb\nLDL-C <2.6 mmol/L (100 mg/dL) |  | SBP <130 mmHg if toleratedb\nLDL-C <1.8 mmol/L (70 mg/dL) and >50% reduction\n_\nin high-risk patients\nLDL-C <1.4 mmol/L (55 mg/dL) and >50% reduction\n_\nin very-high-risk patients | \n>70 years\n_ |  | Stop smoking and lifestyle optimization\nSBP <140 mmHg if toleratedb\nLDL-C <2.6 mmol/L (100 mg/dL) |  | For specific risk factor management in patients >70\n_\nyears old, please see relevant sections in section 4. | \nPatients with CKD |  | Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if toleratedb\nLDL-C <2.6 mmol/L (100 mg/dL) and >50% LDL-C\n_\nreduction\nOtherwise according to ASCVD and DM history |  | LDL-C <1.8 mmol/L (70 mg/dL) in high-risk patients\nand <1.4 mmol/L (55 mg/dL) in very-high risk patients\n(see Table 4) | \nPatients with FH |  | Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if toleratedb\nLDL-C <2.6 mmol/L (100 mg/dL) and >50% LDL-C\n_\nreduction Otherwise according to ASCVD and DM\nhistory |  | LDL-C <1.8 mmol/L (70 mg/dL) in high-risk patients\nand <1.4 mmol/L (55 mg/dL) in very-high risk patients\n(see Table 4) | \nPeople with type 2 DM |  |  |  |  | \nWell-controlled short-standing\nDM (e.g. <10 years), no evidence\nof TOD and no additional ASCVD\nrisk factors |  | Stop smoking and lifestyle optimization |  |  | \nWithout established ASCVD or\nsevere TOD (see Table 4 for\ndefinitions) |  | Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if toleratedb\nLDL-C <2.6 mmol/L (100 mg/dL)\nHbA1c <53 mmol/mol (7.0%) |  | SBP <130 mmHg if toleratedb\nLDL-C <1.8 mmol/L (70 mg/dL) and >50% reduction\n_\nSGLT2 inhibitor or GLP-1RA | \nWith established ASCVD and/or\nsevere TOD (see Table 4 for\ndefinitions) |  | Stop smoking and lifestyle optimisation\nSBP <140 down to 130 mmHg if toleratedb\nLDL-C <1.8 mmol/L (70 mg/dL)\nHbA1c <64 mmol/mol (8.0%)\nSGLT2 inhibitor or GLP1-RA\nCVD: antiplatelet therapy |  | SBP <130 mmHg if toleratedb\nLDL-C <1.4 mmol/L (55 mg/dL) and >50% reduction\n_\nSGLT2 inhibitor or GLP-1RA if not already on\nMay additionally consider novel upcoming treatments:\nDAPT, dual pathway inhibition,a colchicine, icosapent ethyl | \nPatients with established\nASCVD |  | Stop smoking and lifestyle optimization\nSBP <140 down to 130 mmHg if toleratedb\nIntensive oral lipid-lowering therapy aiming at >50%\n_\nLDL-C reduction and LDL-C <1.8 mmol/L (70 mg/dL)\nAntiplatelet therapy |  | SBP <130 mmHg if toleratedb\nLDL-C <1.4 mmol/L (55 mg/dL)\nMay additionally consider novel upcoming treatments:\nDAPT, dual pathway inhibition, colchicine, icosapent ethyl,\netc. | ",
          "bbox": [
            49.9000358581543,
            81.77099609375,
            559.7880249023438,
            657.5169455788352
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3268 ESC Guidelines",
          "page_number": 41,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended for adults of all ages to strive\nfor at least 150 - 300 min a week of moderate-\nintensity or 75 - 150 min a week of vigorous-\nintensity aerobic PA, or an equivalent combina-\ntion thereof, to reduce all-cause mortality, CV\nmortality, and morbidity.371,372 | I | A | \nIt is recommended that adults who cannot per-\nform 150 min of moderate-intensity PA a week\nshould stay as active as their abilities and health\ncondition allow.373,374 | I | B | \nIt is recommended to reduce sedentary time to\nengage in at least light activity throughout the\nday to reduce all-cause and CV mortality and\nmorbidity.375\u0002377 | I | B | \nPerforming resistance exercise, in addition to\naerobic activity, is recommended on 2 or more\ndays per week to reduce all-cause\nmortality.378,379 | I | B | \nLifestyle interventions, such as group or individ-\nual education, behaviour-change techniques, tel-\nephone counselling, and use of consumer-based\nwearable activity trackers, should be considered\nto increase PA participation.380\u0002382 | IIa | B | ESC 2021",
          "bbox": [
            308.8001334450462,
            347.11134847005206,
            553.9383404071515,
            652.0412510463169
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3269",
          "page_number": 42,
          "content": " |  |  |  |  |  | \nAbsolute intensity |  |  | Relative intensity |  |  | \n................................................................................................................ |  |  | ................................................................................................ |  |  | \nIntensity | METa | Examples | %HR\nmax | RPE (Borg\nscale score) | Talk test | \nLight | 1.1\u00022.9 | Walking <4.7 km/h, light household work | 57\u000263 | 10\u000211 |  | \nModerate | 3\u00025.9 | Walking at moderate or brisk pace (4.1\u00026.5 km/h),\nslow cycling (15 km/h), painting/decorating, vacuuming,\ngardening (mowing lawn), golf (pulling clubs in trolley),\ntennis (doubles), ballroom dancing, water aerobics | 64\u000276 | 12\u000213 | Breathing is faster but compatible with\nspeaking full sentences | \nVigorous | >6\n_ | Race-walking, jogging, or running, cycling >15 km/h,\nheavy gardening (continuous digging or hoeing), swim-\nming laps, tennis (singles) | 77\u000295 | 14\u000217 | Breathing very hard, incompatible\nwith carrying on a conversation\ncomfortably | ESC 2021",
          "bbox": [
            49.0515456199646,
            79.9572920365767,
            558.473637507512,
            227.72389439174108
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3269",
          "page_number": 42,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nA healthy diet is recommended as a cornerstone\nof CVD prevention in all individuals.401,402 | I | A | ",
          "bbox": [
            313.4629623413086,
            676.2137715657552,
            558.473637507512,
            724.3751416887555
          ],
          "function_potential": "raw"
        },
        {
          "title": "3270 ESC Guidelines",
          "page_number": 43,
          "content": "It is recommended to adopt a Mediterranean or\nsimilar diet to lower risk of CVD.403,404 | I | A | \nIt is recommended to replace saturated with\nunsaturated fats to lower the risk of\nCVD.405\u0002409 | I | A | \nIt is recommended to reduce salt intake to lower\nBP and risk of CVD.410 | I | A | \nIt is recommended to choose a more plant-\nbased food pattern, rich in fibre, that includes\nwhole grains, fruits, vegetables, pulses, and\nnuts.411,412 | I | B | \nIt is recommended to restrict alcohol consump-\ntion to a maximum of 100 g per week.413\u0002415 | I | B | \nIt is recommended to eat fish, preferably fatty, at\nleast once a week and restrict (processed)\nmeat.406,416\u0002418 | I | B | \nIt is recommended to restrict free sugar con-\nsumption, in particular sugar-sweetened bever-\nages, to a maximum of 10% of energy\nintake.419,420 | I | B | ESC 2021",
          "bbox": [
            44.339311773126774,
            60.35215105329241,
            289.56946614583336,
            308.04370599043995
          ],
          "function_potential": "raw"
        },
        {
          "title": "3270 ESC Guidelines",
          "page_number": 43,
          "content": "Adopt a more plant- and less animal-based food pattern | ESC 2021\nSaturated fatty acids should account for <10% of total energy\nintake, through replacement by PUFAs, MUFAs, and carbohydrates from\nwhole grains | \nTrans unsaturated fatty acids should be minimized as far as possible, with\nnone from processed foods | \n<5 g total salt intake per day | \n30\u000245 g of fibre of per day, preferably from wholegrains | \n>200 g of fruit per day (>2\u00023 servings)\n_ _ | \n>200 g of vegetables per day (>2\u00023 servings)\n_ _ | \nRed meat should be reduced to a maximum of 350 - 500 g a week, in par-\nticular processed meat should be minimized | \nFish is recommended 1\u00022 times per week, in particular fatty fish | \n30 g unsalted nuts per day | \nConsumption of alcohol should be limited to a maximum of 100 g per\nweek | \nSugar-sweetened beverages, such as soft drinks and fruit juices, must be\ndiscouraged | ",
          "bbox": [
            309.74993896484375,
            75.94627380371094,
            554.9690551757812,
            308.04370599043995
          ],
          "function_potential": "raw"
        },
        {
          "title": "3272 ESC Guidelines",
          "page_number": 45,
          "content": "Bariatric surgery for obese high-risk individuals\nshould be considered when lifestyle change does\nnot result in maintained weight loss.455 | IIa | B | ESC 2021",
          "bbox": [
            308.6699905395508,
            60.35187040056501,
            554.2246500651041,
            97.41521344866071
          ],
          "function_potential": "raw"
        },
        {
          "title": "3272 ESC Guidelines",
          "page_number": 45,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that overweight and obese\npeople aim for a reduction in weight to reduce\nBP, dyslipidaemia, and risk of type 2 DM, and\nthus improve their CVD risk profile.450,451 | I | A | \nWhile a range of diets are effective for weight\nloss, it is recommended that a healthy diet in\nregard to CVD risk is maintained over\ntime.452\u0002454 | I | A | ",
          "bbox": [
            44.53214469322791,
            605.6312133789063,
            289.4931335449219,
            726.9831673758371
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "15",
      "title": "1. Diets that aim to reduce ASCVD, including plant-based 457 , 458   and hypocaloric Mediterranean diets, 458 , 459   with modifications to suit local food availability and preferences. 2. Changes to ",
      "start_page": 45,
      "end_page": 54,
      "content": "These diets give broadly similar short-term weight loss. 452 \u0002 454   By 12 months, the effects tend to diminish. 453   Benefits of the Mediterranean diet, however, tend to persist. The quality of nutrients in a diet, for example substituting unsaturated for saturated fats (see section 4.3.2.1 ) and including fibre-rich carbohydrates 460   determines whether a diet is healthy in the long term.\nLow or very low carbohydrate diets may have advantages regard- ing appetite control, lowering triglycerides, and reducing medications for type 2 DM. 461   Such diets may be ketogenic and need medical or at least dietetic supervision. Studies beyond 2 years are scarce. Extreme carbohydrate intakes should be avoided in the long term and plant substitutions of fat and protein for carbohydrates are advantageous over animal ones. 462\nIntermittent fasting diets produce equivalent weight loss to contin- uous energy restriction when matched for energy intake. 463\nMedications approved in Europe as aids to weight loss (orlistat, naltrexone/bupropion, high-dose liraglutide) may supplement lifestyle change to achieve weight loss and maintenance, although\nRecommendations for body weight\nRecommendations Class a Level b\nIt is recommended that overweight and obese people aim for a reduction in weight to reduce\nBP, dyslipidaemia, and risk of type 2 DM, and\nthus improve their CVD risk proﬁle. 450 , 451\nI A\nWhile a range of diets are effective for weight\nloss, it is recommended that a healthy diet in\nregard to CVD risk is maintained over time. 452 \u0002 454\nI A\nContinued\nBariatric surgery for obese high-risk individuals\nshould be considered when lifestyle change does\nnot result in maintained weight loss. 455\nIIa B\nCVD = cardiovascular disease; BP = blood pressure; DM = diabetes mellitus. a Class of recommendation. b Level of evidence.\nESC 2021\n. ....................\n3272 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .................................................................................. sometimes at the expense of side-effects. Meta-analysis of medication-assisted weight loss found favourable effects on BP, gly- caemic control, and ASCVD mortality. 464\nA very effective treatment option for extreme obesity or obesity with comorbidities is bariatric surgery. A meta-analysis indicated that patients undergoing bariatric surgery had over 50% lower risks of total, ASCVD, and cancer mortality compared with people of similar weight who did not have surgery. 455\n4.4. Mental healthcare and psychosocial interventions\nTreatment of an unhealthy lifestyle will reduce CVD risk as well as improve mental health. Smoking cessation, for instance, has a positive effect on depression outcomes, 474 , 475   as do exercise therapy 113 , 476\nand healthy dietary practices. 477   Evidence-based interventions for smoking cessation, and improving PA and diet, are considered useful and applicable for persons with mental disorders. 465 , 478 \u0002 480\nMental disorders are associated with an increased risk of CVD and a worse prognosis in patients with ASCVD, due to CVD events or other death causes, including suicide. 100 , 113 , 305   Mental-health treat- ments effectively reduce stress symptoms and improve quality of life. Several observational studies indicate that treatment or remission of depression reduces CVD risk. 113 , 481 \u0002 484   Psychological interventions in patients with CHD may reduce cardiac mortality (RR 0.79) and alleviate psychological symptoms. 466   Psychotherapy focusing on stress management in ASCVD patients improves CVD outcomes. In SUPRIM (Secondary Prevention in Uppsala Primary Health Care project), patients in the intervention group had a 41% lower rate of\nfatal and non-fatal first recurrent ASCVD events [hazard ratio (HR 0.59)] and fewer recurrent AMIs (HR 0.55). 467   In SWITCHD (Stockholm Women’s Intervention Trial for Coronary Heart Disease), the intervention yielded a substantial reduction in all-cause mortality (OR 0.33). 468   A recent RCT reported that cardiac rehabili- tation (CR) enhanced by stress management produced significant reductions in ASCVD events compared with standard CR alone (HR 0.49). 469   Concerning psychopharmacotherapy of patients with CHD and depression, selective serotonin reuptake inhibitor (SSRI) treat- ment lowers rates of CHD readmission (risk ratio 0.63) and all-cause mortality (risk ratio 0.56). 470   A recent RCT reported that, in patients with ACS and depression, treatment with the SSRI, escitalopram, resulted in a lower rate of the composite endpoint of all-cause mor- tality, myocardial infarction, or percutaneous coronary intervention (PCI) (HR 0.69). 471   Collaborative care for patients with CHD and depression has small beneficial effects on depression, but significantly reduces short-term major cardiac events. 485\nConcerning side-effects of psychopharmacological treatments, many psychiatric drugs are associated with an increased risk of sud- den cardiac death. 486   In patients  with HF, antidepressants are associ- ated with increased risk of cardiac and all-cause mortality (HR 1.27; for details see  supplementary material  for  section 4.4 ). 472   Therefore, ASCVD patients with complex mental disorders, and particularly those needing psychiatric drug treatment, require interdisciplinary cooperation.\n4.5. Smoking intervention\n4.5.1. Smoking cessation Stopping smoking is potentially the most effective of all preventive measures, with substantial reductions in (repeat) myocardial infarc- tions or death. 487 , 488   Lifetime gains in CVD-free years are substantial at all ages, and benefits are obviously even more substantial if other complications from smoking would be accounted for. From age 45 years, gains of 3 - 5 years persist in men to age 65 and in women to age 75 years ( Figure  11 ). Even in heavy smokers (>_20 cigarettes/day), cessation lowers CVD risk within 5 years, although it remains ele- vated beyond 5 years. Total health benefits will be even larger because of gain in non-CVD health.\nRecommendations for mental healthcare and psychoso- cial interventions at the individual level\nRecommendations Class a Level b\nPatients with mental disorders need intensiﬁed\nattention and support to improve adherence to lifestyle changes and drug treatment. 3 , 465\nI C\nIn ASCVD patients with mental disorders, evi-\ndence-based mental healthcare and interdiscipli- nary cooperation are recommended. 100 , 113 , 466\nI B\nASCVD patients with stress should be consid-\nered for referral to psychotherapeutic stress\nmanagement to improve CV outcomes and reduce stress symptoms. 467 \u0002 469\nIIa B\nPatients with CHD and moderate-to-severe\nmajor depression should be considered for anti- depressive treatment with an SSRI. 470 , 471\nIIa B\nIn patients with HF and major depression, SSRIs,\nSNRIs, and tricyclic antidepressants are not rec-\nommended. 472 , 473  c\nIII B\nASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease; CV = cardiovascular; HF = heart failure; SNRI = serotonin-noradrenaline reup- take inhibitor; SSRI = selective serotonin reuptake inhibitor. a Class of recommendation. b Level of evidence. c Details explaining this recommendation are provided in the  supplementary material  section 2.1 .\nESC 2021\nRecommendations for smoking intervention strategies\nRecommendations Class a Level b\nAll smoking of tobacco should be stopped, as tobacco use is strongly and independently causal\nof ASCVD. 487 , 488\nI A\nIn smokers, offering follow-up support, nicotine replacement therapy, varenicline, and bupropion\nindividually or in combination should be\nconsidered. 489 \u0002 494\nIIa A\nSmoking cessation is recommended regardless of weight gain, as weight gain does not lessen the\nASCVD beneﬁts of cessation. 495\nI B\nASCVD = atherosclerotic cardiovascular disease. a Class of recommendation. b Level of evidence.\nESC 2021\n. ............................................................................................................\nESC Guidelines 3273\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n3.0 3.2 3.4 3.4\n3.0 3.1 3.2 3.3\n3.0 3.1 3.3 3.4\n3.1 3.2 3.3 3.4\n2.1 2.3 2.4 2.5\n2.1 2.2 2.3 2.3\n2.0 2.2 2.3 2.4\n2.1 2.2 2.4 2.4\n0.8 0.8 0.9 0.9\n1.6 1.7 1.9 1.9\n0.8 0.8 0.8 0.8\n0.8 0.8 0.8 0.8\n0.8 0.8 0.8 0.8\n1.7 1.7 1.8 1.8\n1.8 1.8 1.8 1.8\n1.7 1.8 1.9 1.9\n2.2 2.3 2.5 2.5\n2.2 2.3 2.4 2.5\n2.0 2.3 2.4 2.4\n3.0\n2.6 2.8 2.9\n2.2 2.4 2.5 2.5\n2.6 2.7 2.9 3.0\n2.6 2.7 2.9 3.0\n2.6 2.7 2.9\n2.8\n0.5 0.5 0.5 0.6\n0.7 0.9 0.9 1.0\n0.5 0.7 0.7 0.7\n0.5 0.6 0.6 0.7\n0.5 0.5 0.6 0.6\n0.8 1.0 1.0 1.1\n0.8 0.9 1.0 1.1\n0.8 0.9 1.0 1.0\n1.2 1.3 1.4 1.5\n1.2 1.3 1.4 1.4\n1.2 1.3 1.4 1.4\n1.9\n1.6 1.7 1.9\n1.2 1.3 1.4 1.5\n1.7 1.8 1.9 1.9\n1.6 1.8 1.9 2.0\n1.7 1.8 1.9\n1.9\n160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119\n90+\n85-89\n80-84\n75-79\n70-74\nSystolic blood pressure (mmHg)\nAge (y)\nLIFE-CVD model CVD-free lifetime gain from smoking cessation (in years)\nNon-HDL cholesterol Women Men\nmmol/L\n150 200 250 mg/dL\n1.0 - 1.4 years 1.5 - 2.0 years\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n150 200 250\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n< 0.5 years 0.5 - 0.9 years ≥ 2.0 years\n4.2 4.4 4.6 4.7\n3.9 4.0 4.2 4.3\n3.8\n3.6 3.6 3.8 3.9\n3.3 3.5 3.6 3.7\n3.4 3.6 3.7 3.8\n3.4 3.6 3.9\n4.1 4.3 4.5 4.6\n3.6 3.6 3.8 3.9\n3.6 3.7 4.0 4.0\n3.7 3.9 4.1 4.2\n3.7 4.0 4.1 4.3\n3.8 3.9 4.0 4.1\n4.2 4.4 4.6 4.7\n4.3 4.5 4.8 4.9\n3.9 4.0 4.3 4.3\n4.0 4.2 4.4 4.5\n4.5 4.7 5.0 5.1\n4.1 4.2 4.4 4.5\n4.4 4.5 4.8 4.9\n4.1 4.3 4.4 4.5\n3.3 3.4 3.6 3.7\n2.9 3.1 3.2 3.3\n2.9\n2.7 2.7 2.9 2.9\n2.4 2.6 2.7 2.7\n2.5 2.7 2.8 2.8\n2.6 2.7 2.9\n3.3 3.5 3.7 3.8\n2.7 2.7 2.9 2.9\n2.8 2.9 3.0 3.1\n2.9 3.0 3.2 3.3\n3.0 3.1 3.3 3.4\n2.8 3.0 3.1 3.2\n3.3 3.5 3.7 3.9\n3.5 3.7 3.9 4.2\n2.9 3.1 3.3 3.4\n3.1 3.2 3.5 3.6\n3.7 3.9 4.2 4.4\n3.1 3.2 3.3 3.5\n3.4 3.7 3.9 4.1\n3.1 3.3 3.4 3.6\n4.1 4.3 4.5 4.5\n4.3 4.5 4.6 4.8\n4.4 4.6 4.9 5.0\n4.5 4.8 5.1 5.2\n3.2 3.3 3.4 3.6\n3.3 3.5 3.7 3.9\n3.5 3.7 4.0 4.2\n3.7 4.0 4.3 4.5\n160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n65-69\n60-64\n55-59\n50-54\n45-49\n160-179 140-159 120-139 100-119\n40-44\nFigure 11  Lifetime atherosclerotic cardiovascular disease benefit from smoking cessation for apparently healthy persons, based on the following risk factors: age, sex, systolic blood pressure, and non-high-density lipoprotein-cholesterol. The model is currently validated for low- and moderate-risk coun- tries. CVD = cardiovascular disease; ESC = European Society of Cardiology; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; SBP = systolic blood pressure. The lifetime benefit is expressed as ‘years of median life expectancy free from myocardial infarction or stroke’ gained from smoking cessation. The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD model 76   multiplied by the HR compared to sustained smoking (0.60) from a meta-analysis of studies on the CVD risk of smoking 496   and multiplied by the HR (0.73) for non-CVD competing mortality. 497   For individualized estimations of lifetime benefit, this table can be used or the electronic version of LIFE- CVD, assessable via the ESC CVD risk app or https://u-prevent.com/.\n3274 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...........................................................................................................................................\nQuitting must be encouraged in all smokers, and passive smoking should be avoided as much as possible. Very brief advice may be advantageous when time is limited ( Table  9 ). A major impetus for ces- sation occurs at the time of diagnosis or treatment of CVD. Prompting a person to try to quit, brief reiteration of CV and other benefits of quitting, and agreeing on a specific plan with a follow-up arrangement are evidence-based interventions. Smokers who quit may expect an average weight gain of 5 kg, but the health benefits of tobacco cessation outweigh risks from weight gain. 495   Persistent or reuptake of smoking is common in patients with CHD, in particular in those with severe depression and environmen- tal exposures. 498   Mood-management therapies may improve out- comes in patients with current or past depression. 499\n4.5.2. Evidence-based drug interventions Drug support for stopping smoking should be considered in all smokers who are ready to undertake this action. Evidence-based drug interven- tions include nicotine-replacement therapy (NRT), bupropion, vareni- cline, and cytisine (not widely available). 489 \u0002 491   All forms of NRT (chewing gum, transdermal nicotine patches, nasal spray, inhaler, sublin- gual tablets) are effective. Combination vs. single-form NRT and 4 mg vs. 2 mg gum can increase success. 492   NRT shows no adverse effects in patients with ASCVD, 493   but evidence of efficacy in this group is incon- clusive. 494   In patients with ASCVD, varenicline (RR 2.6), bupropion (RR 1.4), telephone therapy (RR 1.5), and individual counselling (RR 1.6) all increase success rates. 494   The antidepressant, bupropion, aids long- term smoking cessation with similar efficacy to NRT. 490\nVarenicline 1 mg  b.i.d . (twice a day) increases quitting rates more than two-fold compared with placebo. 491   The RR for abstinence vs. NRT was 1.25 and vs. bupropion, 1.4. Lower or variable doses are also effective and reduce side-effects. Varenicline beyond the 12- week standard regimen is well tolerated. Varenicline initiated in hos- pital following ACS is efficacious and safe. 500\nThe main side-effect of varenicline is nausea, but this usually sub- sides. A causal link between varenicline and neuropsychiatric adverse events is unlikely. 501   Varenicline, bupropion, and NRT do not increase serious CV adverse event risks during or after treatment. 502\nCytisine is effective for smoking cessation, but evidence to date is limited. 491\n4.5.2.1 Electronic cigarettes Electronic cigarettes (e-cigarettes) simulate combustible cigarettes by heating nicotine and other chemicals into a vapour. E-cigarettes\ndeliver nicotine without most of the tobacco chemicals, and are probably less harmful than tobacco. Recent evidence suggests that e-cigarettes are probably more effective than NRT in terms of smoking cessation. 503 \u0002 505   The long- term effects of e-cigarettes on CV and pulmonary health, however, require more research. 506   Dual use with cigarettes should be avoided. Furthermore, as e-cigarettes are addictive, their use should be subject to similar marketing controls as standard cigarettes, espe- cially the flavoured varieties that appeal to children. 507   Despite being lower in toxicants than regular cigarettes, ‘heat-not-burn’ cigarettes do contain tobacco and should be discouraged.\n4.6. Lipids This section covers recommendations for the diagnosis and treat- ment of unfavourable blood lipid levels. More detail and guidance for complex cases/tertiary care, including genetic lipid disorders, are available in the 2019 ESC/European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias. 3\nRecent evidence has confirmed that the key initiating event in athe- rogenesis is the retention of LDL and other cholesterol-rich lipopro- teins within the arterial wall. The causal role of LDL-C, and other apo- B-containing lipoproteins, in the development of ASCVD is demon- strated beyond any doubt by genetic, observational, and interven- tional studies. 20   Meta-analysis of clinical trials has indicated that the relative reduction in CVD risk is proportional to the absolute reduc- tion of LDL-C, irrespective of the drug(s) used to achieve such change, with no evidence of a lower limit for LDL-C values or ‘J-curve’ effect. 21   The absolute benefit of lowering LDL-C depends on the absolute risk of ASCVD and the absolute reduction in LDL-C, so even a small absolute reduction in LDL-C may translate to significant absolute risk reduction in a high- or very-high-risk patient. 22   A recent LDL-C target-driven RCT in patients after ischaemic stroke or transi- ent ischaemic attack (TIA) demonstrated a target LDL-C level of <1.8 mmol/L (70 mg/dL) with the use of statin and, if required, ezetimibe, was associated with a lower CVD risk than those who had a target range of 2.3 \u0002 2.8 mmol/L (90 \u0002 110 mg/dL). 508   Studies on the clinical safety of (very) low achieved LDL-C values have not caused particular concerns, although monitoring for longer periods is required.\n4.6.1. Measurement of lipids and lipoproteins 4.6.1.1 Fasting vs. non-fasting measurements Non-fasting sampling of lipid parameters is recommended for general risk screening, since it has the same prognostic value as fasting sam- ples. 509 , 510   In patients with metabolic syndrome, DM, or hypertrigly- ceridaemia, calculated LDL-C from non-fasting samples should be interpreted with care.\nTable 10 Corresponding non-high-density lipoprotein cholesterol and apolipoprotein B levels for commonly used low-density lipoprotein cholesterol goals\nLDL-C Non-HDL-C Apolipoprotein B\n2.6 mmol/L (100 mg/dL) 3.4 mmol/L (131 mg/dL) 100 mg/dL\n1.8 mmol/L (70 mg/dL) 2.6 mmol/L (100 mg/dL) 80 mg/dL\n1.4 mmol/L (55 mg/dL) 2.2 mmol/L (85 mg/dL) 65 mg/dL\nHDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.\nESC 2021\n. ..................................\nTable 9 ‘Very brief advice’ for smoking cessation\n‘Very brief advice’ on smoking is a proven 30-second clinical intervention,\ndeveloped in the UK, which identiﬁes smokers, advises them on the best method of quitting, and supports subsequent quit attempts. There are\nthree elements to very brief advice: •   ASK - establishing and recording smoking status •   ADVISE - advising on the best ways of stopping •   ACT - offering help\nUK = United Kingdom.\nESC 2021\nESC Guidelines 3275\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.6.1.2 Low-density lipoprotein cholesterol measurement LDL-C can be measured directly, but in most studies and many labo- ratories, LDL-C is calculated using the Friedewald formula:\n•   In mmol/L: LDL-C = total cholesterol  \u0002  HDL-C  \u0002  (0.45  \u0005  trigly- cerides) •   In mg/dL: LDL-C = total cholesterol  \u0002  HDL-C  \u0002  (0.2  \u0005  trigly- cerides)\nThe calculation is only valid when the concentration of triglycer- ides is <4.5 mmol/L ( \u0006 400 mg/dL), and not precise when LDL-C is very low [<1.3 mmol/L (50 mg/dL)]. In patients with low LDL-C lev- els and/or hypertriglyceridaemia (<_800 mg/dL), alternative formulae are available 511 , 512   or LDL-C can be measured directly.\n4.6.1.3 Non-high-density lipoprotein cholesterol The non-HDL-C value is calculated by subtracting HDL-C from total cholesterol. Non-HDL-C, unlike LDL-C, does not require the trigly- ceride concentration to be <4.5 mmol/L (400 mg/dL). It also has an advantage in that it is accurate in a non-fasting setting, and may be more accurate in patients with DM. There is evidence for a role of non-HDL-C as a treatment target as it captures the information regarding all apolipoprotein-B-containing lipoproteins. 513   We suggest it as a reasonable alternative treatment goal for all patients, particularly for those with hypertriglyceridaemia or DM. How non-HDL-C levels correspond to commonly used LDL-C goals is shown in  Table  10 .\n4.6.1.4 Apolipoprotein B Apolipoprotein B provides a direct estimate of the total concentra- tion of atherogenic lipid particles, particularly in patients with ele- vated triglycerides. However, on average, the information conferred by apolipoprotein B is similar to that of calculated LDL-C. 514\nHow apolipoprotein B levels correspond to commonly used LDL-C goals is shown in  Table  10 .\n4.6.2. Defining lipid goals 4.6.2.1 Low-density lipoprotein cholesterol goals\nLDL-C goals are summarized in the recommendations below. As not all drugs are tolerated or available/affordable, treatment should focus on achieving LDL-C levels as close as possible to the given goals. Treatment should be a shared decision-making process between physicians and the patient.\nAs explained earlier in these guidelines ( section 3.2.3.1 ), we propose a stepwise approach to treatment goals, also for LDL-C ( Figures  6 \u0002 8 ). This approach may seem novel but, in reality, resembles clinical prac- tice, where treatment intensification is considered based on anticipated benefit, side-effects, and—importantly—patient preferences. The ulti- mate lipid goals are the same as in the 2019 ESC/EAS dyslipidaemia Guidelines. 3   Evidence from glucose-lowering treatment studies indi- cates that stepwise treatment does not compromise goal attainment, and is associated with fewer side-effects and higher patient satisfac- tion. 66 , 67   In specific cases (at very high risk), the physician may opt to merge both steps and proceed directly to the low LDL-C target level of STEP 2. In apparently healthy people, lifetime treatment benefit of LDL-C reduction may play a role in shared decision-making, together with risk modifiers, comorbidities, patient preference, and frailty.  Figure 12  may support decision-making, as it shows the estimated lifetime benefits in years-free-of-CVD in relation to the total CVD risk profile, calibrated in low-to-moderate CVD risk countries.\nAfter STEP 1, treatment intensification with STEP 2 must be con- sidered in all patients. Given that  lower is better , we encourage liberal intensification of treatment, particularly if submaximal doses of (low- cost) generic statins are used and side-effects are not apparent. The treatment goal of LDL-C <1.4 mmol/L (55 mg/dL) in STEP 2, in patients with established ASCVD or without ASCVD but at very high risk, is lower than the lowest LDL-C goal of 1.8 mmol/L (70 mg/ dL) in the 2016 ESC prevention Guidelines. 2   This low goal was estab- lished based on data from recent Mendelian randomization studies, 80\nmeta-analyses from the Cholesterol Treatment Trialists’ Collaboration, 21   RCTs such as IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial), 515   and— more recently—proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor clinical outcome studies. 516 \u0002 518   The class and level of evi- dence supporting this LDL-C target of <1.4 mmol/L (55 mg/dL) for patients with ASCVD is identical to that in the recent ESC/EAS dysli- pidaemia guidelines. 3   For primary prevention in very- high-risk patients, however, the class of recommendation is lower (Class I in the dyslipidaemia guidelines, Class IIa in the current guidelines), because the Task Force was less unanimous with regards to this low LDL-C target in the primary prevention context. For patients with ASCVD who experience a second vascular event within 2 years (not necessarily of the same type as the first) while tak- ing maximum tolerated statin-based therapy, an even lower LDL-C goal of <1.0 mmol/L (40 mg/dL) may be considered. Importantly, there are no differences in the RR reductions between men and women and between younger and older patients (at least up to age 75 years), or between those with and without DM. 3\n4.6.2.2 Triglyceride-rich lipoproteins and their remnants There are no treatment goals for triglycerides, but <1.7 mmol/L (150 mg/dL) is considered to indicate lower risk, whereas higher levels indicate a need to look for other risk factors.\n4.6.2.3 High-density lipoprotein cholesterol To date, no specific goals for HDL-C levels have been determined in clinical trials, although low HDL-C is associated with (residual) risk in ASCVD patients. PA and other lifestyle factors, rather than drug treatment, remain important means of increasing HDL-C levels.\nRecommendation on low-density lipoprotein choles- terol goals a\nRecommendation Class b Level c\nA stepwise treatment-intensiﬁcation approach is\nrecommended for apparently healthy people at\nhigh or very high CVD risk, as well as patients with established ASCVD and/or DM with con-\nsideration of CVD risk, treatment beneﬁt, risk\nmodiﬁers, comorbidities, and patient preferences.\nI C\nASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus. a Recommendation from  section 3.2 . b Class of recommendation. c Level of evidence.\nESC 2021\n3276 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n1.2 1.4 1.6 1.7\n0.9 1.1 1.3 1.5\n1.3 1.4 1.5 1.6\n1.6\n0.7 0.9 1.0 1.1\n0.9 1.1 1.3 1.3\n1.1 1.3 1.4 1.5\n0.9 1.0 1.2 1.3\n1.0 1.2 1.4 1.5\n1.2 1.4 1.5 1.6\n1.3 1.5 1.7\n1.5 1.7 1.8 1.9\n0.9 1.0 1.2 1.3\n1.1 1.3 1.5 1.6\n1.3 1.4 1.6 1.7\n1.4 1.6 1.7 1.8\n0.9 1.1 1.3 1.4\n1.4 1.5 1.8 1.9\n1.5 1.7 1.8 1.9\n1.1 1.3 1.5 1.6\n1.3 1.6 1.7 1.8\n1.5 1.7 1.9 2.0\n0.9 1.2 1.4 1.5\n1.4 1.5 1.7 1.8\n1.2 1.4 1.6 1.7\n0.6 0.7 0.9 0.9\n0.4 0.5 0.6 0.7\n0.5 0.6 0.7 0.8\n0.9\n0.2 0.3 0.3 0.3\n0.2 0.3 0.5 0.5\n0.4 0.5 0.6 0.6\n0.3 0.4 0.4 0.6\n0.3 0.5 0.5 0.6\n0.5 0.6 0.7 0.7\n0.6 0.7 0.9\n0.8 1.0 1.1 1.2\n0.3 0.4 0.4 0.6\n0.4 0.5 0.7 0.7\n0.5 0.7 0.8 0.9\n0.6 0.8 0.9 1.1\n0.4 0.4 0.6 0.6\n0.7 0.9 1.1 1.1\n0.9 1.0 1.3 1.4\n0.5 0.6 0.8 0.8\n0.6 0.8 0.9 1.1\n0.9 1.1 1.3 1.4\n0.5 0.6 0.7 0.8\n0.8 0.9 1.1 1.2\n0.6 0.7 0.8 0.9\n0.8 1.0 1.1 1.3\n0.6 0.7 0.9 1.0\n0.8 0.9 1.1 1.1\n1.2\n0.4 0.5 0.6 0.6\n0.5 0.6 0.7 0.9\n0.7 0.8 1.0 1.0\n0.5 0.7 0.7 0.8\n0.6 0.8 0.8 1.0\n0.8 1.0 1.0 1.1\n0.9 1.1 1.3\n1.1 1.3 1.4 1.6\n0.5 0.7 0.7 0.8\n0.7 0.8 1.0 1.1\n0.8 1.0 1.2 1.2\n1.1 1.2 1.4 1.4\n0.6 0.6 0.8 0.9\n1.0 1.2 1.3 1.5\n1.2 1.4 1.5 1.6\n0.7 0.9 1.1 1.2\n0.9 1.1 1.3 1.4\n1.2 1.4 1.6 1.6\n0.6 0.8 0.9 1.0\n1.0 1.2 1.4 1.5\n0.8 1.0 1.1 1.2\n0.6 0.7 0.9 0.9\n0.4 0.5 0.6 0.6\n0.3 0.4 0.5 0.5\n0.7\n0.1 0.2 0.3 0.2\n0.2 0.2 0.3 0.4\n0.2 0.3 0.4 0.4\n0.3 0.4 0.5 0.4\n0.3 0.4 0.4 0.4\n0.4 0.5 0.5 0.6\n0.5 0.5 0.7\n0.8 0.9 1.0 1.1\n0.3 0.4 0.5 0.4\n0.4 0.5 0.6 0.6\n0.5 0.6 0.7 0.8\n0.6 0.7 0.9 0.9\n0.3 0.5 0.5 0.6\n0.7 0.8 0.9 1.1\n0.9 1.0 1.2 1.3\n0.4 0.6 0.7 0.8\n0.6 0.7 0.8 0.9\n0.9 1.1 1.3 1.4\n0.5 0.6 0.6 0.8\n0.7 0.9 1.1 1.2\n0.6 0.7 0.7 0.8\n0.3 0.4 0.4 0.4\n0.8 0.8 0.9 0.9\n0.2 0.2 0.2 0.2\n0.2 0.3 0.3 0.3\n0.3 0.3 0.4 0.4\n0.4 0.4 0.5 0.6\n0.5 0.6 0.7 0.7\n0.6 0.7 0.8 0.8\n0.7 0.8 0.9 1.0\n0.9 1.0 1.1 1.1\n1.0 1.1 1.2 1.3\n1.4\n1.2 1.3 1.4\n0.5 0.6 0.7 0.8\n0.6 0.8 0.9 1.0\n0.8 1.0 1.1 1.2\n1.0 1.2 1.3\n1.4\n0.1 0.1 0.2 0.2\n0.2 0.2 0.3 0.4\n0.0 0.0 0.1 0.1\n0.1 0.1 0.1 0.1\n0.1 0.1 0.1 0.1\n0.0 0.1 0.1 0.1\n0.1 0.2 0.2 0.2\n0.1 0.2 0.2 0.3\n0.2 0.2 0.3 0.2\n0.2 0.3 0.3 0.4\n0.2 0.4 0.4 0.5\n0.5\n0.4 0.5 0.6\n0.1 0.1 0.2 0.2\n0.2 0.2 0.2 0.3\n0.2 0.2 0.3 0.4\n0.2 0.3 0.5\n0.5\n0.2 0.3 0.3 0.3\n0.4 0.5 0.5 0.5\n0.1 0.1 0.1 0.1\n0.1 0.1 0.2 0.2\n0.2 0.2 0.2 0.3\n0.2 0.2 0.3 0.3\n0.3 0.4 0.4 0.4\n0.3 0.4 0.5 0.5\n0.4 0.4 0.5 0.5\n0.4 0.5 0.6 0.7\n0.5 0.6 0.7 0.7\n0.9\n0.7 0.8 1.0\n0.2 0.3 0.4 0.4\n0.3 0.4 0.5 0.6\n0.4 0.5 0.6 0.7\n0.6 0.6 0.7\n0.9\n0.1 0.0 0.1 0.1\n0.1 0.1 0.1 0.2\n0.0 0.1 0.0 0.1\n0.1 0.0 0.0 0.1\n0.0 0.0 0.0 0.0\n0.0 0.0 0.0 0.1\n0.0 0.0 0.1 0.1\n0.1 0.1 0.1 0.1\n0.0 0.1 0.1 0.1\n0.1 0.1 0.2 0.2\n0.1 0.2 0.2 0.2\n0.3\n0.2 0.2 0.3\n0.0 0.0 0.0 0.1\n0.1 0.1 0.2 0.1\n0.1 0.2 0.2 0.2\n0.2 0.2 0.3\n0.3\n1.0 1.2 1.4 1.5\n1.2 1.4 1.6 1.7\n1.4 1.5 1.7 1.8\n1.6 1.7 1.9 2.0\n0.5 0.6 0.7 0.8\n0.6 0.8 0.9 1.0\n0.8 0.9 1.1 1.2\n0.9 1.1 1.3 1.4\n0.6 0.8 0.9 1.0\n0.8 1.0 1.1 1.3\n1.0 1.2 1.4 1.5\n1.3 1.4 1.6 1.7\n0.5 0.6 0.7 0.8\n0.6 0.8 0.9 1.0\n0.8 0.9 1.1 1.3\n0.9 1.2 1.4 1.5\n160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n90+\n85-89\n80-84\n75-79\n70-74\n65-69\n60-64\n55-59\n50-54\n45-49\nSystolic blood pressure (mmHg)\nNon-smoking\nSmoking\nAge (y)\nLIFE-CVD model CVD-free lifetime gain from 1 mmol/L LDL-C reduction (in years)\nNon-smoking\nSmoking\nNon-HDL cholesterol\nWomen Men\nmmol/L\n150 200 250 150 200 250 150 200 250 150 200 250 mg/dL\n< 0.5 years\n0.5 - 0.9 years\n1.0 - 1.4 years\n1.5 - 2.0 years\n≥ 2.0 years\n160-179 140-159 120-139 100-119\n40-44\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\nFigure 12  Average years-free-of-cardiovascular disease gained per 1 mmol/L (40 mg/dL) low-density lipoprotein cholesterol reduction in apparently healthy persons. The model is currently validated for low- and moderate-risk countries. Lifetime benefit of 1 mmol/L LDL-C lowering for apparently healthy persons, based on the following risk factors: age, sex, current smoking, SBP, and non-HDL-C. The lifetime benefit is expressed as ‘years of median life expectancy free from myocardial infarction or stroke’ gained from 1 mmol/L LDL-C lowering. For 2 mmol/L LDL-C lowering, the average effect is almost twice as large, and so on. The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD model 76   multiplied by the HR (0.78) from a meta-analysis of the effect of lipid lowering. 22   For individualized estimations of lifetime benefit, this table can be used or the electronic version of LIFE-CVD, assessable via the ESC CVD risk app or https://u-prevent.com/. CVD = cardiovascular disease; ESC = European Society of Cardiology; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LDL-C = low-density lipoprotein cholesterol; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; SBP = systolic blood pressure.\nESC Guidelines 3277\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ........................ 4.6.3. Strategies to control dyslipidaemias The presence of dyslipidaemias secondary to other conditions must be excluded before beginning treatment, as treatment of underlying disease may improve hyperlipidaemia without requiring lipid- lowering therapy. This is particularly true for hypothyroidism. Secondary dyslipidaemias can also be caused by alcohol abuse, DM, Cushing’s syndrome, diseases of the liver and kidneys, as well as by drugs (e.g. corticosteroids). In addition, lifestyle optimization is crucial in all patients with higher than optimal lipid levels.\n4.6.3.1 Strategies to control low-density lipoprotein cholesterol\n4.6.3.1.1. Diet and lifestyle modifications. Dietary factors influence the development of ASCVD, either directly or through their action on traditional risk factors, such as plasma lipids, BP, or glucose levels. Consistent evidence from epidemiological studies indicates that higher consumption of fruit, non-starchy vegetables, nuts, legumes, fish, vegetable oils, yoghurt, and wholegrains, along with a lower intake of red and processed meats, foods higher in refined carbohy- drates, and salt, is associated with a lower incidence of CV events. 519\nMoreover, the replacement of animal fats, including dairy fat, with vegetable sources of fats and PUFAs may decrease the risk of ASCVD. 407   More detail on lifestyle recommendations can be found earlier in this section.\n4.6.3.1.2. Drugs for treatment of dyslipidaemias. The currently available lipid-lowering drugs include inhibitors of 3-hydroxy-3-meth- ylglutaryl-coenzyme A reductase (statins), fibrates, bile acid seques- trants, selective cholesterol absorption inhibitors (e.g. ezetimibe), and—more recently—PCSK9 inhibitors. Bempedoic acid, an oral cholesterol synthesis inhibitor, has recently been approved in several countries. Usage is mainly intended in combination with ezetimibe in patients with statin intolerance. ASCVD outcome trials are not expected before the end of 2022. Additionally, inclisiran, a new small interfering ribonucleic acid, has shown to reduce LDL-C by 50 \u0002 55% when applied subcutaneously twice a year. These results were obtained either on top of statin or without other lipid-lowering therapies, and with almost no side-effects. Inclisiran has been\napproved in several European countries. Results from the ASCVD outcomes trial are expected for 2023. The expected LDL-C reductions in response to therapy are shown in  Figure  13 , and may vary widely among individuals. Therefore, monitoring the effect on LDL-C levels is recommended, with assessment of LDL-C levels 4 - 6 weeks after any treatment strategy initiation or change.\nTreatment Average LDL-C reduction\nIntensity of lipid-lowering treatment\nModerate-intensity statin\nHigh-intensity statin\nHigh-intensity statin plus ezetimibe\nPCSK9 inhibitor\nPCSK9 inhibitor plus high-intensity statin\nPCSK9 inhibitor plus high-intensity statin plus ezetimibe\n30%\n50%\n65%\n60%\n75%\n85%\nFigure 13  Expected low-density lipoprotein cholesterol reductions for combination therapies. LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9. Adapted from Mach  et al . 3\nRecommendations for pharmacological low-density lip- oprotein cholesterol lowering for those  < 70 years of age (for recommendations for persons aged  \u0003 70 years, see respective recommendations tables).\nRecommendations Class a Level b\nIt is recommended that a high-intensity statin is\nprescribed up to the highest tolerated dose to reach the LDL-C goals set for the speciﬁc risk\ngroup. 21 , 520 , 521\nI A\nAn ultimate c   LDL-C goal of <1.4 mmol/L (55 mg/ dL) and LDL-C reduction of >_50% from baseline\nshould be considered in apparently healthy persons\n<70 years at very high risk. 21 , 22 , 522\nIIa C\nAn ultimate c   LDL-C goal of <1.8 mmol/L (70 mg/dL) and LDL-C reduction of >_50% from\nbaseline should be considered in apparently\nhealthy persons <70 years at high risk. 21 , 22 , 522\nIIa C\nIn patients with established ASCVD, lipid-lowering\ntreatment with an ultimate c   LDL-C goal of <1.4\nmmol/L (55 mg/dL) and a >_50% reduction in LDL- C vs. baseline is recommended. 21 , 508 , 515 \u0002 517 , 522\nI A\nIf the goals are not achieved with the maximum\ntolerated dose of a statin, combination with eze-\ntimibe is recommended. 515\nI B\nFor primary prevention patients at very high risk,\nbut without FH, if the LDL-C goal is not\nachieved on a maximum tolerated dose of a sta- tin and ezetimibe, combination therapy including\na PCSK9 inhibitor may be considered.\nIIb C\nContinued . ..........................................................................................\n3278 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................\n4.6.3.1.3. Statins. Statins decrease LDL-C, thereby reducing ASCVD morbidity and mortality as well as the need for coronary artery inter- ventions. Statins also lower triglycerides, and may reduce pancreatitis risk. Therefore, they are the drug of first choice in patients at increased risk of ASCVD. 3\n4.6.3.1.3.1. Adverse effects, interactions, and adherence to statin therapy The most frequent adverse effect of statin therapy is myopathy, but this is rare. A meta-analysis ruled out any contribution to an increase in non-CV mortality. 522   Increased blood sugar and HbA1c levels (i.e. increased risk of type 2 DM) can occur after treatment initiation and are dose dependent, in part linked to slight weight gain, but the bene- fits of statins outweigh the risks for the majority of patients. 527\nAdhering to lifestyle changes when prescribed a statin should lessen the risk of DM. Increased levels of liver enzymes may occur during statin therapy, and are usually reversible. Routine monitoring of liver enzyme values is not indicated.\nAlthough 5 \u0002 10% of patients receiving statins complain of myalgia, in most cases it is not attributable to statins. 3   The risk of myopathy (severe muscular symptoms) can be minimized by identifying vulner- able patients and/or by avoiding statin interactions with specific drugs. Rhabdomyolysis is extremely rare. As statins are prescribed on a long-term basis, possible interactions with other drugs deserve par- ticular and continuous attention, as many patients will receive\npharmacological therapy for concomitant conditions. In practice, management of a patient with myalgia but without a major increase in creatine kinase is based on trial and error, and usually involves switch- ing to a different statin or use of a very low dosage several days a week, with a gradual increase in frequency and dosage. A manage- ment algorithm may help to manage these patients. 3\n4.6.3.1.4. Cholesterol absorption inhibitors (ezetimibe). The com- bination of statin with ezetimibe brings a benefit that is in line with meta-analyses showing that LDL-C reduction has benefits independ- ent of the approach used. 3 , 21   The beneficial effect of ezetimibe is also supported by genetic studies. 528   Together, these data support the position that ezetimibe should be considered as second-line therapy, either on top of statins when the therapeutic goal is not achieved, or when a statin cannot be prescribed.\n4.6.3.1.5. Proprotein convertase subtilisin/kexin type 9 inhibitors. PCSK9 inhibitors (monoclonal antibodies to PCSK9) decrease LDL-C by up to 60%, either as monotherapy or in addition to the maximum tolerated dose of statin and/or other lipid-lowering therapies, such as ezetimibe. Their efficacy appears to be largely independent of back- ground therapy. In combination with high-intensity or maximum toler- ated statins, alirocumab and evolocumab reduced LDL-C by 46 \u0002 73% more than placebo, and by 30% more than ezetimibe. 516 , 517   Among patients in whom statins cannot be prescribed, PCSK9 inhibition reduced LDL-C levels when administered in combination with ezeti- mibe. 529   Both alirocumab and evolocumab effectively lower LDL-C levels in patients who are at high or very high CVD risk, including those with DM, with a large reduction in future ASCVD events. 516 , 517\nPCSK9 inhibitors also lower triglycerides, raise HDL-C and apolipo- protein A-I, and lower lipoprotein(a), although the relative contribu- tions of these lipid modifications remain unknown. PCSK9 inhibitors are costly, and their cost-effectiveness, long-term safety, and effect in primary prevention are as yet unknown. We recommend considering cost-effectiveness in a loco-regional context before implementing rec- ommendations that involve their use. Recommendations for the use of PCSK9 inhibitors are described in the Recommendations for pharma- cological LDL-C lowering. Inclisiran is a long-acting hepatic PCSK9 syn- thesis inhibitor that also lowers LDL-C levels considerably. 530   Its effect on clinical outcomes remains to be established.\n4.6.3.2 Strategies to control plasma triglycerides Although CVD risk is increased when fasting triglycerides are >1.7 mmol/L (150 mg/dL), 531   the use of drugs to lower triglyceride levels may only be considered in high-risk patients when triglycerides are >2.3 mmol/L (200 mg/dL) and triglycerides cannot be lowered by life- style measures. The available pharmacological interventions include statins, fibrates, PCSK9 inhibitors, and n-3 PUFAs (in particular icosa- pent ethyl in doses of 2 \u0002 4 g/day; see  section 4.3.2.4.4 ).\nRecommendations for the treatment of hypertriglyceridaemia are shown in the Recommendations below.\n4.6.3.2.1. Fibrates. Fibrates are used primarily for triglyceride lower- ing and, occasionally, for increasing HDL-C. Evidence supporting the use of these drugs for CVD event reduction is limited, and given the strong evidence favouring statins, routine use of these drugs in CVD prevention is not recommended. 3   To prevent pancreatitis, when\nFor secondary prevention patients not achieving\ntheir goals on a maximum tolerated dose of a\nstatin and ezetimibe, combination therapy including a PCSK9 inhibitor is\nrecommended. 516 , 517\nI A\nFor very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who\ndo not achieve their goals on a maximum toler-\nated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is\nrecommended.\nI C\nIf a statin-based regimen is not tolerated at any\ndosage (even after rechallenge), ezetimibe should be considered. 515 , 523 \u0002 525\nIIa B\nIf a statin-based regimen is not tolerated at any\ndosage (even after rechallenge), a PCSK9 inhibitor added to ezetimibe may be considered. 523 , 524 , 526\nIIb C\nIf the goal is not achieved, statin combination\nwith a bile acid sequestrant may be considered. IIb C\nStatin therapy is not recommended in premenopausal female patients who are consid-\nering pregnancy or are not using adequate\ncontraception.\nIII C\nASCVD = atherosclerotic cardiovascular disease; FH = familial hypercholestero- laemia; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein con- vertase subtilisin/kexin type 9. a Class of recommendation. b Level of evidence. c A stepwise approach to LDL-C targets is recommended; see  section 3.2.3.1  and Figures  6  and  7 . Adapted from   3\nESC 2021\nESC Guidelines 3279\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................................................ triglycerides are >10 mmol/L (900 mg/dL), they must be reduced not only by drugs, but also by restriction of alcohol, treatment of DM, withdrawal of oestrogen therapy, etc. In patients with severe primary hypertriglyceridaemia, referral to a specialist must be considered.\nAn evidence-based approach to the use of lipid-lowering nutra- ceuticals could improve the quality of the treatment, including ther- apy adherence, and achievement of the LDL-C goal in clinical practice. However, it has to be clearly stressed that there are still no outcome studies proving that nutraceuticals can prevent CVD mor- bidity or mortality. 532\n4.6.4. Important groups\n4.6.4.1 Women The proportional reductions per mmol/L reduction in LDL-C in major vascular events, major coronary events, coronary revasculari- zation, and stroke are similar in women and men. In addition, the rela- tive effects of non-statin drugs that lower LDL-C (ezetimibe and PCSK9 inhibitors, on top of high-intensity statin therapy) are also sim- ilar in both women and men. 3\n4.6.4.2 Older patients ( \u0003 70 years) Compared to the 2019 ESC/EAS dyslipidaemia guidelines, 3   we pro- vide a single cut-off for identifying ‘older persons’ as those >_70 years of age, as opposed to 75 years, for reasons of consistency with other parts of the current guidelines. As a result, class and level of evidence have been modified in some age groups, in particular the category of patients between 70 and 75 years. Although a single age cut-off is now used, it is important to stress that all such age cut-offs are rela- tively arbitrary, and biological age influences this threshold in clinical practice. For example, a very fit 75-year-old person may qualify for a treatment normally reserved for those <70 and, conversely, a very frail 65-year-old person should sometimes be considered ‘older’. General recommendations for lipid-lowering treatment in older patients are summarized below.\nRecent evidence has strengthened the role of LDL-C as an ASCVD risk factor in older patients. 537   Evidence from trials indicates that statins and other lipid-lowering drugs produce significant reductions in major vascular events irrespective of age. 538 , 539   However, there is less direct evidence of statin benefit in those without evidence of ASCVD. Under the age of 70 years, statins are recommended for primary prevention depending on the level of risk. Above that age, initiation of statin treat- ment for primary prevention may be considered when at (very) high risk, but we explicitly recommend also taking other arguments into account, such as risk modifiers, frailty, estimated life-time benefit, comorbidities, and patient preferences (see  section 3.2.3.3  and  Figure 12 ). In case of renal function impairment or risk for drug interactions, the statin dose should be up-titrated carefully. In terms of LDL-C tar- gets, there is insufficient evidence to support targets for primary pre- vention in older patients. Although the conventional LDL-C target of <2.6 mmol/L (100 mg/dL) may seem reasonable, the results of ongoing primary prevention trials in older patients must be awaited [STAREE (STAtin Therapy for Reducing Events in the Elderly) trial; clinicatrials. gov registration: NCT02099123]. Frailty, polypharmacy, and muscle symptoms remain relevant factors to consider in older patients.\n4.6.4.3 Diabetes mellitus Lowering of LDL-C in patients with DM is consistently associated with lower CVD risk. Similar to prevention in apparently healthy individuals, we propose a stepwise approach to lipid control, dependent on risk, estimated lifetime benefit, comorbidities, and patient preferences ( Figure 8 ). PCSK9 inhibitors can also be used in patients with DM not reaching their LDL-C targets with statins and/ or ezetimibe.\nRecommendations for the treatment of dyslipidaemias in older people ( \u0003 70 years).\nRecommendations Class a Level b\nTreatment with statins is recommended for\nolder people with ASCVD in the same way as for younger patients. 538 , 539\nI A\nInitiation of statin treatment for primary preven-\ntion in older people aged >_70 may be consid- ered, if at high risk or above. 538 , 539\nIIb B\nIt is recommended that the statin is started at a\nlow dose if there is signiﬁcant renal impairment\nand/or the potential for drug interactions.\nI C\nASCVD = atherosclerotic cardiovascular disease. a Class of recommendation. b Level of evidence. Adapted from   3\n. ...........................................................................................................\nRecommendations for drug treatments of patients with hypertriglyceridaemia.\nRecommendations Class a Level b\nStatin treatment is recommended as the ﬁrst\ndrug of choice for reducing CVD risk in high-risk\nindividuals with hypertriglyceridaemia [triglycer- ides >2.3 mmol/L (200 mg/dL)]. 533\nI A\nIn patients taking statins who are at LDL-C goal\nwith triglycerides >2.3 mmol/L (200 mg/dL), fenoﬁ-\nbrate or bezaﬁbrate may be considered. 534 \u0002 536\nIIb B\nIn high-risk (or above) patients with triglycerides\n>1.5 mmol/L (135 mg/dL) despite statin treat-\nment and lifestyle measures, n-3 PUFAs (icosa- pent ethyl 2  \u0005  2 g/day) may be considered in\ncombination with a statin. 84\nIIb B\nCVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; PUFA = polyunsaturated fatty acid. a Class of recommendation. b Level of evidence. Adapted from   3\nRecommendations for the treatment of dyslipidaemias in diabetes mellitus.\nRecommendations Class a Level b\nIn patients with type 2 DM at very high risk (e.g.\nwith established ASCVD and/or severe TOD c ), intensive lipid-lowering therapy, ultimately d   aim-\ning at >_50% LDL-C reduction and an LDL-C of\n<1.4 mmol/L (55 mg/dL) is recommended. 21 , 22 , 522 , 540 , 541\nI A\nContinued\nESC 2021\nESC 2021\n3280 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ......................................................\n4.6.4.4 Chronic kidney disease Patients with CKD are at high or very high risk of ASCVD, and have a characteristic dyslipidaemia (high triglycerides, normal LDL-C, and low HDL-C). Statin therapy or statin therapy in combination with ezetimibe (which allows larger LDL-C reductions without increasing the statin dose) has a beneficial effect on ASCVD outcomes in CKD. 543   For patients with end-stage renal disease, however, we rec- ommend that hypolipidaemic therapy should not be initiated (see Recommendations below). If patients with CKD already on a hypoli- pidaemic therapy enter end-stage renal disease, the therapy may be maintained.\n4.6.4.5 Familial Hypercholesterolaemia Patients who could have genetic dyslipidaemias, such as heterozygous FH, can be identified by extreme lipid abnormalities and/or family his- tory ( Table  11 ). An LDL-C >4.9 mmol/L (190 mg/dL) in therapy- naı¨ve patients requires careful evaluation for possible FH. However, in the presence of premature ASCVD or family history, possible FH should be considered at lower LDL-C levels. Besides genetic testing (not always affordable), use of the Dutch Clinical Lipid Network cri- teria ( Table 11 ) is recommended to identify possible FH. Homozygous FH is rare and should always be placed under the care of lipid experts. Treatment guidelines for people with FH can be found in the 2019 ESC/EAS dyslipidaemia Guidelines. 3\n4.7. Blood pressure\nHypertension is one of the most important preventable causes of premature morbidity and mortality. It affects more than 150 million\nIn patients with type 2 DM >40 years at high risk, lipid-lowering treatment with an ultimate\nLDL-C goal of >_50% LDL-C reduction and an\nLDL-C of <1.8 mmol/L (70 mg/dL) is recommended. 540 , 541\nI A\nStatin therapy may be considered in persons\naged <_40 years with type 1 or type 2 DM with evidence of TOD and/or an LDL-C level >2.6\nmmol/L (100 mg/dL), as long as pregnancy is not\nbeing planned.\nIIb C\nIf the LDL-C goal is not reached, statin\ncombination with ezetimibe should be\nconsidered. 515 , 542\nIIa B\nASCVD = atherosclerotic cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular ﬁltration rate; LDL-C = low-density lipoprotein choles- terol; TOD = target organ damage. a Class of recommendation. b Level of evidence. c Severe TOD in this speciﬁc context includes eGFR <45 mL/min/1.73 m 2 ; eGFR 46 \u0002 79 mL/min/1.73 m 2   plus microalbuminuria; proteinuria; presence of micro- vascular disease in at least three different sites (e.g. albuminuria plus retinopathy plus neuropathy). See  Table  4  for details. d A stepwise approach to LDL-C targets is recommended; see  section 3.2.3.1  and Figure  8 . Adapted from   3\nRecommendations for lipid management in patients with moderate-to-severe chronic kidney disease (Kidney Disease Outcomes Quality Initiative stages 3 \u0002 5).\nRecommendations Class a Level b\nThe use of statins or statin/ezetimibe combina-\ntion is recommended in patients with non-dialy- sis-dependent, stage 3 \u0002 5 CKD. 525 , 544 , 545\nI A\nIn patients already on statins, ezetimibe, or a sta-\ntin/ezetimibe combination at the time of dialysis initiation, continuation of these drugs should be\nconsidered, particularly in patients with ASCVD.\nIIa C\nIn patients with dialysis-dependent CKD who\nare free of ASCVD, commencing statin therapy is not recommended. 546 , 547\nIII A\nASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease. a Class of recommendation. b Level of evidence. Adapted from   3\nTable 11 Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia\nCriteria (choose only one score per group, the highest applicable; diagnosis is based on the total number of points obtained)\nPoints\n1) Family history\nFirst-degree relative with known premature (men aged <55 years; women <60 years) coronary or vascular dis-\nease, or ﬁrst-degree relative with known LDL-C above\nthe 95 th   percentile\n1\nFirst-degree relative with tendinous xanthomata and/or\narcus cornealis, or children aged <18 years with LDL-C\nabove the 95th percentile\n2\n2) Clinical history\nPatient with premature (men aged <55 years; women\n<60 years) CAD\n2\nPatient with premature (men aged <55 years; women\n<60 years) cerebral or peripheral vascular disease\n1\n3) Physical examination\nTendinous xanthomata 6\nArcus cornealis before age 45 years 4\n4) LDL-C levels (without treatment)\nLDL-C >_8.5 mmol/L (326 mg/dL) 8\nLDL-C 6.5 \u0002 8.4 mmol/L (251 \u0002 325 mg/dL) 5\nLDL-C 5.0 \u0002 6.4 mmol/L (191 \u0002 250 mg/dL) 3\nLDL-C 4.0 \u0002 4.9 mmol/L (155 \u0002 190 mg/dL) 1\n5) DNA analysis\nFunctional mutation in the  LDLR, apolipoprotein B,  or\nPCSK9  genes\n8\nA ‘deﬁnite’ FH diagnosis requires >8 points\nA ‘probable’ FH diagnosis requires 6 \u0002 8 points\nA ‘possible’ FH diagnosis requires 3 \u0002 5 points\nCAD = coronary artery disease; DNA = deoxyribonucleic acid; FH = familial hyper- cholesterolaemia; LDL-C = low-density lipoprotein cholesterol; LDLR = low-density lipoprotein receptor; PCSK9 = proprotein convertase subtilisin/kexin type 9.\n",
      "keywords": [
        "obesity",
        "alcohol",
        "cvd risk",
        "lipid",
        "hypertension",
        "genetic",
        "reduce",
        "hypocaloric",
        "atherosclerosis",
        "class i",
        "based",
        "diabetes",
        "coronary artery",
        "sex",
        "food",
        "female",
        "triglyceride",
        "level c",
        "suit",
        "changes",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "smoking",
        "recommended",
        "risk factor",
        "modifications",
        "may be considered",
        "diet"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3273",
          "page_number": 46,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nPatients with mental disorders need intensified\nattention and support to improve adherence to\nlifestyle changes and drug treatment.3,465 | I | C | \nIn ASCVD patients with mental disorders, evi-\ndence-based mental healthcare and interdiscipli-\nnary cooperation are recommended.100,113,466 | I | B | \nASCVD patients with stress should be consid-\nered for referral to psychotherapeutic stress\nmanagement to improve CV outcomes and\nreduce stress symptoms.467\u0002469 | IIa | B | \nPatients with CHD and moderate-to-severe\nmajor depression should be considered for anti-\ndepressive treatment with an SSRI.470,471 | IIa | B | \nIn patients with HF and major depression, SSRIs,\nSNRIs, and tricyclic antidepressants are not rec-\nommended.472,473 c | III | B | ESC 2021",
          "bbox": [
            48.99032350019975,
            228.6802185058594,
            294.1171123798077,
            449.6482424054827
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3273",
          "page_number": 46,
          "content": "Recommendations | Classa | Levelb | \n |  |  | \nAll smoking of tobacco should be stopped, as\ntobacco use is strongly and independently causal\nof ASCVD.487,488 | I | A | \nIn smokers, offering follow-up support, nicotine\nreplacement therapy, varenicline, and bupropion\nindividually or in combination should be\nconsidered.489\u0002494 | IIa | A | \nSmoking cessation is recommended regardless\nof weight gain, as weight gain does not lessen the\nASCVD benefits of cessation.495 | I | B | ESC 2021",
          "bbox": [
            313.3750810623169,
            411.4105907786976,
            558.511976453993,
            555.4603925432477
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3275",
          "page_number": 48,
          "content": "‘Very brief advice’ on smoking is a proven 30-second clinical intervention,\ndeveloped in the UK, which identifies smokers, advises them on the best\nmethod of quitting, and supports subsequent quit attempts. There are\nthree elements to very brief advice: | ESC 2021\n• ASK - establishing and recording smoking status | \n• ADVISE - advising on the best ways of stopping | \n• ACT - offering help | ",
          "bbox": [
            49.92082290649414,
            82.18225606282552,
            295.1741027832031,
            183.1326416015625
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3275",
          "page_number": 48,
          "content": "LDL-C | Non-HDL-C | Apolipoprotein B | ESC 2021\n2.6 mmol/L (100 mg/dL) | 3.4 mmol/L (131 mg/dL) | 100 mg/dL | \n1.8 mmol/L (70 mg/dL) | 2.6 mmol/L (100 mg/dL) | 80 mg/dL | \n1.4 mmol/L (55 mg/dL) | 2.2 mmol/L (85 mg/dL) | 65 mg/dL | ",
          "bbox": [
            314.268505859375,
            668.7130737304688,
            562.9060668945312,
            718.8096507679332
          ],
          "function_potential": "raw"
        },
        {
          "title": "3276 ESC Guidelines",
          "page_number": 49,
          "content": "Recommendation | Classb | Levelc | ESC 2021\nA stepwise treatment-intensification approach is\nrecommended for apparently healthy people at\nhigh or very high CVD risk, as well as patients\nwith established ASCVD and/or DM with con-\nsideration of CVD risk, treatment benefit, risk\nmodifiers, comorbidities, and patient\npreferences. | I | C | ",
          "bbox": [
            45.349189213344026,
            525.8858947753906,
            290.63812255859375,
            624.3070138784556
          ],
          "function_potential": "raw"
        },
        {
          "title": "3278 ESC Guidelines",
          "page_number": 51,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that a high-intensity statin is\nprescribed up to the highest tolerated dose to\nreach the LDL-C goals set for the specific risk\ngroup.21,520,521 | I | A | \nAn ultimatec LDL-C goal of <1.4 mmol/L (55 mg/\ndL) and LDL-C reduction of >50% from baseline\n_\nshould be considered in apparently healthy persons\n<70 years at very high risk.21,22,522 | IIa | C | \nAn ultimatec LDL-C goal of <1.8 mmol/L (70\nmg/dL) and LDL-C reduction of >50% from\n_\nbaseline should be considered in apparently\nhealthy persons <70 years at high risk.21,22,522 | IIa | C | \nIn patients with established ASCVD, lipid-lowering\ntreatment with an ultimatec LDL-C goal of <1.4\nmmol/L (55 mg/dL) and a >50% reduction in LDL-\n_\nC vs. baseline is recommended.21,508,515\u0002517,522 | I | A | \nIf the goals are not achieved with the maximum\ntolerated dose of a statin, combination with eze-\ntimibe is recommended.515 | I | B | \nFor primary prevention patients at very high risk,\nbut without FH, if the LDL-C goal is not\nachieved on a maximum tolerated dose of a sta-\ntin and ezetimibe, combination therapy including\na PCSK9 inhibitor may be considered. | IIb | C | ",
          "bbox": [
            308.78735107421875,
            425.6877777099609,
            553.9657104492187,
            743.8781869070871
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3279",
          "page_number": 52,
          "content": "For secondary prevention patients not achieving\ntheir goals on a maximum tolerated dose of a\nstatin and ezetimibe, combination therapy\nincluding a PCSK9 inhibitor is\nrecommended.516,517 | I | A | \nFor very-high-risk FH patients (that is, with\nASCVD or with another major risk factor) who\ndo not achieve their goals on a maximum toler-\nated dose of a statin and ezetimibe, combination\ntherapy including a PCSK9 inhibitor is\nrecommended. | I | C | \nIf a statin-based regimen is not tolerated at any\ndosage (even after rechallenge), ezetimibe\nshould be considered.515,523\u0002525 | IIa | B | \nIf a statin-based regimen is not tolerated at any\ndosage (even after rechallenge), a PCSK9 inhibitor\nadded to ezetimibe may be considered.523,524,526 | IIb | C | \nIf the goal is not achieved, statin combination\nwith a bile acid sequestrant may be considered. | IIb | C | \nStatin therapy is not recommended in\npremenopausal female patients who are consid-\nering pregnancy or are not using adequate\ncontraception. | III | C | ",
          "bbox": [
            48.87356185913086,
            60.35187176295689,
            294.372063269982,
            343.4081573486328
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3280 ESC Guidelines",
          "page_number": 53,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nStatin treatment is recommended as the first\ndrug of choice for reducing CVD risk in high-risk\nindividuals with hypertriglyceridaemia [triglycer-\nides >2.3 mmol/L (200 mg/dL)].533 | I | A | \nIn patients taking statins who are at LDL-C goal\nwith triglycerides >2.3 mmol/L (200 mg/dL), fenofi-\nbrate or bezafibrate may be considered.534\u0002536 | IIb | B | \nIn high-risk (or above) patients with triglycerides\n>1.5 mmol/L (135 mg/dL) despite statin treat-\nment and lifestyle measures, n-3 PUFAs (icosa-\npent ethyl 2 \u0005 2 g/day) may be considered in\ncombination with a statin.84 | IIb | B | ESC 2021",
          "bbox": [
            44.49687433242798,
            237.56394653320314,
            289.620354546441,
            408.14217049734935
          ],
          "function_potential": "raw"
        },
        {
          "title": "3280 ESC Guidelines",
          "page_number": 53,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nTreatment with statins is recommended for\nolder people with ASCVD in the same way as\nfor younger patients.538,539 | I | A | \nInitiation of statin treatment for primary preven-\ntion in older people aged >70 may be consid-\n_\nered, if at high risk or above.538,539 | IIb | B | \nIt is recommended that the statin is started at a\nlow dose if there is significant renal impairment\nand/or the potential for drug interactions. | I | C | ESC 2021",
          "bbox": [
            308.8738778921274,
            338.6642211914062,
            553.9322291782925,
            473.2322235107422
          ],
          "function_potential": "raw"
        },
        {
          "title": "3280 ESC Guidelines",
          "page_number": 53,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with type 2 DM at very high risk (e.g.\nwith established ASCVD and/or severe TODc),\nintensive lipid-lowering therapy, ultimatelyd aim-\ning at >50% LDL-C reduction and an LDL-C of\n_\n<1.4 mmol/L (55 mg/dL) is\nrecommended.21,22,522,540,541 | I | A | ",
          "bbox": [
            308.8738778921274,
            653.5932271321615,
            553.9322291782925,
            749.774189540318
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3281",
          "page_number": 54,
          "content": "In patients with type 2 DM >40 years at high\nrisk, lipid-lowering treatment with an ultimate\nLDL-C goal of >50% LDL-C reduction and an\n_\nLDL-C of <1.8 mmol/L (70 mg/dL) is\nrecommended.540,541 | I | A | \nStatin therapy may be considered in persons\naged <40 years with type 1 or type 2 DM with\n_\nevidence of TOD and/or an LDL-C level >2.6\nmmol/L (100 mg/dL), as long as pregnancy is not\nbeing planned. | IIb | C | \nIf the LDL-C goal is not reached, statin\ncombination with ezetimibe should be\nconsidered.515,542 | IIa | B | ESC 2021",
          "bbox": [
            48.96920424241286,
            59.78513445172991,
            294.17217445373535,
            220.30339249320653
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3281",
          "page_number": 54,
          "content": "Criteria (choose only one score per group, the\nhighest applicable; diagnosis is based on the total\nnumber of points obtained) |  | Points | ESC 2021\n1) Family history |  |  | \nFirst-degree relative with known premature (men aged\n<55 years; women <60 years) coronary or vascular dis-\nease, or first-degree relative with known LDL-C above\nthe 95th percentile |  | 1 | \nFirst-degree relative with tendinous xanthomata and/or\narcus cornealis, or children aged <18 years with LDL-C\nabove the 95th percentile |  | 2 | \n2) Clinical history |  |  | \nPatient with premature (men aged <55 years; women\n<60 years) CAD |  | 2 | \nPatient with premature (men aged <55 years; women\n<60 years) cerebral or peripheral vascular disease |  | 1 | \n3) Physical examination |  |  | \nTendinous xanthomata |  | 6 | \nArcus cornealis before age 45 years |  | 4 | \n4) LDL-C levels (without treatment) |  |  | \nLDL-C >8.5 mmol/L (326 mg/dL)\n_ |  | 8 | \nLDL-C 6.5\u00028.4 mmol/L (251\u0002325 mg/dL) |  | 5 | \nLDL-C 5.0\u00026.4 mmol/L (191\u0002250 mg/dL) |  | 3 | \nLDL-C 4.0\u00024.9 mmol/L (155\u0002190 mg/dL) |  | 1 | \n5) DNA analysis |  |  | \nFunctional mutation in the LDLR, apolipoprotein B, or\nPCSK9 genes |  | 8 | \nA ‘definite’ FH diagnosis requires >8 points |  |  | \nA ‘probable’ FH diagnosis requires 6\u00028 points |  |  | \nA ‘possible’ FH diagnosis requires 3\u00025 points |  |  | ",
          "bbox": [
            314.28396745161575,
            91.80596923828125,
            559.5040283203125,
            469.1070302327474
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3281",
          "page_number": 54,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nThe use of statins or statin/ezetimibe combina-\ntion is recommended in patients with non-dialy-\nsis-dependent, stage 3\u00025 CKD.525,544,545 | I | A | \nIn patients already on statins, ezetimibe, or a sta-\ntin/ezetimibe combination at the time of dialysis\ninitiation, continuation of these drugs should be\nconsidered, particularly in patients with ASCVD. | IIa | C | \nIn patients with dialysis-dependent CKD who\nare free of ASCVD, commencing statin therapy\nis not recommended.546,547 | III | A | ESC 2021",
          "bbox": [
            48.96920424241286,
            536.9192220052083,
            294.17217445373535,
            683.5001961844308
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "16",
      "title": "ESC 2021 ESC 2021",
      "start_page": 54,
      "end_page": 55,
      "content": "ESC 2021\n. ...................................................................................................................\nESC Guidelines 3281\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .................................... people across Europe, over 1 billion globally, with a prevalence of \u0006 30 \u0002 45% in adults, increasing with age to more than 60% in people aged >60 years, and accounting for  \u0006 10 million deaths globally per annum. 577   Despite extensive evidence for the effectiveness of BP- lowering treatments at reducing CVD risk and death, the detection, treatment, and control of BP in Europe and globally remains suboptimal. 578\nThis section covers recommendations for the diagnosis and treat- ment of hypertension to be applied in routine primary and secondary care. More detail and guidance for complex cases/tertiary care are available in the 2018 ESC/European Society of Hypertension (ESH) Guidelines for the management of arterial hypertension. 4\nSummary of recommendations for the clinical manage- ment of hypertension\nRecommendations Class a Level b\nClassiﬁcation of BP\nIt is recommended that BP should be classiﬁed as optimal, normal, high-normal, or grades 1 - 3\nhypertension, according to ofﬁce BP.\nI C\nDiagnosis of hypertension\n",
      "keywords": [
        "recommended",
        "cvd risk",
        "hypertension",
        "age",
        "level b"
      ],
      "tables": [
        {
          "title": "3282 ESC Guidelines",
          "page_number": 55,
          "content": "Treatment of hypertension: drug treatment |  |  | \nIt is recommended to initiate antihypertensive\ntreatment with a two-drug combination in most\npatients, preferably as a single-pill combination.\nExceptions are frail older patients and those\nwith low-risk, grade 1 hypertension (particularly\nif SBP <150 mmHg).560\u0002565 | I | B | \nIt is recommended that the preferred combina-\ntions include a RAS blocker (i.e. an ACE inhibitor\nor ARB) with a CCB or diuretic, but other com-\nbinations of the five major classes can be used\n(ACE inhibitor, ARB, beta-blocker, CCB, thia-\nzide/thiazide-like diuretic).566\u0002569 | I | A | \nIt is recommended, if BP remains uncontrolled\nwith a two-drug combination, that treatment be\nincreased to a three-drug combination, usually a\nRAS blocker with a CCB and a diuretic, prefera-\nbly as a single-pill combination.563,570,571 | I | A | \nIt is recommended, if BP is not controlled by a\nthree-drug combination, that treatment should\nbe increased by the addition of spironolactone,\nor if not tolerated, other diuretics such as ami-\nloride or higher doses of other diuretics, an\nalpha-blocker or beta-blocker, or\nclonidine.555,572\u0002574 | I | B | \nThe combination of two RAS blockers is not\nrecommended.575,576 | III | A | \nManagement of CVD risk in hypertensive patients |  |  | \nStatin therapy is recommended for many\npatients with hypertension.d | Section 4.6 |  | 21\nAntiplatelet therapy is indicated for secondary\nprevention in patients with hypertension.e | Section 4.9 |  | ESC 20",
          "bbox": [
            308.69361368815106,
            60.33735148111979,
            553.9144999186198,
            455.02567884657117
          ],
          "function_potential": "raw"
        },
        {
          "title": "3282 ESC Guidelines",
          "page_number": 55,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nClassification of BP |  |  | \nIt is recommended that BP should be classified\nas optimal, normal, high-normal, or grades 1 - 3\nhypertension, according to office BP. | I | C | \nDiagnosis of hypertension |  |  | \nIt is recommended to base the diagnosis of\nhypertension on:\n\u0007 Repeated office BP measurements, on more\nthan one visit, except when hypertension is\nsevere (e.g. grade 3 and especially in high-risk\npatients)\nor\n\u0007 Out-of-office BP measurement with ABPM and/\nor HBPM when feasible. | I\nI | C\nC | \nAssessment of HMOD |  |  | \nTo evaluate for the presence of HMOD, meas-\nurement of serum creatinine, eGFR, electrolytes,\nand ACR is recommended for all patients. A 12-\nlead ECG is recommended for all patients, and\nechocardiography is recommended for those\nwith ECG abnormalities or signs/symptoms of\nLV dysfunction. Fundoscopy or retinal imaging is\nrecommended for patients with grades 2 or 3\nhypertension and all hypertensive patients with\nDM.548\u0002551 | I | B | \nThresholds for initiation of drug treatment of hypertension |  |  | \nFor grade 1 hypertension, treatment initiation\nbased on absolute CVD risk, estimated lifetime\nbenefit, and the presence of HMOD is\nrecommended.552,553 | I | C | \nFor patients with grade 2 hypertension or higher,\ndrug treatment is recommended.4,552 | I | A | \nOffice BP treatment targets |  |  | \nIt is recommended that the first objective of\ntreatment is to lower BP to <140/90 mmHg in\nall patients, and that subsequent BP targets are\ntailored to age and specific comorbidities.552,554 | I | A | \nIn treated patients aged 18\u000269 years, it is rec-\nommended that SBP should ultimately be low-\nered to a target range of 120 - 130 mmHg in\nmost patients.552,554\u0002556 | I | A | \nIn treated patients aged >70 years, it is recom-\n_\nmended that SBP should generally be targeted to\n<140 and down to 130 mmHg if\ntolerated.552,554,557 | I | A | \nIn all treated patients, DBP is recommended to\nbe lowered to <80 mmHg.555,558,559 | I | A | \nTreatment of hypertension: lifestyle interventions |  |  | \nLifestyle interventions are recommended for\npeople with high-normal BP or higher.c | I | A | ",
          "bbox": [
            44.391246230513964,
            86.94777018229166,
            289.4931335449219,
            729.1381421770368
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "17",
      "title": "It is recommended to base the diagnosis of hypertension on:",
      "start_page": 55,
      "end_page": 63,
      "content": "\u0007  Repeated ofﬁce BP measurements, on more\nthan one visit, except when hypertension is severe (e.g. grade 3 and especially in high-risk\npatients)\nor \u0007  Out-of-ofﬁce BP measurement with ABPM and/\nor HBPM when feasible.\nI\nI\nC\nC\nAssessment of HMOD\nTo evaluate for the presence of HMOD, meas- urement of serum creatinine, eGFR, electrolytes,\nand ACR is recommended for all patients. A 12-\nlead ECG is recommended for all patients, and echocardiography is recommended for those\nwith ECG abnormalities or signs/symptoms of\nLV dysfunction. Fundoscopy or retinal imaging is recommended for patients with grades 2 or 3\nhypertension and all hypertensive patients with\nDM. 548 \u0002 551\nI B\nThresholds for initiation of drug treatment of hypertension\nFor grade 1 hypertension, treatment initiation\nbased on absolute CVD risk, estimated lifetime\nbeneﬁt, and the presence of HMOD is recommended. 552 , 553\nI C\nFor patients with grade 2 hypertension or higher,\ndrug treatment is recommended. 4 , 552 I A\nOfﬁce BP treatment targets\nIt is recommended that the ﬁrst objective of treatment is to lower BP to <140/90 mmHg in\nall patients, and that subsequent BP targets are\ntailored to age and speciﬁc comorbidities. 552 , 554\nI A\nIn treated patients aged 18 \u0002 69 years, it is rec-\nommended that SBP should ultimately be low-\nered to a target range of 120 - 130 mmHg in most patients. 552 , 554 \u0002 556\nI A\nIn treated patients aged >_70 years, it is recom-\nmended that SBP should generally be targeted to\n<140 and down to 130 mmHg if tolerated. 552 , 554 , 557\nI A\nIn all treated patients, DBP is recommended to\nbe lowered to <80 mmHg. 555 , 558 , 559 I A\nTreatment of hypertension: lifestyle interventions\nLifestyle interventions are recommended for\npeople with high-normal BP or higher. c I A\nContinued\nTreatment of hypertension: drug treatment\nIt is recommended to initiate antihypertensive\ntreatment with a two-drug combination in most\npatients, preferably as a single-pill combination. Exceptions are frail older patients and those\nwith low-risk, grade 1 hypertension (particularly if SBP <150 mmHg). 560 \u0002 565\nI B\nIt is recommended that the preferred combina-\ntions include a RAS blocker (i.e. an ACE inhibitor\nor ARB) with a CCB or diuretic, but other com- binations of the ﬁve major classes can be used\n(ACE inhibitor, ARB, beta-blocker, CCB, thia-\nzide/thiazide-like diuretic). 566 \u0002 569\nI A\nIt is recommended, if BP remains uncontrolled\nwith a two-drug combination, that treatment be\nincreased to a three-drug combination, usually a RAS blocker with a CCB and a diuretic, prefera-\nbly as a single-pill combination. 563 , 570 , 571\nI A\nIt is recommended, if BP is not controlled by a\nthree-drug combination, that treatment should be increased by the addition of spironolactone,\nor if not tolerated, other diuretics such as ami-\nloride or higher doses of other diuretics, an alpha-blocker or beta-blocker, or\nclonidine. 555 , 572 \u0002 574\nI B\nThe combination of two RAS blockers is not recommended. 575 , 576 III A\nManagement of CVD risk in hypertensive patients\nStatin therapy is recommended for many\npatients with hypertension. d\nSection 4.6\nAntiplatelet therapy is indicated for secondary prevention in patients with hypertension. e\nSection 4.9\nABPM = ambulatory blood pressure monitoring; ACE = angiotensin-converting enzyme; ACR = albumin-to-creatinine ratio; ARB = angiotensin receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CCB = calcium channel blocker; DBP = diastolic blood pressure; DM = diabetes mellitus; ECG = electrocardiogram; eGFR = estimated glomerular ﬁltration rate; HBPM = home blood pressure monitoring; HMOD = hypertension-mediated organ dam- age; LV = left ventricular; RAS = renin \u0002 angiotensin system; SBP = systolic blood pressure. a Class of recommendation. b Level of evidence. c See  section 4.3  for details. d See  section 4.6  for details. e See  section 4.9  for details.\nESC 2021\n. ...........................................................................................................................................................................\n3282 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ..................................................................... 4.7.1. Definition and classification of hypertension BP is classified according to seated office BP ( Table  12 ), with approxi- mately corresponding values according to ABPM or home BP average values in  Table  13 .\n4.7.2. Blood pressure measurement 4.7.2.1 Office blood pressure measurement Office BP should be measured in standardized conditions using validated auscultatory or (semi)automatic devices, as described in Table  14 .\n4.7.2.2 Unattended automated office blood pressure measurement Repeated automated office BP readings may improve the reproduci- bility of BP measurement. If the patient is seated alone and unob- served, unattended automated office BP measurement may reduce or eliminate the ‘white-coat’ effect, and unattended automated office BP measurements are usually lower than conventional office BP measurements, and more similar to ambulatory daytime BP or home BP values. There is limited information on the prognostic value of unattended automated office BP measurements. 4\n4.7.2.3 Ambulatory blood pressure monitoring ABPM is the average of repeated automated measurements of BP during the daytime, night-time, and over 24 h. ABPM is a better pre-\ndictor of hypertension-mediated organ damage (HMOD) and clinical outcomes than office BP, and identifies ‘white-coat’ hypertension and masked hypertension (see below). Diagnostic thresholds for hyper- tension are lower with ABPM than office BP ( Table  12 ). 4\n4.7.2.4 Home blood pressure monitoring Home BP is the average of all BP readings performed with a validated semiautomatic monitor, for at least 3 consecutive days (ideally 6 - 7 days), with readings in the morning and evening, taken seated in a quiet room after 5 min of rest. Home BP monitoring (HBPM) thresh- olds for the diagnosis of hypertension are lower than those for office BP ( Table  12 ). Patient self-monitoring may have a beneficial effect on medication adherence and BP control. 4\nClinical indications for ambulatory or home monitoring are shown in  Table  15 .\n4.7.3 Screening and diagnosis of hypertension Ideally, all adults should be screened for the presence of hyperten- sion, 578 , 579   but most countries lack the required resources and infra- structure. Formally, these guidelines recommend opportunistic screening at least in susceptible individuals, such as those who are overweight or have a family history of hypertension (see  section 3.1 ).\nESC 2021\nTable 12 Categories for conventionally measured seated ofﬁce blood pressure a\nCategory SBP (mmHg) DBP (mmHg)\nOptimal <120 and <80\nNormal 120 \u0002 129 and/or 80 \u0002 84\nHigh-normal 130 \u0002 139 and/or 85 \u0002 89\nGrade 1 hypertension 140 \u0002 159 and/or 90 \u0002 99\nGrade 2 hypertension 160 \u0002 179 and/or 100 \u0002 109\nGrade 3 hypertension >_180 and/or >_110\nIsolated systolic\nhypertension b >_140 and <90\nBP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure. a BP category is deﬁned according to seated clinic BP and by the highest level of BP, whether systolic or diastolic. b Isolated systolic hypertension is graded 1, 2, or 3 according to SBP values in the ranges indicated.\nTable 13 Deﬁnitions of hypertension according to ofﬁce, ambulatory, and home blood pressure\nCategory SBP (mmHg) DBP (mmHg)\nOfﬁce BP a >_140 and/or >_90\nAmbulatory BP\nDaytime (or awake) mean >_135 and/or >_85\nNight-time (or asleep) mean >_120 and/or >_70\n24-h mean >_130 and/or >_80\nHome BP mean >_135 and/or >_85\nBP = blood pressure; DBP = diastolic blood pressure; SBP = systolic blood pressure. a Refers to conventional ofﬁce BP rather than unattended ofﬁce BP.\nTable 14 Considerations in blood pressure measurement\nPatients should be seated comfortably in a quiet environment for 5 min\nbefore BP measurements.\nThree BP measurements should be recorded, 1 \u0002 2 min apart, and addi-\ntional measurements if the ﬁrst two readings differ by >10 mmHg. BP is recorded as the average of the last two BP readings.\nAdditional measurements may have to be performed in patients with\nunstable BP values due to arrhythmias, such as in patents with AF, in whom manual auscultatory methods should be used as most automated\ndevices have not been validated for BP measurement in AF.\nUse a standard bladder cuff (12 \u0002 13 cm wide and 35 cm long) for most\npatients, but use larger and smaller cuffs for larger (arm circumference >32 cm) and smaller (arm circumference <26 cm) arms, respectively.\nThe cuff should be positioned at the level of the heart with the back and\narm supported, to avoid muscle contraction and isometric-exercise- dependant increases in BP.\nWhen using auscultatory methods, use phase I and V (sudden reduction/\ndisappearance) Korotkoff sounds to identify SBP and DBP, respectively.\nMeasure BP in both arms at the ﬁrst visit to detect possible between-arm differences. Use the arm with the higher value as the reference.\nMeasure BP 1 min and 3 min after standing from the seated position in all\npatients at the ﬁrst measurement to exclude orthostatic hypotension.\nLying and standing BP measurements should also be considered in subse- quent visits in older people, in people with DM, and in other conditions\nin which orthostatic hypotension may frequently occur. Initial orthostatic\nhypotension may occur <1 min after standing and may be difﬁcult to detect with conventional measurement techniques.\nRecord heart rate and use pulse palpation to exclude arrhythmia.\nAF = atrial ﬁbrillation; BP = blood pressure; DBP = diastolic blood pressure; DM = diabetes mellitus; SBP = systolic blood pressure. . ......................................................................................................\nESC 2021\nESC 2021\nESC Guidelines 3283\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...............................................................................\nWhen hypertension is suspected, the diagnosis of hypertension should be confirmed, either by repeated office BP measurements over a number of visits, or by 24-h ABPM or HBPM ( Figure  14 ).\n4.7.3.1 White-coat and masked hypertension White-coat hypertension refers to BP that is elevated in the office but is normal when measured by ABPM or HBPM. It occurs in up to 30 \u0002 40% of patients. The risk associated with white-coat hyperten- sion is lower than sustained hypertension but may be higher than normotension. People with white-coat hypertension should receive lifestyle advice to reduce their CV risk and be offered BP measure- ment at least every 2 years by ABPM or HBPM because of high rates of transition to sustained hypertension. Routine drug treatment for white-coat hypertension is not indicated. Masked hypertension refers to patients with a normal office BP but an elevated BP on ABPM or HBPM. These patients often have HMOD and are at a CV risk level at least equivalent to sustained hypertension. It is more common in younger people and in those with high-normal office BP. In masked hypertension, lifestyle changes are recommended, and drug treatment should be considered to control ‘out-of-office’ BP, with periodic monitoring of BP, usually with HBPM.\n4.7.4. Clinical evaluation and risk stratification in hypertensive patients The routine work-up for hypertensive patients is shown in  Table  16 . Alongside clinical examination, this is designed to:\nTable 15 Indications for home blood pressure monitor- ing or ambulatory blood pressure monitoring\nConditions in which white-coat hypertension is more common, for example: •   Grade 1 hypertension on ofﬁce BP measurement •   Marked ofﬁce BP elevation without HMOD\nConditions in which masked hypertension is more common, for example: •   High-normal ofﬁce BP •   Normal ofﬁce BP in individuals with HMOD or at high total CV risk\nPostural and post-prandial hypotension in untreated and treated patients\nEvaluation of resistant hypertension\nEvaluation of BP control, especially in treated higher-risk patients\nExaggerated BP response to exercise\nWhen there is considerable variability in the ofﬁce BP\nEvaluating symptoms consistent with hypotension during treatment\nSpeciﬁc indications for ABPM rather than HBPM: •   Assessment of nocturnal BP values and dipping status (e.g. suspicion\nof nocturnal hypertension, such as in sleep apnoea, CKD, DM,\nendocrine hypertension, or autonomic dysfunction)\nABPM = ambulatory blood pressure monitoring; BP = blood pressure; CKD = chronic kidney disease; CV = cardiovascular; DM = diabetes mellitus; HBPM = home blood pressure monitoring; HMOD = hypertension-mediated organ damage.\nScreening and diagnosis of hypertension\nRepeat visits for office BP measurement\nOR\nOut-of-office BP measurement (ABPM or HBPM)\nRepeat BP measurement a least annually\nRepeat BP measurement a least every 5 years\nRepeat BP measurement at least every 3 years\nBlood pressure measurement\nIndications for ABPM or HBPM\nOut-of-office BP measurement (ABPM or HBPM)\nHigh-normal 130–139 mmHg / 85–89 mmHg\nOptimal <120/80 mmHg\nNormal 120–129 mmHg / 80–84 mmHg\nHypertension ≥ 140/90 mmHg\nConsider masked hypertension\nFigure 14  Screening and diagnosis of hypertension. ABPM = ambulatory blood pressure monitoring; BP = blood pressure; HBPM = home blood pres- sure monitoring.\nESC 2021\n3284 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...................................................................................................\n•   Assess risk factors for ASCVD (see  section 3.2 ), or the presence of cardiac, vascular, or renal disease •   Detect evidence of HMOD, e.g. LV hypertrophy, renal disease, or retinopathy •   Consider potential secondary causes of hypertension, e.g. reno- vascular disease, hyperaldosteronism, or pheochromocytoma (see  Table  17 ). Also, carefully evaluate substance abuse (e.g. cocaine), drugs that may increase BP (e.g. cyclosporine, sympati- comimetics), liquorice, etc. More detail on work-up of suspected secondary hypertension is provided elsewhere. 4\nEchocardiography is recommended in patients with ECG abnor- malities, and should be considered when the result will influence clini- cal decision-making. Fundoscopy is recommended in grade 2 or 3 hypertension and in all patients with DM. The routine measurement of other biomarkers and use of vascular imaging are not recommended. 548 \u0002 551\n4.7.5. Treatment of hypertension The treatment of hypertension involves lifestyle interventions for all patients and drug therapy for most patients.\n4.7.5.1 Lifestyle interventions to lower blood pressure and/or reduce car- diovascular risk Lifestyle interventions are indicated for all patients with high-normal BP or hypertension because they can delay the need for drug treat- ment or complement the BP-lowering effect of drug treatment. Moreover, most lifestyle interventions have health benefits beyond their effect on BP. Lifestyle is discussed extensively in  section 4.3 .\n4.7.5.2 Initiation of drug treatment Drug treatment decisions in CVD prevention are mostly based on absolute CVD risk, risk modifiers, comorbidities, estimated benefit of treatment, frailty, and patient preferences. The same is true for hypertension. Drug treatment of grade 1 hypertension (SBP 140 - 159 mmHg) has level A evidence for reducing CVD risk. In younger patients, however, the absolute 10-year CVD risk is often low, and lifetime benefit of treatment should be considered and com- municated before instituting treatment ( Figure  6  and  section 3.2.3.6 ). In many such cases, the absolute lifetime benefit per 10-mmHg\nreduction in SBP is at least moderate to high [ Figure  15  (lifetime bene- fit calibrated in low-to-moderate CVD risk countries]. Also, the pres- ence of HMOD mandates treatment of grade 1 hypertension. For grade 2 hypertension or higher (SBP >160 mmHg), treatment is rec- ommended, because not only is the lifetime benefit of reducing BP almost universally high in such patients, there is also the importance of reducing the risk of HMOD resulting in other morbidities such as renal disease, haemorrhagic cerebrovascular disease, and HF.\n4.7.5.3 Blood pressure treatment targets When drug treatment is used, the aim is to control BP to target within 3 months. Evidence now suggests that the BP targets in the previous iteration of this guideline 2   were too conservative, especially for older patients. In line with the stepwise approach ( section 3.2.3.1 ), it is now recommended that the first step in all treated patients should achieve a treated SBP <140 mmHg and diastolic BP (DBP) <80 mmHg. 552 , 554   The recommended ultimate SBP treatment target range for younger patients (18 \u0002 69 years) is 120 \u0002 130 mmHg, although some patients may safely achieve lower treated SBP levels than this and, if they are well tolerated, there is no need to back- titrate treatment. 552 , 554 \u0002 556   The ultimate target SBP for patients aged >_70 years is <140 mmHg and down to 130 mmHg if toler- ated. 552 , 554 , 557 , 580   This change in the BP target range for older people compared with the 2016 ESC prevention guidelines 2   is supported by evidence that these treatment targets are safely achieved in many older patients and are associated with significant reductions in the risk of major stroke, HF, and CV death. 557 , 580   It also takes into account that the even lower SBP in the intensively treated group in SPRINT (Systolic Blood Pressure Intervention Trial) (mean 124 mmHg) probably reflects a conventional office SBP range of 130 \u0002 139 mmHg. 555   It is recogniz ed, however, that the evidence sup- porting more strict targets is less strong for very old people (>80 years) and those who are frail. Also, in these older and especially frail\nTable 16 Routine tests for patients with hypertension\nRoutine tests\nHaemoglobin and/or haematocrit\nFasting blood glucose and/or HbA1c\nBlood lipids: total cholesterol, LDL-C, HDL-C, triglycerides\nBlood potassium and sodium\nBlood uric acid\nBlood creatinine and eGFR\nBlood liver function tests\nUrine analysis: microscopic; urinary protein by dipstick or, ideally, ACR\n12-lead ECG\nACR = albumin-to-creatinine ratio; ECG = electrocardiogram; eGFR = estimated glomerular ﬁltration rate; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.\nTable 17 Patient characteristics that should raise the suspicion of secondary hypertension.\nCharacteristics\nYounger patients (<40 years) with grade 2 hypertension or onset of any\ngrade of hypertension in childhood\nAcute worsening of hypertension in patients with previously documented\nchronically stable normotension\nResistant hypertension (BP uncontrolled despite treatment with optimal\nor best-tolerated doses of three or more drugs including a diuretic, and conﬁrmed by ABPM or HBPM)\nSevere (grade 3) hypertension or a hypertension emergency\nPresence of extensive HMOD\nClinical or biochemical features suggestive of endocrine causes of hyper- tension or CKD\nClinical features suggestive of OSA\nSymptoms suggestive of pheochromocytoma or family history of\npheochromocytoma\nABPM = ambulatory blood pressure monitoring; BP = blood pressure; CKD = chronic kidney disease; HBPM = home blood pressure monitoring; HMOD = hypertension-mediated organ damage; OSA = obstructive sleep apnoea. Adapted from   4\nESC 2021\n. .......................................................................\nESC 2021\nESC Guidelines 3285\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n1.1 1.2 1.4 1.5\nn/a n/a n/a n/a\n1.2 1.3 1.4 1.5\n1.5\nn/a n/a n/a n/a\n0.8 1.0 1.1 1.2\n1.0 1.3 1.4 1.5\nn/a n/a n/a n/a\n0.9 1.1 1.2 1.3\n1.0 1.3 1.4 1.5\n1.2 1.3 1.5\n1.3 1.5 1.6 1.7\nn/a n/a n/a n/a\n1.0 1.1 1.3 1.4\n1.2 1.3 1.4 1.5\n1.3 1.4 1.5 1.6\nn/a n/a n/a n/a\n1.3 1.4 1.6 1.7\n1.3 1.5 1.7 1.7\n1.0 1.2 1.4 1.5\n1.1 1.4 1.6 1.6\n1.3 1.6 1.7 1.8\nn/a n/a n/a n/a\n1.3 1.4 1.6 1.6\n1.1 1.2 1.4 1.5\n0.5 0.7 0.8 0.8\nn/a n/a n/a n/a\n0.4 0.5 0.7 0.7\n0.8\nn/a n/a n/a n/a\n0.2 0.3 0.4 0.5\n0.4 0.4 0.5 0.6\nn/a n/a n/a n/a\n0.3 0.4 0.5 0.5\n0.4 0.5 0.6 0.7\n0.5 0.7 0.9\n0.7 0.9 1.0 1.1\nn/a n/a n/a n/a\n0.4 0.4 0.6 0.6\n0.5 0.6 0.7 0.8\n0.6 0.7 0.9 1.0\nn/a n/a n/a n/a\n0.6 0.8 1.0 1.0\n0.8 1.0 1.1 1.2\n0.4 0.5 0.7 0.7\n0.6 0.7 0.8 1.0\n0.8 1.0 1.2 1.3\nn/a n/a n/a n/a\n0.7 0.8 1.0 1.1\n0.5 06 0.7 0.8\n0.8 0.9 1.0 1.2\nn/a n/a n/a n/a\n0.7 0.8 1.0 1.0\n1.1\nn/a n/a n/a n/a\n0.4 0.6 0.7 0.8\n0.6 0.7 0.9 0.9\nn/a n/a n/a n/a\n0.5 0.7 0.8 0.9\n0.7 0.9 0.9 1.0\n0.8 1.0 1.1\n1.0 1.2 1.3 1.4\nn/a n/a n/a n/a\n0.7 0.7 0.9 1.0\n0.8 0.9 1.1 1.1\n1.0 1.1 1.2 1.3\nn/a n/a n/a n/a\n0.9 1.1 1.2 1.3\n1.0 1.3 1.4 1.5\n0.7 0.8 1.0 1.0\n0.8 1.0 1.2 1.2\n1.1 1.3 1.5 1.5\nn/a n/a n/a n/a\n0.9 1.1 1.3 1.3\n0.7 0.9 1.0 1.1\n0.6 0.7 0.8 0.8\nn/a n/a n/a n/a\n0.3 0.4 0.5 0.5\n0.7\nn/a n/a n/a n/a\n0.1 0.2 0.3 0.3\n0.2 0.3 0.4 0.4\nn/a n/a n/a n/a\n0.2 0.4 0.4 0.4\n0.3 0.5 0.5 0.5\n0.5 0.5 0.6\n0.7 0.9 0.9 1.0\nn/a n/a n/a n/a\n0.4 0.4 0.5 0.5\n0.5 0.5 0.7 0.7\n0.6 0.7 0.8 0.8\nn/a n/a n/a n/a\n0.7 0.7 0.8 1.0\n0.8 0.9 1.0 1.2\n0.4 0.5 0.6 0.7\n0.5 0.6 0.8 0.9\n0.8 1.0 1.2 1.3\nn/a n/a n/a n/a\n0.7 0.8 1.0 1.1\n0.5 0.6 0.7 0.7\n0.3 0.3 0.4 0.4\n0.7 0.8 0.8 0.8\nn/a n/a n/a n/a\n0.2 0.3 0.3 0.3\n0.3 0.3 0.3 0.3\nn/a n/a n/a n/a\n0.4 0.5 0.6 0.6\n0.6 0.6 0.7 0.8\n0.6 0.7 0.8 0.9\n0.8 0.9 1.0 1.0\n0.9 1.0 1.1 1.2\n1.2\n1.1 1.2 1.3\nn/a n/a n/a n/a\nn/a n/a n/a n/a\n0.7 0.9 1.0 1.1\n0.9 1.1 1.2\n1.3\n0.1 0.1 0.2 0.2\n0.2 0.2 0.3 0.3\nn/a n/a n/a n/a\n0.0 0.1 0.1 0.1\n0.1 0.1 0.1 0.1\nn/a n/a n/a n/a\n0.1 0.2 0.2 0.2\n0.1 0.2 0.2 0.3\n0.2 0.1 0.3 0.2\n0.2 0.3 0.3 0.4\n0.2 0.3 0.4 0.4\n0.5\n0.3 0.5 0.5\nn/a n/a n/a n/a\nn/a n/a n/a n/a\n0.2 0.2 0.3 0.4\n0.2 0.3 0.4\n0.5\n0.2 0.2 0.3 0.3\n0.3 0.4 0.5 0.5\nn/a n/a n/a n/a\n0.1 0.1 0.2 0.2\n0.2 0.2 0.2 0.2\nn/a n/a n/a n/a\n0.3 0.3 0.3 0.4\n0.3 0.3 0.4 0.5\n0.3 0.4 0.4 0.5\n0.4 0.5 0.6 0.6\n0.5 0.5 0.6 0.7\n0.8\n0.6 0.7 0.9\nn/a n/a n/a n/a\nn/a n/a n/a n/a\n0.4 0.5 0.6 0.6\n0.5 0.6 0.7\n0.8\n0.1 0.0 0.0 0.1\n0.1 0.1 0.1 0.2\nn/a n/a n/a n/a\n0.0 0.0 0.0 0.1\n0.0 0.0 0.0 0.0\nn/a n/a n/a n/a\n0.0 0.0 0.1 0.1\n0.1 0.1 0.1 0.1\n0.0 0.1 0.1 0.1\n0.1 0.1 0.2 0.1\n0.1 0.2 0.2 0.2\n0.3\n0.2 0.2 0.3\nn/a n/a n/a n/a\nn/a n/a n/a n/a\n0.1 0.2 0.2 0.2\n0.2 0.2 0.3\n0.3\nn/a n/a n/a n/a\n1.1 1.3 1.4 1.5\n1.3 1.4 1.6 1.7\n1.4 1.6 1.7 1.8\nn/a n/a n/a n/a\n0.6 0.7 0.8 0.9\n0.7 0.8 1.0 1.1\n0.8 1.0 1.2 1.3\nn/a n/a n/a n/a\n0.7 0.9 1.0 1.2\n0.9 1.1 1.3 1.4\n1.1 1.3 1.4 1.6\nn/a n/a n/a n/a\n0.6 0.7 0.8 0.9\n0.7 0.9 1.0 1.2\n0.9 1.1 1.3 1.4\n160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139 100-119 160-179 140-159 120-139\n100-119\n160-179\n140-159\n120-139\n100-119\n90+\n85-89\n80-84\n75-79\n70-74\n65-69\n60-64\n55-59\n50-54\n45-49\nSystolic blood pressure (mmHg)\nNon-smoking\nSmoking\nAge (y)\nLIFE-CVD model CVD-free lifetime gain from 10 mmHg Systolic Blood Pressure reduction (in years)\nNon-smoking\nSmoking\nNon-HDL cholesterol\nWomen Men\nmmol/L\n150 200 250 150 200 250 150 200 250 150 200 250 mg/dL\n< 0.5 years\n0.5 - 0.9 years\n1.0 - 1.4 years\n1.5 - 2.0 years\n≥ 2.0 years\n160-179 140-159 120-139 100-119\n40-44\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9\n4.0-4.9\n5.0-5.9\n6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\n3.0-3.9 4.0-4.9 5.0-5.9 6.0-6.9\nFigure 15  Lifetime benefit from lowering systolic blood pressure by 10 mmHg for apparently healthy persons, based on the following risk factors: age, sex, current smoking, systolic blood pressure, non-high-density lipoprotein cholesterol. The model is currently validated for low- and moderate-risk coun- tries. The lifetime benefit is expressed as ‘years of median life expectancy free from myocardial infarction or stroke’ gained from 10 mmHg SBP lowering. The lifetime benefit is calculated by estimating lifetime CVD risk with the LIFE-CVD model multiplied by the HR (0.80) from a meta-analysis of the effect of BP lowering. For 20 mmHg SBP lowering, the average effect is almost twice as large, etc. For individualized estimations of lifetime benefit, this table can be used or the electronic version of LIFE-CVD, assessable via the ESC CVD risk app or https://u-prevent.com/. BP = blood pressure; CVD = cardiovascular disease; ESC = European Society of Cardiology; HDL-C = high-density lipoprotein cholesterol; HR = hazard ratio; LIFE-CVD = LIFEtime-perspective CardioVascular Disease; N/A = not applicable; SBP = systolic blood pressure.\n3286 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .......................... patients, it may be difficult to achieve the recommended target BP range due to poor tolerability or adverse effects, and high-quality measurement and monitoring for tolerability and adverse effects is especially important in these groups. 580\nCompared to previous ESC/ESH Hypertension Guidelines, 4   we changed the cut-off for identifying who is ’older’ from 65 to 70 years for reasons of consistency with other parts of the current guidelines. Although a single age cut-off is provided, it is important to stress that biological age influences this threshold in clinical practice. For\nexample, a very fit 75-year-old person may qualify for a treatment policy normally reserved for those <70 and, vice versa, a very frail 65-year-old person should sometimes be considered ‘older’.\nBP targets for patient subgroups with various comorbidities are shown in  Table  18 .\n4.7.5.3.1. Blood pressure targets according to ambulatory and home blood pressure monitoring. There are no outcome-based tri- als that have used ABPM or HBPM to guide treatment. Therefore,\n.........................................................................................................................................................\nTable 18 Recommended ofﬁce blood pressure target ranges. The ﬁrst step in all groups is a reduction to systolic blood pressure  < 140 mmHg. The subsequent optimal goals are listed below.\nAge group Ofﬁce SBP treatment target ranges (mmHg)\nHypertension 1  DM 1  CKD 1  CAD 1  Stroke/TIA\n18  2  69 years 120 \u0002 130 120 \u0002 130 <140 \u0002 130 120 \u0002 130 120 \u0002 130\nLower SBP acceptable if tolerated\n\u0003 70 years < 140 mmHg, down to 130 mmHg if tolerated\nLower SBP acceptable if tolerated\nDBP treatment target (mmHg) <80 for all treated patients\nCAD = coronary artery disease; CKD = chronic kidney disease; DBP = diastolic blood pressure; DM = diabetes mellitus; SBP = systolic blood pressure; TIA = transient ischae- mic attack.\nInitial therapy Dual combination\nConsider beta-blockers at any treatment step, when there is a specific indication for their use, e.g. heart failure, angina, post-myocardial infarction, atrial fibrillation, or younger women with, or planning, pregnancy\nConsider monotherapy in low-risk grade 1 hypertension (systolic BP <150mmHg), or in very old ( ≥80 years) or frailer patients\nACEi or ARB + CCB or diuretic\n1 pill\nConsider referral to a specialist centre for further investigation\nStep 3 Triple combination + spironolactone or other drug\nStep 2 Triple combination ACEi or ARB + CCB + diuretic\nResistant hypertension Add spironolactone (25-50 mg o.d.) or other diuretic, alpha-blocker or beta-blocker\n1 pill\n2 pills\nBeta-blockers\nFigure 16  Core drug treatment strategy for hypertension. This algorithm is appropriate for most patients with hypertension-mediated organ damage, diabetes mellitus, cerebrovascular disease, and peripheral artery disease. ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; BP = blood pressure; CCB = calcium channel blocker; HF = heart failure;  o.d . =  omni die  (once a day).\nESC 2021\nESC Guidelines 3287\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ......................................................................................................... ABPM and HBPM BP targets are extrapolated from observational data. A treated office SBP of 130 mmHg likely corresponds to a 24-h SBP of 125 mmHg and home SBP <130 mmHg. 4\n4.7.5.4 Drug treatment of hypertension The most important driver of benefit is the magnitude of BP lowering. Single-drug therapy will rarely achieve optimal BP control.\nInitial therapy with a combination of two drugs  should be considered usual care for hypertension. 560 \u0002 563 , 565 , 581   The only exceptions would be patients with a baseline BP close to the recom- mended target, who might achieve that target with a single drug, or very old (>80 years) or frail patients who may better tolerate a more gentle reduction of BP. Initial combination therapy, even low-dose combination therapy, is more effective at lowering BP than mono- therapy, 560 , 561 , 565   and will reduce BP faster and reduce heterogeneity in response. 560 , 565   Moreover, initial combination therapy does not increase risk of adverse effects. 560 \u0002 563 , 565   Initiating therapy with two drugs will also help overcome treatment inertia where patients remain on one drug long term despite inadequate BP control. 562\nSingle-pill strategy to treat hypertension:  poor adherence to BP-lowering medication is a major cause of poor BP control rates, and is directly related to the number of pills. 581   Single-pill combina- tion therapy (if available) is the preferred strategy. This strategy will control BP in most patients. 560 \u0002 565\nRecommended drug therapy and treatment algorithm:  five major classes of BP-lowering drug therapy have shown benefit in reducing CV events; angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, calcium chan- nel blockers (CCBs), and thiazide or thiazide-like diuretics. 582   A rec- ommended treatment algorithm based on best available evidence, pragmatic considerations (e.g. combination pill availability), and path- ophysiological reasoning is shown in  Figure  16 . 4   A combination of an ACE inhibitor or ARB with a CCB or thiazide/thiazide-like diuretic is the preferred initial therapy for most patients with hyper- tension. 566 \u0002 569   For those in whom treatment requires escalation to three drugs, a combination of an ACE inhibitor or ARB with a CCB and a thiazide/thiazide-like diuretic should be used. 563 , 570 , 571   Beta- blockers should be used when there is a specific indication (e.g. angina, post myocardial infarction, arrythmia, HFrEF, or as an alterna- tive to an ACE inhibitor or ARB in women of child-bearing poten- tial). 582   Combinations of an ACE inhibitor and an ARB are not recommended because of no added benefit on outcomes and increased risk of harm. 575 , 576\nSpecific modifications to the treatment algorithm are recom- mended for patients with CHD, CKD, HF, and AF. 4\n4.7.6. Resistant hypertension Resistant hypertension is defined as BP being uncontrolled despite treatment with optimal or best-tolerated doses of three or more drugs including a diuretic, and confirmed by ABPM or HBPM. The prevalence of resistant hypertension is likely to be <10% of treated hypertensive patients. Spironolactone is the most effective drug for lowering BP in resistant hypertension when added to existing treat- ment; however, the risk of hyperkalaemia is increased in patients with\nCKD and eGFR <45 mL/min/m 2   and blood potassium levels >4.5 mmol/L. 555 , 572   Potassium-binding drugs reduce the risk of hyperka- laemia. 573   When spironolactone is not tolerated, amiloride, alpha- blockers, beta-blockers, or centrally acting drugs, such as clonidine, have evidence supporting their use. 555 , 572 , 574   Renal denervation and device-based therapy may be considered for specific cases, and are discussed in the 2018 ESC/ESH hypertension guidelines. 4\n4.7.7. Management of hypertension in women The diagnosis and treatment of hypertension in women is similar to that in men, except for women of child-bearing potential or during pregnancy, because of potential adverse effects of some drugs on the foetus, especially in the first trimester. In addition, the effect of oral contraceptive pills on the risk of developing or worsening hyperten- sion should be considered. 4\n4.7.8. Duration of treatment and follow-up Treatment of hypertension is usually maintained indefinitely because cessation of treatment usually results in a return of BP to pretreat- ment levels. In some patients with successful lifestyle changes, it may be possible to gradually reduce the dose or number of drugs. After BP is stable and controlled, visits should be scheduled at least annu- ally, and include the control of other risk factors, renal function, and HMOD, as well as reinforce lifestyle advice. When there is a loss of BP control in a previously well-controlled patient, non-compliance with therapy should be considered. Self-measurement of BP using HBPM helps engage the patient in their own management and can improve BP control. HBPM is essential to monitor BP control in patients with a significant ‘white-coat effect’ or masked hypertension. Supervision of patient follow-up increasingly involves nurses and pharmacists and is likely to become increasingly supported by tele- medicine and app-based technologies.\n4.8. Diabetes mellitus\nRecommendations for the treatment of patients with diabetes mellitus\nRecommendations Class a Level b\nScreening\nWhen screening for DM in individuals with or without ASCVD, assessment of HbA1c (which\ncan be done non-fasting) or fasting blood glu-\ncose should be considered. 583\nIIa A\nLifestyle\nLifestyle changes including smoking cessation, a\nlow saturated fat, high-ﬁbre diet, aerobic PA, and\nstrength training are recommended. 584\nI A\nReduction in energy intake is recommended to patients, to help achieve lower body weight or\nprevent or slow weight gain. 584\nI B\nFor those motivated to try, considerable weight loss with use of low-calorie diets followed by\nfood reintroduction and weight-maintenance\nphases early after diagnosis can lead to DM remission and should be considered. 585 , 586\nIIa A\nContinued . .................................................................\n3288 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 4.8.1. Key risk factor concepts and newer paradigms Except for glucose management, prevention of ASCVD follows the same principles as for people without type 2 DM. Achieving BP and LDL-C targets is particularly important. More recently, trial evidence has shown that drugs in the sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide-1 receptor agonist (GLP- 1RA) classes lower ASCVD, HF, and renal risks independently of baseline HbA1c and whether patients are on metformin. Such bene- fits are most evident in those with existing ASCVD, HF, or CKD, but appear to extend to groups at elevated risk. This has led to newer treatment algorithms.\n4.8.1.1 Lifestyle intervention Lifestyle management is a first priority for ASCVD prevention and management of DM. Most persons with DM are obese, so weight control is crucial. Several dietary patterns can be adopted, where the predominance of fruits, vegetables, wholegrain cereals, and low-fat protein sources is more important than the precise proportions of total energy provided by the major macronutrients. Salt intake should be restricted. Specific recommendations include limiting saturated and trans fats and alcohol intake, monitoring carbohydrate consump- tion, and increasing dietary fibre. A Mediterranean-type diet, where fat sources are derived primarily from monounsaturated oils, is pro- tective against ASCVD. More detail is provided in  section 4.3.2 . A combination of aerobic and resistance exercise training is effec- tive in preventing the progression of type 2 DM and for the control of glycaemia. Smokers should be offered cessation support (see  sec- tion 4.5 ). Lifestyle intervention lowers future microvascular and mac- rovascular risks as well as mortality in the longer term. 603   Intensive lifestyle changes with low-calorie diets and mean weight losses in the region of 10 kg leads to remission of type 2 DM in around 46% of cases at 1 year and 36% by 2 years. 585   In those with prediabetes, other ASCVD risk factors should be assessed both before (to incen- tivize improvements) and after lifestyle changes have taken place. 604\n4.8.1.2 Glycaemic control The UKPDS 587   established the importance of intensive glucose low- ering with respect to CVD risk reduction in persons newly diagnosed with DM, with better evidence to support metformin, which cor- rectly remains the first agent of choice for the majority of patients diagnosed with DM. Three trials were conducted to see if CV events could be reduced further with more intensive glycaemia treat- ment. 559 , 588 , 593   However, there were unexpected increases in total and ASCVD deaths in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial 559   and a similar trend in VADT (Veterans Affairs Diabetes Trial). 593   The results prompted concerns about pursuing tight glucose control, particularly in older people with DM and in those with existing ASCVD. Subsequent meta-analyses of relevant trials showed reductions in non-fatal AMI and CAD events, but no effect on stroke or total mortality. 605 , 606   The meta-analyses suggested that CVD benefits for an average HbA1c reduction of 0.9% over 5 years were less than via treatment of cholesterol and BP. HbA1c targets should be personalized to individual characteristics and preferences.\nFour trials of dipeptidyl peptidase-4 inhibitors 607 \u0002 610   in patients with DM and existing ASCVD or at high risk demonstrated non- inferiority (i.e. safety) but not superiority with respect to CVD risk.\nGlycaemia targets\nA target HbA1c for the reduction of CVD risk\nand microvascular complications of DM of\n<7.0% (53 mmol/mol) is recommended for the majority of adults with either type 1 or type 2\nDM. 587 , 588\nI A\nFor patients with a long duration of DM and in old or frail adults, a relaxing of the HbA1c tar-\ngets (i.e. less stringent) should be considered. 588\nIIa B\nA target HbA1c of <_6.5% (48 mmol/mol) should be considered at diagnosis or early in the course\nof type 2 DM in persons who are not frail and\ndo not have ASCVD. 587 , 588\nIIa B\nTreatment of hyperglycaemia and ASCVD/cardiorenal risks\nMetformin is recommended as ﬁrst-line therapy,\nfollowing evaluation of renal function, in the\nmajority of patients without previous ASCVD, CKD, or HF. 589\nI B\nIn persons with type 2 DM with ASCVD, metfor-\nmin should be considered, unless contraindica-\ntions are present. 5 , 590 \u0002 592\nIIa B\nAvoidance of hypoglycaemia and excessive\nweight gain should be considered. 559 , 588 , 593 IIa B\nIn persons with type 2 DM and ASCVD, the use\nof a GLP-1RA or SGLT2 inhibitor with proven outcome beneﬁts is recommended to reduce\nCV and/or cardiorenal outcomes. 590 \u0002 592\nI A\nIn patients with type 2 DM and TOD, c   the use of an SGLT2 inhibitor or GLP-1RA with proven\noutcome beneﬁts may be considered to reduce\nfuture CV and total mortality. 594 \u0002 597\nIIb B\nIn patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve\nASCVD and/or cardiorenal outcomes. 598 , 599\nI A\nIn patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor with proven outcome beneﬁts\nis recommended to lessen HF hospitalizations\nand CV death. 600 , 601\nI A\nIn patients with type 2 DM but without ASCVD, HF, or CKD, use of an SGLT2 inhibitor or GLP-\n1RA should be considered based on estimated\nfuture risks (e.g. with the ADVANCE risk score or DIAL model) for adverse CVD or cardiorenal\noutcomes from risk factor proﬁles. 602\nIIa B\nACR = albumin-to-creatinine ratio; ADVANCE = Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation; ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; CV = car- diovascular; DIAL = Diabetes lifetime-perspective prediction; DM = diabetes mellitus; eGFR = estimated glomerular ﬁltration rate; GLP-1RA = glucagon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; PA = physical activity; SGLT2 = sodium-glucose cotransporter 2; TOD = target organ damage. a Class of recommendation. b Level of evidence. c See  Table  4  for details.\nESC 2021\nESC Guidelines 3289\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ........................................................................................................................... There was, however, an increase in the rate of hospitalization for HF with saxagliptin in the SAVOR-TIMI 53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Thrombolysis in Myocardial Infarction) trial. 608\n4.8.1.3 Newer diabetes mellitus drug classes: cardiovascular disease benefits Recent trials from two classes of drugs (SGLT2 inhibitors and GLP- 1RAs) have shown CVD benefits that appear independent of glycaemic control and, where examined, of baseline metformin use. 596 , 597 , 611   Their results have recently been systematically meta- analysed ( Supplementary Figures 1  \u0002  4 ). 590 , 591\nFor SGLT2 inhibitors, three trials demonstrated the CV benefits of empagliflozin, canagliflozin, and dapagliflozin. 611 \u0002 613   Major adverse CV events (MACE) were reduced modestly, by 14%, with no clear effect on stroke and an unclear effect on myocardial infarction. 590\nHowever, reductions in incident HF hospitalization/CVD death by 24% and renal endpoints by 44% were seen. 590   The MACE benefits were evident only in those with baseline ASCVD, but HF and renal benefits appeared to extend to those with type 2 DM with multiple risk factors. However, a more recent trial in people with type 2 DM and ASCVD showed ertugliflozin to be non-inferior to placebo with respect to MACE outcomes. 614   Whether the results represent a class effect is, therefore, not clear. Four further SGLT2 inhibitor trials demonstrated the benefit of canagliflozin 598   and dapagliflozin 599   in patients with CKD [with DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) showing similar benefits in people without DM], and dapagliflozin 600   and empagliflo- zin 601   in patients with HFrEF, with both trials showing similar benefits in those without type 2 DM.\nThe specific pattern of trial results (e.g. early separation of curves for HF hospitalization) suggests that the benefits of SGLT2 inhibitors may relate more to cardiorenal haemodynamic effects than to athe- rosclerosis. 600   Other than genitourinary infections, rates of adverse events (including diabetic ketoacidosis) were generally low. One trial showed an excess of amputations and fractures, 612   but none of the other trials noted imbalances. Patients should be advised on the importance of genitourinary hygiene before being prescribed these medications.\nGLP-1RAs reduce MACE, CV death, and all-cause mortality by around 12%, with around a 9% reduction in myocardial infarction and a 16% reduction in stroke. 591   Furthermore, HF is lowered by 9% and a composite renal outcome was lowered by 17%. The results cannot be explained by lowering of glucose levels and, in multiple SGLT2 inhibitor and GLP-1RA trials, subgroup analyses suggested that these benefits could be independent of metformin use. 594 \u0002 597   Most trials were conducted in patients with existing ASCVD or, in the REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes) trial, with a significant proportion of patients at high risk for CVD. 615   Side-effects of this class mainly include nausea and vomiting, which can lessen with gradual up-titration. Risks of hypoglycaemia can be reduced by lowering doses of sulphonylureas or insulin.\nThe largely positive results of these two classes of drugs (SGLT2 inhibitors and GLP-1RAs) have led to rapid changes in DM algo- rithms, but with some differences in interpretation. 602   Most DM guidelines, including those within the 2020 American Diabetes Association (ADA)/European Association for the Study of Diabetes\n(EASD) consensus report, 592   recommend that metformin should be used as first-line treatment, while the ESC Guidelines 5   recommended in 2019 that SGLT2 inhibitors and GLP-1RAs may be used without metformin in people with DM and CVD or at high risk of CVD, as reviewed. 602   A subset of the writing groups of the ADA/EASD con- sensus report and the ESC Guidelines 616   was convened as an expert panel. The expert panel emphasized the overall commonalities of approach and the need to ensure that people with type 2 DM, CVD, HF, or CKD are treated appropriately with an SGLT2 inhibitor or GLP-1RA. The panel concluded that this approach should be initiated independent of background therapy, glycaemic control, or individual- ized treatment goals. 616   The view of the ESC is that metformin should be considered, but is not mandatory first-line treatment in patients with ASCVD or evidence of TOD. Certainly, the initiation of metformin in such patients should not forego or delay the initiation of evidence-based SGLT2 inhibitors or GLP-1RAs. A risk score plus cost-effective analyses would be useful to determine which patients free from ASCVD or evidence of TOD may be recommended for these newer drugs. In all the above, there is no evidence of any sex interaction in benefits. Finally, people with type 2 DM should be involved in decision-making after explanation of the potential benefits and side-effects of the drugs.\n4.8.2. Type 1 diabetes mellitus The DCCT (Diabetes Control and Complications Trial) established the importance of tight glucose control to lessen the risks of both microvascular and macrovascular disease in both men and women with type 1 DM. 617   A 27-year follow-up of this trial showed that 6.5 years of intensive DM therapy was associated with a modestly lower all-cause mortality rate. 617   A glycaemic target for HbA1c of 6.5 \u0002 7.5% (48 \u0002 58 mmol/mol) appears to be a balanced approach for long-term care.\nRecently, metformin was shown not to lower progression of caro- tid IMT in persons with type 1 DM considered to be at elevated CVD risk. 618   Its use is not recommended in type 1 DM for this indication. SGLT2 inhibitors improve metabolic control in type 1 DM and may complement insulin therapy in selected patients.\n4.9. Antithrombotic therapy\n. ............................................... Recommendations for antithrombotic therapy\nRecommendations Class a Level b\nAspirin 75 - 100 mg daily is recommended for secondary prevention of CVD. 619 I A\nClopidogrel 75 mg daily is recommended as an\nalternative to aspirin in secondary prevention in case of aspirin intolerance. 620\nI B\nClopidogrel 75 mg daily may be considered in\npreference to aspirin in patients with established\n",
      "keywords": [
        "alcohol",
        "peripheral artery",
        "base",
        "cvd risk",
        "hypertension",
        "diagnosis",
        "risk stratification",
        "diabetes",
        "coronary artery",
        "arb",
        "sex",
        "indication",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "atrial fibrillation",
        "smoking",
        "risk factor",
        "recommended",
        "echocardiography",
        "ejection fraction",
        "may be considered",
        "diet",
        "diabetic",
        "heart failure",
        "level b",
        "physical activity",
        "orthostatic",
        "diastolic"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3283",
          "page_number": 56,
          "content": "Patients should be seated comfortably in a quiet environment for 5 min\nbefore BP measurements. | ESC 2021\nThree BP measurements should be recorded, 1\u00022 min apart, and addi-\ntional measurements if the first two readings differ by >10 mmHg. BP is\nrecorded as the average of the last two BP readings. | \nAdditional measurements may have to be performed in patients with\nunstable BP values due to arrhythmias, such as in patents with AF, in\nwhom manual auscultatory methods should be used as most automated\ndevices have not been validated for BP measurement in AF. | \nUse a standard bladder cuff (12\u000213 cm wide and 35 cm long) for most\npatients, but use larger and smaller cuffs for larger (arm circumference\n>32 cm) and smaller (arm circumference <26 cm) arms, respectively. | \nThe cuff should be positioned at the level of the heart with the back and\narm supported, to avoid muscle contraction and isometric-exercise-\ndependant increases in BP. | \nWhen using auscultatory methods, use phase I and V (sudden reduction/\ndisappearance) Korotkoff sounds to identify SBP and DBP, respectively. | \nMeasure BP in both arms at the first visit to detect possible between-arm\ndifferences. Use the arm with the higher value as the reference. | \nMeasure BP 1 min and 3 min after standing from the seated position in all\npatients at the first measurement to exclude orthostatic hypotension.\nLying and standing BP measurements should also be considered in subse-\nquent visits in older people, in people with DM, and in other conditions\nin which orthostatic hypotension may frequently occur. Initial orthostatic\nhypotension may occur <1 min after standing and may be difficult to\ndetect with conventional measurement techniques. | \nRecord heart rate and use pulse palpation to exclude arrhythmia. | ",
          "bbox": [
            314.4084129333496,
            381.35589090983075,
            560.9220581054688,
            716.3296081542969
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3283",
          "page_number": 56,
          "content": "Category | SBP (mmHg) |  | DBP (mmHg) | ESC 2021\nOptimal | <120 | and | <80 | \nNormal | 120\u0002129 | and/or | 80\u000284 | \nHigh-normal | 130\u0002139 | and/or | 85\u000289 | \nGrade 1 hypertension | 140\u0002159 | and/or | 90\u000299 | \nGrade 2 hypertension | 160\u0002179 | and/or | 100\u0002109 | \nGrade 3 hypertension | >180\n_ | and/or | >110\n_ | \nIsolated systolic\nhypertensionb | >140\n_ | and | <90 | ",
          "bbox": [
            49.933661965762866,
            391.0309753417969,
            295.1741027832031,
            505.9158848353795
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3283",
          "page_number": 56,
          "content": "Category |  | SBP\n(mmHg) |  |  |  | DBP\n(mmHg) | ESC 2021\nOffice BPa |  | >140\n_ |  | and/or |  | >90\n_ | \nAmbulatory BP |  |  |  |  |  |  | \nDaytime (or awake) mean |  | >135\n_ |  | and/or |  | >85\n_ | \nNight-time (or asleep) mean |  | >120\n_ |  | and/or |  | >70\n_ | \n24-h mean |  | >130\n_ |  | and/or |  | >80\n_ | \nHome BP mean |  | >135\n_ |  | and/or |  | >85\n_ | ",
          "bbox": [
            49.933661965762866,
            608.8460083007812,
            295.1741027832031,
            708.5359148297991
          ],
          "function_potential": "raw"
        },
        {
          "title": "3284 ESC Guidelines",
          "page_number": 57,
          "content": "Conditions in which white-coat hypertension is more common, for\nexample:\n• Grade 1 hypertension on office BP measurement\n• Marked office BP elevation without HMOD | ESC 2021\nConditions in which masked hypertension is more common, for example:\n• High-normal office BP\n• Normal office BP in individuals with HMOD or at high total CV risk | \nPostural and post-prandial hypotension in untreated and treated patients | \nEvaluation of resistant hypertension | \nEvaluation of BP control, especially in treated higher-risk patients | \nExaggerated BP response to exercise | \nWhen there is considerable variability in the office BP | \nEvaluating symptoms consistent with hypotension during treatment | \nSpecific indications for ABPM rather than HBPM:\n• Assessment of nocturnal BP values and dipping status (e.g. suspicion\nof nocturnal hypertension, such as in sleep apnoea, CKD, DM,\nendocrine hypertension, or autonomic dysfunction) | ",
          "bbox": [
            45.38211441040039,
            92.18894449869792,
            292.1971130371094,
            307.12062377929686
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3285",
          "page_number": 58,
          "content": "Routine tests | ESC 2021\nHaemoglobin and/or haematocrit | \nFasting blood glucose and/or HbA1c | \nBlood lipids: total cholesterol, LDL-C, HDL-C, triglycerides | \nBlood potassium and sodium | \nBlood uric acid | \nBlood creatinine and eGFR | \nBlood liver function tests | \nUrine analysis: microscopic; urinary protein by dipstick or, ideally, ACR | \n12-lead ECG | ",
          "bbox": [
            49.93783049149947,
            81.77099609375,
            295.1741027832031,
            211.1818054199219
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3285",
          "page_number": 58,
          "content": "Characteristics | ESC 2021\nYounger patients (<40 years) with grade 2 hypertension or onset of any\ngrade of hypertension in childhood | \nAcute worsening of hypertension in patients with previously documented\nchronically stable normotension | \nResistant hypertension (BP uncontrolled despite treatment with optimal\nor best-tolerated doses of three or more drugs including a diuretic, and\nconfirmed by ABPM or HBPM) | \nSevere (grade 3) hypertension or a hypertension emergency | \nPresence of extensive HMOD | \nClinical or biochemical features suggestive of endocrine causes of hyper-\ntension or CKD | \nClinical features suggestive of OSA | \nSymptoms suggestive of pheochromocytoma or family history of\npheochromocytoma | ",
          "bbox": [
            314.2826789855957,
            92.09322357177734,
            559.5040283203125,
            280.0348876953125
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3287",
          "page_number": 60,
          "content": " | Age group |  | Office SBP treatment target ranges (mmHg) |  |  |  |  | \n |  |  | ......................................\nHypertension | ..............................\n1 DM | ................................\n1 CKD | ..............................\n1 CAD | .......................\n1 Stroke/TIA | \n | 18 2 69 years |  | 120\u0002130 | 120\u0002130 | <140\u0002130 | 120\u0002130 | 120\u0002130 | \n |  |  | Lower SBP acceptable if tolerated |  |  |  |  | \n | \u000370 years |  | <140 mmHg, down to 130 mmHg if tolerated\nLower SBP acceptable if tolerated |  |  |  |  | \n | DBP treatment target (mmHg) |  | <80 for all treated patients |  |  |  |  | ",
          "bbox": [
            40.15810012817383,
            92.12218366350446,
            564.5680541992188,
            187.843994140625
          ],
          "function_potential": "raw"
        },
        {
          "title": "3288 ESC Guidelines",
          "page_number": 61,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nScreening |  |  | \nWhen screening for DM in individuals with or\nwithout ASCVD, assessment of HbA1c (which\ncan be done non-fasting) or fasting blood glu-\ncose should be considered.583 | IIa | A | \nLifestyle |  |  | \nLifestyle changes including smoking cessation, a\nlow saturated fat, high-fibre diet, aerobic PA, and\nstrength training are recommended.584 | I | A | \nReduction in energy intake is recommended to\npatients, to help achieve lower body weight or\nprevent or slow weight gain.584 | I | B | \nFor those motivated to try, considerable weight\nloss with use of low-calorie diets followed by\nfood reintroduction and weight-maintenance\nphases early after diagnosis can lead to DM\nremission and should be considered.585,586 | IIa | A | ",
          "bbox": [
            308.7951939900716,
            503.64068603515625,
            553.8524954659598,
            737.8121534075055
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3289",
          "page_number": 62,
          "content": "Glycaemia targets |  |  | \nA target HbA1c for the reduction of CVD risk\nand microvascular complications of DM of\n<7.0% (53 mmol/mol) is recommended for the\nmajority of adults with either type 1 or type 2\nDM.587,588 | I | A | \nFor patients with a long duration of DM and in\nold or frail adults, a relaxing of the HbA1c tar-\ngets (i.e. less stringent) should be considered.588 | IIa | B | \nA target HbA1c of <6.5% (48 mmol/mol) should\n_\nbe considered at diagnosis or early in the course\nof type 2 DM in persons who are not frail and\ndo not have ASCVD.587,588 | IIa | B | \nTreatment of hyperglycaemia and ASCVD/cardiorenal risks |  |  | \nMetformin is recommended as first-line therapy,\nfollowing evaluation of renal function, in the\nmajority of patients without previous ASCVD,\nCKD, or HF.589 | I | B | \nIn persons with type 2 DM with ASCVD, metfor-\nmin should be considered, unless contraindica-\ntions are present.5,590\u0002592 | IIa | B | \nAvoidance of hypoglycaemia and excessive\nweight gain should be considered.559,588,593 | IIa | B | \nIn persons with type 2 DM and ASCVD, the use\nof a GLP-1RA or SGLT2 inhibitor with proven\noutcome benefits is recommended to reduce\nCV and/or cardiorenal outcomes.590\u0002592 | I | A | \nIn patients with type 2 DM and TOD,c the use of\nan SGLT2 inhibitor or GLP-1RA with proven\noutcome benefits may be considered to reduce\nfuture CV and total mortality.594\u0002597 | IIb | B | \nIn patients with type 2 DM and CKD, the use of\nan SGLT2 inhibitor is recommended to improve\nASCVD and/or cardiorenal outcomes.598,599 | I | A | \nIn patients with type 2 DM and HFrEF, use of an\nSGLT2 inhibitor with proven outcome benefits\nis recommended to lessen HF hospitalizations\nand CV death.600,601 | I | A | \nIn patients with type 2 DM but without ASCVD,\nHF, or CKD, use of an SGLT2 inhibitor or GLP-\n1RA should be considered based on estimated\nfuture risks (e.g. with the ADVANCE risk score\nor DIAL model) for adverse CVD or cardiorenal\noutcomes from risk factor profiles.602 | IIa | B | ESC 2021",
          "bbox": [
            48.876433753967284,
            60.33735148111979,
            294.0714461715133,
            603.7962493896484
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3290 ESC Guidelines",
          "page_number": 63,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAspirin 75 - 100 mg daily is recommended for\nsecondary prevention of CVD.619 | I | A | \nClopidogrel 75 mg daily is recommended as an\nalternative to aspirin in secondary prevention in\ncase of aspirin intolerance.620 | I | B | \nClopidogrel 75 mg daily may be considered in\npreference to aspirin in patients with established\nASCVD.620,621 | IIb | A | \nConcomitant use of a proton pump inhibitor is\nrecommended in patients receiving antiplatelet\ntherapy who are at high risk of gastrointestinal\nbleeding.622,623 | I | A | ",
          "bbox": [
            308.8169523540296,
            564.0183492024739,
            553.8524780273438,
            735.7711922781808
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "18",
      "title": "ASCVD. 620 , 621",
      "start_page": 63,
      "end_page": 65,
      "content": "IIb A\nConcomitant use of a proton pump inhibitor is\nrecommended in patients receiving antiplatelet\ntherapy who are at high risk of gastrointestinal bleeding. 622 , 623\nI A\nContinued\n3290 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................................................\n4.9.1. Antithrombotic therapy in individuals without atherosclerotic disease In 2009, a meta-analysis in patients with low CVD risk reported a 12% reduction in ASCVD with aspirin but a significant increase in major bleeding. 619   CVD risk reduction and bleeding risks were similar in men and women. 631   More contemporary primary prevention trials reported no or little benefit in patients without ASCVD and a consis- tent increase in bleeding. 624 , 626 , 627   An updated meta-analysis did not show a reduction in all-cause or CV mortality with aspirin, but did show a lower risk of non-fatal myocardial infarction (RR 0.82) and ischaemic stroke (RR 0.87). 628   Conversely, aspirin was associated with a higher risk of major bleeding (RR 1.50), intracranial bleeding (RR 1.32), and major gastrointestinal bleeding (RR 1.52), with no dif- ference in the risk of fatal bleeding (RR 1.09). Bleeding risks were par- ticularly increased in older persons. Other recent meta-analyses found very similar results. 629 , 630   Overall, although aspirin should not be given routinely to patients without established ASCVD, we cannot exclude that in some patients at high or very high CVD risk, the benefits outweigh the risks. 632 , 633   In patients with DM and no evident ASCVD, the ASCEND study reported a 12% risk reduction and a significant increase in major bleeding, but not in fatal or intracranial bleeding. 624   A meta-analysis of aspirin for primary prevention in DM found a number needed to treat of 95 to prevent one major adverse ischaemic event in 5 years. 625\nHence, as in patients without DM, aspirin may be considered if CVD risk is exceptionally high. Only one in four patients in the ASCEND study were being treated with a proton pump inhibitor. Wider use than this could potentially amplify the benefit of aspirin in primary prevention for patients at higher atherosclerotic risk.\nIn apparently healthy persons <70 years of age with (very) high CVD risk, further studies are needed. Until then, decisions in these high-risk persons should be made on a case-by-case basis, taking both ischaemic risk and bleeding risk into consideration.\n4.9.2. Antithrombotic therapy in individuals with established atherosclerotic disease In established atherosclerotic disease, aspirin is associated with signifi- cant reductions in serious vascular events, including stroke and coro- nary events, and a 10% reduction in total mortality. 619   These benefits outweigh the bleeding hazards.\nIn patients with previous myocardial infarction, stroke, or LEAD, clopidogrel showed a slight superiority for ischaemic events with respect to aspirin, with a similar safety profile. 620\nSubgroup analysis suggested a greater benefit of clopidogrel in patients with LEAD. A meta-analysis showed a clinically modest risk reduction with P2Y 12  inhibitor monotherapy (number needed to treat: 244), and no effect on all-cause or vascular mortality and major bleeding. 621   More guidance on antithrombotic treatment in the specific settings of CAD, cerebrovascular disease, and LEAD, including possible indications for dual pathway inhibition in patients with LEAD, is given in  section 6 .\n4.9.3. Proton pump inhibitors Proton pump inhibitors reduce the risk of gastrointestinal bleeding in patients treated with antiplatelet drugs and may be a useful adjunctive therapy to improve safety. 634 , 635   Proton pump inhibitors that specifi- cally inhibit CYP2C19 (omeprazole or esomeprazole) may reduce the pharmacodynamic response to clopidogrel. Although this interac- tion has not been shown to affect the risk of ischaemic events, coad- ministration of omeprazole or esomeprazole with clopidogrel is not recommended. 622\n4.10. Anti-inflammatory therapy\nAcknowledging that the process of atherosclerosis has inflamma- tory components has led to the investigation of various anti- inflammatory therapies in recent years. The first study to examine the effects of reducing inflammation without impacting lipid levels was CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome Study), in which the monoclonal antibody, canakinu- mab, provided proof-of-concept for anti-inflammatory therapy in high-risk patients. 636   This particular drug was, however, not fur- ther developed for this indication because of the risk of fatal infec- tions and high costs. Methotrexate was the second anti- inflammatory drug studied for this purpose, but was not proven effective in reducing CVD outcomes. 637\nIn 2019, COLCOT (Colchicine Cardiovascular Outcomes Trial) reported a significant reduction (HR 0.77) in CVD outcomes with low-dose colchicine [0.5 mg  o.d . (once a day)] in patients with a recent AMI. The more recent LoDoCo2 (second low-dose colchi- cine) trial reinforced these results in patients with chronic CAD (HR 0.69). 85   This study observed a trend towards increased non-CV mor- tality, which requires further attention.\nThe use of colchicine in daily practice remains to be established based on further clinical study data and experiences in daily practice. Nonetheless, the encouraging results justify consideration of low- dose colchicine in selected, high-risk patients.\nRecommendation for anti-inﬂammatory therapy\nRecommendation Class a Level b\nLow-dose colchicine (0.5 mg  o.d .) may be consid-\nered in secondary prevention of CVD, particu- larly if other risk factors are insufﬁciently\ncontrolled or if recurrent CVD events occur\nunder optimal therapy. 85 , 86\nIIb A\nCVD = cardiovascular;  o.d . =  omni die  (once a day). a Class of recommendation. b Level of evidence.\nESC 2021\n. ...........................................................................................................\nIn patients with DM at high or very high CVD\nrisk, low-dose aspirin may be considered for pri-\nmary prevention in the absence of clear contraindications. 5 , 624 , 625\nIIb A\nAntiplatelet therapy is not recommended in indi-\nviduals with low/moderate CV risk due to the increased risk of major bleeding. 624 , 626 \u0002 630\nIII A\nASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; DM = dia- betes mellitus. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 3291\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .......................................................................................................... 4.11. Cardiac rehabilitation and prevention programmes\nCR is a comprehensive, multidisciplinary intervention not just includ- ing exercise training and PA counselling, but also education, risk fac- tor modification, diet/nutritional counselling, and vocational and psychosocial support. 358   Prevention and rehabilitation programmes after ASCVD events or revascularization reduce CV hospitalizations, myocardial infarction, CV mortality and, in some programmes, all- cause mortality. 638 , 640 \u0002 642   They may also reduce depressive/anxiety symptoms. 649   In patients with chronic HF (mainly HFrEF), exercise- based cardiac rehabilitation (EBCR) may improve all-cause mortality, reduce hospital admissions, and improve exercise capacity and quality of life. 639 , 650   CR is generally cost-effective. 651\nClinical trials and registries are highly heterogeneous, which influ- ences national guidelines, legislation, and reimbursement. 652 , 653   The results of recent reviews provide clinicians with minimal require- ments for successful CR after ACS or coronary artery bypass graft:\n•   CR is a comprehensive multidisciplinary intervention 466 , 649 , 654 , 655\n•   CR is supervised and carried out by adequately trained health professionals, including cardiologists 649\n•   CR starts as soon as possible after the initial CV event 649\n•   EBCR includes aerobic and muscular resistance exercise, which should be individually prescribed based on pre-exercise screen- ing and exercise testing 656\n•   The dose of EBCR (number of weeks of exercise training  \u0005 average number of sessions/week  \u0005  average duration of session in minutes) exceeds 1000 638\n•   The number of EBCR sessions needs to exceed 36 641\n•   During CR, all individually recognized CV risk factors need to be addressed and treated. 642\nRecently, the European Association of Preventive Cardiology (EAPC) proposed minimal and optimal standards for improvement of secondary prevention through CR programmes in Europe. 657\nAlthough exercise training prescription should adopt the FITT (fre- quency, intensity, time duration, and type of exercise) model, inter- clinician variance and disagreement exists. 658   To optimize exercise training, the EAPC has introduced a digital, interactive decision sup- port tool; the EXPERT (EXercise Prescription in Everyday practice & Rehabilitation Training) Tool (https://www.escardio.org/Education/ Practice-Tools/CVD-prevention-toolbox/expert-tool). 659   No single exercise component is a significant predictor of mortality; only adher- ence to the full intervention improves outcome. 660\nDespite proven benefits, rates of referral, participation, and imple- mentation are low. 653 , 660 , 661   Uptake seems lower in women, but a variety of other intrapersonal, interpersonal, clinical, logistical, health system, and CR programme-related factors affect participation and adherence. 662   CR enrolment is higher if trained nurses or allied healthcare providers intervene face-to-face, whereas adherence may be higher when remote interventions are implemented (i.e. home- based). 643 Nurse-coordinated programmes can increase effectiveness. 644 \u0002 646   Home-based CR with or without telemonitor- ing may increase participation and appear similarly effective as centre-based CR. 647   Telehealth interventions are more effective than no intervention, 648   but may also complement conventional CR. Also, mobile device-based healthcare (mHealth) delivery through smart- phones may be as effective as traditional centre-based CR, showing significant improvements in health-related quality of life. 663   These novel interventions may support the patient to maintain long-term healthy behaviours after specialized CR programmes. 664\n",
      "keywords": [
        "secondary prevention",
        "ascvd",
        "hfref",
        "recommended",
        "cvd risk",
        "lipid",
        "older",
        "may be considered",
        "atherosclerosis",
        "diet",
        "primary prevention",
        "coronary artery",
        "exercise",
        "age",
        "indication",
        "level b"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3291",
          "page_number": 64,
          "content": "In patients with DM at high or very high CVD\nrisk, low-dose aspirin may be considered for pri-\nmary prevention in the absence of clear\ncontraindications.5,624,625 | IIb | A | \nAntiplatelet therapy is not recommended in indi-\nviduals with low/moderate CV risk due to the\nincreased risk of major bleeding.624,626\u0002630 | III | A | ESC 2021",
          "bbox": [
            48.86418424333845,
            60.35216849190848,
            294.25811157226565,
            146.61818368094308
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3291",
          "page_number": 64,
          "content": " |  |  | \nRecommendation | Classa | Levelb | \n |  |  | \nLow-dose colchicine (0.5 mg o.d.) may be consid-\nered in secondary prevention of CVD, particu-\nlarly if other risk factors are insufficiently\ncontrolled or if recurrent CVD events occur\nunder optimal therapy.85,86 | IIb | A | ESC 2021",
          "bbox": [
            313.4629623413086,
            329.3097798665365,
            558.611181640625,
            413.4782289777483
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3292 ESC Guidelines",
          "page_number": 65,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nParticipation in a medically supervised, struc-\ntured, comprehensive, multidisciplinary EBCR\nand prevention programme for patients after\nASCVD events and/or revascularization, and for\npatients with HF (mainly HFrEF), is recom-\nmended to improve patient outcomes.638\u0002642 | I | A | \nMethods to increase CR and prevention referral\nand uptake should be considered (i.e. electronic\nprompts or automatic referrals, referral and liai-\nson visits, structured follow-up by nurses or\nhealth professionals, and early programme initia-\ntion after discharge).643\u0002646 | IIa | B | \nHome-based CR, telehealth, and mHealth inter-\nventions may be considered to increase patient\nparticipation and long-term adherence to\nhealthy behaviours.647,648 | IIb | B | ESC 2021",
          "bbox": [
            44.49687433242798,
            110.702197265625,
            289.620354546441,
            329.2322267804827
          ],
          "function_potential": "raw"
        },
        {
          "title": "3292 ESC Guidelines",
          "page_number": 65,
          "content": " |  |  | \nRecommendations | Classa | Levelb,c | \n |  |  | \nPolicies and population approaches to PA, diet,\nsmoking and tobacco use, and alcohol in gov-\nernmental restrictions and mandates, media and\neducation, labelling and information, economic\nincentives, schools, worksites, and community\nsettings follow different levels of recommenda-\ntions (see specific tables in the supplementary\nmaterial for section 5). |  |  | \nPutting in place measures to reduce air pollution,\nincluding reducing PM emission and gaseous pol-\nlutants, reducing the use of fossil fuels, and limit-\ning carbon dioxide emissions, are recommended,\nto reduce CVD mortality and morbidity. | I | C | ESC 2021",
          "bbox": [
            308.8738778921274,
            506.02178548177085,
            554.011962890625,
            687.4121900285993
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "19",
      "title": "5. Policy interventions at the population level",
      "start_page": 65,
      "end_page": 67,
      "content": "Recommendations for cardiac rehabilitation\nRecommendations Class a Level b\nParticipation in a medically supervised, struc- tured, comprehensive, multidisciplinary EBCR\nand prevention programme for patients after\nASCVD events and/or revascularization, and for patients with HF (mainly HFrEF), is recom-\nmended to improve patient outcomes. 638 \u0002 642\nI A\nMethods to increase CR and prevention referral and uptake should be considered (i.e. electronic\nprompts or automatic referrals, referral and liai-\nson visits, structured follow-up by nurses or health professionals, and early programme initia-\ntion after discharge). 643 \u0002 646\nIIa B\nHome-based CR, telehealth, and mHealth inter-\nventions may be considered to increase patient participation and long-term adherence to\nhealthy behaviours. 647 , 648\nIIb B\nASCVD = atherosclerotic cardiovascular disease; CR = cardiac rehabilitation; EBCR = exercise-based cardiac rehabilitation; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; mHealth = mobile device-based healthcare. a Class of recommendation. b Level of evidence.\nRecommendations for policy interventions at the popu- lation level\nRecommendations Class a Level b ,c\nPolicies and population approaches to  PA, diet,\nsmoking and tobacco use, and alcohol  in gov- ernmental restrictions and mandates, media and\neducation, labelling and information, economic\nincentives, schools, worksites, and community settings follow different levels of recommenda-\ntions (see speciﬁc tables in the  supplementary\nmaterial  for  section 5 ).\nPutting in place measures to reduce air pollution,\nincluding reducing PM emission and gaseous pol-\nlutants, reducing the use of fossil fuels, and limit- ing carbon dioxide emissions, are recommended,\nto reduce CVD mortality and morbidity.\nI C\nCVD = cardiovascular disease; PA = physical activity; PM = particulate matter. a Class of recommendation. b Level of evidence. c Level of evidence applies less well to policy interventions, and the type of empir- ical evidence varies widely across the separate approaches suggested.\nESC 2021\n. .................................................................\nESC 2021\n3292 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 5.1. Population-level approaches to the prevention of cardiovascular disease Population level approaches to CVD prevention centre around upstream measures requiring broad public-health interventions tar- geting lifestyle and promoting monitoring of CVD. These measures are designed to address populations and are intended to shift the population attributable risk. This is based on a prevention paradox described by Geoffrey Rose in 1981. 665   The population attributable risk depends on the RR and on the prevalence of a risk factor in the general population. If the prevalence of a significant RR factor is low, then the population attributable risk may be modest. Conversely, if a low-impact RR factor is common, the population attributable risk may be high. This prevention approach following the Geoffrey Rose paradigm 665 , 666   states that small shifts in the risk of disease across a whole population consistently lead to greater reductions in disease burden than does a large shift in high-risk individuals only. 667 , 668   In other words, many people exposed to a small risk may generate more disease than a few exposed to a conspicuous risk. This population-wide approach— as opposed to strategies targeting high- risk individuals—has major advantages at the population level whilst sometimes having only a modest benefit at the individual level, because it addresses the CV health of a large number of individuals over the entire life course. It should be noted that high-risk and population-level prevention strategies are not mutually exclusive and must therefore coexist. Prevalence of high-risk conditions and incidence rates of CVD vary across countries. Many of their underlying causes are known, and they are closely related to dietary habits, PA, smoking, alcohol, employment, social deprivation, and the environment. The objective of population approaches to prevention of CVD is to control the underlying determinants of CV health and, in this way, reduce popula- tion incidence rates. The population approach may bring numerous benefits, such as narrowing the gap in health inequalities, preventing other conditions such as cancer, pulmonary diseases, and type 2 DM, and saving costs from the avoided CV events and early retirement due to health problems. Individual behaviour is enacted in an environment with hierarchical levels, which encompass individual choice, family influence, cultural and ethnic grouping, workplace, healthcare, and policy at the regional, state and global levels (e.g. EU policies and international trade agreements). The aim of this section of the guidelines is to provide evidence-based suggestions for the most effective interventions to reduce CVD risk at the population level, improve CVD health, and promote healthy choices at the community, regional, and global level. Health challenges cannot be solved by the healthcare systems alone and require political support. To advance this cause, the WHO has been organizing Global Conferences on Health promotion since 1990.\n5.2. Specific risk factor interventions at the population level Population-level interventions aim to alter the societal environment, modify certain social determinants of health, and provide incentives to encourage changes in individual behaviour and exposure to risk fac- tors. Social determinants of health include socioeconomic status (edu- cation, occupation, and income), wealth inequalities, neighbourhood and urban design, and social networks, to name but a few. Healthcare\nprofessionals play an important role in advocating evidence-based population-level interventions. By modifying the general context, one can induce healthy decisions as a default in entire populations (all age groups and particularly vulnerable ones). The task for both national and local authorities is to create social environments that provide healthier defaults, taking health literacy into account. 669 , 670   The evi- dence presented here builds on recent comprehensive reviews and individual studies, noting that it is rarely feasible to use an RCT to eval- uate population-level interventions (in contrast to individual-level interventions). 671 , 672   The importance of heart disease in women has become apparent and sex differences in CVD prevention have prompted sex-specific awareness campaigns with the aim of reducing sex disparities in research and clinical care. While interpreting this section, it is important to recognize that there are often vested inter- ests, which may influence policy decisions on health promotion.\nThe  supplementary material  for this section presents evidence for population-level strategies dealing with specific risk factor interven- tions for PA ( section 5.2.1 ), diet ( section 5.2.2 ), smoking and tobacco use ( section 5.2.3 ), and alcohol consumption ( section 5.2.4 ). Lifestyle changes at the population level take time, may be expensive, and need to be sustained over time. Furthermore, the benefits may be slow to manifest;  however, they persist over the long term and improve health-related quality of life and well-being.\n5.2.1. Physical activity Please see the  supplementary material  section 3.1 .\n5.2.2. Diet Please see the  supplementary material  section 3.2 .\n5.2.3. Smoking and tobacco use Please see the  supplementary material  section 3.3 .\n5.2.4. Alcohol Please see the  supplementary material  section 3.4 .\n5.3. Environment, air pollution, and climate change Air pollution contributes to mortality and morbidity. It specifically increases the risk of respiratory and CV diseases, notably CAD, HF, cardiac arrhythmias and arrest, cerebrovascular disease, and venous thromboembolism. 158 , 673 , 674   Loss of life-expectancy due to ambient air pollution has been estimated at 2.9 years, accounting for an esti- mated global excess mortality of 8.8 million/year. 159   Plausible mecha- nisms by which air pollution is linked to CVD include promoting atherosclerosis, inflammation, thrombosis, systemic vascular dysfunc- tion, myocardial fibrosis, epigenetic changes, and interactions with traditional risk factors. 158\nImportant sources of fine particles are road traffic, power plants, and industrial and residential heating using oil, coal, and wood. Main components of outdoor air pollution include airborne PM (ranging in size from coarse particles 2.5 \u0002 10  m m, fine particles <2.5  m m (PM 2.5 ), and ultrafine particles <0.1  m m in diameter) and gaseous pollutants such as ozone, nitrogen dioxide, volatile organic compounds, carbon monoxide, and sulphur dioxide, produced primarily by fossil fuel combustion. 158 , 675   Up to one-third of Europeans living in urban areas\nESC Guidelines 3293\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...................................................................................... are exposed to levels exceeding EU air-quality standards. The EU Commission released a policy package to be implemented by 2030, with measures to reduce harmful emissions from traffic, energy plants, and agriculture.\nIndoor air pollution and exposure to noise must also be highlighted. Household air pollution, such as that produced from burning biomass, accounts for over 3 million deaths worldwide. 38   It has been estimated by the WHO that 30% of the European population is exposed to nightly levels of noise exceeding 55 dB. 161   These levels have been associated with hypertension, arteriosclerosis, CAD, CV mortality, and stroke. It should be noted that mitigating efforts to reduce noise exposure have not, as yet, proven to have a beneficial health effect. 161\nThe extent to which environmental exposures in soil and water contribute to CVD has also been established. 157   Interventions to reduce this pollution are required, including factory regulations and drinking water controls. 157\nPatient organizations and health professionals have an important role in supporting education and policy initiatives. Information on patients’ behaviour during smog peaks is needed. Economic incentives, such as reduced taxes on electric and hybrid cars, can con- tribute to the improvement of air quality as well as incentives encour- aging the use of public transport. Urban design promoting the construction of new houses and schools in areas remote from high- ways and polluting industries needs to be urged. ‘Clean air’ legislation aimed at promoting decreased particle emissions, and promotion of public transport should also be encouraged. The urgency of accepting what might appear as ‘comfort sacrifices’ for distant health benefits, and the transitory high costs of reorganizing entire sec- tions of industry, probably remain a major dilemma to the population- based approach. An example of such legislation is the European Green Deal, by which the EU aims to be climate neutral by 2050.\n5.3.1.Climate change Climate change resulting from the increasing use of fossil fuels, as a major source of both air pollution and ‘greenhouse’ gases, is becoming a major public health and environmental concern. Societal measures to reduce such fuels, and transfer towards renewable sources, are becom- ing urgent to reduce air pollution and climate change. 676   The impact of diet, notably long-term non-sustainable meat-based food production chains, as well as the impact of sedentary lifestyles on climate-altering variables, will also need to be addressed by policy makers.\n5.4. Implications for public health policy and advocacy at the governmental and non-governmental level Please see the  supplementary material  section 3.5 .\n",
      "keywords": [
        "alcohol",
        "cvd risk",
        "hypertension",
        "atherosclerosis",
        "sedentary",
        "sex",
        "ascvd",
        "smoking",
        "recommended",
        "risk factor",
        "ejection fraction",
        "may be considered",
        "diet",
        "heart failure",
        "level b",
        "physical activity",
        "population",
        "level",
        "exercise",
        "hfref",
        "interventions",
        "tobacco",
        "should be considered",
        "policy",
        "ethnic",
        "age"
      ],
      "tables": [
        {
          "title": "3294 ESC Guidelines",
          "page_number": 67,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nAspirin 75 - 100 mg daily is recommended for\npatients with a previous myocardial infarction or\nrevascularization.619 | I | A | \nAspirin 75 - 100 mg daily may be considered in\npatients without a history of myocardial infarc-\ntion or revascularization, but with definitive evi-\ndence of CAD on imaging.622 | IIb | C | \nIn ACS, DAPT with a P2Y inhibitor in addition\n12\nto aspirin is recommended for 12 months, unless\nthere are contraindications such as excessive\nrisk of bleeding.681\u0002683 | I | A | \nIn patients with CCS, clopidogrel 75 mg daily is\nrecommended, in addition to aspirin, for 6\nmonths following coronary stenting, irrespective\nof stent type, unless a shorter duration (1 - 3\nmonths) is indicated due to risk or occurrence\nof life-threatening bleeding.622 | I | A | \nAdding a second antithrombotic drug (a P2Y\n12\ninhibitor or low-dose rivaroxaban) to aspirin for\nlong-term secondary prevention should be con-\nsidered in patients with a high risk of ischaemic\nevents and without high bleeding\nrisk.83,622,687\u0002689 | IIa | A | ",
          "bbox": [
            308.8001334450462,
            429.6562255859375,
            553.8524733323318,
            734.6371656145368
          ],
          "function_potential": "raw"
        }
      ]
    },
    {
      "number": "20",
      "title": "6. Risk management of disease- specific cardiovascular disease",
      "start_page": 67,
      "end_page": 70,
      "content": "This section addresses CVD prevention in specific clinical contexts. A significant number of patients already have such comorbidities, which put them at additional risk. The general principles of lifestyle modification and treatment of major risk factors are outlined in  sec- tion 4 . In this section, only disease-specific aspects are added.\n6.1.Coronary artery disease Disease-specific acute management of coronary syndromes is cov- ered in detail in recent guidelines. 677 \u0002 680\nAs for antithrombotic therapy, dual antiplatelet therapy (DAPT) for 12 months, preferably with prasugrel or ticagrelor, is the standard antithrombotic treatment after ACS. 681 \u0002 683   There are conflicting data as to whether prasugrel is preferable to ticagrelor. 684 , 685   A 6- month duration of DAPT after ACS is generally too short, 686   but may be considered in selected patients at high bleeding risk.\nIn patients with chronic coronary syndromes (CCS) undergoing elective PCI, the standard duration of DAPT is 6 months, but short- ening this to 1 - 3 months is an option when bleeding risk is very high. 622   Clopidogrel is the P2Y 12  inhibitor of choice, but prasugrel and ticagrelor may be considered after complex interventions. 622\nProlonged DAPT (>12 months) following PCI for either ACS or CCS is an option for patients who tolerate DAPT well and have fea- tures of high ischaemic risk. 687 , 688   In patients with stable CAD, dual- pathway inhibition with low-dose rivaroxaban (2.5 mg  b.i.d .) and aspirin improved CV outcomes at the price of more major bleeding events than aspirin alone. 83\nBased on the above, and in line with the CCS Guidelines, 622   adding a second antithrombotic drug (P2Y 12  inhibitor or low-dose rivaroxa- ban) to aspirin for long-term secondary prevention should be consid- ered for patients who are at high ischaemic risk and do not have a high risk of bleeding. It may also be considered in patients who are at moderate ischaemic risk and without a high risk of bleeding, but the benefits are lower. 622   More details on antithrombotic treatment options are found in the ESC Guidelines for CCS. 622\nRecommendations for patients with coronary artery disease\nRecommendations Class a Level b\nAspirin 75 - 100 mg daily is recommended for\npatients with a previous myocardial infarction or revascularization. 619\nI A\nAspirin 75 - 100 mg daily may be considered in\npatients without a history of myocardial infarc- tion or revascularization, but with deﬁnitive evi-\ndence of CAD on imaging. 622\nIIb C\nIn ACS, DAPT with a P2Y 12  inhibitor in addition\nto aspirin is recommended for 12 months, unless there are contraindications such as excessive\nrisk of bleeding. 681 \u0002 683\nI A\nIn patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6\nmonths following coronary stenting, irrespective\nof stent type, unless a shorter duration (1 - 3 months) is indicated due to risk or occurrence\nof life-threatening bleeding. 622\nI A\nAdding a second antithrombotic drug (a P2Y 12 inhibitor or low-dose rivaroxaban) to aspirin for long-term secondary prevention should be con-\nsidered in patients with a high risk of ischaemic\nevents and without high bleeding risk. 83 , 622 , 687 \u0002 689\nIIa A\nContinued . .......................................................................................\n3294 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ...................................................................................\nThe management of dyslipidaemia and hypertension in patients with CAD is discussed in  sections 4.6  and  4.7 , respectively. For ACE inhibitors (or ARBs) and beta-blockers, see also the 2019 ESC Guidelines for diagnosis and management of CCS. 622\n6.2. Heart failure The management of HF aims to improve mortality, hospitalization rate, and quality of life. 690   To achieve this, multidisciplinary manage- ment programmes and structured follow-up with patient education, optimization of medical treatment, using telehealth facilities, lifestyle changes, psychosocial support, and improved access to care are fundamental. 691 \u0002 694\nRegarding the management of CVD risk factors, similar basic rules apply for those with and without HF. However, in HF, low choles- terol levels 695 , 696   and low body weight are associated with increased mortality. 697 , 698   Initiation of lipid-lowering therapy is not recom- mended in patients with HF without compelling indications for their use. 3   Whereas unintentional weight loss is associated with a worse prognosis regardless of baseline BMI, the effects of intentional weight loss remain unclear.\nConversely, regular exercise training (particularly combined aero- bic and resistance exercises) improves clinical status in all patients with HF 650 , 699 , 700   and improves CVD burden and prognosis in HFrEF. 700 , 701\nIt is recommended to screen all patients with HF for both CV and non-CV comorbidities; if present, they should be treated. 690   These diseases include CAD, hypertension, lipid disorders, DM, obesity, cachexia and sarcopenia, thyroid disorders, CKD, anaemia, iron defi- ciency, and sleep apnoea. 690\nFor patients with symptomatic HFrEF, neurohormonal antagonists [ACE inhibitors, 702 \u0002 705   ARBs, 706   angiotensin receptor neprilysin inhibitors (ARNIs), 707 \u0002 710   beta-blockers, 711 \u0002 717   and mineralocorti- coid receptor antagonists (MRAs) 718 , 719 ] improve survival and reduce the risk of HF hospitalizations. 690   These drugs also reduce the\nrisk of CV events in patients with symptomatic HFrEF. 702 \u0002 719\nImportantly, these drugs should be up-titrated to the maximum toler- ated doses, which may be different for men and women, particularly in patients recently discharged after HF hospitalization. 690 , 720 , 721\nSGLT2 inhibitors (currently dapagliflozin and empagliflozin) added on top of neurohormonal blockade reduces the risk of CV death and worsening HF in patients with symptomatic HFrEF, with or without DM, 600 , 601   and are recommended for all patients with symptomatic HFrEF already treated with an ACE inhibitor (or ARNI), a beta- blocker, and an MRA.\nRecently, an oral soluble guanylate cyclase receptor stimulator (vericiguat), administered along with standard neurohormonal block- ade in symptomatic patients with HFrEF with recent HF hospitaliza- tion, reduced the composite of death from any cause or HF hospitalization. 722\nOther drugs bring additional moderate benefits for selected patients with symptomatic HFrEF. Diuretics, 723 , 724   ivabradine, 725 , 726\nand hydralazine 727 , 728   should be considered, and digoxin 729   may be considered as complementary therapies in specific patients with symptomatic HFrEF. Some of these therapies reduce CV morbidity and mortality (e.g. ivabradine).\nAdditionally, for selected patients with symptomatic HFrEF, there are indications for an implantable cardioverter defibrillator to reduce the risk of sudden death and all-cause mortality, and for cardiac resynchronization therapy to reduce morbidity and mortality (for details, see 2021 HF Guidelines). 690\nAdding a second antithrombotic drug to aspirin\nfor long-term secondary prevention may be con-\nsidered in patients with a moderate risk of ischaemic events and without a high bleeding\nrisk. 83 , 622 , 687 \u0002 689\nIIb A\nACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hyperten-\nsion, or DM). 622\nI A\nBeta-blockers are recommended in patients with\nLV dysfunction or systolic HF. 622 I A\nIn patients with established ASCVD, oral lipid-\nlowering treatment with an ultimate LDL-C goal\nof <1.4 mmol/L (55 mg/dL) and a >_50% reduc- tion in LDL-C vs. baseline is recommended.\nI A\nACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; ARB = angiotensin receptor blocker; ASCVD = atherosclerotic cardiovascular disease; CAD = coronary artery disease; CCS = chronic coronary syndromes; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; HF = heart failure; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular. a Class of recommendation. b Level of evidence.\nESC 2021\nRecommendations regarding pharmacological and non- pharmacological interventions for patients with symp- tomatic (New York Heart Association class II 2 IV) heart failure with reduced ejection fraction (left ventricular ejection fraction  < 40 % ) with proven beneﬁts on clinical outcomes, including cardiovascular morbidity and mortality.\nRecommendations Class a Level b\nIt is recommended that patients with HF are\nenrolled in a comprehensive CR programme to reduce the risk of HF hospitalization and death. c\n691-694\nI A\nEBCR is recommended in stable symptomatic patients with HFrEF to reduce the risk of HF\nhospitalization. 700 , 701\nI A\nIt is recommended to screen patients with HF\nfor both CV and non-CV comorbidities which, if present, should be treated, provided safe and\neffective interventions exist, not only to alleviate\nsymptoms but also to improve prognosis. c\nI A\nAn ACE inhibitor is recommended, in addition\nto a beta-blocker and an MRA, for patients with\nsymptomatic HFrEF to reduce the risk of HF hospitalization and death. 702 \u0002 705\nI A\nA beta-blocker is recommended, in addition to an\nACE inhibitor (or an ARNI) and an MRA, for\npatients with stable, symptomatic HFrEF to reduce the risk of HF hospitalization and death. 711 \u0002 717\nI A\nContinued . ........................................................................................\nESC Guidelines 3295\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................................................................................................... 6.3. Cerebrovascular diseases Interventions for cerebrovascular diseases depend on the type of event, i.e. ischaemic or haemorrhagic. 732 , 733   Ischaemic events are mainly caused by atherothrombosis, cardiac embolism, or small ves- sel disease. 734   Other mechanisms (e.g. arterial dissection, patent fora- men ovale, thrombophilia, inherited diseases) are relatively rare. Intracerebral haemorrhage is mostly caused by hypertensive angiop- athy and/or cerebral amyloid angiopathy. 735   Bleeding can be precipi- tated by surges in BP values, use of anticoagulants, or diseases impairing coagulation. 733 , 735\nIn patients with ischaemic stroke or TIA, antithrombotics prevent further vascular events. Cardioembolic ischaemia, which occurs mainly in AF, requires anticoagulation (see  sections 3.4.3  and 6.6 ). 736 \u0002 742   In non-cardioembolic mechanism, platelet inhibitors are recommended. 619 , 620 , 743 \u0002 753\nIn non-cardioembolic ischaemic stroke, aspirin is the most studied antithrombotic drug. Aspirin 75 \u0002 150 mg/day reduces the risk of recurrent ischaemic stroke and serious vascular events. 619 , 743\nClopidogrel shows slight superiority to aspirin. 620   In patients with ischaemic stroke or TIA and ipsilateral carotid stenosis, ticagrelor added to aspirin compared to aspirin alone reduced the risk of stroke or death at 1 month, without an increase of severe bleeding. 754   Adding aspirin to clopidogrel was associated with a non-significant reduction in major vascular events and an increased long-term bleeding risk. 747 \u0002 749\nHowever, in patients with minor ischaemic stroke or TIA, a short course of DAPT with aspirin and clopidogrel is beneficial. 750 , 751\nSimilarly, ticagrelor and aspirin vs. aspirin alone reduces stroke or death at 30 days after mild-to-moderate ischaemic stroke or TIA not treated with thrombolysis or thrombectomy. However, DAPT with ticagrelor and aspirin did not improve the incidence of disability and contributed to severe bleeding. 755   DAPT with dipyridamole plus aspirin also showed superiority over aspirin alone. 744   In patients with ischaemic stroke, however, dipyridamole plus aspirin vs. clopidogrel alone showed similar rates of recurrent stroke, including haemorrhagic stroke, 745   but more major haemorrhagic events. In patients with non- cardioembolic ischaemic stroke, oral vitamin K antagonists are not superior to aspirin and carry a higher bleeding risk. 752 , 753   In the absence of a definite cause of ischaemia and a presumed occult cardioembolic\nAn MRA is recommended for patients with\nHFrEF already treated with an ACE inhibitor (or\nan ARNI) and a beta-blocker, to reduce the risk of HF hospitalization and death. 718 , 719\nI A\nSacubitril/valsartan is recommended as a\nreplacement for an ACE inhibitor to reduce the risk of HF hospitalization and death in patients\nwith HFrEF. 707 , 730\nI B\nAn ARB is recommended to reduce the risk of\nHF hospitalization or CV death in symptomatic patients with HFrEF who are unable to tolerate\nan ACE inhibitor and/or ARNI (patients should\nalso receive a beta-blocker and an MRA). 706\nI B\nDapagliﬂozin or empagliﬂozin are recom-\nmended, in addition to optimal treatment of an\nACE inhibitor (or ARNI), a beta-blocker, and an MRA, for patients with HFrEF to reduce the risk\nof HF hospitalization and death. 600 , 601 , 730\nI A\nVericiguat may be considered in patients with symp-\ntomatic HFrEF who have experienced HF worsen- ing despite treatment with an ACE inhibitor (or an\nARNI), a beta-blocker, and an MRA, to reduce the\nrisk of HF hospitalization or CV death. 722\nIIb B\nDiuretics are recommended in patients with\nHFrEF with signs and/or symptoms of congestion\nto reduce the risk of HF hospitalization. 723 , 724\nI C\nIvabradine should be considered in symptomatic patients with LVEF <_35%, in sinus rhythm, and with\na resting heart rate >_70 bpm despite treatment\nwith an evidence-based dose of a beta-blocker (or maximum tolerated dose below that), an ACE\ninhibitor (or an ARNI), and an MRA, to reduce the\nrisk of HF hospitalization or CV death. 725\nIIa B\nIvabradine should be considered in symptomatic\npatients with LVEF <_35%, in sinus rhythm, and\nwith a resting heart rate >_70 b.p.m. who are unable to tolerate or have contraindications for\na beta-blocker to reduce the risk of HF hospital-\nization or CV death. Patients should also receive an ACE inhibitor (or ARNI) and an MRA. 726\nIIa C\nHydralazine and isosorbide dinitrate should be\nconsidered in self-identiﬁed black patients with\nLVEF <_35% or with LVEF <45% combined with a dilated LV in NYHA class III \u0002 IV despite treat-\nment with an ACE inhibitor (or ARNI), a beta-\nblocker, and an MRA, to reduce the risk of HF hospitalization and death. 731\nIIa B\nHydralazine and isosorbide dinitrate may be con-\nsidered in patients with symptomatic HFrEF who cannot tolerate ACE inhibitors, ARBs, or ARNIs\n(or if they are contraindicated), to reduce the\nrisk of death. 728\nIIb B\nContinued\nDigoxin may be considered in patients with\nsymptomatic HFrEF in sinus rhythm despite\ntreatment with an ACE inhibitor (or ARNI), a beta-blocker, and an MRA, to reduce the risk of\nhospitalizations (all-cause and HF). 729\nIIb B\nACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; b.p.m. = beats per minute; CR = cardiac rehabilitation; CV = cardiovascular; EBCR = exercise-based cardiac rehabilitation; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LV = left ventricle; LVEF = left ventricular ejection fraction; MRA = min- eralocorticoid receptor antagonist; NYHA = New York Heart Association. a Class of recommendation. b Level of evidence. c Applies to all patients with HF, regardless of LVEF. For implantable cardioverter-deﬁbrillator and cardiac resynchronization recom- mendations, see   690\n. ...............................................\nESC 2021\n3296 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .............................................................. source (e.g. embolic stroke of undetermined cause), neither dabigatran nor rivaroxaban are better than aspirin. 756 , 757\nRecommendations for BP and lipid management are congruent to the general recommendations outlined in  sections 4.6  and  4.7.4 . In patients with either ischaemic or haemorrhagic cerebrovascular disease who have a BP of 140/90 mmHg or higher, lowering BP reduces the risk of recurrent stroke. 758 , 759   Optimal BP targets in these patients are uncertain, as is the optimal drug regimen. 760\nMost evidence is available for ACE inhibitors, ARBs, and diuretics. Comorbidities may guide the choice of antihypertensive agent. In patients with recent lacunar stroke, the target SBP is <130 mmHg. 761\nIn patients with stroke (ischaemic or haemorrhagic) or TIA with an LDL-C level of 100 - 190 mg/dL, atorvastatin 80 mg/day reduced the overall incidence of strokes and CV events. 762   A recent trial sup- ported an LDL-C target of <1.8 mmol/L (70 mg/dL). 508\nEvidence of cerebrovascular lesions (e.g. white matter hyperinten- sities, lacunes, non-lacunar ischaemia) in the absence of any stroke history is a relatively common finding at neuroimaging, especially in older patients. Silent cerebrovascular disease is a marker of increased risk of stroke. 763 , 764   Arterial hypertension, DM, and cigarette smok- ing contribute to these lesions and should be attended to. There are no studies addressing the best treatment options for silent cerebral ischaemia. 765\n6.4. Lower extremity artery disease Symptomatic or asymptomatic LEAD (ABI <_0.90) is associated with a doubling of the 10-year rate of coronary events, CV mortality, and total mortality. 125   Within 5 years of LEAD diagnosis, 20% develop AMI or stroke, and mortality is 10 \u0002 15%. 767\nAll LEAD patients require lifestyle improvement and pharmacolog- ical therapy. Smoking cessation increases walking distance and lowers amputation risk. 2   In patients  with DM, glycaemic control improves limb outcomes. 768   Statins provide modest improvements in walking distance, and lower the risk of adverse limb events. 769 , 770   Combining a statin with ezetimibe 771   or a PCSK9 inhibitor also has beneficial effects. 772\nPlatelet inhibitors are used to prevent limb-related and general CV events. The optimal antiplatelet strategy remains unclear. 773   DAPT is currently recommended only after intervention (irrespective of the stent type) for at least 1 month.\nIn the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, low-dose rivaroxaban added to aspirin in CVD patients with an ABI <0.90 reduced not only ASCVD events, but also major adverse limb events, including amputation (HR 0.54),\nRecommendations for patients with cerebrovascular disease\nRecommendations Class a Level b\nIn patients with a cerebrovascular event,\nimprovement of lifestyle factors in addition to appropriate pharmacological management is\nrecommended. 732 , 733 , 741\nI A\nIn patients with ischaemic stroke or TIA, preven- tion with antithrombotics is recommended;\nchoice of antithrombotic depends on the mecha-\nnism of event. Use of an antiplatelet is recom- mended for patients with non-cardioembolic\nischaemic stroke or TIA, and use of an anticoa-\ngulant is recommended in patients with cardi- oembolic ischaemic stroke or TIA. 732 , 741\nI A\nIn patients with non-cardioembolic ischaemic\nstroke or TIA, prevention with aspirin only, or\ndipyridamole plus aspirin, or clopidogrel alone is recommended. 620 , 743 \u0002 745\nI A\nIn patients with minor ischaemic stroke c   or TIA,\nDAPT with aspirin and clopidogrel or with aspirin and ticagrelor, for 3 weeks after the acute\nevent should be considered. 750 , 751 , 755\nIIa A\nIn patients with stroke or TIA who have BP of\n140/90 mmHg or higher, BP lowering is recommended. 757 , 766\nI A\nBP = blood pressure; DAPT = dual antiplatelet therapy; TIA = transient ischaemic attack. a Class of recommendation. b Level of evidence. c Minor ischaemic stroke deﬁned as score at National Institutes of Health Stroke Scale <_3, or <_5 depending on the trial.\nESC 2021\nRecommendations for patients with lower extremity artery disease: best medical therapy\nRecommendations Class a Level b\nSmoking cessation is recommended in all\npatients with LEAD. 29 , 781 I B\nHealthy diet and PA are recommended for all\npatients with LEAD. I C\n",
      "keywords": [
        "obesity",
        "cvd risk",
        "lipid",
        "hypertension",
        "management",
        "specific",
        "diabetes",
        "coronary artery",
        "arb",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "nyha",
        "smoking",
        "recommended",
        "ejection fraction",
        "may be considered",
        "diet",
        "pcsk9",
        "heart failure",
        "anticoagulation",
        "level b",
        "sglt2",
        "cholesterol",
        "class ii",
        "ldl-c",
        "older",
        "systolic",
        "lvef"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3295",
          "page_number": 68,
          "content": "Adding a second antithrombotic drug to aspirin\nfor long-term secondary prevention may be con-\nsidered in patients with a moderate risk of\nischaemic events and without a high bleeding\nrisk.83,622,687\u0002689 | IIb | A | \nACE inhibitors (or ARB) are recommended if a\npatient has other conditions (e.g. HF, hyperten-\nsion, or DM).622 | I | A | \nBeta-blockers are recommended in patients with\nLV dysfunction or systolic HF.622 | I | A | \nIn patients with established ASCVD, oral lipid-\nlowering treatment with an ultimate LDL-C goal\nof <1.4 mmol/L (55 mg/dL) and a >50% reduc-\n_\ntion in LDL-C vs. baseline is recommended. | I | A | ESC 2021",
          "bbox": [
            48.87103711641752,
            60.35187176295689,
            294.15633477105035,
            233.01814705984933
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3295",
          "page_number": 68,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIt is recommended that patients with HF are\nenrolled in a comprehensive CR programme to\nreduce the risk of HF hospitalization and death.c\n691-694 | I | A | \nEBCR is recommended in stable symptomatic\npatients with HFrEF to reduce the risk of HF\nhospitalization.700,701 | I | A | \nIt is recommended to screen patients with HF\nfor both CV and non-CV comorbidities which, if\npresent, should be treated, provided safe and\neffective interventions exist, not only to alleviate\nsymptoms but also to improve prognosis.c | I | A | \nAn ACE inhibitor is recommended, in addition\nto a beta-blocker and an MRA, for patients with\nsymptomatic HFrEF to reduce the risk of HF\nhospitalization and death.702\u0002705 | I | A | \nA beta-blocker is recommended, in addition to an\nACE inhibitor (or an ARNI) and an MRA, for\npatients with stable, symptomatic HFrEF to reduce\nthe risk of HF hospitalization and death.711\u0002717 | I | A | ",
          "bbox": [
            313.3351350264116,
            463.50221659342446,
            558.3879817082332,
            732.4831673758371
          ],
          "function_potential": "raw"
        },
        {
          "title": "3296 ESC Guidelines",
          "page_number": 69,
          "content": "An MRA is recommended for patients with\nHFrEF already treated with an ACE inhibitor (or\nan ARNI) and a beta-blocker, to reduce the risk\nof HF hospitalization and death.718,719 | I | A | \nSacubitril/valsartan is recommended as a\nreplacement for an ACE inhibitor to reduce the\nrisk of HF hospitalization and death in patients\nwith HFrEF.707,730 | I | B | \nAn ARB is recommended to reduce the risk of\nHF hospitalization or CV death in symptomatic\npatients with HFrEF who are unable to tolerate\nan ACE inhibitor and/or ARNI (patients should\nalso receive a beta-blocker and an MRA).706 | I | B | \nDapagliflozin or empagliflozin are recom-\nmended, in addition to optimal treatment of an\nACE inhibitor (or ARNI), a beta-blocker, and an\nMRA, for patients with HFrEF to reduce the risk\nof HF hospitalization and death.600,601,730 | I | A | \nVericiguat may be considered in patients with symp-\ntomatic HFrEF who have experienced HF worsen-\ning despite treatment with an ACE inhibitor (or an\nARNI), a beta-blocker, and an MRA, to reduce the\nrisk of HF hospitalization or CV death.722 | IIb | B | \nDiuretics are recommended in patients with\nHFrEF with signs and/or symptoms of congestion\nto reduce the risk of HF hospitalization.723,724 | I | C | \nIvabradine should be considered in symptomatic\npatients with LVEF <35%, in sinus rhythm, and with\n_\na resting heart rate >70 bpm despite treatment\n_\nwith an evidence-based dose of a beta-blocker (or\nmaximum tolerated dose below that), an ACE\ninhibitor (or an ARNI), and an MRA, to reduce the\nrisk of HF hospitalization or CV death.725 | IIa | B | \nIvabradine should be considered in symptomatic\npatients with LVEF <35%, in sinus rhythm, and\n_\nwith a resting heart rate >70 b.p.m. who are\n_\nunable to tolerate or have contraindications for\na beta-blocker to reduce the risk of HF hospital-\nization or CV death. Patients should also receive\nan ACE inhibitor (or ARNI) and an MRA.726 | IIa | C | \nHydralazine and isosorbide dinitrate should be\nconsidered in self-identified black patients with\nLVEF <35% or with LVEF <45% combined with\n_\na dilated LV in NYHA class III\u0002IV despite treat-\nment with an ACE inhibitor (or ARNI), a beta-\nblocker, and an MRA, to reduce the risk of HF\nhospitalization and death.731 | IIa | B | \nHydralazine and isosorbide dinitrate may be con-\nsidered in patients with symptomatic HFrEF who\ncannot tolerate ACE inhibitors, ARBs, or ARNIs\n(or if they are contraindicated), to reduce the\nrisk of death.728 | IIb | B | ",
          "bbox": [
            44.34068335256269,
            60.35202012743269,
            289.4931335449219,
            696.2052459716797
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3296 ESC Guidelines",
          "page_number": 69,
          "content": "Digoxin may be considered in patients with\nsymptomatic HFrEF in sinus rhythm despite\ntreatment with an ACE inhibitor (or ARNI), a\nbeta-blocker, and an MRA, to reduce the risk of\nhospitalizations (all-cause and HF).729 | IIb | B | ESC 2021",
          "bbox": [
            308.6699905395508,
            60.35202012743269,
            554.2246500651041,
            121.39623151506696
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3297",
          "page_number": 70,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nSmoking cessation is recommended in all\npatients with LEAD.29,781 | I | B | \nHealthy diet and PA are recommended for all\npatients with LEAD. | I | C | \nIn patients with intermittent claudication:\n\u0007 Supervised exercise training is\nrecommended782\u0002784 | I | A | \n\u0007 Non-supervised exercise training is recom-\nmended when supervised exercise training is not\nfeasible or available. | I | C | \nAntiplatelet therapy is recommended in patients\nwith symptomatic LEAD.c | I | C | \nIn patients with LEAD and hypertension, it is\nrecommended to control BP at <140/90\nmmHg.776,785,786 | I | A | \nIn patients with LEAD and DM, strict glycaemic\ncontrol is recommended.768 | I | A | \nACE inhibitors or ARBs should be considered as\nfirst-line therapy in patients with PAD and\nhypertension.d 575,787 | IIa | B | \nIn patients with DM and chronic symptomatic\nLEAD without high bleeding risk, a combination\nof low-dose rivaroxaban (2.5 mg b.i.d.) and\naspirin (100 mg o.d.) may be considered.774 | IIb | B | ESC 2021",
          "bbox": [
            313.2975387573242,
            333.3181488037109,
            558.4411156063989,
            655.0971810477121
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3297",
          "page_number": 70,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIn patients with a cerebrovascular event,\nimprovement of lifestyle factors in addition to\nappropriate pharmacological management is\nrecommended.732,733,741 | I | A | \nIn patients with ischaemic stroke or TIA, preven-\ntion with antithrombotics is recommended;\nchoice of antithrombotic depends on the mecha-\nnism of event. Use of an antiplatelet is recom-\nmended for patients with non-cardioembolic\nischaemic stroke or TIA, and use of an anticoa-\ngulant is recommended in patients with cardi-\noembolic ischaemic stroke or TIA.732,741 | I | A | \nIn patients with non-cardioembolic ischaemic\nstroke or TIA, prevention with aspirin only, or\ndipyridamole plus aspirin, or clopidogrel alone is\nrecommended.620,743\u0002745 | I | A | \nIn patients with minor ischaemic strokec or TIA,\nDAPT with aspirin and clopidogrel or with\naspirin and ticagrelor, for 3 weeks after the acute\nevent should be considered.750,751,755 | IIa | A | \nIn patients with stroke or TIA who have BP of\n140/90 mmHg or higher, BP lowering is\nrecommended.757,766 | I | A | ESC 2021",
          "bbox": [
            48.99032350019975,
            377.2152160644531,
            294.1171123798077,
            682.1961800711496
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "21",
      "title": "In patients with intermittent claudication:",
      "start_page": 70,
      "end_page": 72,
      "content": "\u0007  Supervised exercise training is\nrecommended 782 \u0002 784\nI A\n\u0007  Non-supervised exercise training is recom- mended when supervised exercise training is not\nfeasible or available.\nI C\nAntiplatelet therapy is recommended in patients with symptomatic LEAD. c I C\nIn patients with LEAD and hypertension, it is\nrecommended to control BP at <140/90\nmmHg. 776 , 785 , 786\nI A\nIn patients with LEAD and DM, strict glycaemic\ncontrol is recommended. 768 I A\nACE inhibitors or ARBs should be considered as\nﬁrst-line therapy in patients with PAD and hypertension. d  575 , 787\nIIa B\nIn patients with DM and chronic symptomatic\nLEAD without high bleeding risk, a combination of low-dose rivaroxaban (2.5 mg  b.i.d .) and\naspirin (100 mg  o.d .) may be considered. 774\nIIb B\nACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker;  b.i.d . =  bis in die  (twice a day); BP = blood pressure; CCB = calcium channel blocker; DM = diabetes mellitus; LEAD = lower extremity artery disease;  o.d.  =  omni die (once a day); PA = physical activity; PAD = peripheral artery disease. a Class of recommendation. b Level of evidence. c Evidence is not available for all sites. When evidence is available, recommenda- tions speciﬁc for the vascular site are presented in corresponding sections. d CCBs should be proposed in black individuals.\nESC 2021\n. .............................................................................................................\nESC Guidelines 3297\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .........................................................................................................\nalbeit at the cost of higher major bleeding risk. 774   These results, com- bined with similar benefits of rivaroxaban vs. aspirin monotherapy, sug- gest a benefit of anticoagulants in LEAD. However, further studies are needed. Optimal antithrombotic therapy is addressed in more detail in the 2017 ESC/European Society for Vascular Surgery (ESVS) Guidelines. 775   Importantly, in patients with isolated asymptomatic LEAD (e.g. low ABI), antiplatelet treatment is not recommended. 775\nRecommendations for BP and lipid management are congruent to the general recommendations outlined in  sections 4.6  and  4.7 . Hypertension targets are based mainly on INVEST (INternational VErapamil-SR/Trandolapril STudy). 776   An SBP below 110 \u0002 120 mmHg may increase CV events in patients with LEAD. 776   ACE inhibitors and ARBs reduce CV events in patients with LEAD, 575 , 777   and are pre- ferred (as monotherapy or as part of a combination drug regimen). 778\nBeta-blockers are not contraindicated in mild-to-moderate LEAD as they do not affect walking capacity or adverse limb events, 779   and sig- nificantly reduce coronary events. 780   Nevertheless, beta-blockers should be carefully considered in critical limb-threatening ischaemia.\n6.5. Chronic kidney disease Severe CKD is associated with a very high risk of CVD and is consid- ered a CAD risk equivalent (see  section 3.2 ). As GFR declines, non- traditional risk factors emerge and non-atherosclerotic CVD event risk increases. 204   Trials often exclude patients with eGFR <30 mL/ min/1.73 m 2 . In patients on dialysis, coronary syndromes may present atypically, and angina equivalents— such as shortness of breath or fatigue—are frequent. 788   Standard CVD risk management is effective in patients on dialysis, but unique haemodialysis-specific syndromes (i.e. intradialytic hypotension and myocardial stunning) associated with mortality complicate treatment and modify outcomes.\nRisk classification of patients with various degrees of CKD is sum- marized in  Table  4 . Treatment with a statin or statin/ezetimibe combi- nation is recommended in CKD patients with sufficiently high CVD risk, but not in those treated with kidney replacement therapy. This recommendation is built on evidence from SHARP (Study of Heart and Renal Protection), which demonstrated a reduction of major atherosclerotic events. 525   Statins should be dosed according to a moderate-intensity regimen based on limited experience and risks associated with high-intensity regimens. 543   Subgroup analysis of a recent study with a PCSK9 inhibitor has shown that the benefits may extend to those with earlier CKD stages (60 \u0002 90 as well as 30 \u0002 60 mL/min/1.73 m 2 ). 789\nTreatment with an ACE inhibitor or an ARB is recommended in patients with DM, hypertension, and albuminuria. These medications should be titrated to the maximum tolerated dose (Kidney Disease Improving Global Outcomes grading 1B). Individualized HbA1c targets, ranging from 6.5% to <8.0% in patients with DM and non-dialysis-dependent CKD, are recom- mended in parallel. The role of SGLT2 inhibitors and GLP-1RAs in CKD associated with DM is addressed in  section 4.8 . Dapagliflozin has shown promising reno- and cardioprotective effects, 599   and more studies investigating SGLT2 inhibitors in CKD patients without DM are ongoing. 790\nOverall, the management of CAD in CKD patients must be informed by the modification of its clinical presentation in CKD, as well as comorbidity and risks of treatment side-effects. Treatment of established risk factors is often suboptimal in patients with CKD.\n6.6. Atrial fibrillation The simple ‘Atrial fibrillation Better Care’ (ABC) holistic pathway (‘A’ = Anticoagulation/Avoid stroke; ‘B’ = Better symptom man- agement; ‘C’ = Cardiovascular and Comorbidity optimization) streamlines integrated care of patients with AF. 215   The ABC path- way lowers risk of all-cause death and the composite of stroke, major bleeding, CV death, or first hospitalization, 791   and lowers rates of CV events 792 , 793   and health-related costs. 794\nThe ‘C’ component of the ABC pathway refers to identification and management of concomitant diseases, cardiometabolic risk factors, and unhealthy lifestyle factors. Therapy of underlying con- ditions improves rhythm control in persistent AF and HF. 216   In obese patients, weight reduction prevents AF recurrences and symptoms. 795 \u0002 802   Given that hypertension precipitates AF, treat- ment of hypertension is mandatory. Alcohol excess is a risk factor for incident AF, 803 , 804   and abstinence reduced AF recurrences in regular drinkers. 798   Many studies have demonstrated beneficial effects of moderate exercise/PA. 805 \u0002 807   The incidence of AF appears, however, to be increased in elite athletes, mainly related to endurance sports. 808 \u0002 811   Patients should be encouraged to practise moderate-intensity exercise and remain physically active to prevent AF incidence or recurrence, but avoid excessive endurance exercise. CR is a universally recommended pro- gramme for patients with ACS and/or revascularization, and for patients with HF. 639 , 640 , 655   The benefits of EBCR are more uncer- tain in patients with AF, but CR remains recommended in patients with the aforementioned indications. 812   Continuous PAP may improve rhythm control and attenuate AF recurrences in OSA patients. 813 \u0002 816   Intensive glycaemic control does not affect the rate of new-onset AF. 817   Optimal glycaemic control during the 12 months before AF ablation does, however, reduce AF recurrence after ablation. 818   All patients with HF and AF should receive guideline-adherent HF therapy. 819\nRecommendations in patients with chronic kidney dis- ease: best medical therapy a\nRecommendations Class b Level c\nTreatment with an ACE inhibitor or an ARB is\nrecommended in patients with DM, hyperten- sion, and albuminuria. These medications should\nbe titrated to the highest approved dose that is\ntolerated.\nI B\nAn SGLT2 inhibitor with proven outcome\nbeneﬁts should be considered for the prevention\nof renal deterioration and mortality in patients with CKD. 599\nIIa B\nCombination treatment with ACE inhibitors and\nARBs is not recommended. III C\nACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CKD = chronic kidney disease; DM = diabetes mellitus; SGLT2 = sodium-glucose cotransporter 2. a Recommendations on CKD management in patients with DM are found in  sec- tion 4.8 . b Class of recommendation. c Level of evidence. . ................................................................\nESC 2021\n3298 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................\n6.7. Multimorbidity The older adult population is growing fast and survival after acute CVD has improved, 820   leading to an increasing number of older patients with CVD and multimorbidity. 821 , 822   This development is associated with high healthcare costs, 823 , 824   worse outcome meas- ures, higher readmission rates, 825   and mortality. 826\nUp to 70% of patients aged >_70 years have at least one CVD and two-thirds also develop non-CVD comorbidities. Multimorbidity is important in patients with CVD. 823\nThe prevailing CV conditions in patients aged >60 years are hyper- tension, hyperlipidaemia, ischaemic heart disease, arrhythmia, DM, and CAD. 823   Other frequent comorbidities include anaemia and arthritis. Low vision, back and neck problems, osteoarthritis, COPD, depression, and cancer are the most common non-CV comorbidities in CVD patients. Most studies have found no sex differences in the number of comorbidities. However, men have more CVD comorbid- ities and women have more non-CVD comorbidities (in particular more depression). 822 , 826 , 827\nSo far, guidance for the treatment of CVD has focused mainly on single CVDs. In multimorbid patients, application of a single guideline for one CVD is often not feasible as therapeutic competition is highly prevalent (22.6%) 820   and treatment for one condition can worsen a coexisting condition. The challenges for managing CVD and multi- morbidity are disease-disease, disease-drug, and drug-drug interac- tions. 820   Further, pharmacokinetics can be different in patients with comorbidities, and life expectancy has to be taken into account when starting a new medication. A value-based approach should always be discussed and proposed when possible. 820   The incremental benefit of medication when added to an already complex regimen is often uncertain. 828   Moreover, care for multimorbid CVD patients is often fragmented and given by multiple providers, complicating decision- making and adherence to recommended treatment. 820\nMultimorbid CVD patients have been underrepresented in most clinical trials that underlie the guidelines. Trials including patients with multimorbidity and endpoints that matter to patients, pragmatic tri- als, and the use of registries and big data could help elucidate how to optimize treatment and care for patients with CVD and multimorbidity. 820\nThere is a plea for a paradigm shift from disease-focused to patient-centred care for multimorbid CVD patients, with a central place for patients’ overarching goals of care. 828   ‘What matters to you?’ should be the central question, instead of ‘what is the matter?’.\nPatient-centred care should include assessment of patients’ prefer- ences, interpretation of the evidence and its application to the spe- cific patient, consideration of overall prognosis, including life expectancy, functional status, and quality of life, and clinical feasibility. Adherence to treatment, the occurrence of adverse drug events, the economic burden, and the stress experienced by caregivers should be taken into account when optimizing therapies and care plans where adherence to essential medication is emphasized and non- essential drugs are stopped. 828   Furthermore, advanced care planning should be initiated early. Multidisciplinary teams and close collabora- tion between primary care workers and specialists is needed. Finally, automated decision support systems for multimorbidity and CVD could help in aligning the relevant evidence and making adequate decisions. 829\n",
      "keywords": [
        "alcohol",
        "peripheral artery",
        "cvd risk",
        "lipid",
        "hypertension",
        "claudication",
        "diabetes",
        "arb",
        "sex",
        "level c",
        "statin",
        "atrial fibrillation",
        "sbp",
        "recommended",
        "risk factor",
        "may be considered",
        "pcsk9",
        "anticoagulation",
        "physical activity",
        "sglt2",
        "arrhythmia",
        "older",
        "egfr",
        "glucose",
        "ablation",
        "exercise",
        "hba1c",
        "blood pressure",
        "ace inhibitor",
        "calcium channel"
      ],
      "tables": [
        {
          "title": "3298 ESC Guidelines",
          "page_number": 71,
          "content": " |  |  | \nRecommendations | Classb | Levelc | \n |  |  | \nTreatment with an ACE inhibitor or an ARB is\nrecommended in patients with DM, hyperten-\nsion, and albuminuria. These medications should\nbe titrated to the highest approved dose that is\ntolerated. | I | B | \nAn SGLT2 inhibitor with proven outcome\nbenefits should be considered for the prevention\nof renal deterioration and mortality in patients\nwith CKD.599 | IIa | B | 21\nCombination treatment with ACE inhibitors and\nARBs is not recommended. | III | C | ESC 20",
          "bbox": [
            308.84007835388184,
            86.94777018229166,
            553.9765150282118,
            245.4972381591797
          ],
          "function_potential": "raw"
        },
        {
          "title": "ESC Guidelines 3299",
          "page_number": 72,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nIdentification and management of risk factors\nand concomitant diseases are recommended to\nbe an integral part of treatment.795 | I | B | \nModification of unhealthy lifestyle and targeted\ntherapy of intercurrent conditions is recom-\nmended to reduce AF burden and symptom\nseverity.216,795\u0002802 | I | B | \nAttention to good BP control is recommended\nin AF patients with hypertension to reduce AF\nrecurrences and risk of stroke and\nbleeding.800,801 | I | B | \nIn obese patients with AF, weight loss together\nwith management of other risk factors should be\nconsidered to reduce AF incidence, AF progres-\nsion, AF recurrences, and symptoms.795\u0002797 | IIa | B | \nAdvice and management to avoid alcohol excess\nshould be considered for AF prevention and in\nAF patients considered for oral anticoagulant\ntherapy.798,803,804 | IIa | B | \nPA should be considered to help prevent AF\nincidence or recurrence, with the exception of\nexcessive endurance exercise, which may pro-\nmote AF.805\u0002812 | IIa | C | \nOptimal management of OSA may be consid-\nered to reduce AF incidence, AF progression, AF\nrecurrences, and symptoms.813\u0002816 | IIb | C | ESC 2021",
          "bbox": [
            48.966475350516184,
            96.96527303059896,
            293.8291751637178,
            440.3441598074777
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "22",
      "title": "7. Key messages",
      "start_page": 72,
      "end_page": 75,
      "content": "Risk factors and risk classification\n•   The major risk factors for ASCVD are cholesterol, BP, cigarette smoking, DM, and adiposity. •   Risk factors are treated in a stepwise approach to reach the ulti- mate treatment goals in apparently healthy people, patients with established ASCVD, and patients with DM. •   10-year CVD risk is estimated in apparently healthy people aged 40 \u0002 69 years with SCORE2, and in people aged >_70 years with SCORE2-OP. •   Age-specific 10-year CVD risk thresholds—together with con- sideration of risk modifiers, frailty, comorbidities, lifetime CVD risk, treatment benefit, polypharmacy, and patient preferences— guide treatment decisions for lipid and BP treatment. •   There are various options of communicating the (residual) CVD risk, and this should be tailored to the individual patient.\nRecommendations for lifestyle interventions and man- agement of risk factors and concomitant diseases in patients with atrial ﬁbrillation 215\nRecommendations Class a Level b\nIdentiﬁcation and management of risk factors\nand concomitant diseases are recommended to\nbe an integral part of treatment. 795\nI B\nModiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recom-\nmended to reduce AF burden and symptom\nseverity. 216 , 795 \u0002 802\nI B\nAttention to good BP control is recommended\nin AF patients with hypertension to reduce AF\nrecurrences and risk of stroke and bleeding. 800 , 801\nI B\nIn obese patients with AF, weight loss together\nwith management of other risk factors should be\nconsidered to reduce AF incidence, AF progres- sion, AF recurrences, and symptoms. 795 \u0002 797\nIIa B\nAdvice and management to avoid alcohol excess\nshould be considered for AF prevention and in AF patients considered for oral anticoagulant\ntherapy. 798 , 803 , 804\nIIa B\nPA should be considered to help prevent AF\nincidence or recurrence, with the exception of excessive endurance exercise, which may pro-\nmote AF. 805 \u0002 812\nIIa C\nOptimal management of OSA may be consid- ered to reduce AF incidence, AF progression, AF\nrecurrences, and symptoms. 813 \u0002 816\nIIb C\nAF = atrial ﬁbrillation; BP = blood pressure; OSA = obstructive sleep apnoea; PA = physical activity. a Class of recommendation. b Level of evidence.\nESC 2021\nESC Guidelines 3299\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Risk modifiers\n•   Psychosocial stress is associated with risk of ASCVD. •   Current risk scores may under- or overestimate CVD risk in dif- fering ethnic minority groups. •   CAC scoring is the best-established imaging modality to improve CVD risk stratification. •   Frailty is a functional risk factor of both CV and non-CV morbid- ity and mortality. •   Frailty assessment is not a method to determine eligibility for any particular treatment, but rather serves to build an individualized care plan with predefined priorities. •   Family history should be enquired about routinely, and a positive family history of premature ASCVD should be followed by com- prehensive CVD risk assessment. •   Current data does not support the use of genomic risk scores in CVD risk assessment in primary prevention. •   ASCVD development and prognosis are linked to social gradients. •   Air pollution is strongly associated with ASCVD. •   Additional circulating and urine biomarkers should not be rou- tinely measured. •   Assess CVD risk in persons with obesity.\nClinical conditions\n•   CKD is an independent risk factor for ASCVD, and ASCVD is the leading cause of death in CKD. •   A short-term reduction in albuminuria by approximately 30% upon starting RAAS inhibition is associated with improved CV and kidney outcomes. •   Similarly, SGLT2 inhibitors are associated with long-term bene- fits in CV and renal risks. •   AF is associated with an increased risk of death and an increased risk of CVD. •   Ischaemic HF constitutes the most advanced clinical manifesta- tion of atherosclerosis within the myocardium. •   The diagnosis of overt HF, as well as asymptomatic presentation with LV dysfunction, increases the risk of CVD events (myocar- dial infarction, ischaemic stroke, CV death). •   There is an overlap between cancer and CV risk factors; CV risk in patients with cancer depends on both the CV toxicity of treat- ments and patient-related factors. •   Signs or symptoms of cardiac dysfunction should be monitored before, periodically during, and after treatment. •   Exercise should be strongly advised, in particular aerobic exer- cise, to prevent cardiotoxicity. •   COPD is a major risk factor for CVD, especially ASCVD, stroke, and HF. •   COPD patients are prone to arrhythmias (AF and ventricular tachycardia) and sudden cardiac death. •   All COPD patients should be investigated for CVD. •   Common COPD medications are usually safe in terms of CV adverse events. •   Chronic inflammatory conditions increase CVD risk. •   Infection with HIV is associated with an increased risk of LEAD and CAD. •   There is an association between influenza and periodontitis infections and ASCVD.\n•   Migraine, particularly migraine with aura, is an independent risk factor for stroke and ischaemic cardiac disease. •   The risk of ischaemic stroke in subjects with migraine with aura is magnified by the use of combined hormonal contraceptives and cigarette smoking. •   Non-restorative sleep and a sleep duration that varies signifi- cantly up or down from the optimum of 7 h are associated with increased CV risk. •   Mental disorders are common in the general population (12- month prevalence of 27%) and are associated with excess mortality. •   The onset of CVD increases the risk of mental disorders by 2.2- fold, leading to a worse prognosis. •   Some mental disorders—even symptoms of anxiety and depres- sion—are associated with the development of CVD and with a worse prognosis in those with existing CVD (CHD, arterial hypertension, AF, HF). •   Excess mortality is mainly caused by behaviour-dependent risk factors (e.g. smoking addiction) and an impaired capacity for self- care (e.g. treatment adherence). •   NAFLD is associated with other cardiometabolic risk factors. •   Patients with NAFLD should be evaluated for other cardiometa- bolic risk factors. •   Sex-specific conditions: •   Preeclampsia and pregnancy-related hypertension are asso- ciated with a higher risk of CVD. •   Polycystic ovary syndrome confers a significant risk for future development of DM. •   ED is associated with future CV events and mortality in men. •   CVD risk should be assessed in men with ED. •   Asking about ED should be a standard procedure in routine CV risk assessment in men.\nRisk factors and interventions at the individual level\n•   Regular PA is a mainstay of ASCVD prevention. •   Aerobic PA in combination with resistance exercise and the reduction of sedentary time are recommended for all adults. •   A healthy diet lowers the risk of CVD and other chronic diseases. •   A shift from a more animal- to plant-based food pattern may reduce CVD. •   Achieving and maintaining a healthy weight through lifestyle changes has favourable effects on risk factors (BP, lipids, glucose metabolism) and lowers CVD risk. •   When changes in diet and PA—as well as other conventional, non-invasive interventions—are unsuccessful, bariatric surgery should be considered for high-risk individuals. •   Anti-obesity medications with protective ASCVD effects may also be considered. •   Patients with mental disorders have sharply increased lifestyle risks that need recognition and treatment. •   Mental healthcare improves stress symptoms and quality of life, reduces the risk of suicide, and may improve CV outcomes. •   The treatment of ASCVD patients with mental disorders requires interdisciplinary cooperation and communication. •   Stopping smoking rapidly reduces CVD risk and is the most cost-effective strategy for ASCVD prevention.\n3300 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ •   There is strong evidence for medication-assisted interventions: NRT, bupropion, varenicline, and drugs in combination. The most effective are assistance using drug therapy and follow-up support. •   Lower is better: the effect of LDL-C on the risk of CVD appears to be determined by both the baseline level and the total dura- tion of exposure to LDL-C. •   Lowering LDL-C with statins, ezetimibe, and—if needed and cost-effective—PCSK9 inhibitors, decreases the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C. •   When LDL-C goals according to level of risk cannot be attained, aim to reduce LDL-C by >_50% and then strive to reduce other risk factors as part of a shared decision-making process with the patient. •   When hypertension is suspected, the diagnosis should be con- firmed by repeated office BP measurement at different visits, or ABPM or HBPM. •   Lifestyle interventions are indicated for all patients with hyper- tension and can delay the need for drug treatment or comple- ment the BP-lowering effect of drug treatment. •   BP-lowering drug treatment is recommended in many adults when office BP is >_140/90 mmHg and in all adults when BP is >_160/100 mmHg. •   BP treatment goals are lower than in the previous ESC CVD pre- vention guidelines for all patient groups, including independent older patients. •   Wider use of single-pill combination therapy is recommended to reduce poor adherence to BP treatment. •   A simple drug treatment algorithm should be used to treat most patients, based on combinations of a renin \u0002 angiotensin system (RAS) blocker with a CCB or thiazide/thiazide-like diuretic, or all three. Beta-blockers may also be used where there is a guideline-directed indication. •   Many patients with hypertension will be at sufficient risk to bene- fit from statin therapy for primary prevention. Antiplatelet ther- apy is indicated for secondary prevention. •   A multifactorial approach, including lifestyle changes, is critical in persons with type 2 DM. •   Management of hyperglycaemia reduces the risk of microvascu- lar complications and, to a lesser extent, the risk of CVD. Glycaemic targets should be relaxed in older adults and frail individuals. •   New antihyperglycaemic drugs are particularly important for per- sons with type 2 DM with existing ASCVD and (heightened risk of) HF or renal disease, broadly irrespective of glycaemia levels.\nType 1 diabetes mellitus\n•   Intensive management of hyperglycaemia in DM reduces the risk of micro- and macrovascular complications and premature mor- tality; a target of 6.5 \u0002 7.5% (48 \u0002 58 mmol/mol) HbA1c is recommended. •   Metformin is not recommended in type 1 DM to lower CVD risk. •   Dapagliflozin has been recommended for use in type 1 DM, although there is an increased risk of diabetic ketoacidosis with such therapies.\n•   Targeting other risk factors, in particular smoking, BP, and cho- lesterol levels, remains an important means to lower CVD risk in type 1 DM. •   All patients with established ASCVD require some form of antithrombotic therapy. •   Anti-inflammatory therapy is a promising strategy in CVD prevention. •   Patients after ACS and/or coronary artery bypass graft/PCI, or with chronic HFrEF, should participate as early as possible in structured, multidisciplinary EBCR and prevention programmes. •   EBCR and prevention programmes must comply with certain quality standards and be individualized to each patient’s profile. •   Participation and long-term adherence to these programmes has to be encouraged and enhanced. Telerehabilitation and mHealth may help towards achieving this target.\nPopulation-level approaches to cardiovascular disease prevention\nPhysical activity\n•   A significant percentage of the worldwide population, in particu- lar the European population, shows high levels of sedentary behaviour and physical inactivity. •   The percentage of those exercising at a regular level is greater in men than in women. •   Global progress to increase PA has been slow, largely due to lack of awareness and investment. •   The optimal dose of different types of PA for CVD and general prevention is still controversial and subjected to frequent updates. Increasing moderate-to-vigorous PA and reducing sit- ting time, however, is beneficial and any level of PA is considered better than none. •   PA for health promotion should be implemented by physicians in the same way as drug prescription and should also be pro- moted by other healthcare professionals. •   Population-based interventions are effective in promoting PA for groups based on age, sex, and race, for high-, middle-, and low-income populations, and for different environments (e.g. kindergarten, school, gyms, companies, and worksites in general). •   Daily PA at school should be practised for at least 3 h/week, and preferably for 60 minutes per day. •   Population-based approaches are complementary to individual- centred interventions. •   Diet •   Structural measures such as changes in agricultural supply chain and food industry, product reformulation, limitations on (digital) marketing to children, taxes on unhealthy foods/nutrients, and consumer-friendly nutrition labelling will improve healthy food choices. •   Healthy environments in the community, on public transport, at schools, and in workplaces will stimulate a healthier lifestyle. •   The WHO Global Action Plan for the Prevention and Control of Non-Communicable Diseases 2013 \u0002 2020 extended to 2025 recommends to develop goals in global, regional, and national agendas. Within the 10 voluntary targets to reach in 2025 is a 30% relative reduction in mean population intake of sodium/ salt. 830\nESC Guidelines 3301\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Smoking and tobacco use\n•   Adolescence is the most vulnerable period for the uptake of smoking, with lifelong consequences. •   Previous prevention campaigns reduced tobacco use in girls much less than in boys. •   Teenagers should be informed that smoking is not helpful in weight control. •   High taxes on all tobacco products is the most effective policy measure to reduce smoking uptake by the young. •   There should be restrictions on smokeless tobacco due to strong evidence of harm. •   Also, restrictions on e-cigarettes due to evidence of harm. •   Plain packaging is effective in reducing the attractiveness of tobacco products. •   There should be restrictions on advertising, promotion, and sponsorship by the tobacco industry. •   A goal would be to make a common European decision to achieve a smoking-free Europe by 2030.\nAlcohol\n•   Alcohol intake is associated with increased CV mortality, and alcohol use is the leading risk factor for premature death and dis- ability among people aged 15 \u0002 49 years. •   The interventions for addressing the harmful use of alcohol are cost-effective, with a good return (i.e. increasing alcoholic bever- age minimum unit pricing and excise taxes, restricting access to alcoholic beverages, and implementing comprehensive restric- tions and bans on advertising and the promotion of alcoholic beverages). •   Healthcare providers may inquire about alcohol intake in every medical evaluation and should inform patients that alcohol is energy-dense: it provides 7 kcal/g and no nutrients.\nEnvironment, air pollution, and climate change\n•   Air pollution contributes to mortality and morbidity, and specifi- cally increases the risk of respiratory and CV diseases. •   Environmental exposure has taken on new urgency, as air pollu- tion, in addition to its health effects, has also been ascribed as a major contributor to climate changes, notably through the burn- ing of fossil fuels leading to increasing emissions of carbon dioxide.\nRisk management of disease-specific cardiovascular disease Coronary artery disease\n•   Multidimensional prevention is crucial for short- and long-term outcomes in CAD.\nHeart failure\n•   Patients with HF benefit from multidisciplinary care management programmes. •   Several neurohormonal antagonists, as well as novel molecules, improve clinical outcomes in symptomatic patients with HFrEF.\nCerebrovascular diseases\n•   Ischaemic events are mainly caused by atherothrombosis, cardi- oembolism, or small vessel disease, whereas intracerebral\nhaemorrhage is mostly caused by hypertensive angiopathy or cerebral amyloid angiopathy. •   Platelet inhibitors are recommended for non-cardioembolic events and anticoagulants for cardioembolic events. •   In patients with a previous stroke or TIA and high BP, BP lower- ing reduces the recurrence risk. •   In patients with stroke or TIA, statins prevent CVD and cerebro- vascular events. •   Lower extremity artery disease •   LEAD is associated with an increased CVD risk. •   Antiplatelet therapy (alone or in combination with low-dose oral anticoagulation) reduces the risk of adverse limb events and overall CVD risk in patients with LEAD. •   Smoking cessation and control of other CVD risk factors improve prognosis.\nChronic kidney disease\n•   Hypertension, dyslipidaemia, and DM are prevalent among indi- viduals with CKD and require a high-risk treatment strategy approach. •   Risk management includes lifestyle, smoking cessation, nutrition, sufficient RAAS blockade, target BP control, lipid management, and—in established CVD—aspirin. •   A high value is placed on self-management education pro- grammes and team-based integrated care in patients with DM, CKD, and CVD.\nAtrial fibrillation\n•   Holistic management of patients with AF improves prognosis and reduces health-related costs. •   Comprehensive risk-factor modification and targeting underlying conditions reduce AF burden and recurrence.\nMultimorbidity\n•   The number of patients with multiple CV and non-CV comor- bidities is rapidly increasing. •   Therapeutic competition should be considered in multimorbid patients, as the treatment of one condition might worsen a coex- isting condition. •   A paradigm shift from disease-focused to patient-centred care for multimorbid CVD patients is recommended.\n",
      "keywords": [
        "obesity",
        "alcohol",
        "cvd risk",
        "lipid",
        "hypertension",
        "atherosclerosis",
        "sedentary",
        "risk stratification",
        "diabetes",
        "coronary artery",
        "sex",
        "score2-op",
        "indication",
        "secondary prevention",
        "statin",
        "ascvd",
        "atrial fibrillation",
        "smoking",
        "recommended",
        "risk factor",
        "diet",
        "diabetic",
        "pcsk9",
        "messages",
        "heart failure",
        "sudden cardiac death",
        "anticoagulation",
        "physical activity",
        "level b",
        "score2"
      ],
      "tables": []
    },
    {
      "number": "23",
      "title": "8. Gaps in evidence",
      "start_page": 75,
      "end_page": 83,
      "content": "CVD risk classification\n•   Country-specific risk algorithms for patients with established CVD and people with DM. •   Formal comparison of effectiveness and cost-effectiveness of CVD risk-guided treatment vs. treatment guided by risk factor level. •   Comparison of the precision of competing risk-adjusted CVD risk models vs. standard CVD risk models. •   Incorporating potential risk markers into conventional risk mod- els, such as socioeconomic status and ethnicity. •   Comparison of treatment benefit-guided strategy vs. risk-guided strategy in reducing risk factor levels and CVD risk.\n3302 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ •   Management of CVD risk in older people (>85 years) with marked fragility, for whom no data currently exist. •   Comparison of different methods for the estimation of lifetime CVD risk and lifetime benefit of risk factor treatment.\nRisk modifiers Psychosocial factors\n•   More evidence that psychosocial factors improve risk prediction beyond the classical risk-factor models.\nEthnicity\n•   Whether recalibration of factors for ethnicity are homogeneous in various European countries. •   Risks associated with other ethnic backgrounds.\nFrailty\n•   Consensus on a clinically orientated screening tool for frailty to be applied across the spectrum of ASCVD. •   Quantitative contribution of frailty to the global CVD risk- prediction scheme. •   At which degree of frailty treatment of specific risk factors should be less aggressive.\nFamily history\n•   Disentangle the role and (genetic, socioeconomic, etc.) mecha- nisms of family history on CVD risk.\nGenetics\n•   The potential of polygenic risk scores to complement existing risk scores.\nSocioeconomic determinants\n•   More evidence from different risk regions that the inclusion of socioeconomic factors improves risk prediction beyond classical risk factor models in both men and women.\nEnvironmental exposure\n•   Whether air pollution reclassifies risk in individual patients.\nBiomarkers\n•   Added value of biomarkers in risk classification.\nClinical conditions Chronic kidney disease\n•   Identification of a good biomarker, besides albuminuria, and per- haps the use of CAC score to subclassify CV risk in CKD. •   Early and precise identification of progressive CKD with novel biomarkers that are more sensitive than eGFR and albuminuria.\nAtrial fibrillation\n•   Evaluate the effect of interventions aimed at reducing outcomes beyond stroke. •   Is AF a causal factor for increased CVD morbidity and mortality? •   Stroke risk prediction for low-risk AF patients.\n•   Emerging evidence suggests that stroke can occur in patients with AF even after sinus rhythm is restored.\nHeart failure\n•   It remains unknown whether patients with HFrEF of ischaemic origin should have different target LDL-C levels than those rec- ommended for secondary prevention in individuals without HF.\nCancer\n•   RCTs using preventive therapy to demonstrate a clear effect on prevention of CV events.\nChronic obstructive pulmonary disease\n•   Although common pathophysiological pathways between CVD and COPD are probable, they remain to be clarified.\nInflammatory conditions\n•   The optimal way of integrating information on chronic inflamma- tory conditions into CVD risk assessment. •   The effect of modern anti-inflammatory drugs on CV risk [e.g. anti-tumour necrosis factor (TNF), interleukin (IL)-1, IL-17, IL-23 biologics].\nInfections\n•   Large-scale studies to assess the efficacy of influenza vaccination or periodontitis treatment in preventing CVD. •   The association of infection with HIV and total CVD risk.\nMigraine\n•   There are no data that allow reliable identification of subgroups of migraineurs at particular high risk (e.g. active migraine, high- frequency auras, young subjects, women). •   The role of comorbid factors (e.g. patent foramen ovale, throm- bophilic factors) is unclear, and at the moment there is no indica- tion to screen or to manage for these factors.\nSleep disorders\n•   There is lack of evidence that the inclusion of sleep improves risk prediction. •   Trials are needed that target the complex pathways linking sleep disturbances with CVD.\nMental disorders\n•   The precise mechanism by which mental disorders increase CVD remains uncertain. •   How the consideration of mental disorders improves CV risk models.\nNon-alcoholic fatty liver disease\n•   Whether NAFLD increases CV risk beyond traditional risk factors.\nSex-specific conditions\n•   The degree to which increased CVD risk associated with several of the female-specific conditions occurs independently of\nESC Guidelines 3303\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ conventional CVD risk factors, although data in women are still underpowered compared to men. •   Information on whether female-specific conditions improve risk classification. •   There are insufficient data to draw conclusions on a possible increased risk of hypertension or DM with premature menopause. •   Studies on the specificities of CVD disease in the transgender population are scarce.\nErectile dysfunction\n•   The benefit of routine screening for ED and the most effective tool to assess it are still unclear. •   The benefit of assessment of subclinical vascular disease in men with ED and low-to-intermediate CVD risk is unclear.\nRisk factors and interventions at the individual level Physical activity and exercise\n•   Knowledge of the relative importance of the various characteris- tics of aerobic PA and resistance exercise, or their combination, on all-cause mortality, CV incidence, and mortality. •   Understanding how sex, age, weight, race/ethnicity, occupation, and socioeconomic status may modify associations between PA and health outcomes. •   Implementation of strategies to achieve long-term adherence to PA. •   Evaluation of the effects of eHealth tools in promoting PA.\nNutrition\n•   Effective strategies to encourage people to change their diet and to enjoy and maintain a healthy diet.\nBody weight\n•   Knowledge and implementation of effective lifestyle and medication-assisted strategies to achieve weight loss and main- tain a long-term healthy weight.\nMental healthcare and psychosocial interventions\n•   The effectiveness of mental healthcare for the prevention of major CVD events. •   How to implement effective CVD prevention measures in this high-risk population of patients with mental disorders.\nSmoking intervention\n•   A better understanding of how to incorporate effective smoking cessation into clinical practice.\nLipids\n•   Direct empirical evidence for the stepwise approach to treat- ment intensification from RCTs. The feasibility and effects of reaching LDL-C levels <1.4 mmol/L (55 mg/dL) needs further investigation, especially in primary care. •   Particularly among people at low-to-moderate CVD risk, older people, and for newer interventions, more evidence of the effects of lipid-modifying treatments on overall mortality is needed in the form of long-term post-trial follow-up in RCTs.\n•   The cost-effectiveness of using lifetime CVD risk and more pre- cise CVD risk scores to target interventions needs further investigation. •   The value of triglycerides or HDL-C values as a target for therapy. •   Whether lipoprotein(a) lowering against background statin, eze- timibe and PCSK9i therapy can reduce the risk of ASCVD. •   Whether functional foods and food supplements with a lipid- lowering effect can safely reduce the risk of CVD.\nBlood pressure\n•   What is the incremental benefit, over CVD risk calculators, of measures of HMOD in reclassifying the CV risk of patients with hypertension? •   Direct empirical evidence for the stepwise approach to treat- ment intensification from RCTs. •   What are the benefits of BP treatment for patients with BP in the high-normal range? •   More data on the benefits of BP treatment in very old people and the influence of frailty. •   Effect of single-pill vs. multidrug treatment strategies on adher- ence to treatment, BP control, and clinical outcomes. •   Effectiveness of antihypertensive treatment in preventing cogni- tive dysfunction or dementia. •   Efficacy and cost-effectiveness of invasive procedures and devi- ces for the treatment of hypertension. •   Sex-specific BP treatment thresholds for men and women.\nDiabetes mellitus\n•   More work is needed to develop risk scores for both MACE and HF in type 2 DM. •   Whether combined SGLT2 inhibitor and GLP-1RA treatments lower MACE or other outcomes beyond either drug alone requires testing. •   Longer-term safety of newer classes of drug is required.\nAntithrombotic therapy\n•   The role of antithrombotic therapy in primary prevention in (very) high-risk individuals remains to be established.\nCardiac rehabilitation and prevention programmes\n•   The effect and the optimal delivery of EBCR in women, older/ frail patients, patients with cardiac implantable electronic devi- ces, after heart transplantation or valve replacement, and in patients with AF, stroke, HFpEF, LEAD, or multiple comorbidities. •   Alternative and cost-effective models of CR need to ensure par- ticipation globally, including low- and middle-income countries. •   Large RCTs investigating the long-term effects of home-based telerehabilitation and mHealth are needed.\nEnvironment, air pollution, and climate change\n•   Individual-level exposure studies are needed to better specify the effect of mitigating measures.\nRisk management of disease-specific cardiovascular disease Coronary artery disease\n3304 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. .......................................................................... •   The efficacy and safety of aspirin or other antithrombotic ther- apy in patients without clinical manifestations of CAD—but with atherosclerotic disease identified on imaging, such as CCTA— requires further assessment. •   The optimal long-term antithrombotic therapy in patients at high risk of ischaemic events is uncertain. •   Clinical studies comparing the efficacy and safety of P2Y 12   inhibi- tors vs. low-dose rivaroxaban or other factor Xa inhibitors, in combination with aspirin, are warranted to determine which subgroups will derive greater clinical benefit with each strategy.\nHeart failure\n•   For patients with HFpEF, no specific pharmacotherapy or device implantation has been shown to modify the risk of any CV outcome. •   Lower dosage of HF treatments in women with HFrEF needs to be addressed, since women were underrepresented in many HF trials.\nCerebrovascular disease\n•   The optimal selection of patient for a short course of DAPT. •   The optimal antihypertensive regimen and target BP. •   The optimal target level of LDL-C. •   Optimal treatment for patients with silent cerebrovascular disease.\nLower extremity artery disease\n•   The optimal type and potency of antithrombotic therapy in patients with different manifestations of symptomatic or asymp- tomatic LEAD are partly unclear.\nChronic kidney disease\n•   Few CVD trials have a focus on patients with CKD, particularly those with advanced CKD. •   Additional prospective studies focusing on diagnosis, prevention, and treatment of CAD and CVD are needed in CKD.\nAtrial fibrillation\n•   The effects of various CV risk factors and comorbidities in AF. •   Optimal treatment of OSA and its effect on AF progression and symptoms.\nMultimorbidity\n•   The effect of different clusters or combinations of CV and non- CV comorbidities on CV outcomes. •   Optimal, pragmatic treatment strategies in patients with CV and non-CV comorbidities, with particular focus on treatment adherence and therapeutic competition.\n9. ‘What to do’ and ‘what not to do’ messages from the guidelines\nRecommendations Class a Level b\nRecommendations for cardiovascular disease risk assessment\nSystematic global CVD risk assessment is recommended in individuals with any major vascular risk factor (i.e. family history of\npremature CVD, FH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or comorbidities increasing CVD risk).\nI C\nSystematic CVD risk assessment in men <40 years of age and women <50 years of age with no known CV risk factors is not\nrecommended. III C\nRecommendations for cardiovascular disease risk estimation\nIn apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estima-\ntion of 10-year fatal and non-fatal CVD risk with SCORE2 is recommended. I B\nIn apparently healthy people >_70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estima-\ntion of 10-year fatal and nonfatal CVD risk with SCORE2-OP is recommended. I B\nPatients with established CVD and/or DM and/or moderate-to-severe renal disease and/or genetic/rarer lipid or BP disorders are\nto be considered at high or very high CVD risk. I A\nA stepwise treatment-intensiﬁcation approach aiming at intensive risk factor treatment is recommended for apparently healthy\npeople at high or very high CVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk, treatment beneﬁt of risk factors, risk modiﬁers, comorbidities, and patient preferences.\nI B\nTreatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid or BP dis-\norders who are at very high risk (SCORE2 >_7.5% for age under 50; SCORE2 >_10% for age 50 \u0002 69; SCORE2-OP >_15% for age >_70 years).\nI C\nRecommendation for cardiovascular disease risk communication\nAn informed discussion about CVD risk and treatment beneﬁts tailored to the needs of a patient is recommended. I C\nRecommendations for risk modiﬁers\nThe routine collection of other potential modiﬁers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended. III B\nContinued\nESC Guidelines 3305\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nRecommendations for cardiovascular disease risk assessment in speciﬁc clinical conditions\nIn all CKD patients, with or without DM, appropriate screening for ASCVD and kidney disease progression, including monitoring\nchanges in albuminuria is recommended. I C\nIt is recommended to monitor cardiac dysfunction using imaging techniques and circulating biomarkers before, periodically during, and after cancer treatment. I B\nScreening for CV risk factors and optimization of the CV risk proﬁle is recommended in patients on treatment for cancer. I C\nIt is recommended that all COPD patients be investigated for ASCVD and ASCVD risk factors. I C\nIn patients with CVD, obesity, and hypertension, regular screening for non-restorative sleep is indicated (e.g. by the question:\n‘how often have you been bothered by trouble falling or staying asleep, or sleeping too much?’). I C\nIf there are signiﬁcant sleep problems, which are not responding within 4 weeks to sleep hygiene, referral to a specialist is\nrecommended. I C\nIt is recommended that mental disorders with either signiﬁcant functional impairment or decreased use of healthcare systems be\nconsidered as inﬂuencing total CVD risk. I C\nIt is recommended for adults of all ages to strive for at least 150 \u0002 300 min a week of moderate-intensity or 75 \u0002 150 min a week\nof vigorous-intensity aerobic PA, or an equivalent combination thereof, to reduce all-cause mortality, CV mortality, and\nmorbidity.\nI A\nIt is recommended that adults who cannot perform 150 min of moderate-intensity PA a week should stay as active as their abil- ities and health condition allow. I B\nIt is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV\nmortality and morbidity. I B\nPerforming resistance exercise, in addition to aerobic activity, is recommended on 2 or more days per week to reduce all-cause mortality. I B\nRecommendations for nutrition and alcohol\nA healthy diet is recommended as a cornerstone of CVD prevention in all individuals. I A\nIt is recommended to adopt a Mediterranean or similar diet to lower risk of CVD. I A\nIt is recommended to replace saturated with unsaturated fats to lower the risk of CVD. I A\nIt is recommended to reduce salt intake to lower BP and risk of CVD. I A\nIt is recommended to choose a more plant-based food pattern, rich in ﬁbre, that includes whole grains, fruits, vegetables, pulses,\nand nuts. I B\nIt is recommended to restrict alcohol consumption to a maximum of 100 g per week. I B\nIt is recommended to eat ﬁsh, preferably fatty, at least once a week and restrict (processed) meat. I B\nIt is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy\nintake. I B\nRecommendations for body weight\nIt is recommended that overweight and obese people aim for a reduction in weight to reduce BP, dyslipidaemia, and risk of type 2 DM, and thus improve their CVD risk proﬁle. I A\nWhile a range of diets are effective for weight loss, it is recommended that a healthy diet in regard to CVD risk is maintained\nover time. I A\nRecommendations for mental healthcare and psychosocial interventions at the individual level\nPatients with mental disorders need intensiﬁed attention and support to improve adherence to lifestyle changes and drug treatment. I C\nIn ASCVD patients with mental disorders, evidence-based mental healthcare and interdisciplinary cooperation are\nrecommended. I B\nIn patients with HF and major depression, SSRIs, SNRIs, and tricyclic antidepressants are not recommended. III B\nRecommendations for smoking intervention strategies\nAll smoking of tobacco should be stopped, as tobacco use is strongly and independently causal of ASCVD. I A\nSmoking cessation is recommended regardless of weight gain, as weight gain does not lessen the ASCVD beneﬁts of cessation. I B\nRecommendations on low-density lipoprotein cholesterol goals\nA stepwise treatment-intensiﬁcation approach is recommended for apparently healthy people at high or very high CVD risk, as well as patients with established ASCVD and/or DM with consideration of CVD risk, treatment beneﬁt, risk modiﬁers, comorbid-\nities, and patient preferences.\nI C\nContinued\n3306 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nRecommendations for pharmacological low-density lipoprotein cholesterol lowering for those  < 70 years of age\nIt is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the LDL-C goals set for the\nspeciﬁc risk group. I A\nIn patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a >_50% reduction in LDL-C vs. baseline is recommended. I A\nIf the goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended. I B\nFor secondary prevention patients not achieving their goals on a maximum tolerated dose of a statin and ezetimibe, combination\ntherapy including a PCSK9 inhibitor is recommended. I A\nFor very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goals on a maxi- mum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended. I C\nStatin therapy is not recommended in premenopausal female patients who are considering pregnancy or are not using adequate\ncontraception. III C\nRecommendation for drug treatments of patients with hypertriglyceridaemia\nStatin treatment is recommended as the ﬁrst drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridae-\nmia [triglycerides >2.3 mmol/L (200 mg/dL)]. I A\nRecommendations for the treatment of dyslipidaemias in older people ( \u0003 70 years)\nTreatment with statins is recommended for older people with ASCVD in the same way as for younger patients. I A\nIt is recommended that the statin is started at a low dose if there is signiﬁcant renal impairment and/or the potential for drug interactions. I C\nRecommendation for the treatment of dyslipidaemias in diabetes mellitus\nIn patients with type 2 DM at very high risk (e.g. with established ASCVD and/or severe TOD) intensive lipid-lowering therapy,\nultimately aiming at >_50% LDL-C reduction  and  an LDL-C of <1.4 mmol/L (55 mg/dL) is recommended. I A\nIn patients with type 2 DM >40 years at high risk, lipid-lowering treatment with an ultimate LDL-C goal of >_50% LDL-C reduction\nand an LDL-C of <1.8 mmol/L (70 mg/dL) is recommended. I A\nRecommendations for lipid management in patients with moderate-to-severe chronic kidney disease (Kidney Disease Outcomes\nQuality Initiative stages 3 \u0002 5)\nThe use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent, stage 3 \u0002 5 CKD. I A\nIn patients with dialysis-dependent CKD who are free of ASCVD, commencing statin therapy is not recommended. III A\nRecommendations for the clinical management of hypertension\nClassiﬁcation of BP\nIt is recommended that BP should be classiﬁed as optimal, normal, high-normal, or grades 1 \u0002 3 hypertension, according to ofﬁce BP. I C\nDiagnosis of hypertension\nIt is recommended to base the diagnosis of hypertension on: •   Repeated ofﬁce BP measurements, on more than one visit, except when hypertension is severe (e.g. grade 3 and especially in high-risk patients) or\nI C\n•   Out-of-ofﬁce BP measurement with ABPM and/or HBPM when feasible. I C\nAssessment of HMOD\nTo evaluate for the presence of HMOD, measurement of serum creatinine, eGFR, electrolytes, and ACR is recommended for all\npatients. A 12-lead ECG is recommended for all patients, and echocardiography is recommended for those with ECG abnormal- ities or signs/symptoms of LV dysfunction. Fundoscopy or retinal imaging is recommended for patients with grades 2 or 3 hyper-\ntension and all hypertensive patients with DM.\nI B\nThresholds for initiation of drug treatment of hypertension\nFor grade 1 hypertension, treatment initiation based on absolute CVD risk, estimated lifetime beneﬁt, and the presence of HMOD is recommended. I C\nFor patients with grade 2 hypertension or higher, drug treatment is recommended. I A\nOfﬁce BP treatment targets\nIt is recommended that the ﬁrst objective of treatment is to lower BP to <140/90 mmHg in all patients, and that subsequent BP targets are tailored to age and speciﬁc comorbidities. I A\nContinued\nESC Guidelines 3307\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nIn treated patients aged 18 \u0002 69 years, it is recommended that SBP should ultimately be lowered to a target range of 120 \u0002 130\nmmHg in most patients. I A\nIn treated patients aged >_70 years, it is recommended that SBP should generally be targeted to <140 and down to 130 mmHg if\ntolerated. I A\nIn all treated patients, DBP is recommended to be lowered to <80 mmHg. I A\nTreatment of hypertension: lifestyle interventions\nLifestyle interventions are recommended for people with high-normal BP or higher. I A\nTreatment of hypertension: drug treatment\nIt is recommended to initiate antihypertensive treatment with a two-drug combination in most patients, preferably as a single-pill combination. Exceptions are frail older patients and those with low-risk, grade 1 hypertension (particularly if SBP <150 mmHg). I B\nIt is recommended that the preferred combinations include a RAS blocker (i.e. an ACE inhibitor or ARB) with a CCB or diuretic,\nbut other combinations of the ﬁve major classes can be used (ACE inhibitor, ARB, beta-blocker, CCB, thiazide/thiazide-like\ndiuretic).\nI A\nIt is recommended, if BP remains uncontrolled with a two-drug combination, that treatment be increased to a three-drug combi-\nnation, usually a RAS blocker with a CCB and a diuretic, preferably as a single-pill combination. I A\nIt is recommended, if BP is not controlled by a three-drug combination, that treatment should be increased by the addition of spi-\nronolactone, or if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, an alpha-blocker or beta- blocker, or clonidine.\nI B\nThe combination of two RAS blockers is not recommended. III A\nRecommendations for the treatment of patients with diabetes mellitus\nLifestyle\nLifestyle changes including smoking cessation, a low saturated fat, high-ﬁbre diet, aerobic PA, and strength training are recommended. I A\nReduction in energy intake is recommended to patients, to help achieve lower body weight or prevent or slow weight gain. I A\nGlycaemia target\nA target HbA1c for the reduction of CVD risk and microvascular complications of DM of <7.0% (53 mmol/mol) is recommended for the majority of adults with either type 1 or type 2 DM. I A\nTreatment of hyperglycaemia and ASCVD/cardiorenal risks\nMetformin is recommended as ﬁrst-line therapy, following evaluation of renal function, in the majority of patients without pre-\nvious ASCVD, CKD, or HF. I B\nIn persons with type 2 DM and ASCVD, the use of a GLP-1RA or SGLT2 inhibitor with proven outcome beneﬁts is recom- mended to reduce CV and/or cardiorenal outcomes. I A\nIn patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve CVD and/or cardiorenal\noutcomes. I A\nIn patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor with proven outcome beneﬁts is recommended to lessen HF hospitalizations and CV death. I A\nRecommendations for antithrombotic therapy\nAspirin 75 \u0002 100 mg daily is recommended for secondary prevention of CVD. I A\nClopidogrel 75 mg daily is recommended as an alternative to aspirin in secondary prevention in case of aspirin intolerance. I B\nConcomitant use of a proton pump inhibitor is recommended in patients receiving antiplatelet therapy who are at high risk of gas- trointestinal bleeding. I B\nAntiplatelet therapy is not recommended in individuals with low/moderate CV risk due to the increased risk of major bleeding. III A\nRecommendations for cardiac rehabilitation\nParticipation in a medically supervised, structured, comprehensive, multidisciplinary EBCR and prevention programme for patients after ASCVD events and/ or revascularization, and for patients with HF (mainly HFrEF), is recommended to improve patient\noutcomes.\nI A\nRecommendation for policy interventions at the population level\nPutting in place measures to reduce air pollution, including reducing PM emission and gaseous pollutants, reducing the use of fossil fuels, and limiting carbon dioxide emissions, are recommended, to reduce CVD mortality and morbidity. I C\nContinued\n3308 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\nRecommendations for patients with coronary artery disease\nAspirin 75 \u0002 100 mg daily is recommended for patients with a previous myocardial infarction or revascularization. I A\nIn ACS, DAPT with a P2Y 12  inhibitor in addition to aspirin is recommended for 12 months, unless there are contraindications\nsuch as excessive risk of bleeding. I A\nIn patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6 months following coronary stenting, irrespective of stent type, unless a shorter duration (1 \u0002 3 months) is indicated due to risk or the occurrence of life-threatening\nbleeding.\nI A\nACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM). I A\nBeta-blockers are recommended in patients with LV dysfunction or systolic HF. I A\nIn patients with established ASCVD, oral lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a\n>_50% reduction in LDL-C vs. baseline is recommended. I A\nRecommendations regarding pharmacological and nonpharmacological interventions for patients with symptomatic (New York Heart\nAssociation class II-IV) heart failure with reduced ejection fraction (left ventricular ejection fraction  < 40 % ) with proven beneﬁts on clin- ical outcomes, including cardiovascular morbidity and mortality\nIt is recommended that patients with HF are enrolled in a comprehensive CR programme to reduce the risk of HF hospitalization\nand death. I A\nEBCR is recommended in stable symptomatic patients with HFrEF to reduce the risk of HF hospitalization. I A\nIt is recommended to screen patients with HF for both CV and non-CV comorbidities, which, if present, should be treated, pro-\nvided safe and effective interventions exist, not only to alleviate symptoms but also to improve prognosis. I A\nAn ACE inhibitor is recommended, in addition to a beta-blocker and an MRA, for patients with symptomatic HFrEF to reduce the\nrisk of HF hospitalization and death. I A\nA beta-blocker is recommended, in addition to an ACE inhibitor (or an ARNI) and an MRA, for patients with stable, symptomatic\nHFrEF to reduce the risk of HF hospitalization and death. I A\nAn MRA is recommended for patients with HFrEF already treated with an ACE inhibitor (or an ARNI) and a beta-blocker, to\nreduce the risk of HF hospitalization and death. I A\nSacubitril/valsartan is recommended as a replacement for an ACE inhibitor to reduce the risk of HF hospitalization and death in\npatients with HFrEF. I B\nAn ARB is recommended to reduce the risk of HF hospitalization or CV death in symptomatic patients with HFrEF who are\nunable to tolerate an ACE inhibitor and/or ARNI (patients should also receive a beta-blocker and an MRA). I B\nDapagliﬂozin or empagliﬂozin are recommended, in addition to optimal treatment of an ACE inhibitor (or ARNI), a beta-blocker,\nand an MRA, for patients with HFrEF to reduce the risk of HF hospitalization and death. I A\nDiuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to reduce the risk of HF\nhospitalization. I C\nRecommendations for patients with cerebrovascular disease\nIn patients with a cerebrovascular event, improvement of lifestyle factors in addition to appropriate pharmacological management\nis recommended. I A\nIn patients with ischaemic stroke or TIA, prevention with antithrombotics is recommended; choice of antithrombotic depends on the mechanism of event. Use of an antiplatelet is recommended for patients with non-cardioembolic ischaemic stroke or TIA,\nand use of an anticoagulant is recommended in patients with cardioembolic ischaemic stroke or TIA.\nI A\nIn patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin, or clopi-\ndogrel alone is recommended. I A\nIn patients with stroke or TIA who have BP of 140/90 mmHg or higher, BP lowering is recommended. I A\nRecommendations for patients with lower extremity artery disease: best medical therapy\nSmoking cessation is recommended in all patients with LEAD. I B\nHealthy diet and PA are recommended for all patients with LEAD. I C\nIn patients with intermittent claudication: •   Supervised exercise training is recommended I A\n•   Non-supervised exercise training is recommended when supervised exercise training is not feasible or available. I C\nAntiplatelet therapy is recommended in patients with symptomatic LEAD. I C\nIn patients with LEAD and hypertension, it is recommended to control BP at <140/90 mmHg. I A\nIn patients with LEAD and DM, strict glycaemic control is recommended. I A\nContinued\nESC Guidelines 3309\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ................................................................................................ 10. Quality indicators\nQuality indicators (QIs) are tools that may be used to evaluate care quality, including that of processes of care and clinical outcomes. 730\nThey may also serve as a mechanism for enhancing adherence to guideline recommendations, through quality assurance endeavours and benchmarking of care providers. 831   As such, the role of QIs in driving quality improvement is increasingly recognized and attracts interest from healthcare authorities, professional organizations, payers, and the public. 832\nThe ESC recognizes the need for measuring and reporting the quality and outcomes of CV care. One aspect of this is the develop- ment and implementation of QIs for CVD. The methodology by which the ESC QIs are developed has been published 832   and, to date, a suite of QIs for an initial tranche of CV conditions has been pro- duced. 833 , 834   To facilitate quality improvement initiatives, the disease- specific ESC QIs are included in corresponding ESC Clinical Practice Guidelines. 215 , 680   This is further enhanced by way of their integration into the EORP (EURObservational Research Programme) and the EuroHeart (European Unified Registries On Heart Care Evaluation and Randomized Trials) project. 835\nFor CVD prevention, QIs are available for specific conditions, such as the management of high BP 836   and secondary lipid prevention. 837\nHowever, a comprehensive set of QIs that encompasses the depth and breadth of CVD prevention is lacking. Such a set may evaluate the adoption of, and adherence to, the guideline recommendations provided in this document, and may be applied retrospectively to assess the delivery of evidence-based care. Thus, and in line with other ESC Clinical Practice Guidelines, the process of developing and defining QIs for CVD prevention has been initiated during the writing of this guideline and the results will be published in a separate document.\n",
      "keywords": [
        "obesity",
        "alcohol",
        "cvd risk",
        "lipid",
        "hypertension",
        "genetic",
        "sedentary",
        "diabetes",
        "hfpef",
        "coronary artery",
        "biomarker",
        "arb",
        "score2-op",
        "sex",
        "female",
        "evidence",
        "secondary prevention",
        "statin",
        "ascvd",
        "sbp",
        "atrial fibrillation",
        "smoking",
        "risk factor",
        "recommended",
        "echocardiography",
        "ejection fraction",
        "diet",
        "pcsk9",
        "heart failure",
        "cac score"
      ],
      "tables": [
        {
          "title": "ESC Guidelines 3305",
          "page_number": 78,
          "content": " |  |  | \nRecommendations | Classa | Levelb | \n |  |  | \nRecommendations for cardiovascular disease risk assessment |  |  | \nSystematic global CVD risk assessment is recommended in individuals with any major vascular risk factor (i.e. family history of\npremature CVD, FH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or comorbidities\nincreasing CVD risk). | I | C | \nSystematic CVD risk assessment in men <40 years of age and women <50 years of age with no known CV risk factors is not\nrecommended. | III | C | \nRecommendations for cardiovascular disease risk estimation |  |  | \nIn apparently healthy people <70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorders, estima-\ntion of 10-year fatal and non-fatal CVD risk with SCORE2 is recommended. | I | B | \nIn apparently healthy people >70 years of age without established ASCVD, DM, CKD, genetic/rarer lipid or BP disorder, estima-\n_\ntion of 10-year fatal and nonfatal CVD risk with SCORE2-OP is recommended. | I | B | \nPatients with established CVD and/or DM and/or moderate-to-severe renal disease and/or genetic/rarer lipid or BP disorders are\nto be considered at high or very high CVD risk. | I | A | \nA stepwise treatment-intensification approach aiming at intensive risk factor treatment is recommended for apparently healthy\npeople at high or very high CVD risk, as well as patients with established ASCVD and/or DM, with consideration of CVD risk,\ntreatment benefit of risk factors, risk modifiers, comorbidities, and patient preferences. | I | B | \nTreatment of ASCVD risk factors is recommended in apparently healthy people without DM, CKD, genetic/rarer lipid or BP dis-\norders who are at very high risk (SCORE2 >7.5% for age under 50; SCORE2 >10% for age 50\u000269; SCORE2-OP >15% for age\n_ _ _\n>70 years).\n_ | I | C | \nRecommendation for cardiovascular disease risk communication |  |  | \nAn informed discussion about CVD risk and treatment benefits tailored to the needs of a patient is recommended. | I | C | \nRecommendations for risk modifiers |  |  | \nThe routine collection of other potential modifiers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests\nor imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended. | III | B | ",
          "bbox": [
            48.93575091891819,
            428.7321482340495,
            558.3878217424665,
            755.2731519426618
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3306 ESC Guidelines",
          "page_number": 79,
          "content": "Recommendations for cardiovascular disease risk assessment in specific clinical conditions |  |  | \nIn all CKD patients, with or without DM, appropriate screening for ASCVD and kidney disease progression, including monitoring\nchanges in albuminuria is recommended. | I | C | \nIt is recommended to monitor cardiac dysfunction using imaging techniques and circulating biomarkers before, periodically during,\nand after cancer treatment. | I | B | \nScreening for CV risk factors and optimization of the CV risk profile is recommended in patients on treatment for cancer. | I | C | \nIt is recommended that all COPD patients be investigated for ASCVD and ASCVD risk factors. | I | C | \nIn patients with CVD, obesity, and hypertension, regular screening for non-restorative sleep is indicated (e.g. by the question:\n‘how often have you been bothered by trouble falling or staying asleep, or sleeping too much?’). | I | C | \nIf there are significant sleep problems, which are not responding within 4 weeks to sleep hygiene, referral to a specialist is\nrecommended. | I | C | \nIt is recommended that mental disorders with either significant functional impairment or decreased use of healthcare systems be\nconsidered as influencing total CVD risk. | I | C | \nIt is recommended for adults of all ages to strive for at least 150\u0002300 min a week of moderate-intensity or 75\u0002150 min a week\nof vigorous-intensity aerobic PA, or an equivalent combination thereof, to reduce all-cause mortality, CV mortality, and\nmorbidity. | I | A | \nIt is recommended that adults who cannot perform 150 min of moderate-intensity PA a week should stay as active as their abil-\nities and health condition allow. | I | B | \nIt is recommended to reduce sedentary time to engage in at least light activity throughout the day to reduce all-cause and CV\nmortality and morbidity. | I | B | \nPerforming resistance exercise, in addition to aerobic activity, is recommended on 2 or more days per week to reduce all-cause\nmortality. | I | B | \nRecommendations for nutrition and alcohol |  |  | \nA healthy diet is recommended as a cornerstone of CVD prevention in all individuals. | I | A | \nIt is recommended to adopt a Mediterranean or similar diet to lower risk of CVD. | I | A | \nIt is recommended to replace saturated with unsaturated fats to lower the risk of CVD. | I | A | \nIt is recommended to reduce salt intake to lower BP and risk of CVD. | I | A | \nIt is recommended to choose a more plant-based food pattern, rich in fibre, that includes whole grains, fruits, vegetables, pulses,\nand nuts. | I | B | \nIt is recommended to restrict alcohol consumption to a maximum of 100 g per week. | I | B | \nIt is recommended to eat fish, preferably fatty, at least once a week and restrict (processed) meat. | I | B | \nIt is recommended to restrict free sugar consumption, in particular sugar-sweetened beverages, to a maximum of 10% of energy\nintake. | I | B | \nRecommendations for body weight |  |  | \nIt is recommended that overweight and obese people aim for a reduction in weight to reduce BP, dyslipidaemia, and risk of type 2\nDM, and thus improve their CVD risk profile. | I | A | \nWhile a range of diets are effective for weight loss, it is recommended that a healthy diet in regard to CVD risk is maintained\nover time. | I | A | \nRecommendations for mental healthcare and psychosocial interventions at the individual level |  |  | \nPatients with mental disorders need intensified attention and support to improve adherence to lifestyle changes and drug\ntreatment. | I | C | \nIn ASCVD patients with mental disorders, evidence-based mental healthcare and interdisciplinary cooperation are\nrecommended. | I | B | \nIn patients with HF and major depression, SSRIs, SNRIs, and tricyclic antidepressants are not recommended. | III | B | \nRecommendations for smoking intervention strategies |  |  | \nAll smoking of tobacco should be stopped, as tobacco use is strongly and independently causal of ASCVD. | I | A | \nSmoking cessation is recommended regardless of weight gain, as weight gain does not lessen the ASCVD benefits of cessation. | I | B | \nRecommendations on low-density lipoprotein cholesterol goals |  |  | \nA stepwise treatment-intensification approach is recommended for apparently healthy people at high or very high CVD risk, as\nwell as patients with established ASCVD and/or DM with consideration of CVD risk, treatment benefit, risk modifiers, comorbid-\nities, and patient preferences. | I | C | ",
          "bbox": [
            44.342996749877926,
            60.33735148111979,
            553.8524525201143,
            711.8461499895368
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3307",
          "page_number": 80,
          "content": "Recommendations for pharmacological low-density lipoprotein cholesterol lowering for those <70 years of age |  |  | \nIt is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the LDL-C goals set for the\nspecific risk group. | I | A | \nIn patients with established ASCVD, lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a\n>50% reduction in LDL-C vs. baseline is recommended.\n_ | I | A | \nIf the goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended. | I | B | \nFor secondary prevention patients not achieving their goals on a maximum tolerated dose of a statin and ezetimibe, combination\ntherapy including a PCSK9 inhibitor is recommended. | I | A | \nFor very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goals on a maxi-\nmum tolerated dose of a statin and ezetimibe, combination therapy including a PCSK9 inhibitor is recommended. | I | C | \nStatin therapy is not recommended in premenopausal female patients who are considering pregnancy or are not using adequate\ncontraception. | III | C | \nRecommendation for drug treatments of patients with hypertriglyceridaemia |  |  | \nStatin treatment is recommended as the first drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridae-\nmia [triglycerides >2.3 mmol/L (200 mg/dL)]. | I | A | \nRecommendations for the treatment of dyslipidaemias in older people (\u000370 years) |  |  | \nTreatment with statins is recommended for older people with ASCVD in the same way as for younger patients. | I | A | \nIt is recommended that the statin is started at a low dose if there is significant renal impairment and/or the potential for drug\ninteractions. | I | C | \nRecommendation for the treatment of dyslipidaemias in diabetes mellitus |  |  | \nIn patients with type 2 DM at very high risk (e.g. with established ASCVD and/or severe TOD) intensive lipid-lowering therapy,\nultimately aiming at >50% LDL-C reduction and an LDL-C of <1.4 mmol/L (55 mg/dL) is recommended.\n_ | I | A | \nIn patients with type 2 DM >40 years at high risk, lipid-lowering treatment with an ultimate LDL-C goal of >50% LDL-C reduction\n_\nand an LDL-C of <1.8 mmol/L (70 mg/dL) is recommended. | I | A | \nRecommendations for lipid management in patients with moderate-to-severe chronic kidney disease (Kidney Disease Outcomes\nQuality Initiative stages 3\u00025) |  |  | \nThe use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent, stage 3\u00025 CKD. | I | A | \nIn patients with dialysis-dependent CKD who are free of ASCVD, commencing statin therapy is not recommended. | III | A | \nRecommendations for the clinical management of hypertension |  |  | \nClassification of BP |  |  | \nIt is recommended that BP should be classified as optimal, normal, high-normal, or grades 1\u00023 hypertension, according to office\nBP. | I | C | \nDiagnosis of hypertension |  |  | \nIt is recommended to base the diagnosis of hypertension on:\n• Repeated office BP measurements, on more than one visit, except when hypertension is severe (e.g. grade 3 and especially in\nhigh-risk patients) or | I | C | \n• Out-of-office BP measurement with ABPM and/or HBPM when feasible. | I | C | \nAssessment of HMOD |  |  | \nTo evaluate for the presence of HMOD, measurement of serum creatinine, eGFR, electrolytes, and ACR is recommended for all\npatients. A 12-lead ECG is recommended for all patients, and echocardiography is recommended for those with ECG abnormal-\nities or signs/symptoms of LV dysfunction. Fundoscopy or retinal imaging is recommended for patients with grades 2 or 3 hyper-\ntension and all hypertensive patients with DM. | I | B | \nThresholds for initiation of drug treatment of hypertension |  |  | \nFor grade 1 hypertension, treatment initiation based on absolute CVD risk, estimated lifetime benefit, and the presence of\nHMOD is recommended. | I | C | \nFor patients with grade 2 hypertension or higher, drug treatment is recommended. | I | A | \nOffice BP treatment targets |  |  | \nIt is recommended that the first objective of treatment is to lower BP to <140/90 mmHg in all patients, and that subsequent BP\ntargets are tailored to age and specific comorbidities. | I | A | ",
          "bbox": [
            48.87792644094914,
            60.33735148111979,
            558.3877912248884,
            685.4271981375558
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3308 ESC Guidelines",
          "page_number": 81,
          "content": "In treated patients aged 18\u000269 years, it is recommended that SBP should ultimately be lowered to a target range of 120\u0002130\nmmHg in most patients. | I | A | \nIn treated patients aged >70 years, it is recommended that SBP should generally be targeted to <140 and down to 130 mmHg if\n_\ntolerated. | I | A | \nIn all treated patients, DBP is recommended to be lowered to <80 mmHg. | I | A | \nTreatment of hypertension: lifestyle interventions |  |  | \nLifestyle interventions are recommended for people with high-normal BP or higher. | I | A | \nTreatment of hypertension: drug treatment |  |  | \nIt is recommended to initiate antihypertensive treatment with a two-drug combination in most patients, preferably as a single-pill\ncombination. Exceptions are frail older patients and those with low-risk, grade 1 hypertension (particularly if SBP <150 mmHg). | I | B | \nIt is recommended that the preferred combinations include a RAS blocker (i.e. an ACE inhibitor or ARB) with a CCB or diuretic,\nbut other combinations of the five major classes can be used (ACE inhibitor, ARB, beta-blocker, CCB, thiazide/thiazide-like\ndiuretic). | I | A | \nIt is recommended, if BP remains uncontrolled with a two-drug combination, that treatment be increased to a three-drug combi-\nnation, usually a RAS blocker with a CCB and a diuretic, preferably as a single-pill combination. | I | A | \nIt is recommended, if BP is not controlled by a three-drug combination, that treatment should be increased by the addition of spi-\nronolactone, or if not tolerated, other diuretics such as amiloride or higher doses of other diuretics, an alpha-blocker or beta-\nblocker, or clonidine. | I | B | \nThe combination of two RAS blockers is not recommended. | III | A | \nRecommendations for the treatment of patients with diabetes mellitus |  |  | \nLifestyle |  |  | \nLifestyle changes including smoking cessation, a low saturated fat, high-fibre diet, aerobic PA, and strength training are\nrecommended. | I | A | \nReduction in energy intake is recommended to patients, to help achieve lower body weight or prevent or slow weight gain. | I | A | \nGlycaemia target |  |  | \nA target HbA1c for the reduction of CVD risk and microvascular complications of DM of <7.0% (53 mmol/mol) is recommended\nfor the majority of adults with either type 1 or type 2 DM. | I | A | \nTreatment of hyperglycaemia and ASCVD/cardiorenal risks |  |  | \nMetformin is recommended as first-line therapy, following evaluation of renal function, in the majority of patients without pre-\nvious ASCVD, CKD, or HF. | I | B | \nIn persons with type 2 DM and ASCVD, the use of a GLP-1RA or SGLT2 inhibitor with proven outcome benefits is recom-\nmended to reduce CV and/or cardiorenal outcomes. | I | A | \nIn patients with type 2 DM and CKD, the use of an SGLT2 inhibitor is recommended to improve CVD and/or cardiorenal\noutcomes. | I | A | \nIn patients with type 2 DM and HFrEF, use of an SGLT2 inhibitor with proven outcome benefits is recommended to lessen HF\nhospitalizations and CV death. | I | A | \nRecommendations for antithrombotic therapy |  |  | \nAspirin 75\u0002100 mg daily is recommended for secondary prevention of CVD. | I | A | \nClopidogrel 75 mg daily is recommended as an alternative to aspirin in secondary prevention in case of aspirin intolerance. | I | B | \nConcomitant use of a proton pump inhibitor is recommended in patients receiving antiplatelet therapy who are at high risk of gas-\ntrointestinal bleeding. | I | B | \nAntiplatelet therapy is not recommended in individuals with low/moderate CV risk due to the increased risk of major bleeding. | III | A | \nRecommendations for cardiac rehabilitation |  |  | \nParticipation in a medically supervised, structured, comprehensive, multidisciplinary EBCR and prevention programme for patients\nafter ASCVD events and/ or revascularization, and for patients with HF (mainly HFrEF), is recommended to improve patient\noutcomes. | I | A | \nRecommendation for policy interventions at the population level |  |  | \nPutting in place measures to reduce air pollution, including reducing PM emission and gaseous pollutants, reducing the use of fossil\nfuels, and limiting carbon dioxide emissions, are recommended, to reduce CVD mortality and morbidity. | I | C | ",
          "bbox": [
            44.342930408234295,
            60.35215105329241,
            553.8524528382317,
            685.4271981375558
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "ESC Guidelines 3309",
          "page_number": 82,
          "content": "Recommendations for patients with coronary artery disease |  |  | \nAspirin 75\u0002100 mg daily is recommended for patients with a previous myocardial infarction or revascularization. | I | A | \nIn ACS, DAPT with a P2Y inhibitor in addition to aspirin is recommended for 12 months, unless there are contraindications\n12\nsuch as excessive risk of bleeding. | I | A | \nIn patients with CCS, clopidogrel 75 mg daily is recommended, in addition to aspirin, for 6 months following coronary stenting,\nirrespective of stent type, unless a shorter duration (1\u00023 months) is indicated due to risk or the occurrence of life-threatening\nbleeding. | I | A | \nACE inhibitors (or ARB) are recommended if a patient has other conditions (e.g. HF, hypertension, or DM). | I | A | \nBeta-blockers are recommended in patients with LV dysfunction or systolic HF. | I | A | \nIn patients with established ASCVD, oral lipid-lowering treatment with an ultimate LDL-C goal of <1.4 mmol/L (55 mg/dL) and a\n>50% reduction in LDL-C vs. baseline is recommended.\n_ | I | A | \nRecommendations regarding pharmacological and nonpharmacological interventions for patients with symptomatic (New York Heart\nAssociation class II-IV) heart failure with reduced ejection fraction (left ventricular ejection fraction <40%) with proven benefits on clin-\nical outcomes, including cardiovascular morbidity and mortality |  |  | \nIt is recommended that patients with HF are enrolled in a comprehensive CR programme to reduce the risk of HF hospitalization\nand death. | I | A | \nEBCR is recommended in stable symptomatic patients with HFrEF to reduce the risk of HF hospitalization. | I | A | \nIt is recommended to screen patients with HF for both CV and non-CV comorbidities, which, if present, should be treated, pro-\nvided safe and effective interventions exist, not only to alleviate symptoms but also to improve prognosis. | I | A | \nAn ACE inhibitor is recommended, in addition to a beta-blocker and an MRA, for patients with symptomatic HFrEF to reduce the\nrisk of HF hospitalization and death. | I | A | \nA beta-blocker is recommended, in addition to an ACE inhibitor (or an ARNI) and an MRA, for patients with stable, symptomatic\nHFrEF to reduce the risk of HF hospitalization and death. | I | A | \nAn MRA is recommended for patients with HFrEF already treated with an ACE inhibitor (or an ARNI) and a beta-blocker, to\nreduce the risk of HF hospitalization and death. | I | A | \nSacubitril/valsartan is recommended as a replacement for an ACE inhibitor to reduce the risk of HF hospitalization and death in\npatients with HFrEF. | I | B | \nAn ARB is recommended to reduce the risk of HF hospitalization or CV death in symptomatic patients with HFrEF who are\nunable to tolerate an ACE inhibitor and/or ARNI (patients should also receive a beta-blocker and an MRA). | I | B | \nDapagliflozin or empagliflozin are recommended, in addition to optimal treatment of an ACE inhibitor (or ARNI), a beta-blocker,\nand an MRA, for patients with HFrEF to reduce the risk of HF hospitalization and death. | I | A | \nDiuretics are recommended in patients with HFrEF with signs and/or symptoms of congestion to reduce the risk of HF\nhospitalization. | I | C | \nRecommendations for patients with cerebrovascular disease |  |  | \nIn patients with a cerebrovascular event, improvement of lifestyle factors in addition to appropriate pharmacological management\nis recommended. | I | A | \nIn patients with ischaemic stroke or TIA, prevention with antithrombotics is recommended; choice of antithrombotic depends on\nthe mechanism of event. Use of an antiplatelet is recommended for patients with non-cardioembolic ischaemic stroke or TIA,\nand use of an anticoagulant is recommended in patients with cardioembolic ischaemic stroke or TIA. | I | A | \nIn patients with non-cardioembolic ischaemic stroke or TIA, prevention with aspirin only, or dipyridamole plus aspirin, or clopi-\ndogrel alone is recommended. | I | A | \nIn patients with stroke or TIA who have BP of 140/90 mmHg or higher, BP lowering is recommended. | I | A | \nRecommendations for patients with lower extremity artery disease: best medical therapy |  |  | \nSmoking cessation is recommended in all patients with LEAD. | I | B | \nHealthy diet and PA are recommended for all patients with LEAD. | I | C | \nIn patients with intermittent claudication:\n• Supervised exercise training is recommended | I | A | \n• Non-supervised exercise training is recommended when supervised exercise training is not feasible or available. | I | C | \nAntiplatelet therapy is recommended in patients with symptomatic LEAD. | I | C | \nIn patients with LEAD and hypertension, it is recommended to control BP at <140/90 mmHg. | I | A | \nIn patients with LEAD and DM, strict glycaemic control is recommended. | I | A | ",
          "bbox": [
            48.87792644094914,
            60.33735148111979,
            558.3879065135169,
            709.4152069091797
          ],
          "function_potential": "auto_generate"
        },
        {
          "title": "3310 ESC Guidelines",
          "page_number": 83,
          "content": "Recommendations in patients with chronic kidney disease: best medical therapy |  |  | \nTreatment with an ACE inhibitor or an ARB is recommended in patients with DM, hypertension, and albuminuria. These medica-\ntions should be titrated to the highest approved dose that is tolerated. | I | B | \nCombination treatment with ACE inhibitors and ARBs is not recommended. | III | C | \nRecommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial\nfibrillation |  |  | \nIdentification and management of risk factors and concomitant diseases are recommended to be considered an integral part of\ntreatment. | I | B | \nModification of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and\nsymptom severity. | I | B | 21\nAttention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and\nbleeding. | I | B | ESC 20",
          "bbox": [
            44.339311773126774,
            60.33735148111979,
            553.9268880208333,
            212.61522565569197
          ],
          "function_potential": "auto_generate"
        }
      ]
    },
    {
      "number": "24",
      "title": "11 Supplementary data",
      "start_page": 83,
      "end_page": 83,
      "content": "Supplementary data  with additional Supplementary Figures, Tables, and text complementing the full text are available on the European Heart Journal website and via the ESC website at https://www.escar dio.org/guidelines.\n",
      "keywords": [
        "data",
        "supplementary"
      ],
      "tables": []
    },
    {
      "number": "25",
      "title": "12. Author information",
      "start_page": 83,
      "end_page": 84,
      "content": "Author/Task Force Member Affiliations: Yvo M. Smulders, Internal Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands;  David Carballo,  Cardiology, Geneva University Hospitals, Geneva, Switzerland; Konstantinos C. Koskinas,  Cardiology, Bern University Hospital  \u0002  INSELSPITAL, Bern, Switzerland;  Maria B € ack,  Unit of Physiotherapy, Department of Health, Medicine and Caring Sciences, Linko¨ping University, Linko¨ping, Sweden, and Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, and Sahlgrenska University Hospital, Gothenburg, Sweden;  Athanase Benetos,  Geriatric Department CHRU de Nancy and ISERM DCAC, Universite´ de Lorraine, Nancy, France; Alessandro Biffi,  Cardiology, FIMS and EFSMA, Rome, Italy;  Jose´- Manuel Boavida,  APDP  \u0002  Diabetes Portugal, IDF-E International Diabetes Federation \u0002 Europe, Lisbon, Portugal; Davide Capodanno,  Cardiothoracic, Vascular and Transplants, Policlinico “G. Rodolico-San Marco”, University of Catania, Catania, Italy; Bernard Cosyns,  Cardiology, Centrum voor Hart en vaatziekte (CHVZ) Universitair Ziekenhuis Brussel, Brussels, Belgium;  Carolyn A. Crawford,  (Northern Ireland), ESC Patient Forum, Sophia Antipolis, France; Constantinos H. Davos, Cardiovascular Research Laboratory, Biomedical Research Foundation, Academy of\nRecommendations in patients with chronic kidney disease: best medical therapy\nTreatment with an ACE inhibitor or an ARB is recommended in patients with DM, hypertension, and albuminuria. These medica-\ntions should be titrated to the highest approved dose that is tolerated. I B\nCombination treatment with ACE inhibitors and ARBs is not recommended. III C\nRecommendations for lifestyle interventions and management of risk factors and concomitant diseases in patients with atrial ﬁbrillation\nIdentiﬁcation and management of risk factors and concomitant diseases are recommended to be considered an integral part of\ntreatment. I B\nModiﬁcation of unhealthy lifestyle and targeted therapy of intercurrent conditions is recommended to reduce AF burden and symptom severity. I B\nAttention to good BP control is recommended in AF patients with hypertension to reduce AF recurrences and risk of stroke and\nbleeding. I B\nABPM = ambulatory blood pressure monitoring; ACE = angiotensin-converting enzyme; ACR = albumin-to-creatinine ratio; ACS = acute coronary syndromes; AF = atrial ﬁbril- lation; ARB = angiotensin receptor blocker; ARNI = angiotensin receptor neprilysin inhibitor; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CAC = coronary artery calcium; CCB = calcium channel blocker; CCS = chronic coronary syndromes; CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease; CR = cardiac rehabilitation; CV = cardiovascular; CVD = cardiovascular disease; DAPT = dual antiplatelet therapy; DBP = diastolic blood pressure; DM = diabetes mellitus; EBCR = exercise-based cardiac rehabilitation; ECG = electrocardiogram; eGRF = estimated glomerular ﬁltration rate; FH = familial hypercholesterolaemia; GLP-1RA = gluca- gon-like peptide-1 receptor agonist; HbA1c = glycated haemoglobin; HBPM = home blood pressure monitoring; HF = heart failure; HFrEF = heart failure with reduced ejection fraction; HMOD = hypertension-mediated organ damage; LDL-C = low-density lipoprotein cholesterol; LEAD = lower extremity artery disease; LV = left ventricular; MRA = mineralocorticoid receptor antagonist; PA = physical activity; PCSK9 = proprotein convertase subtilisin/kexin type 9; PM = particulate matter; RAS = renin-angiotensin system; SBP = systolic blood pressure; SCORE2 = Systematic Coronary Risk Estimation 2; SCORE2-OP = Systematic Coronary Risk Estimation 2-Older Persons; SGLT2 = sodium-glu- cose cotransporter 2; SNRI = serotonin-noradrenaline reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TIA = transient ischaemic attack; TOD = target organ damage.\nESC 2021\n3310 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Athens, Athens, Greece; Ileana Desormais,  INSERM, Univ. Limoges, CHU Limoges, IRD, U1094 Tropical Neuroepidemiology, GEIST, Limoges, France; Emanuele Di Angelantonio, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK;  Oscar H. Franco Duran,  ISPM Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland;  Sigrun Halvorsen,  Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway;  F. D. Richard Hobbs , NDPCHS, University of Oxford, Oxford, UK;  Monika Hollander , Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, Utrecht, Netherlands;  Ewa A. Jankowska, Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland;  Matthias Michal,  Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Mainz, Mainz, Germany;  Simona Sacco,  Department of Applied Clinical and Biotechnological Sciences, University of L’Aquila, L’Aquila, Italy; Naveed Sattar,  Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; Lale Tokgozoglu, Cardiology, Hacettepe University, Ankara, Turkey; Serena Tonstad,  Preventive Cardiology, Oslo University Hospital, Oslo, Norway;  Konstantinos P. Tsioufis,  First Cardiology Clinic, Medical School, National and Kapodistrian University, Hippokration Hospital, Athens, Greece;  Ineke van Dis,  European Heart Network, Brussels, Belgium;  Isabelle C. van Gelder,  Cardiology, University of Groningen, University Medical Center Groningen; Groningen, Netherlands;  Christoph Wanner,  Department of Nephrology, University Wu¨rzburg, Germany;  Bryan Williams , Institute of Cardiovascular Science, University College London, London, UK\n",
      "keywords": [
        "hypertension",
        "author",
        "diabetes",
        "coronary artery",
        "arb",
        "score2-op",
        "information",
        "ascvd",
        "sbp",
        "recommended",
        "ejection fraction",
        "pcsk9",
        "heart failure",
        "physical activity",
        "risk estimation",
        "diastolic",
        "electrocardiogram",
        "score2",
        "sglt2",
        "cholesterol",
        "ldl-c",
        "older",
        "dbp",
        "ecg",
        "systolic",
        "exercise",
        "hba1c",
        "blood pressure",
        "ace inhibitor",
        "lipoprotein"
      ],
      "tables": []
    },
    {
      "number": "26",
      "title": "13. Appendix",
      "start_page": 84,
      "end_page": 85,
      "content": "ESC Scientific Document Group Includes Document Reviewers and ESC National Cardiac Societies.\nDocument Reviewers: Guy De Backer (CPG Review Coordinator) (Belgium), Vera Regitz-Zagrosek (CPG Review Coordinator) (Germany), Anne Hege Aamodt (Norway), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Christian Albus (Germany), Riccardo Asteggiano (Italy), Magnus B € ack (Sweden), Michael A. Borger (Germany), Carlos Brotons (Spain), Jelena \u0002 Celutkien _ e (Lithuania), Renata Cifkova (Czech Republic), Maja Cikes (Croatia), Francesco Cosentino (Italy), Nikolaos Dagres (Germany), Tine De Backer (Belgium), Dirk De Bacquer (Belgium), Victoria Delgado (Netherlands), Hester Den Ruijter (Netherlands), Paul Dendale (Belgium), Heinz Drexel (Austria), Volkmar Falk (Germany), Laurent Fauchier (France), Brian A. Ference 1   (United Kingdom), Jean Ferrie`res (France), Marc Ferrini (France), Miles Fisher 2   (United Kingdom), Danilo Fliser (Germany), Zlatko Fras (Slovenia), Dan Gaita (Romania), Simona Giampaoli (Italy), Stephan Gielen (Germany), Ian Graham (Ireland), Catriona Jennings (Ireland), Torben Jorgensen (Denmark), Alexandra Kautzky-Willer (Austria), Maryam Kavousi (Netherlands), Wolfgang Koenig (Germany), Aleksandra Konradi (Russia), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Madalena Lettino (Italy), Basil S. Lewis (Israel), Ale \u0002 s Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Konstantinos Makrilakis (Greece), Giuseppe Mancia (Italy), Pedro Marques-Vidal\n(Switzerland), John William McEvoy (Ireland), Paul McGreavy (United Kingdom), Bela Merkely (Hungary), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Joep Perk (Sweden), Steffen E. Petersen (United Kingdom), Anna Sonia Petronio (Italy), Massimo Piepoli (Italy), Nana Goar Pogosova (Russia), Eva Irene Bossano Prescott (Denmark), Kausik K. Ray (United Kingdom), Zeljko Reiner (Croatia), Dimitrios J. Richter (Greece), Lars Ryde´n (Sweden), Evgeny Shlyakhto (Russia), Marta Sitges (Spain), Miguel Sousa-Uva (Portugal), Isabella Sudano (Switzerland), Monica Tiberi (Italy), Rhian M. Touyz (United Kingdom), Andrea Ungar (Italy), W.M. Monique Verschuren (Netherlands), Olov Wiklund (Sweden), David Wood (United Kingdom/Ireland), Jose Luis Zamorano (Spain).\nESC National Cardiac Societies  actively involved in the review process of the 2021 ESC Guidelines on cardiovascular disease pre- vention in clinical practice:\nAlgeria:  Algerian Society of Cardiology, Naima Hammoudi; Armenia:  Armenian Cardiologists Association, Parounak Zelveian; Austria:  Austrian Society of Cardiology, Peter Siostrzonek; Azerbaijan:  Azerbaijan Society of Cardiology, Elman Alakbarov; Belarus:  Belorussian Scientific Society of Cardiologists, Olga Pavlova;  Belgium:  Belgian Society of Cardiology, Johan De Sutter; Bosnia and Herzegovina:  Association of Cardiologists of Bosnia and Herzegovina, Mirza Dili \u0003 c;  Bulgaria:  Bulgarian Society of Cardiology, Nina Gotcheva;  Croatia:  Croatian Cardiac Society, Bosko Skoric;  Cyprus:  Cyprus Society of Cardiology, Hera Heracleous Moustra; Czech Republic: Czech Society of Cardiology, Renata Cifkova; Denmark: Danish Society of Cardiology, Ann Bovin;  Egypt:  Egyptian Society of Cardiology, Bassem Zarif;  Estonia:  Estonian Society of Cardiology, Margus Viigimaa;  Finland:  Finnish Cardiac Society, Anna-Mari Hekkala; France:  French Society of Cardiology, Serge Kownator;  Georgia: Georgian Society of Cardiology, Zurab Pagava;  Germany:  German Cardiac Society, Ulf Landmesser;  Greece:  Hellenic Society of Cardiology, Harry Grassos;  Hungary:  Hungarian Society of Cardiology, Eszter Szabados; Iceland: Icelandic Society of Cardiology, Karl Andersen;  Ireland:  Irish Cardiac Society, John William McEvoy;  Israel:  Israel Heart Society, Barak Zafrir;  Italy: Italian Federation of Cardiology, Francesco Barill \u0004 a; Kosovo (Republic of):  Kosovo Society of Cardiology, Pranvera Ibrahimi; Kyrgyzstan:  Kyrgyz Society of Cardiology, Erkin Mirrakhimov; Latvia:  Latvian Society of Cardiology, Iveta Mintale;  Lebanon: Lebanese Society of Cardiology, Samir Arnaout;  Lithuania: Lithuanian Society of Cardiology, Rimvydas   \u0002 Slapikas;  Luxembourg: Luxembourg Society of Cardiology, Cristiana Banu;  Malta:  Maltese Cardiac Society, Mark Abela;  Moldova (Republic of):  Moldavian Society of Cardiology, Victor Rudi;  Montenegro:  Montenegro Society of Cardiology, Aneta Boskovic;  Morocco:  Moroccan Society of Cardiology, Mohamed Alami;  Netherlands : Netherlands Society of Cardiology, Hareld M.C. Kemps;  North Macedonia : North Macedonian Society of Cardiology, Marijan Bosevski;  Norway: Norwegian Society of Cardiology, Erik Ekker Solberg;  Poland:  Polish Cardiac Society, Tomasz Zdrojewski;  Portugal:  Portuguese Society of Cardiology, Carlos Rabac¸al;  Romania:  Romanian Society of Cardiology, Dan Gaita;  Russian Federation:  Russian Society of Cardiology, Yury Belenkov;  San Marino:  San Marino Society of\nESC Guidelines 3311\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Cardiology, Luca Bertelli;  Serbia:  Cardiology Society of Serbia, Vojislav Giga;  Slovakia:  Slovak Society of Cardiology, Daniel Pella; Slovenia:  Slovenian Society of Cardiology, Zlatko Fras;  Spain: Spanish Society of Cardiology, Regina Dalmau;  Sweden:  Swedish Society of Cardiology, Anna Kiessling;  Switzerland:  Swiss Society of Cardiology, Otmar Pfister; Syrian Arab Republic: Syrian Cardiovascular Association, Yassin Bani Marjeh;  Tunisia:  Tunisian Society of Cardiology and Cardio-Vascular Surgery, Salem Abdessalem;  Turkey:  Turkish Society of Cardiology, Oner Ozdogan; Ukraine:  Ukrainian Association of Cardiology, Elena Nesukay; United Kingdom of Great Britain and Northern Ireland: British Cardiovascular Society, Riyaz Patel;  Uzbekistan:  Association of Cardiologists of Uzbekistan, Guzal Mullabayeva. ESC Clinical Practice Guidelines Committee (CPG): Colin Baigent (Chairperson) (United Kingdom), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Elena Arbelo (Spain), Riccardo Asteggiano (Italy), Andreas Baumbach (United Kingdom), Michael A. Borger (Germany), Jelena \u0002 Celutkien _ e (Lithuania), Maja Cikes (Croatia), Jean-Philippe Collet (France), Volkmar Falk (Germany), Laurent Fauchier (France), Chris P. Gale (United Kingdom), Sigrun Halvorsen (Norway), Bernard Iung (France), Tiny Jaarsma (Sweden), Aleksandra Konradi (Russia), Konstantinos C. Koskinas (Switzerland), Dipak Kotecha (United Kingdom), Ulf Landmesser (Germany), Basil S. Lewis (Israel), Ale \u0002 s Linhart (Czech Republic), Maja-Lisa Løchen (Norway), Jens Cosedis Nielsen (Denmark), Steffen E. Petersen (United Kingdom), Eva Irene Bossano Prescott (Denmark), Amina Rakisheva (Kazakhstan), Marta Sitges (Spain), Rhian M. Touyz (United Kingdom)\n",
      "keywords": [
        "appendix"
      ],
      "tables": []
    },
    {
      "number": "27",
      "title": "14. References",
      "start_page": 85,
      "end_page": 85,
      "content": "",
      "keywords": [
        "references"
      ],
      "tables": []
    },
    {
      "number": "28",
      "title": "1. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Cifkova R, Davletov K, Dilic M, Dolzhenko M, G",
      "start_page": 85,
      "end_page": 85,
      "content": "",
      "keywords": [
        "vidal",
        "badariene",
        "grobbee",
        "jennings",
        "abreu",
        "ryden",
        "dilic",
        "bruthans",
        "cifkova",
        "aguiar",
        "dolzhenko",
        "maggioni",
        "marques",
        "hoes",
        "bacquer",
        "davletov",
        "backer",
        "kotseva"
      ],
      "tables": []
    },
    {
      "number": "29",
      "title": "5. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocc",
      "start_page": 85,
      "end_page": 87,
      "content": "3312 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Midlife: Implications for Cardiovascular Prevention. J Am Coll Cardiol 2019; 74 :70 \u0002 79. 24. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vas- cular disease.  JAMA  2009; 302 :1993 \u0002 2000. 25. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EP, Sivapalaratnam S, Shah S, Elbers CC, Shah T, Engmann J, Giambartolomei C, White J, Zabaneh D, Sofat R, McLachlan S, UCLEB consortium, Doevendans PA, Balmforth AJ, Hall AS, North KE, Almoguera B, Hoogeveen RC, Cushman M, Fornage M, Patel SR, Redline S, Siscovick DS, Tsai MY, Karczewski KJ, Hofker MH, Verschuren WM, Bots ML, van der Schouw YT, Melander O, Dominiczak AF, Morris R, Ben-Shlomo Y, Price J, Kumari M, Baumert J, Peters A, Thorand B, Koenig W, Gaunt TR, Humphries SE, Clarke R, Watkins H, Farrall M, Wilson JG, Rich SS, de Bakker PI, Lange LA, Davey Smith G, Reiner AP, Talmud PJ, Kivimaki M, Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP. Mendelian randomization of blood lipids for coronary heart disease.  Eur Heart J 2015; 36 :539 \u0002 550. 26. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, Konig IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O’Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mende- lian randomisation study.  Lancet  2012; 380 :572 \u0002 580. 27. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease.  JAMA  2008; 299 :2524 \u0002 2532. 28. HPS3/TIMI55 \u0002 REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease.  N Engl J Med  2017; 377 :1217 \u0002 1227. 29. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD, 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA, 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van\nDingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, Memish ZA. A comparative risk assessment of bur- den of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.  Lancet  2012; 380 :2224 \u0002 2260. 30. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortal- ity: a meta-analysis of individual data for one million adults in 61 prospective studies.  Lancet  2002; 360 :1903 \u0002 1913. 31. Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima JAC, Budoff M, Nasir K, Szklo M, Blumenthal RS, Blaha MJ. Association of Normal Systolic Blood Pressure Level With Cardiovascular Disease in the Absence of Risk Factors.  JAMA Cardiol 2020; 5 :1011 \u0002 1018. 32. Wills AK, Lawlor DA, Matthews FE, Sayer AA, Bakra E, Ben-Shlomo Y, Benzeval M, Brunner E, Cooper R, Kivimaki M, Kuh D, Muniz-Terrera G, Hardy R. Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts.  PLoS Med  2011; 8 :e1000440. 33. Ji H, Niiranen TJ, Rader F, Henglin M, Kim A, Ebinger JE, Claggett B, Merz CNB, Cheng S. Sex Differences in Blood Pressure Associations With Cardiovascular Outcomes.  Circulation  2021; 143 :761 \u0002 763. 34. Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, Cheng S. Sex Differences in Blood Pressure Trajectories Over the Life Course.  JAMA Cardiol 2020; 5 :19 \u0002 26. 35. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors.  BMJ  2004; 328 :1519. 36. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocar- dial infarction in women and men: longitudinal population study. BMJ 1998; 316 :1043 \u0002 1047. 37. Huxley RR, Woodward M. Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies.  Lancet  2011; 378 :1297 \u0002 1305. 38. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.  Lancet  2018; 392 :1923 \u0002 1994. 39. Lv X, Sun J, Bi Y, Xu M, Lu J, Zhao L, Xu Y. Risk of all-cause mortality and cardio- vascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis.  Int J Cardiol  2015; 199 :106 \u0002 115. 40. Gupta R, Gupta S, Sharma S, Sinha DN, Mehrotra R. Risk of Coronary Heart Disease Among Smokeless Tobacco Users: Results of Systematic Review and Meta-Analysis of Global Data.  Nicotine Tob Res  2019; 21 :25 \u0002 31. 41. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.  Lancet 2010; 375 :2215 \u0002 2222. 42. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014; 383 :1973 \u0002 1980. 43. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analy- sis of 2416 population-based measurement studies in 128.9 million children, ado- lescents, and adults.  Lancet  2017; 390 :2627 \u0002 2642. 44. Sun YQ, Burgess S, Staley JR, Wood AM, Bell S, Kaptoge SK, Guo Q, Bolton TR, Mason AM, Butterworth AS, Di Angelantonio E, Vie GA, Bjorngaard JH, Kinge JM, Chen Y, Mai XM. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses.  BMJ 2019; 364 :l1042. 45. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju Sh N, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, Cairns BJ, Huxley R, Jackson Ch L, Joshy G, Lewington S, Manson JE, Murphy N, Patel AV, Samet JM, Woodward M, Zheng W, Zhou M, Bansal N, Barricarte A, Carter B, Cerhan JR, Smith GD, Fang X, Franco OH, Green J, Halsey J, Hildebrand JS, Jung KJ, Korda RJ, McLerran DF, Moore SC, O’Keeffe LM, Paige E, Ramond A, Reeves GK, Rolland B, Sacerdote C, Sattar N, Sofianopoulou E, Stevens J, Thun M, Ueshima H, Yang L, Yun YD, Willeit P, Banks E, Beral V, Chen Z, Gapstur SM, Gunter MJ, Hartge P, Jee SH, Lam TH, Peto R, Potter JD, Willett WC, Thompson SG, Danesh J, Hu FB. Body-mass index and all-cause mortality: individual-participant- data meta-analysis of 239 prospective studies in four continents.  Lancet 2016; 388 :776 \u0002 786. 46. Aune D, Sen A, Prasad M, Norat T, Janszky I, Tonstad S, Romundstad P, Vatten LJ. BMI and all cause mortality: systematic review and non-linear dose-response\nESC Guidelines 3313\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants.  BMJ  2016; 353 :i2156. 47. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, Thompson A, Sarwar N, Kizer JR, Lawlor DA, Nordestgaard BG, Ridker P, Salomaa V, Stevens J, Woodward M, Sattar N, Collins R, Thompson SG, Whitlock G, Danesh J. Separate and combined associa- tions of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies.  Lancet  2011; 377 :1085 \u0002 1095. 48. World Health Organization.  Gender and health . https://www.who.int/health- topics/gender#tab=tab_1  (4 June 2021). 49. Global Health 50/50. Gender and global health. https://globalhealth5050.org/gen der-and-global-health  (4 June 2021). 50. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, De Vries GJ, Epperson CN, Govindan R, Klein SL, Lonardo A, Maki PM, McCullough LD, Regitz-Zagrosek V, Regensteiner JG, Rubin JB, Sandberg K, Suzuki A. Sex and gender: modifiers of health, disease, and medicine.  Lancet 2020; 396 :565 \u0002 582. 51. Peters SAE, Muntner P, Woodward M. Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016.  Circulation  2019; 139 :1025 \u0002 1035. 52. Lee CMY, Mnatzaganian G, Woodward M, Chow CK, Sitas F, Robinson S, Huxley RR. Sex disparities in the management of coronary heart disease in gen- eral practices in Australia.  Heart  2019; 105 :1898 \u0002 1904. 53. Cushman M, Shay CM, Howard VJ, Jimenez MC, Lewey J, McSweeney JC, Newby LK, Poudel R, Reynolds HR, Rexrode KM, Sims M, Mosca LJ, American Heart Association. Ten-Year Differences in Women’s Awareness Related to Coronary Heart Disease: Results of the 2019 American Heart Association National Survey: A Special Report From the American Heart Association. Circulation 2021; 143 :e239 \u0002 e248. 54. Pelletier R, Khan NA, Cox J, Daskalopoulou SS, Eisenberg MJ, Bacon SL, Lavoie KL, Daskupta K, Rabi D, Humphries KH, Norris CM, Thanassoulis G, Behlouli H, Pilote L, GENESIS-PRAXY Investigators. Sex Versus Gender-Related Characteristics: Which Predicts Outcome After Acute Coronary Syndrome in the Young?  J Am Coll Cardiol  2016; 67 :127 \u0002 135. 55. Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, Regitz- Zagrosek V, Miller VM, Day D, Asselbergs FW, den Ruijter HM. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature.  JACC Heart Fail  2019; 7 :258 \u0002 266. 56. Regitz-Zagrosek V, Seeland U. Sex and gender differences in clinical medicine. Handb Exp Pharmacol  2012:3 \u0002 22. 57. Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN, Kirchner HL, Manus JNA, James N, Ayar Z, Gladding P, Good CW, Cleland JGF, Fornwalt BK. Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie?  Eur Heart J  2020; 41 :1249 \u0002 1257. 58. Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, Canham RM, Levine BD, Drazner MH. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study.  Circulation  2006; 113 :1597 \u0002 1604. 59. Maas A, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M, Collins P. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardi- ologists, gynaecologists, and endocrinologists.  Eur Heart J  2021; 42 :967 \u0002 984. 60. Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ  1995; 311 :1356 \u0002 1359. 61. Dorresteijn JA, Visseren FL, Ridker PM, Wassink AM, Paynter NP, Steyerberg EW, van der Graaf Y, Cook NR. Estimating treatment effects for individual patients based on the results of randomised clinical trials.  BMJ 2011; 343 :d5888. 62. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, Lee BJ, Perkins RM, Rossing P, Sairenchi T, Tonelli M, Vassalotti JA, Yamagishi K, Coresh J, de Jong PE, Wen CP, Nelson RG, Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end- stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet  2012; 380 :1662 \u0002 1673. 63. Robbins JM, Strauss G, Aron D, Long J, Kuba J, Kaplan Y. Mortality rates and dia- betic foot ulcers: is it time to communicate mortality risk to patients with dia- betic foot ulceration?  J Am Podiatr Med Assoc  2008; 98 :489 \u0002 493. 64. Brownrigg JR, Hughes CO, Burleigh D, Karthikesalingam A, Patterson BO, Holt PJ, Thompson MM, de Lusignan S, Ray KK, Hinchliffe RJ. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study.  Lancet Diabetes Endocrinol  2016; 4 :588 \u0002 597. 65. International Society of Nephrology. KDIGO 2020  Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease . https://kdigo.org/wp-content/ uploads/2020/10/KDIGO-2020-Diabetes-in-CKD-GL.pdf  (4 June 2021).\n",
      "keywords": [
        "obesity",
        "male",
        "grobbee",
        "hansen",
        "juni",
        "diabetes",
        "aboyans",
        "sex",
        "smoking",
        "recommended",
        "risk factor",
        "ejection fraction",
        "johansson",
        "cosentino",
        "lettino",
        "heart failure",
        "huikuri",
        "gender",
        "cardiovascular risk",
        "cholesterol",
        "bailey",
        "filippatos",
        "federici",
        "systolic",
        "glucose",
        "ostgren",
        "marx",
        "blood pressure",
        "lipoprotein",
        "rocc"
      ],
      "tables": []
    },
    {
      "number": "30",
      "title": "66. Cersosimo E, Johnson EL, Chovanes C, Skolnik N. Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach.  Diabetes Obes Metab  2018; 20 :497",
      "start_page": 87,
      "end_page": 88,
      "content": "3314 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 81. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation 2016; 134 :1419 \u0002 1429. 82. De Bacquer D, Ueda P, Reiner Z, De Sutter J, De Smedt D, Lovic D, Gotcheva N, Fras Z, Pogosova N, Mirrakhimov E, Lehto S, Jernberg T, Kotseva K, Ryden L, Wood D, EUROASPIRE IV and V National Coordinators. Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model.  Eur J Prev Cardiol  2020:[Online ahead of print]. 83. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez- Jaramillo P, O’Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Stork S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp- Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S, COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.  N Engl J Med  2017; 377 :1319 \u0002 1330. 84. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Jr., Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.  N Engl J Med  2019; 380 :11 \u0002 22. 85. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL, LoDoCo2 Trial Investigators. Colchicine in Patients with Chronic Coronary Disease.  N Engl J Med  2020; 383 :1838 \u0002 1847. 86. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L’Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med 2019; 381 :2497 \u0002 2505. 87. Sattar N, Rawshani A, Franzen S, Rawshani A, Svensson AM, Rosengren A, McGuire DK, Eliasson B, Gudbjornsdottir S. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks.  Circulation 2019; 139 :2228 \u0002 2237. 88. Kaasenbrood L, Poulter NR, Sever PS, Colhoun HM, Livingstone SJ, Boekholdt SM, Pressel SL, Davis BR, van der Graaf Y, Visseren FL, CARDS, ALLHAT, and ASCOT Investigators. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.  Circ Cardiovasc Qual Outcomes  2016; 9 :213 \u0002 221. 89. Kengne AP, Patel A, Marre M, Travert F, Lievre M, Zoungas S, Chalmers J, Colagiuri S, Grobbee DE, Hamet P, Heller S, Neal B, Woodward M, ADVANCE Collaborative Group. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes.  Eur J Cardiovasc Prev Rehabil  2011; 18 :393 \u0002 398. 90. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).  Clin Sci (Lond) 2001; 101 :671 \u0002 679. 91. Rawshani A, Sattar N, Franzen S, Rawshani A, Hattersley AT, Svensson AM, Eliasson B, Gudbjornsdottir S. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.  Lancet  2018; 392 :477 \u0002 486. 92. Rawshani A, Rawshani A, Sattar N, Franzen S, McGuire DK, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, Rosengren A, Gudbjornsdottir S. Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes Mellitus. Circulation 2019; 139 :1900 \u0002 1912. 93. Livingstone SJ, Looker HC, Hothersall EJ, Wild SH, Lindsay RS, Chalmers J, Cleland S, Leese GP, McKnight J, Morris AD, Pearson DW, Peden NR, Petrie JR, Philip S, Sattar N, Sullivan F, Colhoun HM. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study.  PLoS Med  2012; 9 :e1001321. 94. Spiegelhalter D, Pearson M, Short I. Visualizing uncertainty about the future. Science  2011; 333 :1393 \u0002 1400. 95. Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, Kaatz S, Mann DM, Sussman JB, Korenstein D, Schardt C, Nagi A, Sloane R, Feldstein DA. Evidence-based risk communication: a systematic review.  Ann Intern Med 2014; 161 :270 \u0002 280.\n",
      "keywords": [
        "stepwise",
        "initiating",
        "newly",
        "10-year risk",
        "lipid",
        "metab",
        "chovanes",
        "diabetes",
        "type",
        "therapy",
        "secondary prevention",
        "statin",
        "diagnosed",
        "cardiovascular risk",
        "antihypertensive",
        "approach",
        "combination",
        "johnson",
        "cersosimo",
        "obes",
        "skolnik",
        "age",
        "patients"
      ],
      "tables": []
    },
    {
      "number": "31",
      "title": "96. Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD. Risk scoring for the primary prevention of cardiovascular disease.  Cochrane Database Syst Rev  2017; 3 :CD006887. 97. Da",
      "start_page": 88,
      "end_page": 91,
      "content": "ESC Guidelines 3315\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 119. Hadamitzky M, Freissmuth B, Meyer T, Hein F, Kastrati A, Martinoff S, Schomig A, Hausleiter J. Prognostic value of coronary computed tomographic angiogra- phy for prediction of cardiac events in patients with suspected coronary artery disease.  JACC Cardiovasc Imaging  2009; 2 :404 \u0002 411. 120. SCOT-HEART Investigators, Newby DE, Adamson PD, Berry C, Boon NA, Dweck MR, Flather M, Forbes J, Hunter A, Lewis S, MacLean S, Mills NL, Norrie J, Roditi G, Shah ASV, Timmis AD, van Beek EJR, Williams MC. Coronary CT Angiography and 5-Year Risk of Myocardial Infarction.  N Engl J Med  2018; 379 :924 \u0002 933. 121. Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GW, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O’Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M, Stehouwer CD, Witteman JC, Moons KG, Bots ML. Common carotid intima- media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA  2012; 308 :796 \u0002 803. 122. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS, American Society of Echocardiography Carotid Intima- Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine.  J Am Soc Echocardiogr  2008; 21 :93 \u0002 111; quiz 189-190. 123. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis.  J Am Coll Cardiol  2010; 55 :1318 \u0002 1327. 124. McDermott MM, Greenland P, Liu K, Guralnik JM, Celic L, Criqui MH, Chan C, Martin GJ, Schneider J, Pearce WH, Taylor LM, Clark E. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study.  Ann Intern Med  2002; 136 :873 \u0002 883. 125. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta- analysis.  JAMA  2008; 300 :197 \u0002 208. 126. Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ, Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults.  J Am Coll Cardiol  2014; 63 :747 \u0002 762. 127. Singh M, Stewart R, White H. Importance of frailty in patients with cardiovascu- lar disease.  Eur Heart J  2014; 35 :1726 \u0002 1731. 128. Tamura Y, Ishikawa J, Fujiwara Y, Tanaka M, Kanazawa N, Chiba Y, Iizuka A, Kaito S, Tanaka J, Sugie M, Nishimura T, Kanemaru A, Shimoji K, Hirano H, Furuta K, Kitamura A, Seino S, Shinkai S, Harada K, Kyo S, Ito H, Araki A. Prevalence of frailty, cognitive impairment, and sarcopenia in outpatients with cardiometabolic disease in a frailty clinic.  BMC Geriatr  2018; 18 :264. 129. Chainani V, Shaharyar S, Dave K, Choksi V, Ravindranathan S, Hanno R, Jamal O, Abdo A, Abi Rafeh N. Objective measures of the frailty syndrome (hand grip strength and gait speed) and cardiovascular mortality: A systematic review. Int J Cardiol  2016; 215 :487 \u0002 493. 130. Higueras-Fresnillo S, Cabanas-Sanchez V, Lopez-Garcia E, Esteban-Cornejo I, Banegas JR, Sadarangani KP, Rodriguez-Artalejo F, Martinez-Gomez D. Physical Activity and Association Between Frailty and All-Cause and Cardiovascular Mortality in Older Adults: Population-Based Prospective Cohort Study.  J Am Geriatr Soc  2018; 66 :2097 \u0002 2103. 131. Vaes B, Depoortere D, Van Pottelbergh G, Mathei C, Neto J, Degryse J. Association between traditional cardiovascular risk factors and mortality in the oldest old: untangling the role of frailty.  BMC Geriatr  2017; 17 :234. 132. Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corra U, Cupples M, Davos CH, Hoefer S, Iliou MC, Schmid JP, Voeller H, Doherty P. Frailty and cardiac rehabilitation: A call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol  2017; 24 :577 \u0002 590. 133. Bachmann JM, Willis BL, Ayers CR, Khera A, Berry JD. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study.  Circulation  2012; 125 :3092 \u0002 3098. 134. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk predic- tion and a 2-stage risk screening strategy for coronary heart disease.  Arterioscler Thromb Vasc Biol  2013; 33 :2261 \u0002 2266. 135. Ripatti S, Tikkanen E, Orho-Melander M, Havulinna AS, Silander K, Sharma A, Guiducci C, Perola M, Jula A, Sinisalo J, Lokki ML, Nieminen MS, Melander O,\nSalomaa V, Peltonen L, Kathiresan S. A multilocus genetic risk score for coro- nary heart disease: case-control and prospective cohort analyses.  Lancet 2010; 376 :1393 \u0002 1400. 136. Sivapalaratnam S, Boekholdt SM, Trip MD, Sandhu MS, Luben R, Kastelein JJ, Wareham NJ, Khaw KT. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study.  Heart 2010; 96 :1985 \u0002 1989. 137. Veronesi G, Gianfagna F, Giampaoli S, Chambless LE, Mancia G, Cesana G, Ferrario MM. Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status.  Prev Med  2014; 64 :75 \u0002 80. 138. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O’Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA  2012; 308 :788 \u0002 795. 139. Antiochos P, Marques-Vidal P, McDaid A, Waeber G, Vollenweider P. Association between parental history and genetic risk scores for coronary heart disease prediction: The population-based CoLaus study. Atherosclerosis 2016; 244 :59 \u0002 65. 140. van Dis I, Geleijnse JM, Kromhout D, Boer J, Boshuizen H, Verschuren WM. Do obesity and parental history of myocardial infarction improve cardiovascular risk prediction?  Eur J Prev Cardiol  2013; 20 :793 \u0002 799. 141. Merry AH, Boer JM, Schouten LJ, Ambergen T, Steyerberg EW, Feskens EJ, Verschuren WM, Gorgels AP, van den Brandt PA. Risk prediction of incident coronary heart disease in The Netherlands: re-estimation and improvement of the SCORE risk function.  Eur J Prev Cardiol  2012; 19 :840 \u0002 848. 142. Musunuru K, Kathiresan S. Genetics of Common, Complex Coronary Artery Disease.  Cell  2019; 177 :132 \u0002 145. 143. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of poly- genic risk scores.  Nat Rev Genet  2018; 19 :581 \u0002 590. 144. Lambert SA, Gil L, Jupp S, Ritchie SC, Xu Y, Buniello A, McMahon A, Abraham G, Chapman M, Parkinson H, Danesh J, MacArthur JAL, Inouye M. The Polygenic Score Catalog as an open database for reproducibility and systematic evaluation.  Nat Genet  2021; 53 :420 \u0002 425. 145. Wand H, Lambert SA, Tamburro C, Iacocca MA, O’Sullivan JW, Sillari C, Kullo IJ, Rowley R, Dron JS, Brockman D, Venner E, McCarthy MI, Antoniou AC, Easton DF, Hegele RA, Khera AV, Chatterjee N, Kooperberg C, Edwards K, Vlessis K, Kinnear K, Danesh JN, Parkinson H, Ramos EM, Roberts MC, Ormond KE, Khoury MJ, Janssens A, Goddard KAB, Kraft P, MacArthur JAL, Inouye M, Wojcik GL. Improving reporting standards for polygenic scores in risk prediction studies.  Nature  2021; 591 :211 \u0002 219. 146. Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores.  Hum Mol Genet  2019; 28 :R133 \u0002 R142. 147. Inouye M, Abraham G, Nelson CP, Wood AM, Sweeting MJ, Dudbridge F, Lai FY, Kaptoge S, Brozynska M, Wang T, Ye S, Webb TR, Rutter MK, Tzoulaki I, Patel RS, Loos RJF, Keavney B, Hemingway H, Thompson J, Watkins H, Deloukas P, Di Angelantonio E, Butterworth AS, Danesh J, Samani NJ, UK Biobank CardioMetabolic Consortium CHD Working Group. Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention.  J Am Coll Cardiol  2018; 72 :1883 \u0002 1893. 148. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, Kathiresan S. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations.  Nat Genet  2018; 50 :1219 \u0002 1224. 149. Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M, Bell S, Bolton T, Burgess S, Dudbridge F, Guo Q, Sofianopoulou E, Stevens D, Thompson JR, Butterworth AS, Wood A, Danesh J, Samani NJ, Inouye M, Di Angelantonio E. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses.  PLoS Med  2021; 18 :e1003498. 150. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM, Dehghan A, Muller DC, Elliott P, Tzoulaki I. Predictive Accuracy of a Polygenic Risk Score-Enhanced Prediction Model vs a Clinical Risk Score for Coronary Artery Disease.  JAMA  2020; 323 :636 \u0002 645. 151. Mosley JD, Gupta DK, Tan J, Yao J, Wells QS, Shaffer CM, Kundu S, Robinson- Cohen C, Psaty BM, Rich SS, Post WS, Guo X, Rotter JI, Roden DM, Gerszten RE, Wang TJ. Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease. JAMA 2020; 323 :627 \u0002 635. 152. Levin MG, Rader DJ. Polygenic Risk Scores and Coronary Artery Disease: Ready for Prime Time?  Circulation  2020; 141 :637 \u0002 640. 153. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, Quyyumi AA, Taylor HA, Gulati M, Harold JG, Mieres JH, Ferdinand KC, Mensah GA, Sperling LS. Socioeconomic Status and Cardiovascular Outcomes: Challenges and Interventions.  Circulation  2018; 137 :2166 \u0002 2178. 154. de Mestral C, Stringhini S. Socioeconomic Status and Cardiovascular Disease: an Update.  Curr Cardiol Rep  2017; 19 :115.\n3316 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 155. Khaing W, Vallibhakara SA, Attia J, McEvoy M, Thakkinstian A. Effects of educa- tion and income on cardiovascular outcomes: A systematic review and meta- analysis.  Eur J Prev Cardiol  2017; 24 :1032 \u0002 1042. 156. Kivimaki M, Pentti J, Ferrie JE, Batty GD, Nyberg ST, Jokela M, Virtanen M, Alfredsson L, Dragano N, Fransson EI, Goldberg M, Knutsson A, Koskenvuo M, Koskinen A, Kouvonen A, Luukkonen R, Oksanen T, Rugulies R, Siegrist J, Singh-Manoux A, Suominen S, Theorell T, Vaananen A, Vahtera J, Westerholm PJM, Westerlund H, Zins M, Strandberg T, Steptoe A, Deanfield J, IPD-Work consortium. Work stress and risk of death in men and women with and with- out cardiometabolic disease: a multicohort study.  Lancet Diabetes Endocrinol 2018; 6 :705 \u0002 713. 157. Burroughs Pena MS, Rollins A. Environmental Exposures and Cardiovascular Disease: A Challenge for Health and Development in Low- and Middle-Income Countries.  Cardiol Clin  2017; 35 :71 \u0002 86. 158. Newby DE, Mannucci PM, Tell GS, Baccarelli AA, Brook RD, Donaldson K, Forastiere F, Franchini M, Franco OH, Graham I, Hoek G, Hoffmann B, Hoylaerts MF, Kunzli N, Mills N, Pekkanen J, Peters A, Piepoli MF, Rajagopalan S, Storey RF, ESC Working Group on Thrombosis, European Association for Cardiovascular Prevention and Rehabilitation, ESC Heart Failure Association. Expert position paper on air pollution and cardiovascular disease.  Eur Heart J 2015; 36 :83 \u0002 93b. 159. Lelieveld J, Pozzer A, Poschl U, Fnais M, Haines A, Munzel T. Loss of life expect- ancy from air pollution compared to other risk factors: a worldwide perspec- tive.  Cardiovasc Res  2020; 116 :1910 \u0002 1917. 160. Liu C, Chen R, Sera F, Vicedo-Cabrera AM, Guo Y, Tong S, Coelho M, Saldiva PHN, Lavigne E, Matus P, Valdes Ortega N, Osorio Garcia S, Pascal M, Stafoggia M, Scortichini M, Hashizume M, Honda Y, Hurtado-Diaz M, Cruz J, Nunes B, Teixeira JP, Kim H, Tobias A, Iniguez C, Forsberg B, Astrom C, Ragettli MS, Guo YL, Chen BY, Bell ML, Wright CY, Scovronick N, Garland RM, Milojevic A, Kysely J, Urban A, Orru H, Indermitte E, Jaakkola JJK, Ryti NRI, Katsouyanni K, Analitis A, Zanobetti A, Schwartz J, Chen J, Wu T, Cohen A, Gasparrini A, Kan H. Ambient Particulate Air Pollution and Daily Mortality in 652 Cities.  N Engl J Med  2019; 381 :705 \u0002 715. 161. Argacha JF, Mizukami T, Bourdrel T, Bind MA. Ecology of the cardiovascular system: Part II - A focus on non-air related pollutants.  Trends Cardiovasc Med 2019; 29 :274 \u0002 282. 162. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ Res 2012; 110 :658 \u0002 662. 163. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D’Agostino RB, Sr., Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez-de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard WJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction.  JAMA  2012; 307 :2499 \u0002 2506. 164. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013; 61 :1146 \u0002 1156. 165. Natriuretic Peptides Studies Collaboration, Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA, Pennells L, Gao P, Burgess S, Freitag DF, Sweeting M, Wood AM, Cook NR, Judd S, Trompet S, Nambi V, Olsen MH, Everett BM, Kee F, Arnlov J, Salomaa V, Levy D, Kauhanen J, Laukkanen JA, Kavousi M, Ninomiya T, Casas JP, Daniels LB, Lind L, Kistorp CN, Rosenberg J, Mueller T, Rubattu S, Panagiotakos DB, Franco OH, de Lemos JA, Luchner A, Kizer JR, Kiechl S, Salonen JT, Goya Wannamethee S, de Boer RA, Nordestgaard BG, Andersson J, Jorgensen T, Melander O, Ballantyne Ch M, DeFilippi C, Ridker PM, Cushman M, Rosamond WD, Thompson SG, Gudnason V, Sattar N, Danesh J, Di Angelantonio E. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant- data meta-analysis.  Lancet Diabetes Endocrinol  2016; 4 :840 \u0002 849. 166. Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW, Ford I, Trompet S, Stott DJ, Kearney PM, Mooijaart SP, Kiechl S, Di Angelantonio E, Sattar N. High-Sensitivity Cardiac Troponin Concentration and Risk of First- Ever Cardiovascular Outcomes in 154,052 Participants.  J Am Coll Cardiol 2017; 70 :558 \u0002 568. 167. Lamelas PM, Maheer K, Schwalm JD. Body mass index and mortality after acute coronary syndromes: a systematic review and meta-analysis.  Acta Cardiol 2017; 72 :655 \u0002 661. 168. Ma WQ, Sun XJ, Wang Y, Han XQ, Zhu Y, Liu NF. Does body mass index truly affect mortality and cardiovascular outcomes in patients after coronary revascu- larization with percutaneous coronary intervention or coronary artery bypass\ngraft? A systematic review and network meta-analysis. Obes Rev 2018; 19 :1236 \u0002 1247. 169. Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A, Hendriks J, Linz D, Gallagher C, Kaye D, Lau D, Sanders P. Complex interaction of obesity, intentional weight loss and heart failure: a systematic review and meta-analysis.  Heart  2020; 106 :58 \u0002 68. 170. Bell JA, Hamer M, Sabia S, Singh-Manoux A, Batty GD, Kivimaki M. The natural course of healthy obesity over 20 years.  J Am Coll Cardiol  2015; 65 :101 \u0002 102. 171. Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, Gutierrez OM, Hosseinpanah F, Iseki K, Kenealy T, Klein B, Kronenberg F, Lee BJ, Li Y, Miura K, Navaneethan SD, Roderick PJ, Valdivielso JM, Visseren FLJ, Zhang L, Gansevoort RT, Hallan SI, Levey AS, Matsushita K, Shalev V, Woodward M, CKD Prognosis Consortium (CKD-PC). Adiposity and risk of decline in glomer- ular filtration rate: meta-analysis of individual participant data in a global consor- tium.  BMJ  2019; 364 :k5301. 172. GBD Chronic Kidney Disease Collaboration. Global, regional, and national bur- den of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.  Lancet  2020; 395 :709 \u0002 733. 173. Celutkiene J, Pudil R, Lopez-Fernandez T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J, Cohen-Solal A, Farmakis D, Tocchetti CG, von Haehling S, Barberis V, Flachskampf FA, Ceponiene I, Haegler-Laube E, Suter T, Lapinskas T, Prasad S, de Boer RA, Wechalekar K, Anker MS, Iakobishvili Z, Bucciarelli- Ducci C, Schulz-Menger J, Cosyns B, Gaemperli O, Belenkov Y, Hulot JS, Galderisi M, Lancellotti P, Bax J, Marwick TH, Chioncel O, Jaarsma T, Mullens W, Piepoli M, Thum T, Heymans S, Mueller C, Moura B, Ruschitzka F, Zamorano JL, Rosano G, Coats AJS, Asteggiano R, Seferovic P, Edvardsen T, Lyon AR. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).  Eur J Heart Fail  2020; 22 :1504 \u0002 1524. 174. Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J. Enalapril and carvedilol for pre- venting chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).  J Am Coll Cardiol  2013; 61 :2355 \u0002 2362. 175. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardi- otoxicity with chemotherapy: a systematic review and meta-analysis.  Eur J Cancer  2013; 49 :2900 \u0002 2909. 176. Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Sodergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflamma- tory joint disorders: 2015/2016 update.  Ann Rheum Dis  2017; 76 :17 \u0002 28. 177. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, Troxel AB, Hennessy S, Kimmel SE, Margolis DJ, Choi H, Mehta NN, Gelfand JM. Risk of major cardio- vascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.  Ann Rheum Dis  2015; 74 :326 \u0002 332. 178. Hung YM, Chang WP, Wei JC, Chou P, Wang PY. Midlife Ankylosing Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years Later: A National Population-Based Study.  Medicine (Baltimore)  2016; 95 :e3596. 179. Adelborg K, Szepligeti SK, Holland-Bill L, Ehrenstein V, Horvath-Puho E, Henderson VW, Sorensen HT. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.  BMJ  2018; 360 :k96. 180. Mahmoud AN, Mentias A, Elgendy AY, Qazi A, Barakat AF, Saad M, Mohsen A, Abuzaid A, Mansoor H, Mojadidi MK, Elgendy IY. Migraine and the risk of cardi- ovascular and cerebrovascular events: a meta-analysis of 16 cohort studies including 1 152 407 subjects.  BMJ Open  2018; 8 :e020498. 181. Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F, Carolei A. Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies.  Eur J Neurol  2015; 22 :1001 \u0002 1011. 182. Chang CL, Donaghy M, Poulter N. Migraine and stroke in young women: case- control study. The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ 1999; 318 :13 \u0002 18. 183. Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, Jamieson DJ. Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke.  Am J Obstet Gynecol 2017; 216 :489 e481 \u0002 489 e487. 184. Engeland A, Bjorge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230,000 women in Norway.  Eur J Epidemiol  2011; 26 :157 \u0002 163.\nESC Guidelines 3317\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 185. Lykke JA, Langhoff-Roos J, Sibai BM, Funai EF, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother.  Hypertension  2009; 53 :944 \u0002 951. 186. Skjaerven R, Wilcox AJ, Klungsoyr K, Irgens LM, Vikse BE, Vatten LJ, Lie RT. Cardiovascular mortality after pre-eclampsia in one child mothers: prospective, population based cohort study.  BMJ  2012; 345 :e7677. 187. Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM, Hannaford P, Smith WC. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study.  BMJ  2003; 326 :845. 188. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009; 373 :1773 \u0002 1779. 189. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.  Hum Reprod Update  2010; 16 :347 \u0002 363. 190. Morgan CL, Jenkins-Jones S, Currie CJ, Rees DA. Evaluation of adverse out- come in young women with polycystic ovary syndrome versus matched, refer- ence controls: a retrospective, observational study.  J Clin Endocrinol Metab 2012; 97 :3251 \u0002 3260. 191. Venkataraman H, Sattar N, Saravanan P. Postnatal testing following gestational diabetes: time to replace the oral glucose tolerance test?  Lancet Diabetes Endocrinol  2015; 3 :754 \u0002 756. 192. Bonamy AK, Parikh NI, Cnattingius S, Ludvigsson JF, Ingelsson E. Birth charac- teristics and subsequent risks of maternal cardiovascular disease: effects of ges- tational age and fetal growth.  Circulation  2011; 124 :2839 \u0002 2846. 193. Lykke JA, Paidas MJ, Damm P, Triche EW, Kuczynski E, Langhoff-Roos J. Preterm delivery and risk of subsequent cardiovascular morbidity and type-II diabetes in the mother.  BJOG  2010; 117 :274 \u0002 281. 194. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single num- ber for advocacy and communication-worldwide more than 850 million individ- uals have kidney diseases.  Nephrol Dial Transplant  2019; 34 :1803 \u0002 1805. 195. GBD 2016 Causes of Death Collaborators. Global, regional, and national age- sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.  Lancet  2017; 390 :1151 \u0002 1210. 196. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.  Lancet  2013; 382 :339 \u0002 352. 197. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all- cause and cardiovascular mortality in general population cohorts: a collabora- tive meta-analysis.  Lancet  2010; 375 :2073 \u0002 2081. 198. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for athe- rosclerotic cardiovascular outcomes in the community.  J Am Coll Cardiol 2003; 41 :47 \u0002 55. 199. Dzaye O, Dudum R, Reiter-Brennan C, Kianoush S, Tota-Maharaj R, Cainzos- Achirica M, Blaha MJ. Coronary artery calcium scoring for individualized cardio- vascular risk estimation in important patient subpopulations after the 2019 AHA/ACC primary prevention guidelines. Prog Cardiovasc Dis 2019; 62 :423 \u0002 430. 200. Chen J, Budoff MJ, Reilly MP, Yang W, Rosas SE, Rahman M, Zhang X, Roy JA, Lustigova E, Nessel L, Ford V, Raj D, Porter AC, Soliman EZ, Wright JT, Jr., Wolf M, He J, CRIC Investigators. Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease.  JAMA Cardiol  2017; 2 :635 \u0002 643. 201. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, Peralta CA, Woodward M, Kramer HJ, Jacobs DR, Sarnak MJ, Coresh J. Subclinical athero- sclerosis measures for cardiovascular prediction in CKD.  J Am Soc Nephrol 2015; 26 :439 \u0002 447. 202. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J Am Soc Nephrol  2005; 16 :507 \u0002 513. 203. Budoff MJ, Rader DJ, Reilly MP, Mohler ER, 3rd, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI, CRIC Study Investigators. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study.  Am J Kidney Dis  2011; 58 :519 \u0002 526. 204. Wanner C, Amann K, Shoji T. The heart and vascular system in dialysis.  Lancet 2016; 388 :276 \u0002 284. 205. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: system- atic review and meta-analysis.  BMJ  2016; 354 :i4482. 206. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial fibrillation as risk factor for cardiovascular disease and death in women compared with men: systematic review and meta-analysis of cohort studies.  BMJ  2016; 532 :h7013.\n",
      "keywords": [
        "obesity",
        "lipid",
        "hypertension",
        "genetic",
        "scoring",
        "atherosclerosis",
        "intima-media",
        "perel",
        "diabetes",
        "coronary artery",
        "sex",
        "atrial fibrillation",
        "cochrane",
        "systolic dysfunction",
        "risk factor",
        "angiography",
        "echocardiography",
        "karmali",
        "lloyd",
        "primary",
        "database",
        "metabolic syndrome",
        "heart failure",
        "physical activity",
        "risk estimation",
        "troponin",
        "cardiovascular risk",
        "syst",
        "older",
        "systolic"
      ],
      "tables": []
    },
    {
      "number": "32",
      "title": "207. Lane DA, Skjoth F, Lip GYH, Larsen TB, Kotecha D. Temporal Trends in Incidence, Prevalence, and Mortality of Atrial Fibrillation in Primary Care.  J Am Heart Assoc  2017; 6 :e005155. 208. Ko D, R",
      "start_page": 91,
      "end_page": 92,
      "content": "3318 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail  2021; 23 :352 \u0002 380. 223. Chew DS, Heikki H, Schmidt G, Kavanagh KM, Dommasch M, Bloch Thomsen PE, Sinnecker D, Raatikainen P, Exner DV. Change in Left Ventricular Ejection Fraction Following First Myocardial Infarction and Outcome.  JACC Clin Electrophysiol  2018; 4 :672 \u0002 682. 224. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.  J Clin Oncol  2005; 23 :8597 \u0002 8605. 225. Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular dis- ease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.  Breast Cancer Res  2011; 13 :R64. 226. Darby S, McGale P, Peto R, Granath F, Hall P, Ekbom A. Mortality from cardio- vascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women.  BMJ  2003; 326 :256 \u0002 257. 227. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radio- therapy for breast cancer.  N Engl J Med  2013; 368 :987 \u0002 998. 228. Dahlen T, Edgren G, Lambe M, Hoglund M, Bjorkholm M, Sandin F, Sjalander A, Richter J, Olsson-Stromberg U, Ohm L, Back M, Stenke L, Swedish CML Group, Swedish CML Register Group. Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A Population- Based Cohort Study.  Ann Intern Med  2016; 165 :161 \u0002 166. 229. Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, Ky B, Sterba M, Cardinale D, Cohen-Solal A, Tocchetti CG, Farmakis D, Bergler-Klein J, Anker MS, Von Haehling S, Belenkov Y, Iakobishvili Z, Maack C, Ciardiello F, Ruschitzka F, Coats AJS, Seferovic P, Lainscak M, Piepoli MF, Chioncel O, Bax J, Hulot JS, Skouri H, Hagler-Laube ES, Asteggiano R, Fernandez TL, de Boer RA, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.  Eur J Heart Fail  2020; 22 :1966 \u0002 1983. 230. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW, Gravdehaug B, von Knobelsdorff-Brenkenhoff F, Bratland A, Storas TH, Hagve TA, Rosjo H, Steine K, Geisler J, Omland T. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J  2016; 37 :1671 \u0002 1680. 231. Narayan HK, French B, Khan AM, Plappert T, Hyman D, Bajulaiye A, Domchek S, DeMichele A, Clark A, Matro J, Bradbury A, Fox K, Carver JR, Ky B. Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. JACC Cardiovasc Imaging  2016; 9 :1131 \u0002 1141. 232. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardi- otoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol  2014; 63 :2751 \u0002 2768. 233. Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity.  Heart 2016; 102 :425 \u0002 430. 234. Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH. Angiotensin II- Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.  JAMA Oncol  2016; 2 :1030 \u0002 1037. 235. Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Pagano JJ, Chow K, Thompson RB, Vos LJ, Ghosh S, Oudit GY, Ezekowitz JA, Paterson DI. Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.  J Clin Oncol  2017; 35 :870 \u0002 877. 236. Jones LW, Habel LA, Weltzien E, Castillo A, Gupta D, Kroenke CH, Kwan ML, Quesenberry CP, Jr., Scott J, Sternfeld B, Yu A, Kushi LH, Caan BJ. Exercise and Risk of Cardiovascular Events in Women With Nonmetastatic Breast Cancer.  J Clin Oncol  2016; 34 :2743 \u0002 2749. 237. Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol 2016; 34 :1122 \u0002 1130.\n",
      "keywords": [
        "kotecha",
        "trends",
        "larsen",
        "fibrillation",
        "heart",
        "prevalence",
        "echocardiography",
        "ejection fraction",
        "primary",
        "care",
        "heart failure",
        "mortality",
        "atrial",
        "older",
        "lane",
        "skjoth",
        "temporal",
        "exercise",
        "incidence",
        "assoc"
      ],
      "tables": []
    },
    {
      "number": "33",
      "title": "238. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comor- bidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.  Lancet Respir ",
      "start_page": 92,
      "end_page": 95,
      "content": "ESC Guidelines 3319\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 261. Macchia A, Rodriguez Moncalvo JJ, Kleinert M, Comignani PD, Gimeno G, Arakaki D, Laffaye N, Fuselli JJ, Massolin HP, Gambarte J, Romero M, Tognoni G. Unrecognised ventricular dysfunction in COPD.  Eur Respir J  2012; 39 :51 \u0002 58. 262. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E, Jr., She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients.  Ann Epidemiol 2006; 16 :63 \u0002 70. 263. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of dia- betes, hypertension and cardiovascular disease in COPD.  Eur Respir J 2008; 32 :962 \u0002 969. 264. Li C, Cheng W, Guo J, Guan W. Relationship of inhaled long-acting bronchodi- lators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials.  Int J Chron Obstruct Pulmon Dis  2019; 14 :799 \u0002 808. 265. Singh S, Singh H, Loftus EV, Jr., Pardi DS. Risk of cerebrovascular accidents and ische- mic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis.  Clin Gastroenterol Hepatol  2014; 12 :382 \u0002 393 e381: quiz e322. 266. Hsue PY, Waters DD. HIV infection and coronary heart disease: mechanisms and management.  Nat Rev Cardiol  2019; 16 :745 \u0002 759. 267. Sinha A, Feinstein MJ. Coronary Artery Disease Manifestations in HIV: What, How, and Why.  Can J Cardiol  2019; 35 :270 \u0002 279. 268. Beckman JA, Duncan MS, Alcorn CW, So-Armah K, Butt AA, Goetz MB, Tindle HA, Sico JJ, Tracy RP, Justice AC, Freiberg MS. Association of Human Immunodeficiency Virus Infection and Risk of Peripheral Artery Disease. Circulation  2018; 138 :255 \u0002 265. 269. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination.  N Engl J Med  2004; 351 :2611 \u0002 2618. 270. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, Ciszewski A, Vakili H, Hoffman EB, Farkouh ME, Cannon CP. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis.  JAMA  2013; 310 :1711 \u0002 1720. 271. Dietrich T, Jimenez M, Krall Kaye EA, Vokonas PS, Garcia RI. Age-dependent associations between chronic periodontitis/edentulism and risk of coronary heart disease.  Circulation  2008; 117 :1668 \u0002 1674. 272. Carrizales-Sepulveda EF, Ordaz-Farias A, Vera-Pineda R, Flores-Ramirez R. Periodontal Disease, Systemic Inflammation and the Risk of Cardiovascular Disease.  Heart Lung Circ  2018; 27 :1327 \u0002 1334. 273. Ryden L, Buhlin K, Ekstrand E, de Faire U, Gustafsson A, Holmer J, Kjellstrom B, Lindahl B, Norhammar A, Nygren A, Nasman P, Rathnayake N, Svenungsson E, Klinge B. Periodontitis Increases the Risk of a First Myocardial Infarction: A Report From the PAROKRANK Study.  Circulation  2016; 133 :576 \u0002 583. 274. Qi J, Zihang Z, Zhang J, Park YM, Shrestha D, Jianling B, Merchant AT. Periodontal Antibodies and All-Cause and Cardiovascular Disease Mortality.  J Dent Res  2020; 99 :51 \u0002 59. 275. Lee YL, Hu HY, Chou P, Chu D. Dental prophylaxis decreases the risk of acute myocardial infarction: a nationwide population-based study in Taiwan.  Clin Interv Aging  2015; 10 :175 \u0002 182. 276. Holmlund A, Lampa E, Lind L. Poor Response to Periodontal Treatment May Predict Future Cardiovascular Disease.  J Dent Res  2017; 96 :768 \u0002 773. 277. Park SY, Kim SH, Kang SH, Yoon CH, Lee HJ, Yun PY, Youn TJ, Chae IH. Improved oral hygiene care attenuates the cardiovascular risk of oral health dis- ease: a population-based study from Korea.  Eur Heart J  2019; 40 :1138 \u0002 1145. 278. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabe E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boufous S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brugha TS, Bryan-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Calabria B, Campbell B, Canter CE, Carabin H, Carapetis J, Carmona L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahiya M, Dahodwala N, Damsere-Derry J, Danaei G, Davis A, De Leo D, Degenhardt L, Dellavalle R, Delossantos A, Denenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel B, Edmond K, Elbaz A, Ali SE, Erskine H, Erwin PJ, Espindola P, Ewoigbokhan SE, Farzadfar F, Feigin V, Felson DT, Ferrari A, Ferri CP, Fevre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe BJ, Gabriel SE, Gakidou E, Ganatra HA, Garcia B, Gaspari F, Gillum RF, Gmel G, Gosselin R, Grainger R, Groeger J, Guillemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill\nC, Hoen B, Hoffman H, Hotez PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lalloo R, Laslett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshultz SE, Liu W, Loane M, Ohno SL, Lyons R, Ma J, Mabweijano J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGill N, McGrath J, Medina-Mora ME, Meltzer M, Mensah GA, Merriman TR, Meyer AC, Miglioli V, Miller M, Miller TR, Mitchell PB, Mocumbi AO, Moffitt TE, Mokdad AA, Monasta L, Montico M, Moradi-Lakeh M, Moran A, Morawska L, Mori R, Murdoch ME, Mwaniki MK, Naidoo K, Nair MN, Naldi L, Narayan KM, Nelson PK, Nelson RG, Nevitt MC, Newton CR, Nolte S, Norman P, Norman R, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortblad K, Osborne R, Ozgediz D, Page A, Pahari B, Pandian JD, Rivero AP, Patten SB, Pearce N, Padilla RP, Perez-Ruiz F, Perico N, Pesudovs K, Phillips D, Phillips MR, Pierce K, Pion S, Polanczyk GV, Polinder S, Pope CA, 3rd, Popova S, Porrini E, Pourmalek F, Prince M, Pullan RL, Ramaiah KD, Ranganathan D, Razavi H, Regan M, Rehm JT, Rein DB, Remuzzi G, Richardson K, Rivara FP, Roberts T, Robinson C, De Leon FR, Ronfani L, Room R, Rosenfeld LC, Rushton L, Sacco RL, Saha S, Sampson U, Sanchez-Riera L, Sanman E, Schwebel DC, Scott JG, Segui-Gomez M, Shahraz S, Shepard DS, Shin H, Shivakoti R, Singh D, Singh GM, Singh JA, Singleton J, Sleet DA, Sliwa K, Smith E, Smith JL, Stapelberg NJ, Steer A, Steiner T, Stolk WA, Stovner LJ, Sudfeld C, Syed S, Tamburlini G, Tavakkoli M, Taylor HR, Taylor JA, Taylor WJ, Thomas B, Thomson WM, Thurston GD, Tleyjeh IM, Tonelli M, Towbin JA, Truelsen T, Tsilimbaris MK, Ubeda C, Undurraga EA, van der Werf MJ, van Os J, Vavilala MS, Venketasubramanian N, Wang M, Wang W, Watt K, Weatherall DJ, Weinstock MA, Weintraub R, Weisskopf MG, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams SR, Witt E, Wolfe F, Woolf AD, Wulf S, Yeh PH, Zaidi AK, Zheng ZJ, Zonies D, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.  Lancet  2012; 380 :2163 \u0002 2196. 279. Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JE, Rexrode KM. Migraine and risk of cardiovascular disease in women: prospective cohort study.  BMJ  2016; 353 :i2610. 280. Schurks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ 2009; 339 :b3914. 281. Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep  2014; 16 :524. 282. Sacco S, Merki-Feld GS, KL AE, Bitzer J Canonico M, Kurth T, Lampl C, Lidegaard O, Anne MacGregor E, MaassenVanDenBrink A, Mitsikostas DD, Nappi RE, Ntaios G, Sandset PM, Martelletti p, European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC).  J Headache Pain  2017; 18 :108. 283. Ornello R, Canonico M, Merki-Feld GS, Kurth T, Lidegaard O, MacGregor EA, Lampl C, Nappi RE, Martelletti P, Sacco S. Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and sug- gestions for future research.  Expert Rev Neurother  2020; 20 :313 \u0002 317. 284. Badran M, Yassin BA, Fox N, Laher I, Ayas N. Epidemiology of Sleep Disturbances and Cardiovascular Consequences. Can J Cardiol 2015; 31 :873 \u0002 879. 285. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis.  Eur J Prev Cardiol  2014; 21 :57 \u0002 64. 286. Ge L, Guyatt G, Tian J, Pan B, Chang Y, Chen Y, Li H, Zhang J, Li Y, Ling J, Yang K. Insomnia and risk of mortality from all-cause, cardiovascular disease, and can- cer: Systematic review and meta-analysis of prospective cohort studies.  Sleep Med Rev  2019; 48 :101215. 287. Yin J, Jin X, Shan Z, Li S, Huang H, Li P, Peng X, Peng Z, Yu K, Bao W, Yang W, Chen X, Liu L. Relationship of Sleep Duration With All-Cause Mortality and Cardiovascular Events: A Systematic Review and Dose-Response Meta-Analysis of Prospective Cohort Studies.  J Am Heart Assoc  2017; 6 :e005947. 288. Kerkhof GA. Epidemiology of sleep and sleep disorders in The Netherlands. Sleep Med  2017; 30 :229 \u0002 239. 289. Remi J, Pollmacher T, Spiegelhalder K, Trenkwalder C, Young P. Sleep-Related Disorders in Neurology and Psychiatry.  Dtsch Arztebl Int  2019; 116 :681 \u0002 688. 290. Kalmbach DA, Cuamatzi-Castelan AS, Tonnu CV, Tran KM, Anderson JR, Roth T, Drake CL. Hyperarousal and sleep reactivity in insomnia: current insights. Nat Sci Sleep  2018; 10 :193 \u0002 201. 291. Tietjens JR, Claman D, Kezirian EJ, De Marco T, Mirzayan A, Sadroonri B, Goldberg AN, Long C, Gerstenfeld EP, Yeghiazarians, Y. Obstructive Sleep\n3320 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy. J Am Heart Assoc 2019; 8 :e010440. 292. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, Mediano O, Chen R, Drager LF, Liu Z, Chen G, Du B, McArdle N, Mukherjee S, Tripathi M, Billot L, Li Q, Lorenzi-Filho G, Barbe F, Redline S, Wang J, Arima H, Neal B, White DP, Grunstein RR, Zhong N, Anderson CS, SAVE Investigators and Coordinators. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea.  N Engl J Med  2016; 375 :919 \u0002 931. 293. Collen J, Lettieri C, Wickwire E, Holley A. Obstructive sleep apnea and cardio- vascular disease, a story of confounders!  Sleep Breath  2020; 24 :1299 \u0002 1313. 294. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S, INCOSACT Initiative (International Collaboration of Sleep Apnea Cardiovascular Trialists). Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science.  Circulation  2017; 136 :1840 \u0002 1850. 295. Kasiakogias A, Tsioufis C, Thomopoulos C, Tousoulis D. Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnoea.  J Hypertens  2014; 32 :2279 \u0002 2280. 296. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, Olesen J, Allgulander C, Alonso J, Faravelli C, Fratiglioni L, Jennum P, Lieb R, Maercker A, van Os J, Preisig M, Salvador-Carulla L, Simon R, Steinhausen HC. The size and burden of mental disorders and other disorders of the brain in Europe 2010.  Eur Neuropsychopharmacol  2011; 21 :655 \u0002 679. 297. Krupchanka D, Mlada K, Winkler P, Khazaal Y, Albanese E. Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study.  Lancet Public Health  2018; 3 :e289 \u0002 e295. 298. Starace F, Mungai F, Baccari F, Galeazzi GM. Excess mortality in people with mental illness: findings from a Northern Italy psychiatric case register.  Soc Psychiatry Psychiatr Epidemiol  2018; 53 :249 \u0002 257. 299. John U, Rumpf HJ, Hanke M, Meyer C. Mental disorders and total mortality after 20 years in an adult general population sample.  Eur Psychiatry  2020; 63 :e30. 300. Lawrence D, Hancock KJ, Kisely S. The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analy- sis of population based registers.  BMJ  2013; 346 :f2539. 301. Scott KM, de Jonge P, Alonso J, Viana MC, Liu Z, O’Neill S, Aguilar-Gaxiola S, Bruffaerts R, Caldas-de-Almeida JM, Stein DJ, de Girolamo G, Florescu SE, Hu C, Taib NI, Lepine JP, Levinson D, Matschinger H, Medina-Mora ME, Piazza M, Posada-Villa JA, Uda H, Wojtyniak BJ, Lim CC, Kessler RC. Associations between DSM-IV mental disorders and subsequent heart disease onset: beyond depression.  Int J Cardiol  2013; 168 :5293 \u0002 5299. 302. Harter M, Baumeister H, Reuter K, Jacobi F, Hofler M, Bengel J, Wittchen HU. Increased 12-month prevalence rates of mental disorders in patients with chronic somatic diseases.  Psychother Psychosom  2007; 76 :354 \u0002 360. 303. Dar T, Radfar A, Abohashem S, Pitman RK, Tawakol A, Osborne MT. Psychosocial Stress and Cardiovascular Disease.  Curr Treat Options Cardiovasc Med  2019; 21 :23. 304. Zhang WY, Nan N, Song XT, Tian JF, Yang XY. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and meta-analysis.  BMJ Open  2019; 9 :e026445. 305. Petersen BD, Stenager E, Mogensen CB, Erlangsen A. The association between heart diseases and suicide: a nationwide cohort study. J Intern Med 2020; 287 :558 \u0002 568. 306. Duflou J. Psychostimulant use disorder and the heart. Addiction 2020; 115 :175 \u0002 183. 307. Schnyder N, Panczak R, Groth N, Schultze-Lutter F. Association between men- tal health-related stigma and active help-seeking: systematic review and meta- analysis.  Br J Psychiatry  2017; 210 :261 \u0002 268. 308. Knaak S, Mantler E, Szeto A. Mental illness-related stigma in healthcare: Barriers to access and care and evidence-based solutions.  Healthc Manage Forum 2017; 30 :111 \u0002 116. 309. Henderson C, Noblett J, Parke H, Clement S, Caffrey A, Gale-Grant O, Schulze B, Druss B, Thornicroft G. Mental health-related stigma in health care and men- tal health-care settings.  Lancet Psychiatry  2014; 1 :467 \u0002 482. 310. Thornicroft G. Physical health disparities and mental illness: the scandal of pre- mature mortality.  Br J Psychiatry  2011; 199 :441 \u0002 442. 311. Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction of cardiovascular disease risk among people with severe mental ill- ness: A cohort study.  PLoS One  2019; 14 :e0221521. 312. Piepoli MF, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano AL, Corra U, Cosyns B, Deaton C, Graham I, Hoes A, Lochen ML, Matrone B, Redon J, Sattar N, Smulders Y, Tiberi M. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology.  Eur J Prev Cardiol 2020; 27 :181 \u0002 205. 313. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Dhalwani NN, Kendrick S, Celis-Morales C, Waterworth DM, Alazawi W,\nSattar N. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults.  BMJ  2019; 367 :l5367. 314. Young L, Cho L. Unique cardiovascular risk factors in women.  Heart 2019; 105 :1656 \u0002 1660. 315. Dam V, Onland-Moret NC, Verschuren WMM, Boer JMA, Benschop L, Franx A, Moons KGM, Boersma E, van der Schouw YT, CREW-consortium. Cardiovascular risk model performance in women with and without hyperten- sive disorders of pregnancy.  Heart  2019; 105 :330 \u0002 336. 316. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN, Gore GC, Ray JG, Nerenberg K, Platt RW. Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications.  Circulation  2019; 139 :1069 \u0002 1079. 317. Riise HKR, Sulo G, Tell GS, Igland J, Nygard O, Iversen AC, Daltveit AK. Association Between Gestational Hypertension and Risk of Cardiovascular Disease Among 617 589 Norwegian Women. J Am Heart Assoc 2018; 7 :e008337. 318. Grandi SM, Reynier P, Platt RW, Basso O, Filion KB. The timing of onset of hypertensive disorders in pregnancy and the risk of incident hypertension and cardiovascular disease.  Int J Cardiol  2018; 270 :273 \u0002 275. 319. Timpka S, Markovitz A, Schyman T, Mogren I, Fraser A, Franks PW, Rich- Edwards JW. Midlife development of type 2 diabetes and hypertension in women by history of hypertensive disorders of pregnancy.  Cardiovasc Diabetol 2018; 17 :124. 320. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of car- diovascular disease in women: a systematic review and meta-analysis. Diabetologia  2019; 62 :905 \u0002 914. 321. Claesson R, Ignell C, Shaat N, Berntorp K. HbA1c as a predictor of diabetes after gestational diabetes mellitus.  Prim Care Diabetes  2017; 11 :46 \u0002 51. 322. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of pol- ycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis.  Oncotarget  2017; 8 :96351 \u0002 96358. 323. Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, Han L. Measuring the global dis- ease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017.  Hum Reprod  2021; 36 :1108 \u0002 1119. 324. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93 :1276 \u0002 1284. 325. Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, Kavousi M, Franco OH. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analy- sis.  JAMA Cardiol  2016; 1 :767 \u0002 776. 326. Ding DC, Tsai IJ, Wang JH, Lin SZ, Sung FC. Coronary artery disease risk in young women with polycystic ovary syndrome. Oncotarget 2018; 9 :8756 \u0002 8764. 327. Hong JS, Yi SW, Kang HC, Jee SH, Kang HG, Bayasgalan G, Ohrr H. Age at menopause and cause-specific mortality in South Korean women: Kangwha Cohort Study.  Maturitas  2007; 56 :411 \u0002 419. 328. Zhao L, Zhu Z, Lou H, Zhu G, Huang W, Zhang S, Liu F. Polycystic ovary syn- drome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget  2016; 7 :33715 \u0002 33721. 329. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early meno- pause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis.  Menopause  2012; 19 :1081 \u0002 1087. 330. DeLay KJ, Haney N, Hellstrom WJ. Modifying Risk Factors in the Management of Erectile Dysfunction: A Review.  World J Mens Health  2016; 34 :89 \u0002 100. 331. Kessler A, Sollie S, Challacombe B, Briggs K, Van Hemelrijck M. The global prevalence of erectile dysfunction: a review.  BJU Int  2019:[Online ahead of print]. 332. Ibrahim A, Ali M, Kiernan TJ, Stack AG. Erectile Dysfunction and Ischaemic Heart Disease.  Eur Cardiol  2018; 13 :98 \u0002 103. 333. Miner M, Nehra A, Jackson G, Bhasin S, Billups K, Burnett AL, Buvat J, Carson C, Cunningham G, Ganz P, Goldstein I, Guay A, Hackett G, Kloner RA, Kostis JB, LaFlamme KE, Montorsi P, Ramsey M, Rosen R, Sadovsky R, Seftel A, Shabsigh R, Vlachopoulos C, Wu F. All men with vasculogenic erectile dysfunc- tion require a cardiovascular workup.  Am J Med  2014; 127 :174 \u0002 182. 334. Montorsi P, Ravagnani PM, Galli S, Salonia A, Briganti A, Werba JP, Montorsi F. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. Eur Urol 2006; 50 :721 \u0002 731.\nESC Guidelines 3321\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 335. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, Aznaouridis KA, Stefanadis CI. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes  2013; 6 :99 \u0002 109. 336. Zhao B, Zhang W. Does erectile dysfunction independently predict cardiovas- cular events? It’s time to act on the evidence. Eur J Prev Cardiol 2018; 25 :1307 \u0002 1311. 337. Chrysant SG. Antihypertensive therapy causes erectile dysfunction.  Curr Opin Cardiol  2015; 30 :383 \u0002 390. 338. Fan Y, Hu B, Man C, Cui F. Erectile dysfunction and risk of cardiovascular and all-cause mortality in the general population: a meta-analysis of cohort studies. World J Urol  2018; 36 :1681 \u0002 1689. 339. Imprialos KP, Stavropoulos K, Doumas M, Tziomalos K, Karagiannis A, Athyros VG. Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Curr Vasc Pharmacol  2018; 16 :130 \u0002 142. 340. Osondu CU, Vo B, Oni ET, Blaha MJ, Veledar E, Feldman T, Agatston AS, Nasir K, Aneni EC. The relationship of erectile dysfunction and subclinical cardiovas- cular disease: A systematic review and meta-analysis.  Vasc Med  2018; 23 :9 \u0002 20. 341. Raheem OA, Su JJ, Wilson JR, Hsieh TC. The Association of Erectile Dysfunction and Cardiovascular Disease: A Systematic Critical Review.  Am J Mens Health  2017; 11 :552 \u0002 563. 342. Gowani Z, Uddin SMI, Mirbolouk M, Ayyaz D, Billups KL, Miner M, Feldman DI, Blaha MJ. Vascular Erectile Dysfunction and Subclinical Cardiovascular Disease. Curr Sex Health Rep  2017; 9 :305 \u0002 312. 343. Shah NP, Cainzos-Achirica M, Feldman DI, Blumenthal RS, Nasir K, Miner MM, Billups KL, Blaha MJ. Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist.  Am J Med 2016; 129 :251 \u0002 259. 344. Gerbild H, Larsen CM, Graugaard C, Areskoug Josefsson K. Physical Activity to Improve Erectile Function: A Systematic Review of Intervention Studies.  Sex Med  2018; 6 :75 \u0002 89. 345. Vlachopoulos C, Jackson G, Stefanadis C, Montorsi P. Erectile dysfunction in the cardiovascular patient.  Eur Heart J  2013; 34 :2034 \u0002 2046. 346. Rachamin Y, Grischott T, Rosemann T, Meyer MR. Inferior control of low- density lipoprotein cholesterol in women is the primary sex difference in modi- fiable cardiovascular risk: A large-scale, cross-sectional study in primary care. Atherosclerosis  2021; 324 :141 \u0002 147. 347. Victor BM, Teal V, Ahedor L, Karalis DG. Gender differences in achieving opti- mal lipid goals in patients with coronary artery disease.  Am J Cardiol 2014; 113 :1611 \u0002 1615. 348. Virani SS, Woodard LD, Ramsey DJ, Urech TH, Akeroyd JM, Shah T, Deswal A, Bozkurt B, Ballantyne CM, Petersen LA. Gender disparities in evidence-based statin therapy in patients with cardiovascular disease. Am J Cardiol 2015; 115 :21 \u0002 26. 349. Xia S, Du X, Guo L, Du J, Arnott C, Lam CSP, Huffman MD, Arima H, Yuan Y, Zheng Y, Wu S, Guang X, Zhou X, Lin H, Cheng X, Anderson CS, Dong J, Ma C. Sex Differences in Primary and Secondary Prevention of Cardiovascular Disease in China.  Circulation  2020; 141 :530 \u0002 539. 350. Hyun KK, Redfern J, Patel A, Peiris D, Brieger D, Sullivan D, Harris M, Usherwood T, MacMahon S, Lyford M, Woodward M. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare. Heart  2017; 103 :492 \u0002 498. 351. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovas- cular disease prevention: what a difference a decade makes.  Circulation 2011; 124 :2145 \u0002 2154. 352. Wandell PE, de Waard AM, Holzmann MJ, Gornitzki C, Lionis C, de Wit N, Sondergaard J, Sonderlund AL, Kral N, Seifert B, Korevaar JC, Schellevis FG, Carlsson AC. Barriers and facilitators among health professionals in primary care to prevention of cardiometabolic diseases: A systematic review.  Fam Pract 2018; 35 :383 \u0002 398. 353. Astin F, Lucock M, Jennings CS. Heart and mind: behavioural cardiology demys- tified for the clinician.  Heart  2019; 105 :881 \u0002 888. 354. Lee WW, Choi KC, Yum RW, Yu DS, Chair SY. Effectiveness of motivational interviewing on lifestyle modification and health outcomes of clients at risk or diagnosed with cardiovascular diseases: A systematic review.  Int J Nurs Stud 2016; 53 :331 \u0002 341. 355. Zulman DM, Haverfield MC, Shaw JG, Brown-Johnson CG, Schwartz R, Tierney AA, Zionts DL, Safaeinili N, Fischer M, Thadaney Israni S, Asch SM, Verghese A. Practices to Foster Physician Presence and Connection With Patients in the Clinical Encounter.  JAMA  2020; 323 :70 \u0002 81. 356. Miller WR, Rose GS. Toward a theory of motivational interviewing.  Am Psychol 2009; 64 :527 \u0002 537. 357. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions.  Implement Sci 2011; 6 :42.\n",
      "keywords": [
        "respir",
        "peripheral artery",
        "lipid",
        "hypertension",
        "fitzgerald",
        "atherosclerosis",
        "thomas",
        "diabetes",
        "coronary artery",
        "sex",
        "secondary prevention",
        "statin",
        "risk factor",
        "pulmonary",
        "chronic",
        "sadatsafavi",
        "physical activity",
        "review",
        "ethnicity",
        "bidity",
        "gender",
        "meta",
        "cardiovascular risk",
        "cholesterol",
        "lancet",
        "analysis",
        "antihypertensive",
        "hba1c",
        "chen",
        "blood pressure"
      ],
      "tables": []
    },
    {
      "number": "34",
      "title": "358. Ambrosetti M, Abreu A, Corra U, Davos CH, Hansen D, Frederix I, Iliou MC, Pedretti RF, Schmid JP, Vigorito C, Voller H, Wilhelm M, Piepoli MF, Bjarnason- Wehrens B, Berger T, Cohen-Solal A, Corne",
      "start_page": 95,
      "end_page": 96,
      "content": "3322 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 378. Liu Y, Lee DC, Li Y, Zhu W, Zhang R, Sui X, Lavie CJ, Blair SN. Associations of Resistance Exercise with Cardiovascular Disease Morbidity and Mortality.  Med Sci Sports Exerc  2019; 51 :499 \u0002 508. 379. Saeidifard F, Medina-Inojosa JR, West CP, Olson TP, Somers VK, Bonikowske AR, Prokop LJ, Vinciguerra M, Lopez-Jimenez F. The association of resistance training with mortality: A systematic review and meta-analysis.  Eur J Prev Cardiol 2019; 26 :1647 \u0002 1665. 380. Cradock KA, OL G, Finucane FM, Gainforth HL, Quinlan LR, Ginis KA. Behaviour change techniques targeting both diet and physical activity in type 2 diabetes: A systematic review and meta-analysis.  Int J Behav Nutr Phys Act 2017; 14 :18. 381. Howlett N, Trivedi D, Troop NA, Chater AM. Are physical activity interven- tions for healthy inactive adults effective in promoting behavior change and maintenance, and which behavior change techniques are effective? A systematic review and meta-analysis.  Transl Behav Med  2019; 9 :147 \u0002 157. 382. Brickwood KJ, Watson G, O’Brien J, Williams AD. Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis.  JMIR Mhealth Uhealth  2019; 7 :e11819. 383. Kyu HH, Bachman VF, Alexander LT, Mumford JE, Afshin A, Estep K, Veerman JL, Delwiche K, Iannarone ML, Moyer ML, Cercy K, Vos T, Murray CJ, Forouzanfar MH. Physical activity and risk of breast cancer, colon cancer, diabe- tes, ischemic heart disease, and ischemic stroke events: systematic review and dose-response meta-analysis for the Global Burden of Disease Study 2013.  BMJ 2016; 354 :i3857. 384. Wahid A, Manek N, Nichols M, Kelly P, Foster C, Webster P, Kaur A, Friedemann Smith C, Wilkins E, Rayner M, Roberts N, Scarborough P. Quantifying the Association Between Physical Activity and Cardiovascular Disease and Diabetes: A Systematic Review and Meta-Analysis.  J Am Heart Assoc 2016; 5 :e002495. 385. Moore SC, Patel AV, Matthews CE, Berrington de Gonzalez A, Park Y, Katki HA, Linet MS, Weiderpass E, Visvanathan K, Helzlsouer KJ, Thun M, Gapstur SM, Hartge P, Lee IM. Leisure time physical activity of moderate to vigorous intensity and mortality: a large pooled cohort analysis. PLoS Med 2012; 9 :e1001335. 386. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, Keadle SK, Arem H, Berrington de Gonzalez A, Hartge P, Adami HO, Blair CK, Borch KB, Boyd E, Check DP, Fournier A, Freedman ND, Gunter M, Johannson M, Khaw KT, Linet MS, Orsini N, Park Y, Riboli E, Robien K, Schairer C, Sesso H, Spriggs M, Van Dusen R, Wolk A, Matthews CE, Patel AV. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults.  JAMA Intern Med  2016; 176 :816 \u0002 825. 387. Arem H, Moore SC, Patel A, Hartge P, Berrington de Gonzalez A, Visvanathan K, Campbell PT, Freedman M, Weiderpass E, Adami HO, Linet MS, Lee IM, Matthews CE. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship.  JAMA Intern Med  2015; 175 :959 \u0002 967. 388. Pelliccia A, Sharma S, Gati S, Back M, Borjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M, ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.  Eur Heart J  2021; 42 :17 \u0002 96. 389. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC, Swain DP, American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise.  Med Sci Sports Exerc  2011; 43 :1334 \u0002 1359. 390. Jakicic JM, Kraus WE, Powell KE, Campbell WW, Janz KF, Troiano RP, Sprow K, Torres A, Piercy KL, 2018 Physical Activity Guidelines Advisory Committee. Association between Bout Duration of Physical Activity and Health: Systematic Review.  Med Sci Sports Exerc  2019; 51 :1213 \u0002 1219. 391. Ainsworth BE, Haskell WL, Herrmann SD, Meckes N, Bassett DR, Jr., Tudor- Locke C, Greer JL, Vezina J, Whitt-Glover MC, Leon AS. 2011 Compendium of Physical Activities: a second update of codes and MET values.  Med Sci Sports Exerc  2011; 43 :1575 \u0002 1581. 392. Howley ET. Type of activity: resistance, aerobic and leisure versus occupational physical activity.  Med Sci Sports Exerc  2001; 33 :S364 \u0002 369; discussion S419-320. 393. Ortega FB, Silventoinen K, Tynelius P, Rasmussen F. Muscular strength in male adolescents and premature death: cohort study of one million participants.  BMJ 2012; 345 :e7279. 394. Ruiz JR, Sui X, Lobelo F, Morrow JR, Jr., Jackson AW, Sjostrom M, Blair SN. Association between muscular strength and mortality in men: prospective cohort study.  BMJ  2008; 337 :a439. 395. Volaklis KA, Halle M, Meisinger C. Muscular strength as a strong predictor of mortality: A narrative review.  Eur J Intern Med  2015; 26 :303 \u0002 310.\n",
      "keywords": [
        "iliou",
        "piepoli",
        "male",
        "hansen",
        "vigorito",
        "diabetes",
        "corne",
        "schmid",
        "diet",
        "frederix",
        "berger",
        "voller",
        "physical activity",
        "solal",
        "cohen",
        "wilhelm",
        "ambrosetti",
        "exercise",
        "abreu",
        "davos",
        "wehrens",
        "bjarnason",
        "corra",
        "pedretti"
      ],
      "tables": []
    },
    {
      "number": "35",
      "title": "396. Chastin SFM, De Craemer M, De Cocker K, Powell L, Van Cauwenberg J, Dall P, Hamer M, Stamatakis E. How does light-intensity physical activity associate with adult cardiometabolic health and morta",
      "start_page": 96,
      "end_page": 98,
      "content": "ESC Guidelines 3323\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 413. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer RM, Verschuren WMM, Sato S, Njolstad I, Woodward M, Salomaa V, Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg P, Gallacher J, de la Camara AG, Volzke H, Dahm CC, Dale CE, Bergmann MM, Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD, Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, Sacerdote C, Wallace RB, Quiros JR, Tumino R, Blazer DG, 2nd, Linneberg A, Daimon M, Panico S, Howard B, Skeie G, Strandberg T, Weiderpass E, Nietert PJ, Psaty BM, Kromhout D, Salamanca-Fernandez E, Kiechl S, Krumholz HM, Grioni S, Palli D, Huerta JM, Price J, Sundstrom J, Arriola L, Arima H, Travis RC, Panagiotakos DB, Karakatsani A, Trichopoulou A, Kuhn T, Grobbee DE, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kauhanen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Despres JP, Cushman M, Cooper JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiman M, Voortman T, Meisinger C, Tjonneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G, Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J, Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective stud- ies.  Lancet  2018; 391 :1513 \u0002 1523. 414. Millwood IY, Walters RG, Mei XW, Guo Y, Yang L, Bian Z, Bennett DA, Chen Y, Dong C, Hu R, Zhou G, Yu B, Jia W, Parish S, Clarke R, Davey Smith G, Collins R, Holmes MV, Li L, Peto R, Chen Z, China Kadoorie Biobank Collaborative Group. Conventional and genetic evidence on alcohol and vascu- lar disease aetiology: a prospective study of 500 000 men and women in China. Lancet  2019; 393 :1831 \u0002 1842. 415. Holmes MV, Dale CE, Zuccolo L, Silverwood RJ, Guo Y, Ye Z, Prieto-Merino D, Dehghan A, Trompet S, Wong A, Cavadino A, Drogan D, Padmanabhan S, Li S, Yesupriya A, Leusink M, Sundstrom J, Hubacek JA, Pikhart H, Swerdlow DI, Panayiotou AG, Borinskaya SA, Finan C, Shah S, Kuchenbaecker KB, Shah T, Engmann J, Folkersen L, Eriksson P, Ricceri F, Melander O, Sacerdote C, Gamble DM, Rayaprolu S, Ross OA, McLachlan S, Vikhireva O, Sluijs I, Scott RA, Adamkova V, Flicker L, Bockxmeer FM, Power C, Marques-Vidal P, Meade T, Marmot MG, Ferro JM, Paulos-Pinheiro S, Humphries SE, Talmud PJ, Mateo Leach I, Verweij N, Linneberg A, Skaaby T, Doevendans PA, Cramer MJ, van der Harst P, Klungel OH, Dowling NF, Dominiczak AF, Kumari M, Nicolaides AN, Weikert C, Boeing H, Ebrahim S, Gaunt TR, Price JF, Lannfelt L, Peasey A, Kubinova R, Pajak A, Malyutina S, Voevoda MI, Tamosiunas A, Maitland-van der Zee AH, Norman PE, Hankey GJ, Bergmann MM, Hofman A, Franco OH, Cooper J, Palmen J, Spiering W, de Jong PA, Kuh D, Hardy R, Uitterlinden AG, Ikram MA, Ford I, Hypponen E, Almeida OP, Wareham NJ, Khaw KT, Hamsten A, Husemoen LL, Tjonneland A, Tolstrup JS, Rimm E, Beulens JW, Verschuren WM, Onland-Moret NC, Hofker MH, Wannamethee SG, Whincup PH, Morris R, Vicente AM, Watkins H, Farrall M, Jukema JW, Meschia J, Cupples LA, Sharp SJ, Fornage M, Kooperberg C, LaCroix AZ, Dai JY, Lanktree MB, Siscovick DS, Jorgenson E, Spring B, Coresh J, Li YR, Buxbaum SG, Schreiner PJ, Ellison RC, Tsai MY, Patel SR, Redline S, Johnson AD, Hoogeveen RC, Hakonarson H, Rotter JI, Boerwinkle E, de Bakker PI, Kivimaki M, Asselbergs FW, Sattar N, Lawlor DA, Whittaker J, Davey Smith G, Mukamal K, Psaty BM, Wilson JG, Lange LA, Hamidovic A, Hingorani AD, Nordestgaard BG, Bobak M, Leon DA, Langenberg C, Palmer TM, Reiner AP, Keating BJ, Dudbridge F, Casas JP, InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data.  BMJ 2014; 349 :g4164. 416. Zeraatkar D, Johnston BC, Bartoszko J, Cheung K, Bala MM, Valli C, Rabassa M, Sit D, Milio K, Sadeghirad B, Agarwal A, Zea AM, Lee Y, Han MA, Vernooij RWM, Alonso-Coello P, Guyatt GH, El Dib R. Effect of Lower Versus Higher Red Meat Intake on Cardiometabolic and Cancer Outcomes: A Systematic Review of Randomized Trials.  Ann Intern Med  2019; 171 :721 \u0002 731. 417. Zhong VW, Van Horn L, Greenland P, Carnethon MR, Ning H, Wilkins JT, Lloyd-Jones DM, Allen NB. Associations of Processed Meat, Unprocessed Red Meat, Poultry, or Fish Intake With Incident Cardiovascular Disease and All- Cause Mortality.  JAMA Intern Med  2020; 180 :503 \u0002 512. 418. Zheng J, Huang T, Yu Y, Hu X, Yang B, Li D. Fish consumption and CHD mor- tality: an updated meta-analysis of seventeen cohort studies.  Public Health Nutr 2012; 15 :725 \u0002 737. 419. Mullee A, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, Freisling H, Fagherazzi G, Mancini FR, Boutron-Ruault MC, Kuhn T, Kaaks R, Boeing H, Aleksandrova K, Tjonneland A, Halkjaer J, Overvad K, Weiderpass E, Skeie G, Parr CL, Quiros JR, Agudo A, Sanchez MJ, Amiano P, Cirera L, Ardanaz E, Khaw KT, Tong TYN, Schmidt JA, Trichopoulou A, Martimianaki G, Karakatsani A, Palli D, Agnoli C, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita B, Verschuren WMM, Boer JMA, Vermeulen R, Ramne S, Sonestedt E, van\nGuelpen B, Holgersson PL, Tsilidis KK, Heath AK, Muller D, Riboli E, Gunter MJ, Murphy N. Association Between Soft Drink Consumption and Mortality in 10 European Countries.  JAMA Intern Med  2019; 179 :1479 \u0002 1490. 420. World Health Organization. Guideline: sugars intake for adults and children. https://www.who.int/publications/i/item/9789241549028  (21 July 2020). 421. Sundfor TM, Svendsen M, Heggen E, Dushanov S, Klemsdal TO, Tonstad S. BMI modifies the effect of dietary fat on atherogenic lipids: a randomized clinical trial.  Am J Clin Nutr  2019; 110 :832 \u0002 841. 422. Mozaffarian D, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Trans fatty acids and cardiovascular disease.  N Engl J Med  2006; 354 :1601 \u0002 1613. 423. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER, 3rd, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.  N Engl J Med  2001; 344 :3 \u0002 10. 424. Mente A, O’Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R, Mony P, Yusuf R, Yusoff K, Szuba A, Oguz A, Rosengren A, Bahonar A, Yusufali A, Schutte AE, Chifamba J, Mann JF, Anand SS, Teo K, Yusuf S, PURE, EPIDREAM and ONTARGET/TRANSCEND Investigators. Associations of uri- nary sodium excretion with cardiovascular events in individuals with and with- out hypertension: a pooled analysis of data from four studies.  Lancet 2016; 388 :465 \u0002 475. 425. Cappuccio FP, Campbell NR. Population Dietary Salt Reduction and the Risk of Cardiovascular Disease: A Commentary on Recent Evidence.  J Clin Hypertens (Greenwich)  2017; 19 :4 \u0002 5. 426. He FJ, Ma Y, Campbell NRC, MacGregor GA, Cogswell ME, Cook NR. Formulas to Estimate Dietary Sodium Intake From Spot Urine Alter Sodium- Mortality Relationship.  Hypertension  2019; 74 :572 \u0002 580. 427. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP. Effect of increased potassium intake on cardiovascular risk factors and disease: system- atic review and meta-analyses.  BMJ  2013; 346 :f1378. 428. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D’Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease.  N Engl J Med  2019; 380 :33 \u0002 44. 429. Huang T, Afzal S, Yu C, Guo Y, Bian Z, Yang L, Millwood IY, Walters RG, Chen Y, Chen N, Gao R, Chen J, Clarke R, Chen Z, Ellervik C, Nordestgaard BG, Lv J, Li L, China Kadoorie Biobank Collaborative Group. Vitamin D and cause- specific vascular disease and mortality: a Mendelian randomisation study involv- ing 99,012 Chinese and 106,911 European adults.  BMC Med  2019; 17 :160. 430. Threapleton DE, Greenwood DC, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C, Cade JE, Gale CP, Burley VJ. Dietary fibre intake and risk of car- diovascular disease: systematic review and meta-analysis.  BMJ  2013; 347 :f6879. 431. Zhang Z, Xu G, Liu D, Zhu W, Fan X, Liu X. Dietary fiber consumption and risk of stroke.  Eur J Epidemiol  2013; 28 :119 \u0002 130. 432. Yao B, Fang H, Xu W, Yan Y, Xu H, Liu Y, Mo M, Zhang H, Zhao Y. Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies.  Eur J Epidemiol  2014; 29 :79 \u0002 88. 433. Giacco R, Costabile G, Della Pepa G, Anniballi G, Griffo E, Mangione A, Cipriano P, Viscovo D, Clemente G, Landberg R, Pacini G, Rivellese AA, Riccardi G. A whole-grain cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome.  Nutr Metab Cardiovasc Dis  2014; 24 :837 \u0002 844. 434. Wang X, Ouyang Y, Liu J, Zhu M, Zhao G, Bao W, Hu FB. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort stud- ies.  BMJ  2014; 349 :g4490. 435. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies.  Lancet  2006; 367 :320 \u0002 326. 436. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable con- sumption and risk of coronary heart disease: a meta-analysis of cohort studies.  J Nutr  2006; 136 :2588 \u0002 2593. 437. Luo C, Zhang Y, Ding Y, Shan Z, Chen S, Yu M, Hu FB, Liu L. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a sys- tematic review and meta-analysis.  Am J Clin Nutr  2014; 100 :256 \u0002 269. 438. Afshin A, Micha R, Khatibzadeh S, Mozaffarian D. Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a sys- tematic review and meta-analysis.  Am J Clin Nutr  2014; 100 :278 \u0002 288. 439. World Cancer Research Fund, American Institute for Cancer Research.  Diet, Nutrition, Physical Activity and Cancer: a Global Perspective,  2018. https://www.wcrf. org/dietandcancer/recommendations/limit-red-processed-meat  (21 July 2020). 440. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, Feldman BS, Pan A, Johnson L, Crowe F, Hu FB, Franco OH. Vitamin D and risk of cause\n3324 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies.  BMJ  2014; 348 :g1903. 441. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.  JAMA  2012; 308 :1024 \u0002 1033. 442. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascu- lar disease.  Cochrane Database Syst Rev  2018; 7 :CD003177. 443. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R, Omega-3 Treatment Trialists’ Collaboration. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77917 Individuals.  JAMA Cardiol  2018; 3 :225 \u0002 234. 444. Hu Y, Hu FB, Manson JE. Marine Omega-3 Supplementation and Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized Controlled Trials Involving 127 477 Participants.  J Am Heart Assoc  2019; 8 :e013543. 445. Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Ridker PM, Ray KK, Katona BG, Himmelmann A, Loss LE, Rensfeldt M, Lundstrom T, Agrawal R, Menon V, Wolski K, Nissen SE. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA 2020; 324 :2268 \u0002 2280. 446. Tverdal A, Selmer R, Cohen JM, Thelle DS. Coffee consumption and mortality from cardiovascular diseases and total mortality: Does the brewing method matter?  Eur J Prev Cardiol  2020; 27 :1986 \u0002 1993. 447. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes.  BMJ  2017; 359 :j5024. 448. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies.  Br J Nutr  2014; 112 :214 \u0002 219. 449. Peng D, Fong A, Pelt AV. Original Research: The Effects of Red Yeast Rice Supplementation on Cholesterol Levels in Adults. Am J Nurs 2017; 117 :46 \u0002 54. 450. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev 2016; 17 :1001 \u0002 1011. 451. Wing RR, Espeland MA, Clark JM, Hazuda HP, Knowler WC, Pownall HJ, Unick J, Wadden T, Wagenknecht L, Action for Health in Diabetes (Look AHEAD) Study Group. Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial.  Diabetes Care  2016; 39 :1345 \u0002 1355. 452. Howell S, Kones R. \"Calories in, calories out\" and macronutrient intake: the hope, hype, and science of calories. Am J Physiol Endocrinol Metab 2017; 313 :E608 \u0002 E612. 453. Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, Kiflen R, Quadri K, Kwon HY, Karamouzian M, Adams-Webber T, Ahmed W, Damanhoury S, Zeraatkar D, Nikolakopoulou A, Tsuyuki RT, Tian J, Yang K, Guyatt GH, Johnston BC. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials.  BMJ  2020; 369 :m696. 454. Tobias DK, Chen M, Manson JE, Ludwig DS, Willett W, Hu FB. Effect of low-fat diet interventions versus other diet interventions on long-term weight change in adults: a systematic review and meta-analysis.  Lancet Diabetes Endocrinol 2015; 3 :968 \u0002 979. 455. Cardoso L, Rodrigues D, Gomes L, Carrilho F. Short- and long-term mortality after bariatric surgery: A systematic review and meta-analysis.  Diabetes Obes Metab  2017; 19 :1223 \u0002 1232. 456. Ma C, Avenell A, Bolland M, Hudson J, Stewart F, Robertson C, Sharma P, Fraser C, MacLennan G. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis.  BMJ  2017; 359 :j4849. 457. Mancini JG, Filion KB, Atallah R, Eisenberg MJ. Systematic Review of the Mediterranean Diet for Long-Term Weight Loss.  Am J Med  2016; 129 :407 \u0002 415 e404. 458. Sofi F, Dinu M, Pagliai G, Cesari F, Gori AM, Sereni A, Becatti M, Fiorillo C, Marcucci R, Casini A. Low-Calorie Vegetarian Versus Mediterranean Diets for Reducing Body Weight and Improving Cardiovascular Risk Profile: CARDIVEG Study (Cardiovascular Prevention With Vegetarian Diet).  Circulation  2018; 137 :1103 \u0002 1113. 459. Huang RY, Huang CC, Hu FB, Chavarro JE. Vegetarian Diets and Weight Reduction: a Meta-Analysis of Randomized Controlled Trials.  J Gen Intern Med 2016; 31 :109 \u0002 116.\n",
      "keywords": [
        "does",
        "alcohol",
        "cvd risk",
        "hypertension",
        "genetic",
        "diabetes",
        "dall",
        "triglyceride",
        "physical",
        "activity",
        "secondary prevention",
        "cocker",
        "morta",
        "risk factor",
        "chastin",
        "health",
        "diet",
        "metabolic syndrome",
        "physical activity",
        "craemer",
        "cardiovascular risk",
        "cholesterol",
        "associate",
        "powell",
        "cardiometabolic",
        "light",
        "adult",
        "blood pressure",
        "insulin",
        "intensity"
      ],
      "tables": []
    },
    {
      "number": "36",
      "title": "460. Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses.  Lancet  2019; 393 :434 \u0002 445. 461. Kirkpa",
      "start_page": 98,
      "end_page": 100,
      "content": "ESC Guidelines 3325\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ M, Leibowitz J, Marston L, Michie S, Morris R, Morris S, Nazareth I, Omar R, Petersen I, Peveler R, Pinfold V, Stevenson F, Zomer E.  Primary care management of cardiovascular risk for people with severe mental illnesses: the Primrose research programme including cluster RCT . Southampton (UK); 2019. 481. Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, van Schaik DJ, Penninx BJ. Depression, anxiety and 6-year risk of cardiovascular disease.  J Psychosom Res 2015; 78 :123 \u0002 129. 482. Gilsanz P, Kubzansky LD, Tchetgen Tchetgen EJ, Wang Q, Kawachi I, Patton KK, Fitzpatrick AL, Kop WJ, Longstreth WT, Jr., Glymour MM. Changes in Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular Health Study.  Stroke  2017; 48 :43 \u0002 48. 483. Smolderen KG, Buchanan DM, Gosch K, Whooley M, Chan PS, Vaccarino V, Parashar S, Shah AJ, Ho PM, Spertus JA. Depression Treatment and 1-Year Mortality After Acute Myocardial Infarction: Insights From the TRIUMPH Registry (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients’ Health Status).  Circulation  2017; 135 :1681 \u0002 1689. 484. Smolderen KG, Spertus JA, Gosch K, Dreyer RP, D’Onofrio G, Lichtman JH, Geda M, Beltrame J, Safdar B, Bueno H, Krumholz HM. Depression Treatment and Health Status Outcomes in Young Patients With Acute Myocardial Infarction: Insights From the VIRGO Study (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients). Circulation 2017; 135 :1762 \u0002 1764. 485. Tully PJ, Baumeister H. Collaborative care for comorbid depression and coro- nary heart disease: a systematic review and meta-analysis of randomised con- trolled trials.  BMJ Open  2015; 5 :e009128. 486. Honkola J, Hookana E, Malinen S, Kaikkonen KS, Junttila MJ, Isohanni M, Kortelainen ML, Huikuri HV. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event.  Eur Heart J  2012; 33 :745 \u0002 751. 487. Critchley JA, Capewell S. Mortality risk reduction associated with smoking ces- sation in patients with coronary heart disease: a systematic review.  JAMA 2003; 290 :86 \u0002 97. 488. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial.  Ann Intern Med  2005; 142 :233 \u0002 239. 489. Hartmann-Boyce J, Chepkin SC, Ye W, Bullen C, Lancaster T. Nicotine replace- ment therapy versus control for smoking cessation.  Cochrane Database Syst Rev 2018; 5 :CD000146. 490. HughesJR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev  2007:CD000031. 491. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation.  Cochrane Database Syst Rev 2016:CD006103. 492. Lindson N, Chepkin SC, Ye W, Fanshawe TR, Bullen C, Hartmann-Boyce J. Different doses, durations and modes of delivery of nicotine replacement ther- apy for smoking cessation.  Cochrane Database Syst Rev  2019; 4 :CD013308. 493. Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes.  Am J Cardiol  2012; 110 :968 \u0002 970. 494. Suissa K, Lariviere J, Eisenberg MJ, Eberg M, Gore GC, Grad R, Joseph L, Reynier PM, Filion KB. Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease: A Network Meta-Analysis of Randomized Controlled Trials.  Circ Cardiovasc Qual Outcomes  2017; 10 :e002458. 495. Hu Y, Zong G, Liu G, Wang M, Rosner B, Pan A, Willett WC, Manson JE, Hu FB, Sun Q. Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality. N Engl J Med  2018; 379 :623 \u0002 632. 496. Mons U, Muezzinler A, Gellert C, Schottker B, Abnet CC, Bobak M, de Groot L, Freedman ND, Jansen E, Kee F, Kromhout D, Kuulasmaa K, Laatikainen T, O’Doherty MG, Bueno-de-Mesquita B, Orfanos P, Peters A, van der Schouw YT, Wilsgaard T, Wolk A, Trichopoulou A, Boffetta P, Brenner H, CHANCES Consortium. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from pro- spective cohort studies of the CHANCES consortium.  BMJ  2015; 350 :h1551. 497. Gellert C, Schottker B, Brenner H. Smoking and all-cause mortality in older people: systematic review and meta-analysis. Arch Intern Med 2012; 172 :837 \u0002 844. 498. Prugger C, Wellmann J, Heidrich J, De Bacquer D, De Backer G, Perier MC, Empana JP, Reiner Z, Fras Z, Jennings C, Kotseva K, Wood D, Keil U, EUROASPIRE Study Group. Readiness for smoking cessation in coronary heart disease patients across Europe: Results from the EUROASPIRE III survey.  Eur J Prev Cardiol  2015; 22 :1212 \u0002 1219. 499. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews.  Addiction 2014; 109 :1414 \u0002 1425. 500. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, Iskander A, Lauzon C, Srivastava N, Clarke A, Cassavar D, Dion D, Haught H, Mehta SR, Baril JF, Lambert C, Madan M, Abramson BL, Dehghani P, EVITA Investigators.\nVarenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome.  Circulation  2016; 133 :21 \u0002 30. 501. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychi- atric disorders (EAGLES): a double-blind, randomised, placebo-controlled clini- cal trial.  Lancet  2016; 387 :2507 \u0002 2520. 502. Benowitz NL, Pipe A, West R, Hays JT, Tonstad S, McRae T, Lawrence D, St Aubin L, Anthenelli RM. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial.  JAMA Intern Med 2018; 178 :622 \u0002 631. 503. Hartmann-Boyce J, McRobbie H, Lindson N, Bullen C, Begh R, Theodoulou A, Notley C, Rigotti NA, Turner T, Butler AR, Hajek P. Electronic cigarettes for smoking cessation.  Cochrane Database Syst Rev  2020; 10 :CD010216. 504. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, Li J, Parrott S, Sasieni P, Dawkins L, Ross L, Goniewicz M, Wu Q, McRobbie HJ. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy.  N Engl J Med  2019; 380 :629 \u0002 637. 505. Li J, Hajek P, Pesola F, Wu Q, Phillips-Waller A, Przulj D, Myers Smith K, Bisal N, Sasieni P, Dawkins L, Ross L, Goniewicz ML, McRobbie H, Parrott S. Cost- effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial. Addiction  2020; 115 :507 \u0002 517. 506. Kavousi M, Pisinger C, Barthelemy JC, Smedt D, Koskinas K, Marques-Vidal P, Panagiotakos D, Prescott EB, Tiberi M, Vassiliou VS, Lochen ML. Electronic ciga- rettes and health with special focus on cardiovascular effects: position paper of the European Association of Preventive Cardiology (EAPC).  Eur J Prev Cardiol 2020:2047487320941993. 507. European Heart Network. Electronic cigarettes and cardiovascular disease  \u0002 an update from the European Heart Network  http://www.ehnheart.org/compo nent/attachments/attachments.html?task=attachment&id=3093  (21 July 2020). 508. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, Cabrejo L, Cha JK, Ducrocq G, Giroud M, Guidoux C, Hobeanu C, Kim YJ, Lapergue B, Lavallee PC, Lee BC, Lee KB, Leys D, Mahagne MH, Meseguer E, Nighoghossian N, Pico F, Samson Y, Sibon I, Steg PG, Sung SM, Touboul PJ, Touze E, Varenne O, Vicaut E, Yelles N, Bruckert E, Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke.  N Engl J Med  2020; 382 :9. 509. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg- Hansen A, Watts GF, European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for man- agement.  Eur Heart J  2011; 32 :1345 \u0002 1361. 510. Cartier LJ, Collins C, Lagace M, Douville P. Comparison of fasting and non- fasting lipid profiles in a large cohort of patients presenting at a community hos- pital.  Clin Biochem  2018; 52 :61 \u0002 66. 511. Sampson M, Ling C, Sun Q, Harb R, Ashmaig M, Warnick R, Sethi A, Fleming JK, Otvos JD, Meeusen JW, Delaney SR, Jaffe AS, Shamburek R, Amar M, Remaley AT. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol  2020; 5 :540 \u0002 548. 512. Penson P, Martin SS, Henney NC, Banach M. Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America [abstract].  Eur Heart J  2020; 41 (Suppl 2):2932. 513. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield MB, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Jr., Ridker PM, Kastelein JJ. Association of LDL cholesterol, non-HDL cholesterol, and apolipo- protein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.  JAMA  2012; 307 :1302 \u0002 1309. 514. Welsh C, Celis-Morales CA, Brown R, Mackay DF, Lewsey J, Mark PB, Gray SR, Ferguson LD, Anderson JJ, Lyall DM, Cleland JG, Jhund PS, Gill JMR, Pell JP, Sattar N, Welsh P. Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease.  Circulation 2019; 140 :542 \u0002 552. 515. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM, IMPROVE-IT Investigators. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.  N Engl J Med  2015; 372 :2387 \u0002 2397. 516. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, FOURIER Steering Committee and Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.  N Engl J Med  2017; 376 :1713 \u0002 1722.\n3326 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 517. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.  N Engl J Med  2018; 379 :2097 \u0002 2107. 518. Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.  J Clin Lipidol  2018; 12 :958 \u0002 965. 519. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardi- ometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study.  Eur Heart J  2016; 37 :1079 \u0002 1081. 520. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ  2009; 338 :b2376. 521. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta- analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52 :1769 \u0002 1781. 522. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 partici- pants in 27 randomised trials.  Lancet  2015; 385 :1397 \u0002 1405. 523. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Pordy R, Gipe DA, ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial.  J Clin Lipidol  2015; 9 :758 \u0002 769. 524. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.  JAMA  2016; 315 :1580 \u0002 1590. 525. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R, SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.  Lancet  2011; 377 :2181 \u0002 2192. 526. Schreml J, Gouni-Berthold I. Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance.  Curr Med Chem  2018; 25 :1538 \u0002 1548. 527. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388 :2532 \u0002 2561. 528. Myocardial Infarction Genetics Consortium Investigators, Stitziel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, Konig I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JI, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O’Donnell CJ, Abecasis G, Sunaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med  2014; 371 :2072 \u0002 2082. 529. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study.  Cardiovasc Drugs Ther  2016; 30 :297 \u0002 304.\n",
      "keywords": [
        "lipid",
        "atherosclerosis",
        "diabetes",
        "morenga",
        "triglyceride",
        "familial hypercholesterolemia",
        "statin",
        "smoking",
        "health",
        "cummings",
        "pcsk9",
        "sudden cardiac death",
        "reynolds",
        "gender",
        "meta",
        "cardiovascular risk",
        "cholesterol",
        "lancet",
        "series",
        "ldl-c",
        "older",
        "carbohydrate",
        "primary prevention",
        "winter",
        "analyses",
        "lipoprotein",
        "mann",
        "systematic",
        "ezetimibe",
        "human"
      ],
      "tables": []
    },
    {
      "number": "37",
      "title": "530. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP, ORION-10 and ORION-11 Investigators. Two Phase 3 Trials of Inclisiran in",
      "start_page": 100,
      "end_page": 101,
      "content": "ESC Guidelines 3327\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Guideline for Lipid Management in CKD: summary of recommendation state- ments and clinical approach to the patient.  Kidney Int  2014; 85 :1303 \u0002 1309. 544. Cholesterol Treatment Trialists’ (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellstrom B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4 :829 \u0002 839. 545. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, Rizzo M, Rysz J, Abdollahi M, Nicholls SJ, Banach M, Lipid and Blood Pressure Meta- Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy–a meta-analysis of 11 randomized con- trolled trials involving 21,295 participants.  Pharmacol Res  2013; 72 :35 \u0002 44. 546. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.  N Engl J Med  2005; 353 :238 \u0002 248. 547. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F, AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.  N Engl J Med 2009; 360 :1395 \u0002 1407. 548. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B, LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.  JAMA  2004; 292 :2343 \u0002 2349. 549. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt P, Olsen MH. Risk prediction is improved by adding markers of subclinical organ damage to SCORE.  Eur Heart J  2010; 31 :883 \u0002 891. 550. Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G, Donal E, Kahan T, Mancia G, Redon J, Schmieder R, Williams B, Agabiti-Rosei E. Non-invasive cardiovascular imaging for evaluating subclinical target organ dam- age in hypertensive patients: A consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). Eur Heart J Cardiovasc Imaging  2017; 18 :945 \u0002 960. 551. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J, ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20 :1813 \u0002 1821. 552. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis.  Lancet 2016; 387 :957 \u0002 967. 553. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, Woodward M, Neal B, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis.  Ann Intern Med  2015; 162 :184 \u0002 191. 554. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta- regression analyses of randomized trials.  J Hypertens  2014; 32 :2285 \u0002 2295. 555. SPRINT Research Group, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC, Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood- Pressure Control.  N Engl J Med  2015; 373 :2103 \u0002 2116. 556. Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B. Effects of a fixed combination of perindopril and indapa- mide on macrovascular and microvascular outcomes in patients with type 2 dia- betes mellitus (the ADVANCE trial): a randomised controlled trial.  Lancet 2007; 370 :829 \u0002 840. 557. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT, Jr., Pajewski NM, SPRINT Research Group. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged >/=75 Years: A Randomized Clinical Trial.  JAMA  2016; 315 :2673 \u0002 2682.\n",
      "keywords": [
        "wright",
        "lipid",
        "hypertension",
        "jaros",
        "bisch",
        "diabetes",
        "inclisiran",
        "statin",
        "wijngaard",
        "raal",
        "investigators",
        "kastelein",
        "phase",
        "cholesterol",
        "orion",
        "trials",
        "koenig",
        "antihypertensive",
        "ldl cholesterol",
        "blood pressure",
        "richardson",
        "guideline",
        "leiter",
        "age",
        "kallend"
      ],
      "tables": []
    },
    {
      "number": "38",
      "title": "558. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved",
      "start_page": 101,
      "end_page": 103,
      "content": "3328 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394 :1540 \u0002 1550. 574. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, Mill JG, Lotufo PA, Amodeo C, Batista MC, Bodanese LC, Carvalho ACC, Castro I, Chaves H, Costa EAS, Feitosa GS, Franco RJS, Fuchs FD, Guimaraes AC, Jardim PC, Machado CA, Magalhaes ME, Mion D, Jr., Nascimento RM, Nobre F, Nobrega AC, Ribeiro ALP, Rodrigues-Sobrinho CR, Sanjuliani AF, Teixeira M, Krieger JE, ReHOT Investigators. Spironolactone Versus Clonidine as a Fourth-Drug Therapy for Resistant Hypertension: The ReHOT Randomized Study (Resistant Hypertension Optimal Treatment).  Hypertension 2018; 71 :681 \u0002 690. 575. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358 :1547 \u0002 1559. 576. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE Investigators. Cardiorenal end points in a trial of aliski- ren for type 2 diabetes.  N Engl J Med  2012; 367 :2204 \u0002 2213. 577. Forouzanfar MH, Liu P, Roth GA, Ng M, Biryukov S, Marczak L, Alexander L, Estep K, Hassen Abate K, Akinyemiju TF, Ali R, Alvis-Guzman N, Azzopardi P, Banerjee A, Barnighausen T, Basu A, Bekele T, Bennett DA, Biadgilign S, Catala- Lopez F, Feigin VL, Fernandes JC, Fischer F, Gebru AA, Gona P, Gupta R, Hankey GJ, Jonas JB, Judd SE, Khang YH, Khosravi A, Kim YJ, Kimokoti RW, Kokubo Y, Kolte D, Lopez A, Lotufo PA, Malekzadeh R, Melaku YA, Mensah GA, Misganaw A, Mokdad AH, Moran AE, Nawaz H, Neal B, Ngalesoni FN, Ohkubo T, Pourmalek F, Rafay A, Rai RK, Rojas-Rueda D, Sampson UK, Santos IS, Sawhney M, Schutte AE, Sepanlou SG, Shifa GT, Shiue I, Tedla BA, Thrift AG, Tonelli M, Truelsen T, Tsilimparis N, Ukwaja KN, Uthman OA, Vasankari T, Venketasubramanian N, Vlassov VV, Vos T, Westerman R, Yan LL, Yano Y, Yonemoto N, Zaki ME, Murray CJ. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317 :165 \u0002 182. 578. Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, Bahonar A, Chifamba J, Dagenais G, Diaz R, Kazmi K, Lanas F, Wei L, Lopez-Jaramillo P, Fanghong L, Ismail NH, Puoane T, Rosengren A, Szuba A, Temizhan A, Wielgosz A, Yusuf R, Yusufali A, McKee M, Liu L, Mony P, Yusuf S, PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, aware- ness, treatment, and control of hypertension in rural and urban communities in high-, middle-,  and low-income countries. JAMA  2013; 310 :959 \u0002 968. 579. Siu AL, US Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement.  Ann Intern Med  2015; 163 :778 \u0002 786. 580. Huang CJ, Chiang CE, Williams B, Kario K, Sung SH, Chen CH, Wang TD, Cheng HM. Effect Modification by Age on the Benefit or Harm of Antihypertensive Treatment for Elderly Hypertensives: A Systematic Review and Meta-analysis.  Am J Hypertens  2019; 32 :163 \u0002 174. 581. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combina- tion antihypertensive medications, adherence, and clinical outcomes: A population-based retrospective cohort study.  PLoS Med  2018; 15 :e1002584. 582. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihyperten- sive drugs - overview and meta-analyses.  J Hypertens  2015; 33 :195 \u0002 211. 583. Sattar N, Preiss D. HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. Diabetologia 2012; 55 :1564 \u0002 1567. 584. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.  Eur Heart J  2013; 34 :3035 \u0002 3087. 585. Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Welsh P, Kean S, Ford I, McConnachie A, Messow CM, Sattar N, Taylor R. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.  Lancet Diabetes Endocrinol  2019; 7 :344 \u0002 355. 586. Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, Amona RA, El Nahas K, Suleiman N, Alnaama A, Al-Hamaq A, Charlson M, Wells MT, Al-Abdulla S, Abou-Samra AB. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol 2020; 8 :477 \u0002 489. 587. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose con- trol with sulphonylureas or insulin compared with conventional treatment and\nrisk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet 1998; 352 :837 \u0002 853. 588. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glu- cose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med  2008; 358 :2560 \u0002 2572. 589. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood- glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet  1998; 352 :854 \u0002 865. 590. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.  Lancet  2019; 393 :31 \u0002 39. 591. Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, Kober L, Petrie MC, McMurray JJV. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.  Lancet Diabetes Endocrinol 2019; 7 :776 \u0002 785. 592. Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, D’Alessio DA, Davies MJ. 2019 update to: Management of hyperglycaemia in type 2 diabe- tes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).  Diabetologia 2020; 63 :221 \u0002 228. 593. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD, VADT Investigators. Glucose control and vas- cular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360 :129 \u0002 139. 594. Hernandez AF, Green JB, Janmohamed S, D’Agostino RB, Sr., Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.  Lancet  2018; 392 :1519 \u0002 1529. 595. Ferrannini G, Gerstein H, Colhoun HM, Dagenais GR, Diaz R, Dyal L, Lakshmanan M, Mellbin L, Probstfield J, Riddle MC, Shaw JE, Avezum A, Basile JN, Cushman WC, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Pais P, Pirags V, Pogosova N, Raubenheimer PJ, Sheu WH, Ryden L. Similar cardio- vascular outcomes in patients with diabetes and established or high risk for cor- onary vascular disease treated with dulaglutide with and without baseline metformin.  Eur Heart J  2020:[Online ahead of print]. 596. Crowley MJ, McGuire DK, Alexopoulos AS, Jensen TJ, Rasmussen S, Saevereid HA, Verma S, Buse JB. Effects of Liraglutide on Cardiovascular Outcomes in Type 2 Diabetes Patients With and Without Baseline Metformin Use: Post Hoc Analyses of the LEADER Trial.  Diabetes Care  2020; 43 :e108 \u0002 e110. 597. Neuen BL, Arnott C, Perkovic V, Figtree G, de Zeeuw D, Fulcher G, Jun M, Jardine MJ, Zoungas S, Pollock C, Mahaffey KW, Neal B, Heerspink HJL. Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.  Diabetes Obes Metab  2021; 23 :382 \u0002 390. 598. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.  N Engl J Med  2019; 380 :2295 \u0002 2306. 599. Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjostrom CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease.  N Engl J Med 2020; 383 :1436 \u0002 1446. 600. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlavek J, Bohm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukat A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjostrand M, Langkilde AM, DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.  N Engl J Med  2019; 381 :1995 \u0002 2008. 601. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bohm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP,\nESC Guidelines 3329\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F, EMPEROR- Reduced Trial Investigators. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.  N Engl J Med  2020; 383 :1413 \u0002 1424. 602. Sattar N, McMurray JJ, Cheng AY. Cardiorenal risk reduction guidance in diabe- tes: can we reach consensus?  Lancet Diabetes Endocrinol  2020; 8 :357 \u0002 360. 603. Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, Zhang B, Feng X, Li H, Chen X, Cheng YJ, Gregg EW, Hu Y, Bennett PH, Li G, Da Qing Diabetes Prevention Study Group. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.  Lancet Diabetes Endocrinol  2019; 7 :452 \u0002 461. 604. Celis-Morales CA, Petermann F, Hui L, Lyall DM, Iliodromiti S, McLaren J, Anderson J, Welsh P, Mackay DF, Pell JP, Sattar N, Gill JMR, Gray SR. Associations Between Diabetes and Both Cardiovascular Disease and All-Cause Mortality Are Modified by Grip Strength: Evidence From UK Biobank, a Prospective Population-Based Cohort Study. Diabetes Care 2017; 40 :1710 \u0002 1718. 605. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, Erqou S, Sattar N. Effect of intensive control of glucose on cardiovascular out- comes and death in patients with diabetes mellitus: a meta-analysis of rando- mised controlled trials.  Lancet  2009; 373 :1765 \u0002 1772. 606. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, Evans GW, Gerstein HC, Holman RR, Moritz TE, Neal BC, Ninomiya T, Patel AA, Paul SK, Travert F, Woodward M. Intensive glucose con- trol and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52 :2288 \u0002 2298. 607. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR, TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.  N Engl J Med  2015; 373 :232 \u0002 242. 608. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.  N Engl J Med  2013; 369 :1317 \u0002 1326. 609. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes.  N Engl J Med  2013; 369 :1327 \u0002 1335. 610. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321 :69 \u0002 79. 611. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.  N Engl J Med  2015; 373 :2117 \u0002 2128. 612. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.  N Engl J Med  2017; 377 :644 \u0002 657. 613. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARE \u0002 TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380 :347 \u0002 357. 614. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK, VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383 :1425 \u0002 1435. 615. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryden L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T, REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394 :121 \u0002 130.\n",
      "keywords": [
        "hypertension",
        "achieved",
        "diabetes",
        "lowering",
        "outcome",
        "secondary prevention",
        "intensive",
        "pressure",
        "ejection fraction",
        "different",
        "heart failure",
        "more",
        "sglt2",
        "systolic",
        "incidence",
        "glucose",
        "antihypertensive",
        "hba1c",
        "blood pressure",
        "metformin",
        "zanchetti",
        "insulin",
        "blood",
        "less",
        "parati",
        "glp-1",
        "weight",
        "elderly",
        "age",
        "effects"
      ],
      "tables": []
    },
    {
      "number": "39",
      "title": "616. Marx N, Davies MJ, Grant PJ, Mathieu C, Petrie JR, Cosentino F, Buse JB. Guideline recommendations and the positioning of newer drugs in type 2 diabe- tes care.  Lancet Diabetes Endocrinol  2021;",
      "start_page": 103,
      "end_page": 107,
      "content": "3330 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis.  J Am Coll Cardiol  2014; 64 :319 \u0002 327. 633. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, Lopez-Jaramillo P, Yusoff K, Santoso A, Gamra H, Talukder S, Christou C, Girish P, Yeates K, Xavier F, Dagenais G, Rocha C, McCready T, Tyrwhitt J, Bosch J, Pais P, International Polycap Study 3 Investigators. Polypill with or without Aspirin in Persons with- out Cardiovascular Disease.  N Engl J Med  2021; 384 :216 \u0002 228. 634. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent C. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.  Lancet Gastroenterol Hepatol  2018; 3 :231 \u0002 241. 635. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF, ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular dis- ease and antithrombotic therapy.  Eur Heart J  2013; 34 :1708 \u0002 1713, 1713a- 1713b. 636. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ, CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.  N Engl J Med  2017; 377 :1119 \u0002 1131. 637. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriaga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ, CIRT Investigators. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.  N Engl J Med  2019; 380 :752 \u0002 762. 638. Anderson L, Thompson DR, Oldridge N, Zwisler AD, Rees K, Martin N, Taylor RS. Exercise-based cardiac rehabilitation for coronary heart disease.  Cochrane Database Syst Rev  2016:CD001800. 639. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJ, Dalal H, Rees K, Singh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart failure.  Cochrane Database Syst Rev  2019; 1 :CD003331. 640. Salzwedel A, Jensen K, Rauch B, Doherty P, Metzendorf MI, Hackbusch M, Voller H, Schmid JP, Davos CH. Effectiveness of comprehensive cardiac rehabil- itation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study (CROS-II).  Eur J Prev Cardiol  2020; 27 :1756 \u0002 1774. 641. Santiago de Araujo Pio C, Marzolini S, Pakosh M, Grace SL. Effect of Cardiac Rehabilitation Dose on Mortality and Morbidity: A Systematic Review and Meta-regression Analysis.  Mayo Clin Proc  2017; 92 :1644 \u0002 1659. 642. van Halewijn G, Deckers J, Tay HY, van Domburg R, Kotseva K, Wood D. Lessons from contemporary trials of cardiovascular prevention and rehabilita- tion: A systematic review and meta-analysis.  Int J Cardiol  2017; 232 :294 \u0002 303. 643. Santiago de Araujo Pio C, Chaves GS, Davies P, Taylor RS, Grace SL. Interventions to promote patient utilisation of cardiac rehabilitation.  Cochrane Database Syst Rev  2019; 2 :CD007131. 644. Jorstad HT, von Birgelen C, Alings AM, Liem A, van Dantzig JM, Jaarsma W, Lok DJ, Kragten HJ, de Vries K, de Milliano PA, Withagen AJ, Scholte Op Reimer WJ, Tijssen JG, Peters RJ. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial.  Heart  2013; 99 :1421 \u0002 1430. 645. Jennings C, Kotseva K, De Bacquer D, Hoes A, de Velasco J, Brusaferro S, Mead A, Jones J, Tonstad S, Wood D, EUROACTION PLUS Study Group. Effectiveness of a preventive cardiology programme for high CVD risk persis- tent smokers: the EUROACTION PLUS varenicline trial. Eur Heart J 2014; 35 :1411 \u0002 1420. 646. Wood DA, Kotseva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O, EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart dis- ease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial.  Lancet  2008; 371 :1999 \u0002 2012. 647. Anderson L, Sharp GA, Norton RJ, Dalal H, Dean SG, Jolly K, Cowie A, Zawada A, Taylor RS. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev  2017; 6 :CD007130. 648. Jin K, Khonsari S, Gallagher R, Gallagher P, Clark AM, Freedman B, Briffa T, Bauman A, Redfern J, Neubeck L. Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis. Eur J Cardiovasc Nurs  2019; 18 :260 \u0002 271. 649. Verschueren S, Eskes AM, Maaskant JM, Roest AM, Latour CHM, Op Reimer WS. The effect of exercise therapy on depressive and anxious symptoms in\npatients with ischemic heart disease: A systematic review.  J Psychosom Res 2018; 105 :80 \u0002 91. 650. Taylor RS, Walker S, Smart NA, Piepoli MF, Warren FC, Ciani O, Whellan D, O’Connor C, Keteyian SJ, Coats A, Davos CH, Dalal HM, Dracup K, Evangelista LS, Jolly K, Myers J, Nilsson BB, Passino C, Witham MD, Yeh GY, ExTraMATCH II Collaboration. Impact of Exercise Rehabilitation on Exercise Capacity and Quality-of-Life in Heart Failure: Individual Participant Meta- Analysis.  J Am Coll Cardiol  2019; 73 :1430 \u0002 1443. 651. Shields GE, Wells A, Doherty P, Heagerty A, Buck D, Davies LM. Cost-effec- tiveness of cardiac rehabilitation: a systematic review. Heart 2018; 104 :1403 \u0002 1410. 652. Bjarnason-Wehrens B, McGee H, Zwisler AD, Piepoli MF, Benzer W, Schmid JP, Dendale P, Pogosova NG, Zdrenghea D, Niebauer J, Mendes M, Cardiac Rehabilitation Section European Association of Cardiovascular Prevention and Rehabilitation. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil 2010; 17 :410 \u0002 418. 653. Benzer W, Rauch B, Schmid JP, Zwisler AD, Dendale P, Davos CH, Kouidi E, Simon A, Abreu A, Pogosova N, Gaita D, Miletic B, Bonner G, Ouarrak T, McGee H, EuroCaReD study group. Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation regis- try.  Int J Cardiol  2017; 228 :58 \u0002 67. 654. Kabboul NN, Tomlinson G, Francis TA, Grace SL, Chaves G, Rac V, Daou- Kabboul T, Bielecki JM, Alter DA, Krahn M. Comparative Effectiveness of the Core Components of Cardiac Rehabilitation on Mortality and Morbidity: A Systematic Review and Network Meta-Analysis.  J Clin Med  2018; 7 :514. 655. Anderson L, Brown JP, Clark AM, Dalal H, Rossau HK, Bridges C, Taylor RS. Patient education in the management of coronary heart disease.  Cochrane Database Syst Rev  2017; 6 :CD008895. 656. Borjesson M, Dellborg M, Niebauer J, LaGerche A, Schmied C, Solberg EE, Halle M, Adami E, Biffi A, Carre F, Caselli S, Papadakis M, Pressler A, Rasmusen H, Serratosa L, Sharma S, van Buuren F, Pelliccia A. Recommendations for par- ticipation in leisure time or competitive sports in athletes-patients with coro- nary artery disease: a position statement from the Sports Cardiology Section of the European Association of Preventive Cardiology (EAPC).  Eur Heart J 2019; 40 :13 \u0002 18. 657. Abreu A, Frederix I, Dendale P, Janssen A, Doherty P, Piepoli MF, Voller H, Secondary Prevention and Rehabilitation Section of EAPC. Standardization and quality improvement of secondary prevention through cardiovascular rehabilita- tion programmes in Europe: The avenue towards EAPC accreditation pro- gramme: A position statement of the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology (EAPC).  Eur J Prev Cardiol  2020:2047487320924912. 658. Hansen D, Rovelo Ruiz G, Doherty P, Iliou MC, Vromen T, Hinton S, Frederix I, Wilhelm M, Schmid JP, Abreu A, Ambrosetti M, Garcia-Porrero E, Coninx K, Dendale P, EAPC EXPERT working group. Do clinicians prescribe exercise simi- larly in patients with different cardiovascular diseases? Findings from the EAPC EXPERT working group survey.  Eur J Prev Cardiol  2018; 25 :682 \u0002 691. 659. Hansen D, Dendale P, Coninx K, Vanhees L, Piepoli MF, Niebauer J, Cornelissen V, Pedretti R, Geurts E, Ruiz GR, Corra U, Schmid JP, Greco E, Davos CH, Edelmann F, Abreu A, Rauch B, Ambrosetti M, Braga SS, Barna O, Beckers P, Bussotti M, Fagard R, Faggiano P, Garcia-Porrero E, Kouidi E, Lamotte M, Neunhauserer D, Reibis R, Spruit MA, Stettler C, Takken T, Tonoli C, Vigorito C, Voller H, Doherty P. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: A digital training and decision support system for opti- mized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology.  Eur J Prev Cardiol  2017; 24 :1017 \u0002 1031. 660. Abell B, Glasziou P, Hoffmann T. The Contribution of Individual Exercise Training Components to Clinical Outcomes in Randomised Controlled Trials of Cardiac Rehabilitation: A Systematic Review and Meta-regression.  Sports Med Open  2017; 3 :19. 661. Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D, Maggioni A, Marques-Vidal P, Jennings C, Abreu A, Aguiar C, Badariene J, Bruthans J, Castro Conde A, Cifkova R, Crowley J, Davletov K, Deckers J, De Smedt D, De Sutter J, Dilic M, Dolzhenko M, Dzerve V, Erglis A, Fras Z, Gaita D, Gotcheva N, Heuschmann P, Hasan-Ali H, Jankowski P, Lalic N, Lehto S, Lovic D, Mancas S, Mellbin L, Milicic D, Mirrakhimov E, Oganov R, Pogosova N, Reiner Z, Stoerk S, Tokgozoglu L, Tsioufis C, Vulic D, Wood D, EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.  Eur J Prev Cardiol  2019; 26 :824 \u0002 835. 662. Resurreccion DM, Moreno-Peral P, Gomez-Herranz M, Rubio-Valera M, Pastor L, Caldas de Almeida JM, Motrico E. Factors associated with non-participation in and dropout from cardiac rehabilitation programmes: a systematic review of prospective cohort studies.  Eur J Cardiovasc Nurs  2019; 18 :38 \u0002 47.\nESC Guidelines 3331\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ 663. Hamilton SJ, Mills B, Birch EM, Thompson SC. Smartphones in the secondary prevention of cardiovascular disease: a systematic review.  BMC Cardiovasc Disord 2018; 18 :25. 664. Giannuzzi P, Temporelli PL, Marchioli R, Maggioni AP, Balestroni G, Ceci V, Chieffo C, Gattone M, Griffo R, Schweiger C, Tavazzi L, Urbinati S, Valagussa F, Vanuzzo D, GOSPEL Investigators. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network.  Arch Intern Med  2008; 168 :2194 \u0002 2204. 665. Rose G. Sick individuals and sick populations.  Int J Epidemiol  1985; 14 :32 \u0002 38. 666. Rose G. Strategy of prevention: lessons from cardiovascular disease.  Br Med J (Clin Res Ed)  1981; 282 :1847 \u0002 1851. 667. Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M. Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated.  J Am Heart Assoc  2018; 7 :e010049. 668. Doyle YG, Furey A, Flowers J. Sick individuals and sick populations: 20 years later.  J Epidemiol Community Health  2006; 60 :396 \u0002 398. 669. Sorensen K, Pelikan JM, Rothlin F, Ganahl K, Slonska Z, Doyle G, Fullam J, Kondilis B, Agrafiotis D, Uiters E, Falcon M, Mensing M, Tchamov K, van den Broucke S, Brand H, HLS-EU Consortium. Health literacy in Europe: compara- tive results of the European health literacy survey (HLS-EU).  Eur J Public Health 2015; 25 :1053 \u0002 1058. 670. Magnani JW, Mujahid MS, Aronow HD, Cene CW, Dickson VV, Havranek E, Morgenstern LB, Paasche-Orlow MK, Pollak A, Willey JZ, American Heart Association Council on Epidemiology and Prevention, Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Peripheral Vascular Disease, Council on Quality of Care and Outcomes Research, Council S. Health Literacy and Cardiovascular Disease: Fundamental Relevance to Primary and Secondary Prevention: A Scientific Statement From the American Heart Association. Circulation 2018; 138 :e48 \u0002 e74. 671. Jorgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T, De Bacquer D, de Sutter J, Franco OH, Logstrup S, Volpe M, Malyutina S, Marques- Vidal P, Reiner Z, Tell GS, Verschuren WM, Vanuzzo D, PEP section of EACPR. Population-level changes to promote cardiovascular health.  Eur J Prev Cardiol 2013; 20 :409 \u0002 421. 672. Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, Jacobs DR, Jr., Kraus WE, Kris-Etherton PM, Krummel DA, Popkin BM, Whitsel LP, Zakai NA, American Heart Association Council on Epidemiology and Prevention, Council on Nutrition, Physical Activity and Metabolism, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on the Kidney in Cardiovascular Disease, Council on Peripheral Vascular Disease, the American Heart Association Advocacy Coordinating Committee. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation 2012; 126 :1514 \u0002 1563. 673. Shah AS, Langrish JP, Nair H, McAllister DA, Hunter AL, Donaldson K, Newby DE, Mills NL. Global association of air pollution and heart failure: a systematic review and meta-analysis.  Lancet  2013; 382 :1039 \u0002 1048. 674. Shah AS, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W, Langrish JP, Newby DE, Mills NL. Short term exposure to air pollution and stroke: system- atic review and meta-analysis.  BMJ  2015; 350 :h1295. 675. Al-Kindi SG, Brook RD, Biswal S, Rajagopalan S. Environmental determinants of cardiovascular disease: lessons learned from air pollution.  Nat Rev Cardiol 2020; 17 :656 \u0002 672. 676. Haines A, Ebi K. The Imperative for Climate Action to Protect Health.  N Engl J Med  2019; 380 :263 \u0002 273. 677. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S, ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST- segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).  Eur Heart J  2016; 37 :267 \u0002 315. 678. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P, ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST- segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).  Eur Heart J  2018; 39 :119 \u0002 177. 679. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S,\nYadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization.  Eur Heart J  2019; 40 :87 \u0002 165. 680. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM, ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients pre- senting without persistent ST-segment elevation. Eur Heart J 2021; 42 :1289 \u0002 1367. 681. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clo- pidogrel in addition to aspirin in patients with acute coronary syndromes with- out ST-segment elevation.  N Engl J Med  2001; 345 :494 \u0002 502. 682. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators. Prasugrel versus clopi- dogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 :2001 \u0002 2015. 683. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes.  N Engl J Med 2009; 361 :1045 \u0002 1057. 684. Schupke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wohrle J, Richardt G, Liebetrau C, Witzenbichler B, Antoniucci D, Akin I, Bott-Flugel L, Fischer M, Landmesser U, Katus HA, Sibbing D, Seyfarth M, Janisch M, Boncompagni D, Hilz R, Rottbauer W, Okrojek R, Mollmann H, Hochholzer W, Migliorini A, Cassese S, Mollo P, Xhepa E, Kufner S, Strehle A, Leggewie S, Allali A, Ndrepepa G, Schuhlen H, Angiolillo DJ, Hamm CW, Hapfelmeier A, Tolg R, Trenk D, Schunkert H, Laugwitz KL, Kastrati A, ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.  N Engl J Med  2019; 381 :1524 \u0002 1534. 685. Navarese EP, Khan SU, Kolodziejczak M, Kubica J, Buccheri S, Cannon CP, Gurbel PA, De Servi S, Budaj A, Bartorelli A, Trabattoni D, Ohman EM, Wallentin L, Roe MT, James S. Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials.  Circulation  2020; 142 :150 \u0002 160. 686. Hahn JY, Song YB, Oh JH, Cho DK, Lee JB, Doh JH, Kim SH, Jeong JO, Bae JH, Kim BO, Cho JH, Suh IW, Kim DI, Park HK, Park JS, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi JH, Choi SH, Gwon HC, SMART- DATE investigators. 6-month versus 12-month or longer dual antiplatelet ther- apy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet  2018; 391 :1274 \u0002 1284. 687. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Jr., Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.  N Engl J Med 2014; 371 :2155 \u0002 2166. 688. Bonaca MP, Braunwald E, Sabatine MS. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction.  N Engl J Med  2015; 373 :1274 \u0002 1275. 689. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstrale W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalan R, Cornel JH, Widimsky P, Leiter LA, THEMIS Steering Committee and Investigators. Ticagrelor in Patients with Stable Coronary Disease and Diabetes.  N Engl J Med 2019; 381 :1309 \u0002 1320. 690. McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bo¨hm M, Burri H, Butler J,   \u0002 Celutkien _ e J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EW, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Piepoli MF, Price S, Rosano GMC, Ruschitzka F, Skibelund AK, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.  Eur Heart J  2021; doi: 10.1093/ eurheartj/ehab368. 691. Phillips CO, Wright SM, Kern DE, Singa RM, Shepperd S, Rubin HR. Comprehensive discharge planning with postdischarge support for older patients with congestive heart failure: a meta-analysis.  JAMA  2004; 291 :1358 \u0002 1367. 692. Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med 1999; 159 :257 \u0002 261. 693. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials.  J Am Coll Cardiol  2004; 44 :810 \u0002 819.\n3332 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ......................................................................................................................................................................... 694. Feltner C, Jones CD, Cene CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, Arvanitis M, Lohr KN, Middleton JC, Jonas DE. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis.  Ann Intern Med  2014; 160 :774 \u0002 784. 695. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cho- lesterol is associated with marked increase in mortality in advanced heart fail- ure.  J Card Fail  2002; 8 :216 \u0002 224. 696. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M, EVEREST Trial Investigators. Prognostic significance of serum total cholesterol and trigly- ceride levels in patients hospitalized for heart failure with reduced ejection frac- tion (from the EVEREST Trial).  Am J Cardiol  2013; 111 :574 \u0002 581. 697. Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, Arbab- Zadeh A, Mukherjee D, Lazar JM. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure.  Am J Cardiol  2015; 115 :1428 \u0002 1434. 698. Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure.  Can J Cardiol  2015; 31 :195 \u0002 202. 699. Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B, Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials.  Circ Heart Fail 2015; 8 :33 \u0002 40. 700. O’Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pina IL, HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF- ACTION randomized controlled trial.  JAMA  2009; 301 :1439 \u0002 1450. 701. Taylor RS, Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal H, Lough F, Rees K, Singh S. Exercise-based rehabilitation for heart failure.  Cochrane Database Syst Rev  2014:CD003331. 702. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).  N Engl J Med  1987; 316 :1429 \u0002 1435. 703. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.  JAMA  1995; 273 :1450 \u0002 1456. 704. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.  Circulation 1999; 100 :2312 \u0002 2318. 705. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.  N Engl J Med  1991; 325 :293 \u0002 302. 706. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left- ventricular systolic function intolerant to angiotensin-converting-enzyme inhibi- tors: the CHARM-Alternative trial.  Lancet  2003; 362 :772 \u0002 776. 707. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure.  N Engl J Med  2014; 371 :993 \u0002 1004. 708. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019; 380 :539 \u0002 548. 709. DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiol  2020; 5 :202 \u0002 207. 710. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bohmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, ALB J, Gniot J, Mozheiko M, Lelonek M, Noe A, Schwende H, Bao W, Butylin D, Pascual-Figal D, TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart fail- ure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.  Eur J Heart Fail  2019; 21 :998 \u0002 1007. 711. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vitovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Janosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in\ncongestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283 :1295 \u0002 1302. 712. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure.  N Engl J Med  2001; 344 :1651 \u0002 1658. 713. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.  N Engl J Med  1996; 334 :1349 \u0002 1355. 714. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).  Lancet  1999; 353 :2001 \u0002 2007. 715. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.  Circulation  2002; 106 :2194 \u0002 2199. 716. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.  Lancet  1999; 353 :9 \u0002 13. 717. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole- Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).  Eur Heart J  2005; 26 :215 \u0002 225. 718. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.  N Engl J Med  1999; 341 :709 \u0002 717. 719. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms.  N Engl J Med  2011; 364 :11 \u0002 21. 720. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer N, Vardeny O, Claggett B, Jhund PS, Solomon SD. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation 2020; 141 :338 \u0002 351. 721. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, ASIAN-HF investigators, Voors AA. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 2019; 394 :1254 \u0002 1263. 722. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM, VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.  N Engl J Med  2020; 382 :1883 \u0002 1893. 723. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ. Diuretics for heart failure.  Cochrane Database Syst Rev  2012:CD003838. 724. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A. Current evi- dence supporting the role of diuretics in heart failure: a meta analysis of rando- mised controlled trials.  Int J Cardiol  2002; 82 :149 \u0002 158. 725. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.  Lancet 2010; 376 :875 \u0002 885. 726. Swedberg K, Komajda M, Bohm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.  J Am Coll Cardiol  2012; 59 :1938 \u0002 1945. 727. Cin \u0004 a CS, Devereaux PJ, McFalls EO, ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG. Coronary-artery revascula- rization before elective major vascular surgery.  N Engl J Med . 2004;  351 : 2795- 804.  Vasc Med  2006; 11 :61-63. 728. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH, Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb HS, Hughes VC, Baker B. Effect of\nESC Guidelines 3333\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314 :1547 \u0002 1552. 729. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure.  N Engl J Med  1997; 336 :525 \u0002 533. 730. Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of Care in the United Kingdom after Removal of Financial Incentives. N Engl J Med 2018; 379 :948 \u0002 957. 731. Taylor AL, Ziesche S, Yancy C, Carson P, D’Agostino R, Jr., Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN, African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.  N Engl J Med  2004; 351 :2049 \u0002 2057. 732. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH, Wilson JA, American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45 :2160 \u0002 2236. 733. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba L, Forsting M, Harnof S, Klijn CJ, Krieger D, Mendelow AD, Molina C, Montaner J, Overgaard K, Petersson J, Roine RO, Schmutzhard E, Schwerdtfeger K, Stapf C, Tatlisumak T, Thomas BM, Toni D, Unterberg A, Wagner M, European Stroke Organisation. European Stroke Organisation (ESO) guidelines for the manage- ment of spontaneous intracerebral hemorrhage.  Int J Stroke  2014; 9 :840 \u0002 855. 734. Ornello R, Degan D, Tiseo C, Di Carmine C, Perciballi L, Pistoia F, Carolei A, Sacco S. Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes: A Systematic Review and Meta-Analysis. Stroke 2018; 49 :814 \u0002 819. 735. Rodrigues MA, Samarasekera N, Lerpiniere C, Humphreys C, McCarron MO, White PM, Nicoll JAR, Sudlow CLM, Cordonnier C, Wardlaw JM, Smith C, Al- Shahi Salman R. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol 2018; 17 :232 \u0002 240. 736. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to pre- vent stroke in patients who have nonvalvular atrial fibrillation.  Ann Intern Med 2007; 146 :857 \u0002 867. 737. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrilla- tion. Analysis of pooled data from five randomized controlled trials.  Arch Intern Med  1994; 154 :1449 \u0002 1457. 738. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.  N Engl J Med  2009; 361 :1139 \u0002 1151. 739. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation.  N Engl J Med  2013; 369 :2093 \u0002 2104. 740. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al- Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.  N Engl J Med  2011; 365 :981 \u0002 992. 741. Klijn CJ, Paciaroni M, Berge E, Korompoki E, Korv J, Lal A, Putaala J, Werring DJ. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.  Eur Stroke J  2019; 4 :198 \u0002 223. 742. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.  N Engl J Med  2011; 365 :883 \u0002 891. 743. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of rando- mised trials of antiplatelet therapy for prevention of death, myocardial infarc- tion, and stroke in high risk patients.  BMJ  2002; 324 :71 \u0002 86. 744. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367 :1665 \u0002 1673.\n",
      "keywords": [
        "diabe",
        "obesity",
        "newer",
        "davies",
        "cvd risk",
        "positioning",
        "genetic",
        "diabetes",
        "coronary artery",
        "drugs",
        "type",
        "mathieu",
        "secondary prevention",
        "atrial fibrillation",
        "smoking",
        "endocrinol",
        "risk factor",
        "ejection fraction",
        "cosentino",
        "diet",
        "heart failure",
        "care",
        "physical activity",
        "lancet",
        "cardiovascular risk",
        "cholesterol",
        "older",
        "systolic",
        "petrie",
        "exercise"
      ],
      "tables": []
    },
    {
      "number": "40",
      "title": "745. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlof B, De Keyser J, Donnan GA, Estol C, Gorelick P",
      "start_page": 107,
      "end_page": 109,
      "content": "3334 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Secondary Prevention of Small Subcortical Strokes Trial. Hypertension 2016; 67 :63 \u0002 69. 761. White CL, Szychowski JM, Pergola PE, Field TS, Talbert R, Lau H, Peri K, Benavente OR, Secondary Prevention of Small Subcortical Strokes Study Investigators. Can blood pressure be lowered safely in older adults with lacunar stroke? The Secondary Prevention of Small Subcortical Strokes study experi- ence.  J Am Geriatr Soc  2015; 63 :722 \u0002 729. 762. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack.  N Engl J Med  2006; 355 :549 \u0002 559. 763. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM, Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study.  Stroke 2003; 34 :1126 \u0002 1129. 764. Bernick C, Kuller L, Dulberg C, Longstreth WT, Jr., Manolio T, Beauchamp N, Price T, Cardiovascular Health Study Collaborative Reseach Group. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study.  Neurology 2001; 57 :1222 \u0002 1229. 765. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study.  Stroke  2010; 41 :600 \u0002 606. 766. Katsanos AH, Filippatou A, Manios E, Deftereos S, Parissis J, Frogoudaki A, Vrettou AR, Ikonomidis I, Pikilidou M, Kargiotis O, Voumvourakis K, Alexandrov AW, Alexandrov AV, Tsivgoulis G. Blood Pressure Reduction and Secondary Stroke Prevention: A Systematic Review and Metaregression Analysis of Randomized Clinical Trials.  Hypertension  2017; 69 :171 \u0002 179. 767. Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, Clair DG, Geraghty PJ, McKinsey JF, Mills JL, Moneta GL, Murad MH, Powell RJ, Reed AB, Schanzer A, Sidawy AN, Society for Vascular Surgery. Society for Vascular Surgery practice guidelines for athero- sclerotic occlusive disease of the lower extremities: management of asympto- matic disease and claudication.  J Vasc Surg  2015; 61 :2S \u0002 41S. 768. Singh S, Armstrong EJ, Sherif W, Alvandi B, Westin GG, Singh GD, Amsterdam EA, Laird JR. Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty.  Vasc Med  2014; 19 :307 \u0002 314. 769. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard-Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudi- cation: a systematic review and meta-analysis of robust randomised controlled studies.  Eur J Vasc Endovasc Surg  2009; 38 :463 \u0002 474. 770. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Jr., Goto S, Ohman EM, Elbez Y, Sritara P, Baumgartner I, Banerjee S, Creager MA, Bhatt DL, REACH Registry Investigators. Statin therapy and long-term adverse limb out- comes in patients with peripheral artery disease: insights from the REACH registry.  Eur Heart J  2014; 35 :2864 \u0002 2872. 771. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. J Am Coll Cardiol  2016; 67 :353 \u0002 361. 772. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).  Circulation  2018; 137 :338 \u0002 350. 773. Schmit K, Dolor RJ, Jones WS, Vemulapalli S, Hasselblad V, Subherwal S, Heidenfelder B, Patel MR. Comparative effectiveness review of antiplatelet agents in peripheral artery disease.  J Am Heart Assoc  2014; 3 :e001330. 774. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Stork S, Zhu J, Lopez- Jaramillo P, O’Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S, COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable periph- eral or carotid artery disease: an international, randomised, double-blind, pla- cebo-controlled trial.  Lancet  2018; 391 :219 \u0002 229. 775. The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS), Aboyans V, Ricco JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debus S, Espinola-Klein C, Kahan T, Kownator S, Mazzolai L, Naylor AR, Roffi M, Rother J, Sprynger M, Tendera M, Tepe G, Venermo M, Vlachopoulos C, Desormais I.\n2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO).  Eur Heart J  2018; 39 :763 \u0002 816. 776. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-Dehoff RM, Handberg EM, Pepine CJ. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.  Hypertension  2010; 55 :48 \u0002 53. 777. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.  N Engl J Med  2000; 342 :145 \u0002 153. 778. Shahin Y, Barnes R, Barakat H, Chetter IC. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pres- sure index in patients with intermittent claudication. Atherosclerosis 2013; 231 :283 \u0002 290. 779. Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease.  Cochrane Database Syst Rev  2013:CD005508. 780. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease.  Am J Cardiol  2001; 87 :1284 \u0002 1286. 781. Bullen C. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease.  Expert Rev Cardiovasc Ther  2008; 6 :883 \u0002 895. 782. Mazari FA, Khan JA, Samuel N, Smith G, Carradice D, McCollum PC, Chetter IC. Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg 2017; 104 :76 \u0002 83. 783. Fakhry F, Spronk S, van der Laan L, Wever JJ, Teijink JA, Hoffmann WH, Smits TM, van Brussel JP, Stultiens GN, Derom A, den Hoed PT, Ho GH, van Dijk LC, Verhofstad N, Orsini M, van Petersen A, Woltman K, Hulst I, van Sambeek MR, Rizopoulos D, Rouwet EV, Hunink MG. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial.  JAMA  2015; 314 :1936 \u0002 1944. 784. Jansen SCP, Hoorweg BBN, Hoeks SE, van den Houten MML, Scheltinga MRM, Teijink JAW, Rouwet EV. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in inter- mittent claudication.  J Vasc Surg  2019; 69 :1293 \u0002 1308 e1292. 785. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the pre- vention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338 :b1665. 786. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F, Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).  J Hypertens  2013; 31 :1281 \u0002 1357. 787. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, Yusuf S, HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.  Eur Heart J  2004; 25 :17 \u0002 24. 788. Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, Marwick TH, Conference Participants. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.  J Am Coll Cardiol  2019; 74 :1823 \u0002 1838. 789. Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, Wasserman SM, Deedwania P, Olsson AG, Sever PS, Keech AC, Giugliano RP, FOURIER Steering Committee and Investigators. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.  J Am Coll Cardiol 2019; 73 :2961 \u0002 2970. 790. Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J  2018; 11 :749 \u0002 761. 791. Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Improved Outcomes by Integrated Care of Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC (Atrial Fibrillation Better Care) Pathway. Am J Med 2018; 131 :1359 \u0002 1366 e1356. 792. Yoon M, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, Kim JY, Sung JH, Pak HN, Lee MH, Joung B, Lip GYH. Improved Population-Based Clinical Outcomes of Patients with Atrial Fibrillation by Compliance with the Simple ABC (Atrial\nESC Guidelines 3335\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................................................................................................................................................................ Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study.  Thromb Haemost  2019; 19 :1695 \u0002 1703. 793. Pastori D, Pignatelli P, Menichelli D, Violi F, Lip GYH. Integrated Care Management of Patients With Atrial Fibrillation and Risk of Cardiovascular Events: The ABC (Atrial fibrillation Better Care) Pathway in the ATHERO-AF Study Cohort.  Mayo Clin Proc  2019; 94 :1261 \u0002 1267. 794. Pastori D, Farcomeni A, Pignatelli P, Violi F, Lip GY. ABC (Atrial fibrillation Better Care) Pathway and Healthcare Costs in Atrial Fibrillation: The ATHERO-AF Study.  Am J Med  2019; 132 :856 \u0002 861. 795. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and cardiometabolic risk factor manage- ment on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial.  JAMA  2013; 310 :2050 \u0002 2060. 796. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction study for atrial fibrillation and impli- cations for the outcome of ablation: the ARREST-AF cohort study.  J Am Coll Cardiol  2014; 64 :2222 \u0002 2231. 797. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long- Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll Cardiol 2015; 65 :2159 \u0002 2169. 798. Voskoboinik A, Kalman JM, De Silva A, Nicholls T, Costello B, Nanayakkara S, Prabhu S, Stub D, Azzopardi S, Vizi D, Wong G, Nalliah C, Sugumar H, Wong M, Kotschet E, Kaye D, Taylor AJ, Kistler PM. Alcohol Abstinence in Drinkers with Atrial Fibrillation.  N Engl J Med  2020; 382 :20 \u0002 28. 799. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study.  J Am Coll Cardiol 2015; 66 :985 \u0002 996. 800. Lip GYH, Coca A, Kahan T, Boriani G, Manolis AS, Olsen MH, Oto A, Potpara TS, Steffel J, Marin F, de Oliveira Figueiredo MJ, de Simone G, Tzou WS, Chiang CE, Williams B, Reviewers, Dan GA, Gorenek B, Fauchier L, Savelieva I, Hatala R, van Gelder I, Brguljan-Hitij J, Erdine S, Lovic D, Kim YH, Salinas-Arce J, Field M. Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS),  Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace  2017; 19 :891 \u0002 911. 801. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrillation and Hypertension.  Hypertension  2017; 70 :854 \u0002 861. 802. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities study. Circ Arrhythm Electrophysiol 2014; 7 :620 \u0002 625. 803. Conen D, Albert CM. Alcohol consumption and risk of atrial fibrillation: how much is too much?  J Am Coll Cardiol  2014; 64 :290 \u0002 292. 804. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis.  J Am Coll Cardiol 2014; 64 :281 \u0002 289. 805. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease.  Mayo Clin Proc  2009; 84 :373 \u0002 383. 806. Mont L. Arrhythmias and sport practice.  Heart  2010; 96 :398 \u0002 405. 807. Menezes AR, Lavie CJ, De Schutter A, Milani RV, O’Keefe J, DiNicolantonio JJ, Morin DP, Abi-Samra FM. Lifestyle modification in the prevention and treat- ment of atrial fibrillation.  Prog Cardiovasc Dis  2015; 58 :117 \u0002 125. 808. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ 1998; 316 :1784 \u0002 1785. 809. Baldesberger S, Bauersfeld U, Candinas R, Seifert B, Zuber M, Ritter M, Jenni R, Oechslin E, Luthi P, Scharf C, Marti B, Attenhofer Jost CH. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists.  Eur Heart J  2008; 29 :71 \u0002 78. 810. Molina L, Mont L, Marrugat J, Berruezo A, Brugada J, Bruguera J, Rebato C, Elosua R. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study.  Europace  2008; 10 :618 \u0002 623. 811. Nielsen JR, Wachtell K, Abdulla J. The Relationship Between Physical Activity and Risk of Atrial Fibrillation-A Systematic Review and Meta-Analysis.  J Atr Fibrillation  2013; 5 :789. 812. Khan H, Kella D, Rauramaa R, Savonen K, Lloyd MS, Laukkanen JA. Cardiorespiratory fitness and atrial fibrillation: A population-based follow-up study.  Heart Rhythm  2015; 12 :1424 \u0002 1430.\n",
      "keywords": [
        "obesity",
        "alcohol",
        "peripheral artery",
        "cunha",
        "hypertension",
        "cotton",
        "atherosclerosis",
        "diabetes",
        "coronary artery",
        "estol",
        "keyser",
        "dahlof",
        "palesch",
        "secondary prevention",
        "statin",
        "atrial fibrillation",
        "smoking",
        "risk factor",
        "sacco",
        "yusuf",
        "diener",
        "donnan",
        "pcsk9",
        "bornstein",
        "physical activity",
        "bath",
        "cardiovascular risk",
        "cholesterol",
        "arrhythmia",
        "mri"
      ],
      "tables": []
    },
    {
      "number": "41",
      "title": "813. Linz D, McEvoy RD, Cowie MR, Somers VK, Nattel S, Levy P, Kalman JM, Sanders P. Associations of Obstructive Sleep Apnea With Atrial Fibrillation and Continuous Positive Airway Pressure Treatment:",
      "start_page": 109,
      "end_page": 110,
      "content": "3336 ESC Guidelines\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n. ............................... Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H, ESC Scientific Document Group, Halvorsen S, Jernberg T, Jortveit J, Blondal M, Ibanez B, Hassager C. 2020 Update of the qual- ity indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indica- tors from the ACVC and the NSTE-ACS guideline group.  Eur Heart J Acute Cardiovasc Care  2021; 10 :224 \u0002 233. 834. Arbelo E, Aktaa S, Bollmann A, D’Avila A, Drossart I, Dwight J, Hills MT, Hindricks G, Kusumoto FM, Lane DA, Lau DH, Lettino M, Lip GYH, Lobban T, Pak HN, Potpara T, Saenz LC, Van Gelder IC, Varosy P, Gale CP, Dagres N, Reviewers, Boveda S, Deneke T, Defaye P, Conte G, Lenarczyk R, Providencia R, Guerra JM, Takahashi Y, Pisani C, Nava S, Sarkozy A, Glotzer TV, Martins Oliveira M. Quality indicators for the care and outcomes of adults with atrial fibrillation.  Europace  2021; 23 :494 \u0002 495.\n",
      "keywords": [
        "airway",
        "treatment",
        "kalman",
        "nattel",
        "fibrillation",
        "sanders",
        "atrial fibrillation",
        "apnea",
        "linz",
        "sleep",
        "associations",
        "atrial",
        "somers",
        "guideline",
        "positive",
        "continuous",
        "cowie",
        "levy",
        "obstructive",
        "mcevoy",
        "pressure"
      ],
      "tables": []
    },
    {
      "number": "42",
      "title": "835. Wallentin L, Gale CP, Maggioni A, Bardinet I, Casadei B. EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials.  Eur Heart J 2019; 40 :2745 \u0002 2749. 836. Casey DE, ",
      "start_page": 110,
      "end_page": 110,
      "content": "ESC Guidelines 3337\nDownloaded from https://academic.oup.com/eurheartj/article/42/34/3227/6358713 by guest on 14 January 2026\n",
      "keywords": [
        "unified",
        "care",
        "evaluation",
        "heart",
        "casey",
        "european",
        "gale",
        "randomized",
        "trials",
        "casadei",
        "maggioni",
        "euroheart",
        "registries",
        "bardinet",
        "wallentin"
      ],
      "tables": []
    }
  ]
}